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Abstract 
Macrophages are dynamic and heterogeneous cells that can be divided into specific, 
phenotypic subsets. Based on Th1/Th2 polarization concept they are referred to as pro-
inflammatory classical M1 (IL-12high, IL-23high, IL-10low) macrophages and anti-inflammatory 
M2 (IL-12low, IL-23low, IL-10high) macrophages. In contrast to T lymphocyte subsets, the 
transcription factor(s) underlying macrophage polarization remain largely unknown.  
 
My research has highlighted the importance of Interferon regulatory factor 5 (IRF5) for 
establishing the pro-inflammatory M1 macrophage phenotype. I was able to show that high 
expression of IRF5 is characteristic of M1 macrophages, in which it transcriptionally 
regulates M1-specific cytokines, chemokines and co-stimulatory molecules. Consequently, 
the depletion of IRF5 in human M1 macrophages results in down-regulation of M1-specific 
cytokines and further evidence for a role of IRF5 in effective immunity stems from my work 
using an in vivo model of polarizing inflammation. IRF5 deficient mice showed a significant 
reduction in serum levels of M1-specific cytokines compared to wild-type littermate controls. 
Therefore, the suppression of macrophage function via inhibition of IRF5 provides a new 
approach to attenuate the inflammatory response.  
 
Tumor necrosis factor (TNF) plays an essential role in the host defence against infections 
but is a major factor in the pathogenesis of chronic inflammatory diseases. The expression 
of TNF is therefore tightly regulated. I was able to demonstrate that IRF5 is not only 
involved in the induction of human TNF gene expression but also crucial for the late phase 
secretion of TNF by human myeloid cells. IRF5 is using a complex molecular mechanism to 
control the TNF gene with two spatially separated regulatory regions (5‟ upstream and 3‟ 
downstream of the gene) and two independent modes of action (direct DNA binding and 
formation of IRF5/RelA complex) being involved. The manipulation of the IRF5/RelA 
interaction could be a putative target for cell-specific modulation of TNF gene expression.  
 
 
 3  
Declaration 
 
 
The experimental data described in this thesis are original and have been performed by 
myself, with exceptions indicated. All collaborations have been acknowledged in the 
appropriate places, either in the materials and methods section or in the result chapters.  
 
This work has been carried out at the Kennedy Insitute of Rheumatology Division and was 
funded by the Arthritis Research UK, Medical Research Council, the European Community 
Seventh Framework Programme FP7/2007-2013 and the Kennedy Institute trustees.  
 
 
Thomas Krausgruber 
May, 2011 
 
 4  
Acknowledgements 
First and foremost, I would like to thank Dr Irina Udalova for her outstanding supervision 
during the course of my PhD and for providing the concept of this study. I would like to 
thank you for your teaching, enthusiasm, inspiration throughout, motivation when needed 
and guidance, but also for giving me the freedom to explore and pursue my own ideas. Your 
overall influence helped me to develop into a mindful and independent scientist.  
 
I thank Dr Jonathan Dean who has always taken an interest in my work, providing critical 
and constructive suggestions. I also thank the late Prof Brian Foxwell for guidance in the 
first year of my PhD. 
 
The technical advice and expertise, that made the generation of the data in this thesis 
possible, were kindly provided by the following people: Miss Katrina Blazkova (so helpful 
throughout and in particular with murine work), Dr David Saliba (investigated the IRF5/RelA 
interaction), Mrs Alessandra Lanfrancotti (virus purification and EMSA), Mrs Helen 
Lockstone and Miss Natasha Sahgal (Micro array analysis), Dr Dilair Baban (RNA 
hybridisation), Dr Daniel Wong (purification of recombinant IRF5 DBD), Dr Irina Udalova 
(EMSA), Dr Tim Smallie (provided luciferase constructs and performed luciferase 
experiments), Dr Saba Alzabin (proliferation assays and help with FCM analysis), Dr Lynn 
Williams (scientific advice), Prof Tracy Hussell (scientific advice) and last but not least, Prof 
Sir Marc Feldmann (scientific as well as personal advice and help).  
 
I would like to thank everyone in my group, both current (Katrina, Scott, David, Hayley, 
Grisha) and past (Fergie, Lionel, Helen) for their help, support and for making those long 
hours in the lab much more enjoyable. Thanks to Tim Smallie, Matt Pierce and Andy 
Kinloch for offering scientific advice and for encouragement when needed. 
 
The compilation of this thesis was only possible because of the proof-reading and 
constructive comments kindly provided by Irina, Jon, Katrina, Hayley, Scott and David.  
 
Most of all, I would like to extend my thanks and love to my now fiancée Julia, for her 
seemingly endless patience and constant support. It was your love and optimism that 
helped my through all this.  
 
Nothing is impossible with you at my side :-)
 5  
Table of contents 
 
ABSTRACT 2 
DECLARATION 3 
ACKNOWLEDGEMENTS 4 
TABLE OF CONTENTS 5 
LIST OF FIGURES 10 
LIST OF TABLES 12 
1. INTRODUCTION 13 
1.1 The immune system 13 
1.1.1 Granulocytes ..................................................................................................... 16 
1.1.2 Monocytes ........................................................................................................ 17 
1.1.3 Dendritic cells.................................................................................................... 18 
1.1.4 Macrophages .................................................................................................... 19 
1.1.5 Natural killer cells .............................................................................................. 26 
1.1.6 T Lymphocytes .................................................................................................. 27 
1.1.7 B-cells ............................................................................................................... 30 
1.2 The Interferon regulatory factor family of transcription factors 31 
1.3 Regulation of the innate immune response by IRF and NF-B family members 32 
1.3.1 Activation of NF-kB proteins by TLR signalling .................................................. 33 
1.3.2 IRF3/IRF7: master regulators of type I IFN induction......................................... 35 
1.3.3 IRF4/IRF8: essential factors for DC development and function ......................... 36 
1.4 Interferon regulatory factor 5 37 
1.4.1 IRF5 gene structure .......................................................................................... 37 
1.4.2 IRF5 protein structure ....................................................................................... 39 
1.4.3 Expression of IRF5 ........................................................................................... 40 
1.4.4 Activation of IRF5 .............................................................................................. 40 
1.4.5 Role of IRF5 in antiviral immunity and cytokine induction .................................. 41 
1.5 Dysfunction of immunity – Role of IRF5 in autoimmune diseases 43 
1.5.1 Systemic lupus erythematosus .......................................................................... 43 
1.5.2 Inflammatory bowel disease .............................................................................. 45 
 6  
1.5.3 Rheumatoid arthritis .......................................................................................... 47 
1.6 Hypothesis of investigation 52 
1.6.1 Specific aims for TNF study (Chapter 3): ........................................................... 52 
1.6.2 Specific aims for macrophage polarization study (Chapter 4 and 5) .................. 53 
 
2. METHODS 54 
2.1 Cell culture 54 
2.1.1 Maintenance of cell lines ................................................................................... 54 
2.1.2 Cryopreservation of cells ................................................................................... 55 
2.2 Work with primary human myeloid cells 55 
2.2.1 Isolation of human peripheral blood mononuclear cells ..................................... 55 
2.2.2 Isolation of human monocytes ........................................................................... 55 
2.2.3 In vitro differentiation of human monocytes ....................................................... 56 
2.3 Work with mice and murine cells 56 
2.3.1 Isolation of bone marrow cells ........................................................................... 56 
2.3.2 In vitro differentiation of bone marrow cells ....................................................... 57 
2.3.3 Isolation and culture of spleen cells ................................................................... 57 
2.3.4 In vivo experiment with IRF5 knock-out mice .................................................... 58 
2.4 MTT cell viability assay 58 
2.5 Quantitative real-time PCR 59 
2.5.1 RNA extraction and quantification ..................................................................... 59 
2.5.2 cDNA synthesis ................................................................................................. 59 
2.5.3 Quantitative real-time PCR 2 standard curve method ........................................ 59 
2.6 Micro array analysis 62 
2.7 Enzyme linked immunosorbent assay (ELISA) 62 
2.7.1 BD™ Cytrometic bead assay (CBA) .................................................................. 65 
2.8 Western blotting 66 
2.8.1 Preparation of whole cell protein extracts .......................................................... 67 
2.8.2 Protein quantification: BCA assay ..................................................................... 67 
2.8.3 SDS-PAGE ....................................................................................................... 67 
2.8.4 Protein transfer ................................................................................................. 67 
2.8.5 Immunoblotting and protein detection ............................................................... 68 
2.9 Electrophoretic mobility shift assay (EMSA) 69 
2.9.1 DNA probe labelling .......................................................................................... 69 
 7  
2.9.2 Binding reaction and gel run .............................................................................. 69 
2.10 Cloning and genetic constructs used in this study 70 
2.10.1 Gene reporter and expression constructs used in this study ........................... 70 
2.10.2 PCR ................................................................................................................ 72 
2.10.3 Restriction digests ........................................................................................... 72 
2.10.4 DNA purification .............................................................................................. 72 
2.10.5 DNA ligation .................................................................................................... 72 
2.10.6 Transformation of chemically competent cells ................................................. 73 
2.10.7 Amplification and isolation of plasmids ............................................................ 73 
2.10.8 Identification of positive clones ........................................................................ 73 
2.11 Transfection and adenoviral infection of cell cultures 73 
2.11.1 Transfection of siRNA oligonucleotides into cell lines ...................................... 74 
2.11.2 Transfection of siRNA oligonucleotides into primary human cells .................... 74 
2.11.3 Transfection of plasmids into cell lines ............................................................ 74 
2.11.4 Adenoviral infection of primary human myeloid cells ....................................... 75 
2.12 Luciferase gene reporter assays 76 
2.13 Immuno-precipitation 76 
2.14 Chromatin immuno-precipitation 77 
2.14.1 Fixation and preparation of nuclear extracts .................................................... 77 
2.14.2 Sonication ....................................................................................................... 78 
2.14.3 Immuno-precipitation ....................................................................................... 78 
2.14.4 DNA purification .............................................................................................. 79 
2.14.5 ChIP primer design ......................................................................................... 79 
2.14.6 ChIP primer testing and optimisations ............................................................. 80 
2.14.7 Real-time PCR analysis .................................................................................. 82 
2.15 Flow cytometry (FCM) analysis 83 
2.16 Mixed lymphocyte reactions (MLR) 84 
2.16.1 MLR with MDDCs as APCs ............................................................................. 84 
2.16.2 MLR with macrophages as APCs .................................................................... 85 
2.17 Bioinformatic analysis 85 
2.18 Statistical analyses 85 
2.19 Buffers and Solutions 86 
2.19.1 General buffers ............................................................................................... 86 
2.19.2 SDS-PAGE and Western blotting .................................................................... 86 
2.19.3 ELISA buffers .................................................................................................. 88 
 8  
2.19.4 EMSA.............................................................................................................. 88 
2.19.5 Chromatin immuno-precipitation...................................................................... 88 
2.19.6 Molecular biology solutions ............................................................................. 89 
 
3. IRF5-MEDIATED HUMAN TNF GENE EXPRESSION 91 
3.1 Introduction 91 
3.2 Results 92 
3.2.1 IRF5 expression is high in MDDCs and controls late phase TNF secretion ....... 92 
3.2.2 si-RNA mediated depletion of IRF5 reduces late-phase TNF secretion ............. 98 
3.2.3 IRF5 is involved in transcriptional regulation of TNF ....................................... 100 
3.2.4 Computational analysis of the human TNF locus ............................................ 103 
3.2.5 Design of ChIP primers ................................................................................... 105 
3.2.6 IRF5 is recruited to a 5‟ upstream and 3‟ downstream region of TNF .............. 105 
3.2.7 IRF5 forms specific physical interactions with RelA ......................................... 109 
3.2.8 RelA is required for IRF5-dependent transactivation of the TNF gene ............. 112 
3.3 Conclusion 115 
 
4. IRF5 PROMOTES INFLAMMATORY MACROPHAGE POLARIZATION 119 
4.1 Introduction 119 
4.2 Results 120 
4.2.1 IRF5 expression is high in human M1 macrophages ....................................... 120 
4.2.2 IRF5 expression is plastic in human macrophages ......................................... 123 
4.2.3 IRF5 influences the polarization of human macrophages ................................ 126 
4.2.4 IRF5 induces the mRNA expression of macrophage lineage-specific  
         cytokines ........................................................................................................  129 
4.2.5 IRF5 directly regulates mRNA expression of lineage-specific cytokines .......... 135 
4.2.6 IRF5 inhibits the transcription of the human IL-10 gene .................................. 141 
4.3 Conclusion 143 
 
5. IRF5 PROMOTES TH1/TH17 RESPONSES AND ITS IMPORTANCE FOR IN 
VIVO INFLAMMATION 147 
5.1 Introduction 147 
5.2 Results 148 
 9  
5.2.1 IRF5 promotes human T lymphocyte proliferation and Th1 responses ............ 148 
5.2.2 IRF5 promotes human Th17 responses .......................................................... 151 
5.2.3 IRF5 regulates the phenotype of mouse macrophages ................................... 155 
5.2.4 Importance of IRF5 in a mouse model of M1 inflammation .............................. 157 
5.3 Conclusion 161 
 
6. DISCUSSION 165 
7. ABBREVIATIONS 176 
8. REFERENCES 180 
9. SUPPLEMENTARY MATERIAL - PUBLICATIONS 206 
 
 10  
List of Figures 
Figure 1.1 Recognition of pathogens by innate cells  ......................................................... 14 
Figure 1.2 Simplified overview of the interplay between innate and adaptive immunity ...... 16 
Figure 1.3 Simplified schematic of myeloid differentiation .................................................. 17 
Figure 1.4 Inducers and selected properties of polarized macrophages ............................. 22 
Figure 1.5 In vitro polarization of macrophages using growth factors ................................. 24 
Figure 1.6 Domain model of IRF family members  ............................................................. 32 
Figure 1.7 Overview of transcription factor activation by TLR signalling  ............................ 33 
Figure 1.8 Human IRF5 gene structure .............................................................................. 38 
Figure 1.9 Schematic representation of healthy versus RA joint ........................................ 50 
Figure 2.1 Melt curve analysis of ChIP primer pairs ........................................................... 81 
Figure 2.2 Improvement of Ct values with Takara master mix ............................................ 82 
Figure 3.1 IRF5 is highly expressed in MDDCs .................................................................. 92 
Figure 3.2 Prolonged TNF secretion in MDDCs ................................................................. 93 
Figure 3.3 Late phase TNF secretion is required for potent T lymphocyte response .......... 95 
Figure 3.4 Ectopic expression of IRF5 in MDMs results in prolonged TNF secretion  
  and increased Th1 responses ........................................................................... 97 
Figure 3.5 siRNA-mediated depletion of IRF5 is not possible in HEK-293-TLR4 cells ........ 98 
Figure 3.6 siRNA-mediated depletion of IRF5 affects late phase secretion of TNF .......... 100 
Figure 3.7 LPS-induced expression of TNF mRNA is IRF5 dependent ............................ 101 
Figure 3.8 IRF5 is involved in transcriptional regulation of TNF ....................................... 103 
Figure 3.9 Schematic of the human TNF locus ................................................................ 104 
Figure 3.10 Recruitment of IRF5 to 5‟ upstream and 3‟ downstream region of TNF ......... 106 
Figure 3.11 In vitro binding of IRF5 to 5‟ upstream and 3‟ downstream regions of TNF .... 108 
Figure 3.12 IRF5 and RelA are recruited to 5‟ upstream and 3‟ downstream regions 
   of the TNF gene in MDDCs .......................................................................... 108 
Figure 3.13 Co-recruitment of RelA and IRF5 to region H ................................................ 109 
Figure 3.14 Ectopic IRF5 specifically interacts with RelA in HEK-293 cells ...................... 110 
Figure 3.15 Endogenous IRF5 interacts with RelA in MDDCs .......................................... 111 
Figure 3.16 RelA is required for IRF5-binding to region H of the TNF gene  .................... 113 
Figure 3.17 RelA is required for IRF5-mediated activation of TNF ................................... 114 
Figure 3.18 Modes of IRF5 recruitment to regions of the human TNF locus ..................... 116 
Figure 4.1 The cytokine environment determines macrophage phenotype ....................... 121 
Figure 4.2 High expression of IRF5 in M1 macrophages and upregulation by GM-CSF ... 122 
 11  
Figure 4.3 IRF5 expression is induced by M1 macrophage maturation protocols ............. 123 
Figure 4.4 Plasticity of macrophages in respond to environmental changes .................... 124 
Figure 4.5 Plastic expression of IRF5 in macrophages .................................................... 125 
Figure 4.6 Ectopic IRF5 influences the production of IL-12p70 and IL-23 ........................ 126 
Figure 4.7 Ectopic IRF5 induces IL-1 and TNF but inhibits IL-10 secretion .................... 127 
Figure 4.8 siRNA-mediated knock-down of IRF5 in M1 macrophages ............................. 128 
Figure 4.9 Depletion of IRF5 influences the production of lineage-specific cytokines ....... 129 
Figure 4.10 IRF5 induces the mRNA expression of lineage–specific cytokines ................ 130 
Figure 4.11 IRF5 depletion influences mRNA expression of lineage-specific cytokines ... 130 
Figure 4.12 IRF5 influences the global expression profile of macrophage subsets .......... 132 
Figure 4.13 IRF5 drives the production of selected lineage specific cytokines ................. 134 
Figure 4.14 LPS-induced recruitment of IRF5 to promoter regions of  
   lineage-specific cytokines ............................................................................. 141 
Figure 4.15 IRF5 inhibits the transcriptional activation of the human IL-10 gene .............. 142 
Figure 4.16 Transcription factors underlying macrophage polarization ............................. 146 
Figure 5.1 IRF5 induced T lymphocyte proliferation ......................................................... 149 
Figure 5.2 IRF5-expressing macrophages induce Th1 activation ..................................... 150 
Figure 5.3 IRF5-expressing macrophages induce Th1 development ................................ 151 
Figure 5.4 IRF5-expressing macrophages induce Th17 activation ................................... 152 
Figure 5.5 IRF5-expressing macrophages induce Th17 development .............................. 153 
Figure 5.6 IRF5-expressing macrophages induce Th17 cytokine profile .......................... 154 
Figure 5.7 IRF5-expressing macrophages do not induce the Treg or Th2 lineage ........... 155 
Figure 5.8 IRF5 expression is high in GM-CSF differentiated BMDMs ............................. 156 
Figure 5.9 Impaired induction of M1 cytokines in BMDMs of IRF5−/− mice ........................ 156 
Figure 5.10 Impaired induction of M1 cytokines in LPS challenged Irf5−/− mice ................ 158 
Figure 5.11 Impaired mRNA induction of M1-specific cytokines in peritoneal cells from  
  Irf5−/− mice   ................................................................................................... 159 
Figure 5.12 Reduction in IFN- and IL-17 production in ex vivo splenocyte cultures ........ 160 
Figure 5.13 Potential feedback loop involving IRF5, IL-23 and GM-CSF .......................... 163 
Figure 6.1 Interplay between M1 macrophages, T lymphocytes and infiltrating cells ........ 172 
 
 
 
 
 
 12  
List of Tables 
Table 2.1: Cell lines used in this study ............................................................................... 54 
Table 2.2: TaqMan primers used in this study .................................................................... 60 
Table 2.3: Antibodies used for ELISA ................................................................................ 63 
Table 2.4: Recombinant proteins used as standards for ELISA ......................................... 65 
Table 2.5: Antibodies and standards used for CBA ............................................................ 66 
Table 2.6: Antibodies used for western blotting .................................................................. 68 
Table 2.7: Oligonucleotide sequences used for generating EMSA probes ......................... 70 
Table 2.8: Expression constructs used in this study ........................................................... 71 
Table 2.9: Luciferase gene reporters ................................................................................. 71 
Table 2.10: Antibodies used for ChIP ................................................................................. 79 
Table 2.11: ChIP primers used for analysing human TNF locus ......................................... 82 
Table 2.12: Primers used for ChIP analysis ....................................................................... 83 
Table 2.13: Antibodies used for FCM analysis ................................................................... 84 
Table 4.1 Newly identified IRF5 target genes ................................................................... 133 
Table 4.2 Putative IRF5 binding sites in -2000/+2000 bp relative to the TSSs of  
  selected genes ................................................................................................. 135 
 
 
 
 
  13  
1. Introduction 
 
1.1 The immune system 
The immune system has been shaped by evolution to allow multicellular organisms to live 
together with microorganisms, e.g. in the microbiota of the gut. However, many 
microorganisms, such as viruses, bacteria, fungi and parasites, have the potential to cause 
disease and threaten host viability. Accordingly, the immune system has evolved to protect 
the body from invasion and infection by pathogenic organisms and employs various 
mechanisms to distinguish particular features of the pathogens from healthy host tissue. In 
vertebrates, the immune system is highly dynamic, using several cell types, tissues and 
organs to provide multiple levels of defence against varying types of pathogens. However, 
the immune system not only provides protection against pathogens but also from “self”. It 
puts the host under permanent surveillance in order to recognise and eliminate unhealthy or 
damaged tissues therefore protecting the body from itself. The immune system has to 
evolve constantly as pathogens develop new ways to avoid detection by the immune 
system and adapt new mechanisms to infiltrate and infect their host.  
 
There are two main arms of the immune system which respond in coordination to challenge 
or invasion - the innate and the adaptive response. All multicellular organisms possess 
innate immunity whereas adaptive immunity appeared during the evolution of vertebrates. 
The innate immune system is composed of a humoral arm, which consists of antimicrobial 
peptides and opsonins, and a cellular arm, which involves specialized cells. These cells are 
able to internalise and digest bacteria and other cells, to scavenge toxic compounds 
produced during metabolism and to produce inflammatory mediators that can kill invading 
pathogens.  
 
The innate arm of the immune response provides the initial line of defence against invading 
microorganisms and is also responsible for initiating and „instructing‟ the adaptive system 
through antigen presentation. It is triggered by germline encoded pattern recognition 
receptors (PRRs) which detect relatively invariant molecular patterns (pathogen-associated 
molecular patterns, PAMPs) found in most microorganisms [1, 2]. This makes the innate 
response largely non-specific as it will react to a wide range of infectious pathogens as well 
as to host tissue damage [3]. The activation of the innate immune system is not only based 
on the recognition of PAMPs but also occurs in the presence of danger signals or danger-
Chapter 1 - Introduction 
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associated molecular patterns (DAMPs) released by injured cells. The release of DAMPs is 
a common event as tissue damage and cell lysis are often associated with infections that 
lead to the release of host molecules. Recognition of these DAMPs by the immune system 
not only allows the sensing of an ongoing infection and subsequent recruitment of more 
immune cells but can also initiate the repair of the damaged tissue [4, 5]. Therefore, the 
innate arm of the immune system not only scans the cellular environment for signs of 
invading pathogens but also recognises the damage caused by them. 
 
Binding of PAMPs to innate PRRs will initiate a rapid and powerful response, associated 
with the initiation of gene expression and the release of inflammatory mediators (Figure 
1.1). Inflammation is a key innate defence mechanism that is characterised by heat, 
redness, swelling, pain, increased blood flow and permeability of local blood vessels as well 
as recruitment of immune cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Recognition of pathogens by innate cells  
Pathogens are recognised via PRRs expressed on innate immune cells. PRR signalling leads to the 
initiation of gene expression and subsequent secretion of inflammatory mediators.  
 
 
 
PRRs can be be broadly divided into 3 classes, transmembrane, cytosolic and secreted 
receptors [6]. Transmembrane PRRs include the Toll-like receptor (TLR) family and the C-
type lectins. TLRs are either expressed on the plasma membrane or in 
endosomal/lysosomal organelles [7]. Membrane-bound TLRs recognise PAMPs that are 
accessible on the cell surface whereas endosomal TLRs mainly detect microbial nucleic 
PAMPs
PRR
Inflammatroy 
mediators
Innate 
immune cell
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acids such as double-stranded RNA. The expression of TLRs is cell-type specific, which 
allows the distribution of recognition functions to various cell types [8]. The C-type lectin 
family consists of Dectin-1 and Dectin-2 that are able to detect compounds of fungal cell 
walls [9].  
 
Cytosolic PRRs include the retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) and 
the nucleotide-binding domain and leucine-rich repeat-containing receptors (NOD-like 
receptors or NLRs). Unlike TLRs, most cell types express RLRs which detect viral 
pathogens [10]. NLR family members are intracellular sensors that can detect degradation 
products of pathogens, stress signals as well as microbial products. NLR signalling results 
in the activation of a multiprotein complex called the inflammasome [11]. Lastly, secreted 
PRRs bind to microbial cell surfaces and can activate the classical as well as lectin 
pathways of the complement system and opsonise pathogens for phagocytosis by 
macrophages and neutrophils [6].  
 
Unlike innate immunity, adaptive immunity is highly specific for a particular pathogen but 
may take extended periods of time to fully initiate an effective response. It requires specific 
“instructions” from innate cells in order to be activated. The activation occurs through highly 
variable, non-germline encoded receptors that bind a specific antigen. The antigens are 
presented as peptide fragments in the context of major histocompatability complex 
molecules (MHC) by specialised antigen presenting cells (APCs) such as macrophages and 
dendritic cells (DCs). Thus, the inflammatory environment provided by innate immune cells 
influences the activation, expansion and selection of pathogen-specific adaptive immune 
cells. The adaptive system is largely mediated by the actions of B and T lymphocytes and is 
characterised by immune specific memory. Memory is generated towards a specific 
pathogen and a repeated encounter usually evokes a more rapid immune response.  
 
Taken together, protective immunity is divided into two systems that are in constant 
interplay with each other: the non-specific innate and the pathogen-specific adaptive 
immunity (Figure 1.2). The cellular repertoire of the immune system and their functions are 
described below.  
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Figure 1.2 Simplified overview of the interplay between innate and adaptive immunity 
Invading pathogens are recognised by innate immune cells leading to the release of inflammatory 
mediators and antigen presentation via MHC. The inflammatory environment provided by the innate 
cells determines the adaptive response, e.g. high levels of IL-12 will provoke a Th1 response 
whereas high levels of IL-4 will lead to a Th2 response. DC - dendritic cell; Mac - macrophage; Gran - 
Granulocyte; Mono - monocyte, NK - natural killer cell; Th0 - naïve T-helper lymphocyte;  
Th1 - T-helper 1 lymphocyte; Th17 - T-helper 17 lymphocyte; Th2 - T-helper 2 lymphocyte, CTL - 
cytotoxic T- lymphocyte 
 
 
1.1.1 Granulocytes 
Granulocytes are a category of white blood cells characterised by the presence of granules 
in their cytoplasm which contain a cocktail of toxic compounds that are harmful to bacteria 
and fungi. Granulocytes are involved in the clearance of pathogens by phagocytosis and 
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recruitment of additional immune cells to the site of infection through the release of chemo- 
attractants. They are among the first circulating cell types recruited to sites of infection or 
tissue damage. There are three types of granulocytes: neutrophil granulocytes, eosinophil 
granulocytes and basophil granulocytes. Neutrophils are the most abundant type of 
circulating white blood cells, constituting 50% to 60% of the total cell count, and are 
professional phagocytes. Eosinophils play a crucial part in the killing of parasites because of 
their unique granule composition. Basophils are one of the least abundant cells in the blood 
and contribute to an increased blood flow to the site of infection [12].  
 
 
1.1.2 Monocytes 
Monocytes are derived from a common myeloid progenitor (CMP) and comprise 
approximately 5-10% of circulating leukocytes. They show some typical morphological 
features such as irregular cell shape, kidney-shaped nucleus, cytoplasmic vesicles and a 
high cytoplasm-to-nucleus ratio. Both human and mouse monocytes can be defined by the 
expression of macrophage-colony stimulating factor (M-CSF) receptor 1 (M-CSFR, CD115) 
and the absence of T and B lymphocyte markers such as cluster of differentiation 4 (CD4) 
and CD19. Monocytes are the progenitors of tissue resident macrophages as well as DCs 
and differentiate into macrophages or DCs in situ during an inflammatory response  
(Figure 1.3) [13].  
 
 
 
 
 
 
 
 
 
Figure 1.3 Simplified schematic of myeloid differentiation 
Hematopoetic stem cells (HSC) produce common myeloid progenitors (CMP) and common lymphoid 
progenitors (CLP). CMPs give rise to the monocyte/macrophage and DC progenitor called MDP. 
During inflammation, monocytes (Mono) can differentiate into monocyte-derived DCs (DC) and 
macrophages (Mac) indicated by dashed lines.  
 
Mono
HSC
CLP
CMP MDP
DC
Mac
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The development of blood monocytes is dependent on the growth factor M-CSF as mice 
deficient in either M-CSF or M-CSFR show a reduced number of monocytes [14, 15]. M-
CSFR is a hematopoietic growth factor receptor expressed not only on monocytes but also 
macrophages, DCs and their progenitors [16], a population of cells often referred to as the 
mononuclear phagocyte system (MPS). The two known ligands for M-CSFR include M-CSF 
[17] and the more recently described IL-34 [18] which are both important for the 
development of the MPS lineage as M-CSF-deficient mice have a milder phenotype than M-
CSFR-deficient mice [14].  
 
Monocytes can be divided into three distinct subpopulations which differ in size, cell surface 
marker expression and chemokine receptors expression [13]. Human CD14+CD16- 
monocytes represent 80% to 90% of blood monocytes. They express high levels of the 
chemokines receptor 2 (CCR2) but low levels of chemokine (C-X3-C motif) receptor 1 
(CX3CR1), produce Interleukin 10 (IL-10) upon stimulation rather than proinflammatory 
cytokines and are excellent phagocytes [19-21]. In contrast to this major subset, 
CD14+CD16+ monocytes express high levels of CX3CR1 and low levels of CCR2 [19]. It has 
been shown that it is this population that is responsible for the production of TNF and IL-1 
upon bacterial lipopolysaccharides (LPS) stimulation [22]. Furthermore, these cells express 
the Fc-gamma receptors CD32 and CD64 which enable the CD14+CD16+ monocytes to 
phagocytose [23]. Interestingly, the proportion of CD14+CD16+ relative to the rest of the 
monocyte population is increased at sites of acute inflammation [24]. The last subset of 
monocytes expresses CD16 but low levels of CD14 (CD14dimCD16+) and lack the 
expression of Fc-gamma receptors. These cells are poor phagocytes and weak responders 
to cell surface TLR stimulation. Instead, they produce TNF and IL-1 in response to viruses 
and immune complexes containing nucleic acids [25].  
 
 
1.1.3 Dendritic cells 
Dendritic cells are specialised antigen-processing and -presenting cells that are equipped 
with high phagocytotic activity as immature cells and high cytokine-producing capacity as 
mature cells. They serve as major APCs and are therefore crucial for an effective and 
pathogen-specific activation of adaptive immunity. DCs are highly migratory cells that can 
move from tissues to lymphoid organs both in steady state (negative selection of T 
lymphocytes, see section 1.1.6) and during infections. DCs mature in the presence of 
infectious agents and release a huge arsenal of inflammatory mediators and upregulate 
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CCR7 which enables rapid migration into lymphoid organs. It is this migratory capacity that 
separates DCs from other APCs in their ability to stimulate naïve T lymphocytes. DC 
maturation is accompanied by up-regulation of MHC class II and co-stimulatory molecules 
as well as increased antigen presentation to naive T lymphocytes [26, 27]. These 
differentiate into the appropriate effector cell type, dependent on the origin of the antigen 
presented and cytokine environment provided by DCs, followed by multiple rounds of 
proliferation before migrating to the site of infection. Both the DC-dependent activation and 
the requirement for proliferation are the reasons for the delayed response of adaptive 
immunity compared to innate immunity.  
 
Like macrophages, DCs are resident within most tissues and are a heterogeneous 
population. The pathways leading to DC differentiation are not entirely understood but the 
current model suggests that monocytes, macrophages and most DCs originate in vivo from 
a hematopoetic stem cell-derived progenitor with myeloid-restricted differentiation potential 
called the common myeloid progenitor (CMP). However, there is ongoing debate whether 
DCs can differentiate from lymphoid progenitors that usually give rise to T and B 
lymphocytes. Steady state DCs can broadly be divided into plasmacytoid DCs (pDCs) and 
conventional DCs (cDCs) [28, 29]. pDCs differ from cDCs in that they are long-lived and 
specialised to respond to viral infection with a massive production of type I interferons (see 
section 1.3.2). cDCs can be further divided into distinct subtypes depending on the tissue 
location (e.g. Langerhans cells in the epidermis of the skin and lamina propria DCs in the 
gut) or surface marker expression (see section 1.3.3).  
 
 
1.1.4 Macrophages 
The zoologist Elie Metchnikoff was the first one to recognise macrophages as phagocytic 
cells responsible for pathogen elimination and formed the basis of macrophage biology and 
innate immunity over 100 years ago. The definition of a macrophage was originally based 
on phagocytosis which led to the term macrophages (from the Greek for large eaters) to 
distinguish these cells from the polymorphonuclear microphages (from the Greek for small 
eaters; later neutrophils). Macrophages represent a heterogeneous population of immune 
cells that evolve within a specific microenvironment out of the MDP progenitors or 
monocytes [30]. Transcription factors that control the development of macrophages from 
progenitors include the Ets family member PU.1 and the Interferon Regulatory Factor (IRF) 
family member IRF8.  
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PU.1 can induce myeloid commitment in immature multipotent progenitor cells [31] and is 
required for the generation of CMPs. In addition, PU.1 controls several cell fate decisions 
along the lineage pathway, particularly during the macrophage vs. DC choice of monocytes 
[13, 28]. The function of PU.1 at a certain progenitor stage depends on its balance with 
antagonistic factors that drive alternative fates. For instance, PU.1 antagonizes C/EBP 
thus driving monocytic differentiation at the expense of granulocyte differentiation [32]. 
Furthermore, high expression of PU.1 is required to induce DC fate in monocytes by 
antagonizing macrophage-inducing transcription factors such as MafB and c-Maf [33]. 
Therefore, PU.1 induces cell development by overruling key regulatory factors of other 
pathways. In addition to these antagonizing functions, PU.1 also controls cell development 
via direct transcriptional activity. As indicated above, the growth factor M-CSF is critical for 
MPS differentiation. Reddy et al showed that PU.1 can transactivate the M-CSF promoter 
[34] and a subsequent study showed that PU.1-deficient myeloid progenitors do not express 
M-CSF and show absence of the monocyte/macrophage lineage [35]. However, ectopic 
expression of M-CSF in PU.1-deficient cells can not rescue macrophage differentiation [35], 
indicating that M-CSF signalling is not sufficient to drive macrophage commitment in the 
absence of PU.1.  
 
A role of IRF8 in myeloid cell development was first suggested by the fact that Irf8-/- mice 
exhibit a systemic expansion of neutrophils [36]. Subsequent studies showed a cell-intrinsic 
function of IRF8 in the differentiation of myeloid cells. Progenitor cells of Irf8-/- mice are 
hyperresponsive to granulocyte/macrophage colony-stimulating factor (GM-CSF) and 
granulocyte colony-stimulationg factor (G-CSF) but their response to M-CSF is markedly 
reduced [37]. Therefore, Irf8-/- progenitor cells differentiate into granulocytes even in the 
presence of M-CSF indicating that IRF8 is important for the differentiation of macrophages 
by inhibiting that of granulocytes. Consistant with that, IRF8 expression is detected in 
myeloid progenitor populations and macrophages but declines in granulocytes [38, 39]. The 
precise molecular function of IRF8 in cell development is not entirely clear but it has been 
shown that IRF8 protects the activated M-CSFR from degradation and thus prolongs  
M-CSF signalling [40]. In addition, IRF8 can interact with PU.1 which greatly increases the 
efficency of target DNA-binding of IRF8 [41].  
 
Among the cells classified as macrophages are many different subtypes with distinct 
immune functions. Many of these functions appear to be opposing in nature: 
proinflammatory vs. anti-inflammatory, immunogenic vs. tolerogenic and tissue-destructive 
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vs. wound healing [42]. Furthermore, macrophages demonstrate a remarkable plasticity that 
allows them to efficiently respond to environmental signals and change their phenotype and 
physiology in response to cytokines and microbial stimuli [43]. Based on the Th1/Th2 
polarization concept [44] these cells can roughly be classified as M1 (classically activated) 
macrophages, which produce proinflammatory cytokines (IL-12high, IL-23high, IL-10low) and 
mediate resistance to pathogens and tissue destruction; and M2 (alternative activated) 
macrophages, which produce anti-inflammatory cytokines (IL-12low, IL-23low, IL-10high ) and 
promote tissue repair and remodelling as well as tumour progression [45, 46]. 
 
Historically, the first cytokine shown to convert resting macrophages into “active cells” was 
the Th1-derived cytokine IFN-. IFN- increased the antigen presenting capacity as well as 
proinflammatory cytokine production of macrophages and enhanced their ability to kill 
intracellular pathogens [47]. Thus, the activation of macrophages with IFN- became known 
as “classical activation” of macrophages also referred to as the M1 phenotype. The 
immunological counterpart of IFN- was identified as IL-4 which is a Th2-derived cytokine. 
Stein et al demonstrated that the expression of mannose receptor (MRC1 or CD206) was 
characteristic of IL-4 activated macrophages [48] and subsequent studies established that 
IL-4 could upregulate a distinctive set of genes, establishing a functional pattern quite 
different from that induced by IFN- [49]. The distinctive effects of IL-4 on macrophages lead 
to the term “alternative activation” or M2 macrophage phenotype, emphasising the contrast 
with “classical activation” by IFN-. Th2 lymphocytes also secrete IL-13, a cytokine that 
shares a receptor complex with IL-4, both signalling through the common IL-4 receptor  
chain. Not surprising, it was found that IL-13 has a redundant as well as a nonredundant 
role in shaping the macrophage phenotype compared to IL-4 [50].  
 
Other groups have extended the definition of alternative macrophage activation very loosely 
to additional mediators of macrophage function, such as IL-10, glucocorticosteroids and 
TGF- [51]. There was a need for a more refined nomenclature of M2 macrophages as 
each stimulus induces both unique and overlapping gene expression repertoires. Mantovani 
and colleagues suggested a further subdivision of M2 macrophages into M2a (IL-4/IL-13 
stimulated, alternatively activated macrophages), M2b (immune complexes, TLR ligand or  
IL-1 stimulated, type II activated macrophages) and M2c (IL-10 stimulated, deactivated 
macrophages) [52] (Figure 1.4). In addition to the M2 macrophage subtypes discussed 
above, tumor-associated macrophages (TAMs) are considered to have an M2-like 
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phenotype. TAMs are recruited into the tumor environment as monocytes from the 
bloodstream by chemoattractants by both malignant and stromal tumors. Several studies 
have indicated that tumors provide a cytokine environment which favours an alternative 
activation of macrophages. For example, TAMs upregulate the expression of IL-10, TGF- 
and other M2-associated genes while downregulating IL-12 expression, antigen 
presentation, antimicrobial and antitumor properties [53-56].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Inducers and selected properties of polarized macrophages 
Macrophage exposure to IFN- and LPS drives M1 polarization equipping them with cytotoxic and 
antitumoral properties. In contrast, M2 macrophages are in general more prone to immunoregulatory 
and immunosuppressive functions. In particular, M2a (exposure to IL-4/IL-13) and M2b (exposure to 
immune complexes and TLR ligands) exert immunoregulatory functions and drive Th2 responses, 
wherease M2c (exposure to IL-10 or Glucocorticosteroids) are more related to suppression of 
immune responses and tissue remodelling.  
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It should be realised though, that any form of classification that results from in vitro 
experiments underscores the complexity of the in vivo situation, where macrophages are 
exposed to a mixture of stimuli and will therefore adopt mixed functional profiles 
accordingly. Furthermore, despite obvious phenotypic differences in M1 vs. M2 
macrophages, the term „„alternatively activated‟‟ to describe IL-4/IL-13 treated macrophages 
is somewhat misleading since IL-4/IL-13, like IFN-, should probably be considered a 
priming rather than an activation stimulus for macrophages. Therefore, a direct comparison 
of IFN- primed and LPS stimulated macrophages to IL-4/IL-13 primed only macrophages 
might not be correct. The observed differential production of proinflammatory cytokines of 
M1 and M2 macrophages may actually solely depend on the presence or absence of a 
microbial stimulus. In fact, there is substantial evidence that IL-4 and IL-13 do not 
necessarily inhibit but may enhance proinflammatory cytokine production, such as IL-12 and 
TNF, when used as a priming agent followed by microbial stimulation [57-60]. Furthermore, 
some investigators use macrophage-like cell lines, such as THP-1, to characterise 
macrophage polarization and formulate one to one correlation to the human/mouse system, 
which is very debatable. Thus, a unified polarization protocol indicating appropriate cell 
types and clarifying priming time as well as the microbial stimulus used might be useful.  
 
One way to overcome the discrepancies in having priming and activation, or priming alone, 
is to use a different polarization protocol. The development of macrophages from 
monocytes depends on lineage-determining growth factors, with M-CSF and GM-CSF 
among the most important ones [61]. As discussed above, disruption of M-CSF signalling 
affects the MPS lineage with a widespread effect on macrophage-lineage development. By 
contrast, GM-CSF-deficient mice show no defects in myeloid development with the 
exception of alveolar macrophage maturation, which is compromised [62]. This points 
towards a significant contribution of M-CSF to general lineage commitment whereas GM-
CSF might be more important for defining macrophage subsets. In vitro culture systems, for 
both human and mouse monocytes, were developed to obtain different types of 
macrophages resulting in the M-CSF and GM-CSF method [63, 64]. By using these culture 
methods monocyte-derived macrophage (MDM) subsets were defined by comparing their 
cytokine profiles following exposure to TLR ligands, such as LPS [63-67]. Similar to IFN-
/LPS, treatment of monocytes with GM-CSF leads to the differentiation of M1 macrophages 
with an IL-12high, IL-23high, IL-10low phenotype upon LPS stimulation whereas the 
employment of M-CSF, followed by LPS stimulation, results in an IL-12low, IL-23low, IL-10high 
phenotype (M2 macrophages) (Figure 1.5). Using this protocol, any differences in cytokine 
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production should reflect the treatment or “priming” with different growth factors (GM-CSF 
for M1 and M-CSF for M2 respectively) as both types receive a microbial stimulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 In vitro polarization of macrophages using growth factors 
Human monocytes (Mono) are cultured either in the presence of GM-CSF or M-CSF for 4-6 days to 
obtain M1 (M1 Mac) and M2 macrophages (M2 Mac) respectively. After differentiation/priming both 
subsets are exposed to TLR ligands such as LPS resulting in an M1 cytokine profile (IL-12
high
, IL-
23
high
, IL-10
low
, GM-CSF treatment) or M2 cytokine profile (IL-12
low
, IL-23
low
, IL-10
high
, M-CSF 
treatment). The same protocol is applicable to the murine system were bone-marrow progenitors can 
be used to generate macrophage subsets.  
 
 
 
In addition to the differences in the cytokine profile of macrophage subsets mentioned 
above, polarized macrophages also differ in the expression of their cell surface receptors. 
M1 macrophages are characteristic of high expression of MHC II, IL-1R1, IL-18R, co-
stimulatory molecules, such as CD80 and CD86, and the chemokine receptor CCR7. M2 
macrophages on the other hand are associated with high levels of scavenger receptors 
(MSR1 and CD36), CD14, CD163, CD209 (DC-SIGN), MRC1, CCR2 as well as the decoy 
IL-1R2 [52, 67-69].  
Mono
GM-CSF
M-CSF
LPS LPS
M2 MacM1 Mac
Differentiation/Priming
Stimulation
Phenotype
IL-12
IL-23
IL-10
IL-12
IL-23
IL-10
 
Chapter 1 - Introduction 
 25  
The M1 program of macrophages is usually associated with protection during acute 
infectious diseases by inducing a strong Th1/Th17 response. Consequently, the protective 
role of M1 macrophages has been exemplified in mice deficient for components of the IL-12 
pathway [70]. An example of a pathogen-induced M1 macrophage polarization and thus 
stimulation of intracellular killing of bacteria includes Listeria monocytogenes which causes 
disease in immunocompromised patients and pregnant women [71]. Similarly, Salmonella 
typhi (typhoid fever) and Salmonella typhimurium (gastroenteritis) induce the M1 
polarization of human and murine macrophages and this induction is associated with the 
control of the infection [72]. In addition, Mycobacterium tuberculosis induces a gene 
signature that corresponds to that of IFN- and therefore polarizes toward the M1 profile 
[73]. Other mycobacterial diseases such as Buruli disease (Mycobacterium ulcerans) and 
opportunistic infections (Mycobacterium avium) are also characterised and controlled by M1 
polarization of macrophages [72].  
 
As mentioned above, M1 polarization supports resistance to intracellular bacteria and 
controls the acute phase of infection. However, an excessive or prolonged M1 program is 
potentially harmful for the host, as demonstrated in acute infections with Escherichia coli or 
Streptococcus species. E. coli infection can cause many diseases, including sepsis, which 
induces a systemic inflammatory response and immune dysregulation that lead to tissue 
damage and potentially multiple organ failure [74]. In vitro, E. coli induces a typical M1 
profile through the recognition of LPS by TLR4 and it has been demonstrated that M1 
macrophage polarization and sepsis severity are related. For instance, patients with severe 
sepsis show high concentrations of M1-specific cytokines that correlates with mortality [75, 
76]. Streptococcus species can cause amongst other things meningitis as well as 
pneumonia in humans and other animals. Host responses are generally characterised by an 
intense inflammatory reaction and an M1 polarization of macrophages. In a murine model of 
pneumonia, mortality correlates with lung inflammation and the presence of M1-specific 
cytokines, like TNF, IL-1 and IL-6  [77]. 
 
As opposed to M1, M2 macrophages promote Th2 responses, resulting in effector functions 
such as parasite encapsulation and killing, but also exacerbation of Th2 cytokine-associated 
pathologies, such as allergies. Nematode and trematode worms like Nippostrongylus, 
Toxocara, Schistosoma, and Taenia induce a strong M2 response and require an IL-4/IL-
13-driven Th2 immune response to clear the infection [68, 78]. Several murine models have 
been used to study the immune response and the contribution of polarized macrophages to 
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control these parasites. Administration of N. brasiliensis induces a strong Th2 response and 
lung pathology is subsequently associated with M2 macrophage polarization [79, 80]. Other 
models include the infection of mice with the parasite S. mansoni which also results in a 
Th2 cytokine response, generally important for the clearance of parasitic infections [81]. Not 
surprisingly, IL-4R-deficient animals, which lack M2 macrophages, do not survive S. 
mansoni infection as a consequence of a shift from Th2 to Th1 response [82]. In humans,  
S. mansoni infection results in the production of IL-4 and the IL-4 protein levels correlate 
with the severity of the disease [83]. 
 
It is well established that pathogens have evolved different strategies to interfere with 
macrophage polarization. For instance, the dengue viruses benefit from a Th2 response 
and subsequent M2 environment. There is a shift in cytokine expression from type I and II 
IFN response to enhanced expression of Th2 cytokines upon virus transmission [84]. These 
Th2 cytokines not only dampen the Th1 response required for viral elimination but also 
induce the M2-specific MRC1, which binds all four serotypes of dengue virus and can be 
exploited by the virus to infect M2 macrophages [85]. Chronic inflammation is also 
associated with M2 macrophage polarization and asthma is the most prominent example. 
Asthma is characterized by enhanced expression of Th2 cytokines in the airway tissues of 
asthmatic patients and murine models of asthma demonstrated the presence of M2 
polarized macrophages [68, 86, 87]. As mentioned above, TAMs have also been described 
as M2 polarized although there are no consistent correlations with IL-4/IL-13 expression 
and tumor progression. This suggests that the tumor environment includes other cytokines 
and mechanisms to influence the phenotype of recruited macrophages.  
 
 
1.1.5 Natural killer cells 
Natural killer (NK) cells are a type of cytotoxic lymphocytes that function in the innate 
immune system. They play a major role in the rejection of tumors and the targeted 
destruction of virus-infected cells through the release of granules. NK cells are activated in 
response to interferons and macrophage-derived cytokines and provide an early source of 
inflammatory mediators such as IFN-, TNF, GM-CSF and chemokines which all support a 
Th1 response [88]. Human NK cells comprise approximately15% of all lymphocytes and 
are defined phenotypically by their expression of cluster of differentiation 56 (CD56) and 
lack of expression of CD3. Furthermore, NK cells are defined by the expression of the Fc-
gamma receptor III (CD16) which enables them to attack an antibody-coated cell [89]. 
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Furthermore, NK cells detect the lack of MHC class I (usually highly expressed on cells) 
which can occur when cells are perturbed by viral infection or cellular transformation. Thus, 
NK cells can distinguish between healthy cells that express MHC class I molecules but 
selectively kill target cells “in distress” that down-regulate MHC class I molecules [90].  
 
 
1.1.6 T Lymphocytes 
T lymphocytes (or T cells) are defined by the expression of the T-cell receptor (TCR), a 
transmembrane immunoglobulin-like protein capable of recognising pathogen-derived 
antigens [91]. The ability of the TCR to recognise an almost infinite array of antigens is due 
a unique system of random mutation and recombination events, commonly referred to as 
V(D)J recombination, of the genes coding for the TCR [92]. T lymphocytes originate from a 
common lymphoid progenitor in the bone marrow and migrate to the thymus where they 
undergo the final stages of their differentiation, the negative selection. The random 
generation of the TCR can lead to recognition of “self” antigens from the host which would 
induce an immune response against the body‟s own tissue. APCs therefore present “self” 
antigens to the lymphocytes in the thymus. The recognition of “self” antigens by  T 
lymphocytes results in the initiation of apoptosis of the reacting cell and therefore only T 
lymphocytes that don‟t recognise self antigens complete their maturation in the thymus [93]. 
The remaining T lymphocytes migrate to the peripheral lymphoid organs on the patrol for 
foreign antigens as either cytotoxic CD8+ T-lymphocytes (CTLs) or CD4+ T-helper (Th) 
lymphocytes [94].  
 
T helper lymphocytes are naïve cells that can only be activated if they receive two distinct 
signals. The first is the recognition of foreign antigens presented by APCs on MHC II by the 
TCR. In addition, a signal from co-stimulatory molecules, such as CD80 and CD86 which 
are expressed by activated APCs, is required. This system is important for the maintenance 
of peripheral tolerance and T lymphocytes will undergo apoptosis if both signals are not 
received [95]. T helper cells expand and differentiate into various effector T lymphocyte 
subsets and depending on the cytokines they produce, these T lymphocyte subsets have 
very different properties and functions. T helper lymphocytes include the well-defined 
effector subsets Th1 lymphocytes and Th2 lymphocytes, as well as the more recently 
described Th17 and Th9 lymphocytes, but also regulatory subsets like regulatory T 
lymphocytes (Tregs) [96, 97].  
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Naïve T helper lymphocytes differentiate into Th1 lymphocytes in the presence of IL-12 [98]. 
Th1 lymphocytes contribute to cell-mediated immunity and are characterised by the 
secretion of IFN- which in turn acts on DCs, macrophages, CTL and natural killer cells to 
increase their respective effector functions [97]. Th1 lymphocytes are important for host 
defence against intracellular pathogens and induction of delayed type hypersensitivity 
responses. However, uncontrolled Th1 responses against self-antigens can lead to the 
development of autoimmunity. Studies showing that mice deficient in the Th1 transcription 
factor T-bet [99] are resistant to the development of experimental autoimmune 
encephalomyelitis (EAE) suggesting that Th1 lymphocytes are the major effector T 
lymphocytes responsible for inducing MS [100]. Because Th1 effector mechanisms seemed 
to explain many histopathological and clinical features of EAE and other autoimmune 
diseases, including type I diabetes and rheumatoid arthritis, Th1 lymphocytes became the 
archetypical inducer of organ-specific autoimmunity [96]. 
 
The differentiation of Th2 lymphocytes is dependent on the transcription factor GATA3 [101] 
and occurs in the presence of IL-4. They are involved in humoral-mediated immunity and 
are essential for clearing extracellular organisms like parasites as well as helminthes. In 
addition, Th2 lymphocytes play an important role in eosinophilic inflammation and IgE 
production in allergic reactions and asthma. Th2 lymphocytes are characterised by the 
production of IL-4, IL-5 as well as IL-13 and regulate macrophage and B cell behaviour 
[102].  
 
More recently, 3 additional helper T lymphocyte subsets have been described: Th17 
lymphocytes, Th9 lymphocytes and regulatory T lymphocytes (Tregs). The hypothesis of 
Th1 lymphocytes being solely responsible for induction of organ-specific autoimmunity was 
challenged when it was shown that animals lacking the Th1 signature cytokine IFN- are not 
resistant but in fact are more susceptible to multiple autoimmune diseases including EAE 
[103] and collagen-induced arthritis [104]. This raised the question whether another subset 
of T lymphocytes might be required for the induction of EAE and other organ-specific 
autoimmune diseases.  
 
The Th1 inducing cytokine IL-12 is composed of the subunits p35 and p40. While IL-12p35 
deficient mice were more susceptible to EAE, surprisingly loss of the IL-12p40 chain made 
mice highly resistant to EAE [105]. In 2000 a novel cytokine chain p19 was discovered and 
Oppmann et al showed that IL-12p40 is not only essential for forming IL-12 but can also pair 
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up with p19 to form a novel cytokine called IL-23 [106]. Thus all previous approaches that 
targeted the p40 chain of IL-12 would also affect IL-23 production. Subsequent experiments 
with p19, p35 and p40 deficient mice showed that p19-/- and p40-/- animals were resistant to 
EAE, whereas p35-/- animals, which lacked IL-12 and Th1 responses but were able to form 
IL-23, remained susceptible to EAE [107]. A follow-up study showed that IL-23 is important 
for the expansion of IL-17-producing T lymphocytes, later called Th17 lymphocytes, which 
are capable of inducing EAE in an adoptive transfer model [108]. Expression of the 
transcription factor RORT is characteristic of Th17 lymphocytes [109]. The cytokine 
environment required for Th17 differentiation is under debate as there are differences 
between human and murine development [110]. One cytokine that is equally important for 
both species is IL-23 [111-114]. Th17 lymphocytes produce IL-17A and IL-17F, which 
belong to the same family and are partly redundant in their effector functions. Both 
cytokines induce pro-inflammatory cytokines like IL-6, IL-1 and TNF as well as pro-
inflammatory chemokines like CXCL1 and IL-8 and thus promote tissue inflammation and 
recruitment of neutrophils to the site of inflammation [115]. 
 
Th17 lymphocytes play an important role in mediating host defences and have a specialized 
role in clearing pathogens that are not adequately handled by Th1 or Th2 lymphocytes 
including bacteria like Citrobacter, Klebsiella pneumoniae and Borrelia burgdorferi, but also 
fungi such as Candida albicans. The receptors for IL-17 are expressed on both 
hematopoietic and non-hematopoietic cells [96, 115]. Consequently, IL-17 cytokines 
promote inflammation on several levels making Th17 lymphocytes particularly suited for the 
promotion of autoimmunity. Elevated levels of IL-17 were detected in several autoimmune 
diseases including MS [116] and rheumatoid arthritis [117, 118] and IL-17 deficiency leads 
to suppression of both CIA [119] and EAE [120]. These studies demonstrated the 
importance of Th17 lymphocytes in autoimmune diseases and led to a reevaluation of the 
role of other effector T lymphocytes in the induction of autoimmune tissue inflammation. 
 
The most recent addition to effector T lymphocytes is the Th9 subset which is induced in the 
presence of TGF- plus IL-4. Th9 lymphocytes are characterized by the secret IL-9 and 
thought to have effector rather than regulatory properties [121, 122]. A bona fide subset-
defining transcription factor for the Th9 lineage is yet to be determined although it has been 
shown that IRF4 is essential for IL-9 production by Th9 lymphocytes [123].  
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While effector T lymphocytes promote inflammation, Tregs serve to control it. Tregs play a 
very important role in autoimmune pathogenesis by maintaining self-tolerance and by 
controlling expansion and activation of autoreactive CD4+ T effector lymphocytes. They are 
characterised by the expression of CD4, CD25 as well as the expression of the transcription 
factor FOXP3 and are thought to suppress autoimmunity by the production of anti-
inflammatory cytokines such as IL-10 and transforming growth factor (TGF)-β [124]. 
 
CD8+ T lymphocytes emerging from the thymus are predestined to become cytotoxic T 
lymphocytes (CTLs). Like T-helper lymphocytes, CTLs require TCR and co-stimulatory 
receptor stimulation to become activated. However, the TCR on CTLs is activated by 
antigens presented in the context of MHC class I explaining the relevance of CTLs for the 
control and clearance of viral infection. They mediate their antiviral effects either by direct 
lysis of infected target cells or by the secretion of potentially toxic cytokines such as IFN- 
and TNF. Because of their memory cell progeny, CTLs also contribute to protection against 
subsequent encounters with the same foreign agent(s) [125, 126].  
 
 
1.1.7 B-cells 
B lymphocytes, or B cells, are derived from common lymphoid progenitor cells in the bone 
marrow and undergo maturation in the spleen. The hallmark of B cells is their ability to 
produce antibodies which are soluble immunoglobulin proteins that are composed of 2 light 
and 2 heavy chains. The light chain is hyper-variable which allows the recognition of a huge 
number of antigens therefore conveying unique specificity. The light chain is epitope 
specific and binds to pathogens which neutralises their effects and marks them for 
phagocytosis by other cells of the immune system. In contrast, the number of heavy chains, 
determining the isotype of the antibody which is important for different effector functions, is 
limited [127]. B cells can switch the heavy chain of an antibody (class switch) while the light 
chain remains unchanged resulting in an antibody that still recognises the same antigen but 
will initiate a different effector function due to the new isotype. B cells retain an 
immunological memory after antibody production by forming memory B cells which enable a 
quicker response when an antigen is encountered again [128].  
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1.2 The Interferon regulatory factor family of transcription 
factors 
Host defence serves two main functions: the generation of an immune response to invading 
pathogens and the suppression of tumor development. These are achieved by the efficient 
coordination of genetic networks in which transcription factors control the expression of a 
distinct set of target genes, depending on the cell type and/or the nature of the stimuli.  
 
Interferon regulatory factors (IRFs) were originally thought to regulate the transcription of 
type I Interferons (IFN) and IFN-inducible genes but members of this family are now 
recognised as major regulators of many aspects of innate and adaptive immune responses. 
The IRF family consists of nine members in human and mice: IRF1, IRF2, IRF3, IRF4 (also 
known as LSIRF, PIP or ICSAT), IRF5, IRF6, IRF7, IRF8 (also known as ICSBP) and IRF9 
(also known as ISGF3γ) [129, 130]. The first member, IRF1, was discovered in 1988 and 
IRF10 was identified in chickens recently, although it is absent in humans and mice [131].  
 
Each IRF protein contains a well-conserved DNA binding domain (DBD) of about 120 amino 
acids at its N-terminus (Figure 1.6). The DBD forms a helix-turn-helix motif and mediates 
specific binding to NGAAANNGAAACT, termed the IFN-stimulated regulatory element 
(ISRE) [129] because it was first identified in the promoters of genes induced by type I IFN, 
namely IFN-αs and IFN-β [131]. An analysis of the crystal structure of the DBD revealed 
that GAAA is the core DNA recognition sequence of the helix-turn-helix motif [132]. ISREs 
can also be found in the promoters of the genes that encode type I IFNs themselves, as 
well as in the promoters of many other genes that are involved in immunity and 
oncogenesis. The sequence domain in the 5‟ region of the IFN genes, termed the virus 
responsive elements (VRE), contains multiple ISREs which are highly conserved both in 
IFN-α and IFN-β gene promoters [133-135]. The C-terminal regions of IRFs, except for IRF1 
and IRF2, contain an IRF association domain (IAD) that is responsible for homo- and 
heteromeric interactions with other family members as well as other transcription factors 
such as PU.1 and signal transducer and activator of transcription (STAT) [129, 130]. These 
interactions can further define the nucleotide sequences adjacent to the core IRF-binding 
motif to which the protein complex binds.  
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Figure 1.6 Domain model of IRF family members  
As shown in this schematic domain model, all IRF members carry a N-terminal DBD which contains 
repeated tryptophan residues (represented by W). All IRFs, except IRF1 and IRF2, have an IRF 
association domain (IAD1) that is needed for interactions with other family members or other 
transcription factors. Another association domain (IAD2) that is just present in IRF1 and IRF2 is 
important for forming homodimers. Adopted and modified from [136].  
 
 
 
1.3 Regulation of the innate immune response by IRF and 
NF-B family members 
Recognition of invading pathogens is central to the host immune system. The innate 
immune system depends on a limited number of germline-encoded PRRs. These recognise 
PAMPs such as bacterial LPS and viral nucleic acids [137]. Three classes of PRRs, 
cytosolic PRRs, membrane-bound TLRs and secreted receptors have been identified. 
Depending on the nature of the pathogen and the cell type involved, signal transduction 
through PRRs leads to the transcriptional induction of various target genes including type I 
IFNs, pro-inflammatory cytokines and chemokines. One of the major, best characterised 
transcription factors that is activated by virtually all PRRs, and which orchestrates the 
expression of these genes, is nuclear factor B (NF-B). In the past few years extensive 
studies have revealed that IRFs are also widely involved in most PRR signalling events 
leading to gene activation and thus, important in linking innate and adaptive immune 
responses.  
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1.3.1 Activation of NF-kB proteins by TLR signalling 
Signalling through TLRs can be broadly categorised into two pathways, namely the myeloid 
differentiation primary-response protein 88 (MyD88) -dependent and the TIR domain 
containing adapter-inducing IFN (TRIF) -dependent pathways (Figure 1.7). All TLRs, 
except TLR3, activate the MyD88 pathway; whereas TLR3 and TLR4 can activate the TRIF 
pathway. Both pathways commonly activate NF-B and IRF family members [137, 138].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Overview of transcription factor activation by TLR signalling  
TLR1, TLR2, TLR4 and TLR6 activation leads to the recruitment of MyD88-adaptor-like (Mal) and 
MyD88 whereas TLR7, TLR8 and TLR9 recruit MyD88 alone. All TLRs, except TLR3, utilise the 
MyD88-dependent pathway which activates NF-B, IRF5 and IRF7. TLR3 recruits TRIF while TLR4 
can recruit the TRIF-related adaptor molecule (TRAM) which in turn recruits TRIF. Signalling via the 
TRIF-dependent pathway leads to the activation of NF-B as well as IRF3, IRF5 and IRF7. Adopted 
and modified from [139].  
 
 
 
The NF-B family of transcription factors consists of 5 members: RelA (p65), RelB, c-Rel, 
NF-B1 (p50 and its precursor p105) and NF-B2 (p52 and its precursor p100). They are 
characterised by the presence of a Rel homology domain (RHD) at the N-terminus which is 
responsible for DNA binding, dimerisation and interaction with the inhibitor of NF-B (IB) 
proteins [140]. NF-B proteins have to form homo- or hetero-dimers dimers in order to bind 
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DNA and activate transcription. RelA:p50 is the most abundant and therefore most widely 
studied NF-κB complex. It is expressed in most cell types and is essential for the induction 
of innate immunity and pro-inflammatory cytokine production. NF-κB complexes containing 
RelA, RelB or c-Rel are able to directly activate transcription, since these proteins contain a 
C-terminal trans-activation domain (TAD) [141]. In contrast, p50 and p52 lack the TAD and 
their respective homodimers can compete with TAD-containing complexes and function as 
transcriptional repressors [142].  
 
The IB proteins interact with NF-κB complexes and retain them in the cytoplasm by 
interfering with the nuclear localization sequence of NF-κB proteins. The “classical” IB 
proteins include IB, IB, IB, IB and BCL-3 which are characterised by the presence 
of an ankyrin repeat domain (ARD) within their C-terminus [143]. The C-terminal halves of 
p105 and p100 also harbor multiple ankyrin repeats that allow them to serve an IκB-like 
function [144].  
 
Activation of NF-B is regulated through the inhibitor of κB kinase (IKK) complex, which 
consists of 2 kinases, IKK and IKK, and a regulatory protein IKK (or NF-B essential 
mediator, NEMO) [145]. Two major signalling pathways (the canonical and the non-
canonical) which result in the activation of NF-B complexes have been characterized [146]. 
The canonical NF-κB signalling pathway is the most well studied and results mainly in 
RelA:p50 and c-Rel:p50 heterodimer activation. During canonical NF-B signalling, 
upstream signals result in phosphorylation of IKK, which in turn phosphorylates the IB, 
resulting in its proteosomal degradation. This releases the NF-B heterodimers, allowing its 
nuclear translocation and promoter binding for inflammatory gene transcription [143, 145, 
146]. 
 
The non-canonical NF-κB pathway is activated in response to a small subset of TNF family 
members, including CD40L, Lymphotoxin and as well as B cell–activating factor (BAFF) 
[143, 145], and is based on inducible processing of p100 and activation of RelB:p52 
heterodimers. It is strictly dependent on IKK and its phosphorylation by NF-κB-inducing 
kinase (NIK) [147]. NIK-activated IKK dimers phosphorylate p100 at specific serine 
residues within its C-terminal ARD resulting in the release of the N-terminal p52 fragment 
bound to RelB and consequently NF-κB activation [148].  
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1.3.2 IRF3/IRF7: master regulators of type I IFN induction 
The initial hypothesis for the model whereby IRF3/IRF7 induces type I IFN genes was the 
positive-feedback model, in which IRF3 is primarily responsible for the induction of IFN- in 
the early phase of a response, whereas IRF7, whose expression is induced by IFN-, 
functions in the later phase of a response to induce IFN- expression [149]. This early view 
was supported by several lines of evidence. IFN- gene induction is reduced in Ifn-/- 
mouse embryonic fibroblasts (MEFs) [150], and IFN/ expression is impaired in Irf3-/- 
MEFs upon Newcastle disease virus (NDV) infection [149]. However, the generation of Irf7-/- 
mice allowed the rigorous assessment of the above model of positive-feedback regulation. 
In MEFs from these knock-out mice, type I IFN gene induction by viruses such as vesicular 
stomatitis virus (VSV), herpes simplex virus-1 (HSV-1) and encephalomyocarditis virus 
(EMCV) is more severely impaired than in Irf3-/- MEFs. Consistently, Irf7-/- mice are more 
vulnerable than Irf3-/- mice to viral infections, which correlate with a marked decrease in 
serum IFN levels [151]. Thus, although IRF7 is initially expressed at a low level, the 
formation of a heterodimer between IRF7 and IRF3, rather than an IRF3 homodimer, is 
presumed to be more important for the production of IFN- and IFN-. The positive-
feedback regulation of IRF7 then comes into effect to achieve the full induction of type I IFN 
genes during the later phase of the response.  
 
Recently, pDCs which are capable of high-level induction of type I IFN genes have gained a 
lot of attention [152-154]. In contrast to cDCs and MEFs, this small DC subset expresses 
high levels of TLR7 and TLR9 in endosomes and produces large amounts of type I IFNs in 
response to corresponding TLR ligands. TLR7 recognises single-stranded RNA (ssRNA) 
derived from genomic RNA of viruses such as influenza virus and VSV, whereas TLR9 
recognises hypomethylated CpG oligodeoxynucleotides in DNA from bacteria or DNA 
viruses such as HSV [155-157]. The induction of type I IFNs is crucially dependent on the 
activation of IRFs and this raises the question of how these TLRs, which exclusively utilise 
MyD88, can activate IRFs. Investigations have shown that IRF7, but not IFR3, directly 
interacts with the death domain of MyD88 in pDCs [158]. Furthermore, IRF7 interacts with 
tumor necrosis factor receptor-associated factor 6 (TRAF6) and another study has revealed 
that Inhibitor of NF-B kinase- (IKK) phosphorylates IRF7 [158, 159].  
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It is unclear why pDCs but not other cell types such as cDCs and macrophages produce 
large amounts of type I IFNs in response to TLR7 and TLR9 ligands. The finding that pDCs 
have a higher constitutive expression level of IRF7 compared with other cell types does not 
fully account for the robust IFN production [160]. Instead, the localisation of TLR ligands 
appears to be critical feature. The TLR9 ligand CpG preferentially co-localises to MyD88-
IRF7-containing endosomal compartments whereas the same ligand mainly localises to 
lysosomes in cDCs and Mphs. This was confirmed by targeting CpG to endosomes which 
resulted in a robust production of type I IFNs in cDCs and Mphs [161, 162]. pDCs have 
therefore a unique mechanism for retaining TLR ligands in the endosomes which accounts 
for the high levels of type I IFN gene induction in these cells.  
 
 
1.3.3 IRF4/IRF8: essential factors for DC development and function 
DCs are professional antigen-presenting cells (APCs) that are crucial for the innate and 
adaptive response to infection. They can sense invading pathogens through PRRs and 
responds by secreting inflammatory mediators as well as by upregulating the surface 
expression of MHC II and costimulatory molecules. DCs also capture, process antigens and 
present antigenic peptides on MHC molecules to T lymphocytes, thereby triggering 
Th1/Th17 and Th2 responses or inducing tolerance. Among the cells classified as DCs are 
many subtypes with distinct immune functions [26]. For Instance, mouse splenic DCs can 
be classified into four subsets: CD4+ DCs, CD8+ DCs (cDCs), CD4- CD8- (double 
negative, DN) DCs and pDCs [29].  
 
These subsets express different sets of genes and the expression of two structurally related 
IRFs, IRF4 and IRF8, is subset-selective [163, 164]. IRF4 is expressed at high levels in DN 
DCs and CD4+ DCs but low in pDCs. As a consequence, the CD4+ DC population is absent 
in Irf4-/- [163]. Conversely, IRF8 is expressed at high levels in pDCs and CD8+ DCs, thus 
Irf8-/- mice are largely devoid of these DC subsets leading to an impaired production of  
IFN- [165, 166]. In support of the complementary control of DC subsets by IRF4 and IRF8, 
Irf4/Irf8-/- double KO mice have only a few DN DCs and are missing all other DC subtypes in 
the spleen [167]. Furthermore, the full differentiation and function of epidermal Langerhans 
cells and dermal DCs require IRF8 [168].   
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Thus, IRF4 and IRF8 play a critical role in the regulation of DC development and function. 
Through their specific activities, IRFs appear to equip DCs with the diversity required for 
directing optimal immune responses. However, the involvement of IRFs in human DC 
subtypes is less clear than it is in mouse DCs and further studies are required.  
 
 
 
1.4 Interferon regulatory factor 5 
IRF5 is a particularly interesting IRF family member with various activities, including 
activation of type I IFN genes, inflammatory cytokines and tumor suppressors. Although 
type I IFN responses are beneficial to the host, inflammatory cytokines that are stimulated 
by IRF5 can be a major contributor to the morbidity and mortality associated with 
autoimmune diseases. For instance, mutations in IRF5 are associated with systemic lupus 
erythematosis [169-171], rheumatoid arthritis [172-175] and inflammatory bowel disease 
[176-178] in several case-control studies.  
 
 
1.4.1 IRF5 gene structure 
The human IRF5 gene was mapped to the chromosome 7q32 and consists of nine exons 
with the first acting as an alternative non-coding exon (Figure 1.8). Four alternative exons 
for the 5‟ UTR (named exon1A, 1B, 1C and 1D) have been identified with the majority of the 
transcripts containing exon 1A [179, 180]. Interestingly, the alternative first exons give rise 
to different 5‟UTRs that could have effects on mRNA stability, mRNA localisation or 
translation. Analysis of the translational efficiency of the alternative 5‟UTRs revealed that 
exon 1A is the most efficient for protein synthesis while exon 1C has an inhibitory effect 
[179].  
 
Exon 6 also participates in the formation of IRF5 isoforms. Two constitutively active 
alternative in-frame splice sites have been identified in this exon leading to the formation of 
two families of isoforms. The splicing affects a repetitive sequence and determines the 
number of sequence repeats in each IRF5 isoform family. The isoforms 5 and 6, with four 
repeats, are expressed in the absence of splicing whereas splicing results in the expression 
of isoform 1 and 4 with two repeats respectively. Both acceptor sites have equal strength 
and therefore equal amounts of alternative transcripts are produced [181]. The repeat motif 
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encodes for a proline-rich region located in a putative PEST domain and could thereby 
participate in protein-protein interactions [182].  
 
In addition, it has been shown recently that IRF5 has two alternative polyA sites generating 
transcripts with either short or long 3‟UTRs [183, 184]. As a consequence, isoforms with a 
long 3‟UTR have two AU-rich elements (ARE) which are known to be responsible for rapid 
mRNA turnover and therefore affect mRNA degradation. On the other hand, isoforms with a 
short 3‟UTR have a longer half-life and the expression levels of these transcripts are 
upregulated in IFN- stimulated cells [179].  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Human IRF5 gene structure 
Protein coding exons are allocated as black and non-coding exons as white squares. The four non-
coding alternative first exons 1A, 1B, 1C and 1D and the associated transcription start sites (TSSs, 
indicated as +1) are shown. Exon 6 has two constitutively active alternative acceptor splice sites and 
the details are shown below the gene structure. Splicing results in the expression of isoforms 1 and 4 
whereas the absence of splicing leads to the expression of isoforms 5 and 6. The alternative polyA 
sites are also shown. The preservation of this site results in a stop codon and transcripts with short 
3‟UTR resulting in mRNA that is more stable compared to transcripts with long 3‟UTR. Adopted and 
modified from [181]. 
 
 
In summary, human IRF5 exists as multiple isoforms generated by the useage of different  
5‟ and 3‟UTRs as well as alternative splicing of exon 6. The resulting isoforms may have 
distinct functions as it has been shown for IRF3 isoforms [185]. It should be mentioned here 
that no alternative splicing of IRF5 occurs in mice and therefore there is only one isoform 
present.  
Chr 7q32
CEN TEL
+1D +1B +1C+1A
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1.4.2 IRF5 protein structure 
The most obvious difference between IRF5 and other family members is highlighted by two 
nuclear localisation signals (NLS), one in the N- and the other in the C-terminus of the 
protein. It has been shown that the 3‟NLS located in the DNA binding domain (DBD) is 
responsible for low levels of nuclear translocation and therefore weak transactivation activity 
of IRF5 in unstimulated cells, while the 5‟NLS is masked and becomes available only after 
phosphorylation which drives its nuclear translocation and strong transactivation function 
[186]. In addition, the IRF5 protein contains a constitutively active nuclear export signal 
(NES) which controls trafficking between nucleus and cytoplasm. The NES is dominant over 
the NLS resulting in cytoplasmic retention of most of the IRF5 protein in unstimulated cells. 
Mutation of the four leucine residues within NES resulted in the nuclear accumulation of 
IRF5 but not stimulation of type I IFN genes, suggesting that nuclear translocation alone is 
not sufficient for IRF5 function [187].  
 
Although a putative autoinhibitory domain close to the C-terminus was discovered same 
time ago [186], its function was revealed only recently. Unphosphorylated IRF5 remains in 
the cytoplasm in an autoinhibited state where binding sites for other proteins, such as 
CREB binding protein (CBP), at the C-terminus are masked. Phosphorylation induces an 
unfolding of the C-terminal region that triggers the formation of homo- or heterodimers with 
other IRFs and this unmasks the CBP binding site. IRF dimers then translocate to the 
nucleus where they interact with CBP and other transcription factors to form complexes that 
bind to promoters and enhancers which contain ISREs. Further experiments showed 
phosphorylation increases the affinity of IRFs for CBP but the response of IRF5 and IRF3 to 
phosphorylation is very different. The increase in affinity of IRF3 for CBP is much greater 
then that for IRF5 [188]. The differences are consistent with the fact that an 
unphosphorylated autoinhibitory domain cannot completely inhibit activation of IRF5 [186], 
and therefore the phosphorylation-dependent switch between autoinhibition and activation 
is more finely tuned in IRF5 than in IRF3. These differences in sensitivity to activation 
between IRF5 and IRF3 could represent distinct functional requirements and are manifested 
in the different physiological roles of IRF family members. For instance, IRF3 is 
constitutively expressed in all cells and acts upon viral infections. It must be strongly 
autoinhibited and activated only in response to a clear signal. Therefore, the sensitivity of a 
given IRF member is likely to be controlled through intermolecular auto-inhibition as 
phosphorylation-induced activation of IRF5 and other IRF family members leads to a 
structural change of the C-terminal autoinhibitory region.  
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1.4.3 Expression of IRF5 
So far little is known about the expression of IRF5 protein in humans. It has been shown 
that IRF5 transcripts can be detected in unstimulated peripheral blood mononuclear cells 
(PBMCs), pDCs, monocytes, monocyte-derived DCs (moDCs), natural killer cells (NK) and 
B lymphocytes but not in T lymphocytes. Furthermore, treatment of these cells with either 
IFN- or HSV-1 cell type specifically enhanced the levels of distinct IRF5 isoform transcripts 
[160, 180]. Although the relative levels of IRF5 mRNA were similar in pDCs, MDDCs and 
monocytes the levels of IRF5 protein were not examined previously.  
 
 
1.4.4 Activation of IRF5 
IRF family members are targets of both Myd88 and TRIF signalling pathways in the TLR-
dependent gene induction programme. It was shown that IRF5 directly interacts with the 
central region of MyD88 as well as with TNF receptor-associated factor 6 (TRAF6) and 
interleukin 1 receptor-associated kinase 1 (IRAK1) [189, 190]. Downstream targets of 
TRAF6 and IRAK1 are the IKK-related kinases IKK (also called IKKi) and TANK binding 
kinase 1 (TBK1) which are known to phosphorylate IRF3 and IRF7 in response to certain 
viruses, dsRNA or LPS signalling. It has been shown that IRF5 is also a substrate for both 
kinases after NDV, VSV and HSV-1 (but not SeV) infection and in in vitro experiments using 
kinase overexpression [187, 191, 192]. Nuclear localisation of IRF5 can be observed after 
phosphorylation by IKK/TBK1 at 4 distinct leucine residues within the NES (at position 150, 
154, 157 and 159) and substitutions of these residues to phosphomimetic aspartic acid 
leads to nuclear retention in unstimulated cells [187, 193]. However, nuclear translocation 
did not result in gene activation suggesting that other posttranslational modifications or 
other co-factors are needed to fully activate IRF5. Additional experiments revealed putative 
phosphorylation sites in the transactivation domain which contains serine-rich domains. 
Phosphorylation of Ser425, Ser427 and Ser430 is likely to contribute to activation by 
destabilising the autoinhibitory conformation of the C-terminus [188] and substitution of 
Ser451, Ser453, Ser456 and Ser462 to aspartic acid produced a protein that functioned as 
a constitutively active transcription factor [193].  
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1.4.5 Role of IRF5 in antiviral immunity and cytokine induction 
IRF5 was first linked to innate immunity in 2001 when it was shown that NDV but not SeV 
could activate IRF5, leading to the induction of distinct IFN- genes [192]. Follow up studies 
revealed that also VSV and HSV-1 can both activate IRF5 resulting in synthesis of active 
IFN- proteins [186]. The experiments described above were conducted with the 2fTGH cell 
line, which expresses IRF3 but not IRF5 or IRF7 and is therefore unable to induce IFN- 
gene transcription upon viral infection. Overexpression of IRF5 was sufficient for 
reconstitution of the anti-viral response and the induction of functional IFN- proteins. The 
authors also examined possible redundancies in the function of IRF5 and IRF7 and found 
that IFN- gene subtypes induced by IRF5 in NDV-infected cells are distinct from the ones 
induced by NDV-infected IRF7-expressing cells. This suggests that the expression profile of 
IFN- genes is dependent on different IRFs expressed in infected cells. A more recent 
study tried to reveal the target genes of IRF5 and IRF7 in BJAB cells after NDV infection 
[194]. It was shown that the genes are only partially overlapping and therefore, IRF5-
induced genes are not a subgroup of genes induced by IRF7. Strong expression of antiviral 
early inflammatory genes was observed in infected IRF5-expressing cells whereas the 
transcripts induced specifically by IRF7 were mitochondrial genes and genes affecting the 
DNA structure.  
 
A number of papers have linked TLR signalling to activation of IRF5 protein. Ligation of 
TLR3, TLR4, TLR5, TLR7/8 and TLR9 with their ligands resulted in the formation of a 
complex composed of MyD88, TRAF6 and IRF5 [189, 190]. Signalling via TLR7/TLR8 
activated IRF5 and IRF7 but not IRF3 in HEK-293-TLR4-CD14/Md2 and 2fTGH cell lines 
and activated IRF5 is needed for production of type I IFNs in these cells. Silencing of IRF5 
with siRNA disrupted signalling from TLR7/TLR8 and significantly reduced the IFN 
response. However, IFN expression was not completely abolished, suggesting that IRF7 
also plays a role in induction of type I IFN in these cells [189].  
 
In 2005 Takaoka et al. generated Irf5-/- mice which developed normally, had no sign of 
abnormal haematopoiesis and almost normal activation of NF-B, p38 or JNK signalling 
pathways. However, myeloid cells (spleen-derived cDCs, pDCs and macrophages) from 
IRF5-deficient mice displayed a significant decrease in expression and secretion of pro-
inflammatory cytokines, namely TNF, IL-6 and IL-12p40, in response to TLR3, TLR4, TLR5 
and TLR9 signalling. Consequently, Irf5-/- mice survived lethal shock induced by CpG and 
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were resistant to LPS-induced endotoxic shock due to marked decrease of serum cytokine 
concentrations of TNF, IL-6 and IL-12p40. Using ChIP, the authors showed CpG-induced 
recruitment of IRF5 to the promoter of IL-12p40 and suggested IRF5-mediated 
transcriptional activation of IL-12p40. Bioinformatic analysis of the TNF and IL-6 promoters 
identified several putative ISREs prompting Takaoka et al to propose that these genes are 
activated by direct binding of IRF5 similarly to IL-12p40. However, the authors provided no 
clear evidence for a direct role of IRF5 in the transcriptional regulation of IL-12p40 as IRF5 
ChIPs were not performed in combination with RNA polymerase II (Pol II) ChIPs (as a 
measurement of active transcription upon cell activation) and the involvement of IRF5 in 
regulating TNF as well as IL-6 expression remains purely speculative.  
 
Surprisingly, TLR9-mediated induction of type I IFNs in pDCs was not impaired [190], 
suggesting that IRF5 may not participate in the induction of type I IFNs in IRF5-deficient 
mice contradicting the studies of others performed in human cells [195]. The authors 
mentioned differences between mice and human (IRF5 isoforms) or the possible role of 
other unknown factors. However, recent experiments with Irf5-/- mice confirmed the 
dependence of IFN-4 and IFN- promoters on IRF5 after NDV infection. As a 
consequence, NDV-induced type I IFN serum levels were decreased in Irf5-/- mice 
compared to wild type mice [196]. A different study performed simultaneously by another 
group revealed that Irf5-/- mice also have lower type I IFNs serum levels after VSV and 
HSV-1 infection [195].  
 
To conclude, it has been shown that IRF5 is important for the host response to viral 
infections and it has been suggested that IRF5 is involved in the induction of pro-
inflammatory cytokines. Yet, to date there are no studies linking IRF5 with direct 
transcriptional regulation of cytokines like TNF or IL-6. Furthermore, IRF5 functions seem to 
be cell type-specific in mice but data obtained to date are not always consistent between 
humans and mice. In general, most studies investigating IRF5 function were performed 
using IRF5 overexpression in various cell lines but its role in primary human cells remains 
elusive. Clearly, there are still open questions and further investigation is needed to clarify 
the role of IRF5 in modulation of the human innate immune response and its contribution to 
autoimmunity. The regulation or manipulation of IRF5 protein levels and its function may 
provide a potential therapeutic target for inflammatory disease as well as viral infections.  
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1.5 Dysfunction of immunity – Role of IRF5 in autoimmune 
diseases 
The immune system is the defence mechanism of the body. It senses the invasion of 
“foreign” pathogens (non-self recognition) and tissue damage (altered-self recognition) and 
protects the host by initiation of an inflammatory, anti-microbial and anti-stress response. 
Dysfunction of the immune system is at the centre of a wide variety of diseases including 
autoimmunity, allergy, infections and cancer.  
 
Like most diseases of the immune system, autoimmune diseases are complex and depend 
on the interplay between environmental, epigenetic and genetic factors all of which result in 
disregulation of downstream biological networks. Invading pathogens or tissue damage 
generally results in a state of inflammation which involves the production of proinflammatory 
cytokines as well as chemokines and the subsequent recruitment of immune cells to the site 
of inflammation. This inflammatory process is then resolved by the production of negative 
regulators of immunity which limit the inflammatory response in order to avoid excessive 
tissue and host damage. Both phases must be precisely coordinated and are therefore 
tightly controlled. This control is disrupted in environmentally and/or genetically pre-
disposed individuals leading to a state of chronic inflammation. This results in severe and 
often irreversible damage to the tissue causing the development of autoimmune diseases. 
An integrative evaluation of the complex network alterations underlying the pathogenesis of 
autoimmune diseases was until recently difficult. However, technical advances now enable 
the analysis of DNA, RNA or proteins in patient samples on a genome wide level (genome-
wide association studies, GWAS). These techniques, combined with bioinformatics, can 
assess the activity of the entire transcriptome in a single sample, enabling the identification 
of genes and single-nucleotide polymorphisms (SNPs) associated with disease pathology.  
 
 
1.5.1 Systemic lupus erythematosus  
Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease with 
heterogeneous clinical manifestations. The spectrum of human SLE ranges from solely skin 
involvement to systemic disease which is characterised by relapsing and remitting course 
with high morbidity. Therefore, SLE patients can have surprisingly different phenotypes, 
with one patient suffering from malar rush whereas another may experience life-threatening 
manifestations such as nephritis [197]. SLE patients are predominantly women and 
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confirming the diagnosis of SLE requires the fulfilment of 4 out of 11 criteria with one being 
the presence of anti-nuclear antibodies (ANA). These ANA are detected in 95% of patients 
but in only less than 0.5% of patients with other autoimmune diseases like rheumatoid 
arthritis (RA) [198]. ANAs are directed against the host‟s chromatin components such as 
double-stranded DNA (released from apoptotic cells), histones and nucleosomes and cause 
the activation of the innate immune system. In addition to these direct effects of ANAs on 
immunity, is thought that many SLE symptoms result from the deposition of antigen-
antibody complexes on tissues [198, 199]. For example, immune complexes can end up in 
the renal glomerular basement membrane resulting in the infiltration of monocytes and 
macrophages and subsequent production of proinflammatory cytokines that ultimately 
induce glomerulonephritis [200].  
 
Several genetic associations with SLE susceptibility have been identified using a candidate 
gene approach where a gene is either hypothesized to play an etiological role based on its 
function or due to its location within a chromosomal region identified by linkage studies. The 
first genes shown to be risk factors for SLE were those encoding human leukocyte antigen 
(HLA) genes [201] followed by the identification of IRF5 [169], protein tyrosine phosphatase 
nonreceptor type 22 (PTPN22) [202] and signal and transducer and activator of 
transcription 4 (STAT4) [203] as risk genes. Four SLE GWAS were published in 2008 [204-
207] providing not only confirmation of previously identified loci (HLA, IRF5 and STAT4) but 
also led to the identification of many novel loci including ITGAM, TNFAIP3 and BANK1. 
Although these GWAS resulted in identification of new risk genes more work is needed to 
elucidate the functional mechanisms of the causal variants.  
 
An example where the causal variant has likely been identified includes IRF5. IRF5 is one 
of the most strongly and consistently SLE-associated loci outside the HLA region and was 
detected using both candidate gene and GWAS approach. Association studies derived from 
multiple ethnic backgrounds ranging from Sweden, Finland, Spain, Argentina and USA to 
Mexico have identified four functional IRF5 variants: 
 
 a 5 bp insertion/deletion (in/del) near the 5‟ untranslated region (UTR) 
 rs2004640 in the first intron 
 a 40 bp in/del in the sixth exon  
 rs10954214 in the 3‟ UTR 
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The strongest association in all cohorts was with SNP rs2004640, with the highest risk 
haplotype in Mexico and consistent association in Europeans [169-171, 184]. However, 
there are population differences as analysis of cases and controls from China revealed only 
a very weak correlation [208]. The haplotypes defined by different combinations of the 
above SNPs are associated with increased, decreased or neutral levels of risk for SLE. 
Important for the work presented in this thesis, increased risk haplotypes are associated 
with an increased expression of IRF5 mRNA and subsequent increase in IRF5 protein 
levels resulting in functional changes in IRF5-mediated signalling [209-212]. 
 
The use of IRF5 deficient mice in murine lupus models further established a role for IRF5 in 
disease pathology. Phenotypes of Irf5-/- mice in the lupus models FcRIIB-/- Yaa and 
FcRIIB-/- have been described. These mice showed diminished autoantibody production, 
attenuated glomerulonephritis and reduced serum IgG autoantibody levels [213]. The 
decrease in autoantibody production found by Richez et al was confirmed by another group. 
Savitsky et al injected Irf5-/- and wild-type mice with pristane oil and found reduced IgG 
glomerular deposits and antinuclear autoantibodies as well as a lack of IgG2a autoantibody 
secretion in the Irf5-/ mice and suggested a role for IRF5 in B cell maturation and 
differentiation [214]. Furthermore, a recent study analysed the phenotype of IRF5-deficient 
MRL/lpr animals which showed again reduced autoantibody production, milder 
glomerulonephritis and consequently improved mouse survival [215]. 
 
 
1.5.2 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) comprises of Crohn‟s Disease and ulcerative colitis, 
which are severe inflammatory disorders of the gastrointestinal tract. They affect as many 
as 1 in 250 people in both Europe and the US and patients often suffer from debilitating 
symptoms including abdominal cramping and bloody diarrhoea [216]. IBD is associated with 
an overactive immune response to the intestinal environment and a consequence of chronic 
inflammation in the gut is the promotion of tumorigenesis. In fact, patients with IBD have a 
higher risk of developing colitis-associated colorecteral cancer [217, 218]. There is no 
current cure for the disease, and treatment consists of long-term immunosuppressive 
therapy with a potential requirement for surgical intervention. 
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Commensal microorganisms contribute to host defence by limiting the growth of potentially 
harmful pathogens via crosstalk with the innate immune system. Despite this mutualism 
between the microbiota and the host, changes in the composition of the intestinal 
environment or colonisation with specific pathogens may alter intestinal homeostasis and 
the nature of the immune response resulting in spontaneous colitis and/or tumorigenesis 
[217, 218]. Therefore, the unique microbial environment of the intestine places the innate 
immune system at the heart of intestinal homeostasis. Several host innate immune 
mechanisms have evolved to deal with the challenge posed by the microbiota. 
Anatomically, a physical barrier formed by a single layer of intestinal epithelial cells (IECs) 
shields the rest of the body from commensal microorganisms in the intestinal lumen. A 
balance between cell death via apoptosis and survival is important for the maintenance of 
intestinal homeostasis as well as barrier function and innate immune cell-derived cytokines 
are regulators of apoptosis. It has been shown that the proinflammatory mediator TNF 
induces the apoptosis of ICEs leading to barrier disruption and subsequently sustained 
inflammation in the intestine [219, 220]. Consequently, TNF-targeting biologics confer 
protection in IBD by modulating apoptosis in the gut and restoring barrier function [221-224]. 
Other innate immune cell-derived cytokines associated with IBD pathology include IL-1, IL-
6, IL-10, IL-18 and IL-23 [217] all of which are associated with the M1 macrophage 
phenotype. In summary, environmental triggers as well as genetic predispositions affect 
intestinal maintenance and cells of the innate immune system are central in orchestrating 
intestinal homeostasis.  
 
GWAS have identified several susceptibility loci for IBD including innate receptors (NOD2 
and TLRs) [225-227], innate-derived cytokines (IL-12p40 and IL-10) and transcriptional 
regulators of the immune response (IRF5) [176-178]. Of those, IL-12p40 is of particular 
interest due to its involvement in the formation of IL-23. IL-23 is a heterodimeric cytokine 
comprising of IL-12p40 and IL-23p19 [106] and is critical in the pathogenesis of a number of 
murine models of autoimmune disease and inflammatory conditions such as EAE [107], 
collagen induced arthritis (CIA) [112] and intestinal inflammation [113]. The functional 
activity of IL-23 has been linked to the maintenance and population expansion of Th17 
lymphocytes, which have an increased expression of the IL-23 receptor (IL-23R) [110]. In 
addition, it has been shown recently that IL-23 can antagonise the development of FoxP3+ 
Treg lymphocytes therefore facilitating intestinal inflammation [228]. Human IBD is 
associated with increased expression of IL-23 and Th17 signature cytokines such as IL-17A 
and IL-17F [229]. GWAS have identified SNPs conferring risk to both Crohn‟s disease and 
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ulcerative colitis in the gene coding for the human IL-23R which further highlights the role of 
IL-23-mediated signalling in IBD [230, 231]. Consequently, neutralisation of IL-23 has been 
shown to be beneficial in numerous murine models of IBD [232, 233]. Although it is 
generally accepted that IL-23 and its effect on Th17 lymphocytes is crucial in mouse models 
of IBD [228, 234], the innate cells that produce IL-23, primarily M1 macrophages, are less 
well studied in this context.  
 
The association of IRF5 with IBD is also unclear although it has recently been described 
that the 5 bp in/del within the 5‟UTR creates an additional binding site for the transcription 
factor SP1 resulting in increased expression of IRF5 mRNA [178]. However the data 
presented here could provide first insights into the role of IRF5 in the pathogenesis of IBD 
and explain its association with the disease.  
 
 
 
1.5.3 Rheumatoid arthritis 
Rheumatoid arthritis was first described more than 200 years ago in the doctoral 
dissertation of Augustin Jacob Landré-Beauvais [235]. Where SLE is inflammation of the 
skin and kidneys, and IBD of the gut, RA is a chronic inflammatory disease of the synovial 
tissue. It affects approximately 1% of the population worldwide [236] and is associated with 
inflammation of the synovial joints as well as progressive destruction of surrounding 
cartilage and bone [237].  
 
Although the etiology of RA remains undefined, the contribution of genetic risk factors has 
been established as the prevalence of the disease is higher in monozygotic twins than in 
the general population [238-240]. In particular, genes of the major histocompatibility 
complex (MHC) on chromosome 6 are tightly linked to RA. This data led to the shared 
epitope hypothesis whereby the DR4 and DR1 subtypes of the DRB1 chain, which is part of 
the MHC class II complex, shared amino acids 70-74 and were most commonly associated 
with RA [241]. GWAS and GWAS meta-analysis identified additional genetic risk factors 
although the association with RA was found to be weaker for all of those risk genes [242-
244].  
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The effects of IRF5 polymorphisms on susceptibility to RA have also been investigated and 
the results were inconsistent. The first two studies conducted could find no significant 
correlation between SNP rs2004640 and RA patients from France, Spain, Sweden and 
Argentina [245, 246]. Nevertheless, recent analysis of four different case-controls cohorts, 
including Korea, Tunisia and Japan, found a very strong association between the IRF5 SNP 
rs2004640 and RA [172-175, 247, 248]. The authors also suggested that this SNP 
contributes more to RA susceptibility in patients that have the shared epitope and/or are 
positive for anti-citrullinated protein antibodies. Moreover, a recent GWAS meta-analysis 
identified IRF5 as a risk gene for RA further supporting its role in this disease [244].   
 
Considering that women are 3 times more susceptible to RA than men, the possible role of 
hormonal factors is at the centre of ongoing discussion and investigation [249, 250]. In 
addition to genetic risk factors, environmental risk factors, most prominently infections and 
smoking [251, 252], have been identified. Infections clearly linked to RA include 
mycobacteria, Escherichia coli and Epstein-Barr virus [253]. Infections may be of particular 
interest as infectious agents can trigger the activation of the innate immune system via TLR 
signalling highlighting the role of pattern recognition. There is a growing body of evidence 
that endogenous ligands of TLRs may contribute to inflammatory cytokine production and 
therefore prolonging the inflammatory responses in RA. For example, murine models of RA 
displayed reduced symptoms when lacking TLR4 [254], or when treated with TLR4 
antagonists [255]. Furthermore, depletion of TLR8 was shown to significantly reduce 
inflammatory cytokine production in ex vivo cultures of synovial membranes derived from 
RA patients [256].  
 
Tissue biopsies of RA patients undergoing joint replacement therapy have constituted a 
major tool for studying characteristics of the disease ex vivo as well as mechanisms of 
dysregulation of inflammation. A hallmark of RA is the increase in size and thickening of the 
synovial membrane due to the recruitment of various cell types, mainly macrophages, 
fibroblasts and Tlymphocytes (Figure 1.9) [257, 258]. These cells spontaneously release 
proinflammatory cytokines such as, TNF, IL-1, IL-6 and GM-CSF even after removal from 
the joint [259-262]. Anti-inflammatory molecules such as IL-10, which are expressed as part 
of normal acute inflammatory responses, can also be detected in RA synovial joints and the 
ex vivo cultures [263].  
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The infiltrating cells were characterised based on surface marker expression and 
macrophages were of particular interest. Synovial macrophages are a major source of 
proinflammatory cytokines in the joint and their cell number in the synovium correlates well 
with the degree of inflammatory disease activity in RA [264]. Recent data suggest that 
synovial macrophage numbers can be used to evaluate disease severity and as predictors 
of responsiveness to therapy. Gerlag and colleagues were the first to identify CD68+ 
macrophages as an RA biomarker associated with clinical responsiveness to corticosteroids 
[265]. Their studies were extended over a wide range of interventions and a strong link 
between the mean change in the Disease Activity Score and the mean change in the 
number of macrophages was noted [264]. In addition to the high sensitivity of the CD68+ 
macrophage population, their numbers showed a distinction between effective and 
ineffective treatment [264].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 Schematic representation of healthy versus RA joint 
The RA joint is characterised by the infiltration of immune cells into the synovial membrane resulting 
in hyperplasticity of the synovial lining and ultimately bone erosion. Adopted and modified from [266].  
 
 
Healthy RA
Bone erosion
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Comparison of macrophage numbers in the joint of RA and spondylarthritis patients showed 
that the total number of macrophages is similar in both forms of arthritis, but the subset 
expressing the M2 specific surface marker, CD163, is clearly increased in spondylarthritis 
[267, 268]. Moreover, the presence of distinct macrophage subsets in both diseases seems 
to be associated with different local inflammatory milieus as the M1 cytokine signature can 
be found in the inflamed joints of RA patients but is absent in spondylarthritis [269]. It is 
desirable to further evaluate the contribution of macrophage subsets to disease severity and 
potentially use them as even better predictors of therapeutic success compared to the 
general macrophage staining with CD68 described above. However this is not possible yet 
due to the lack of a clear distinguishing marker for human macrophage subsets. 
 
The cause behind the spontaneous release of cytokines in the joint is currently not known, 
however the production of TNF has been placed at the centre of disease pathology. First 
support for a dominant role of TNF was provided by both in vitro and in vivo studies. 
Production of a range of proinflammatory cytokines by cultured cells from the joints of RA 
patients can be decreased by a neutralizing antibody to TNF [270, 271]. Murine models of 
arthritis such as the collagen-induced arthritis (CIA) model were used to show that 
treatment with anti-TNF antibodies or soluble TNF receptor abrogated inflammation in the 
synovium [272]. An open Phase I/II clinical trial involving 20 patients with active RA showed 
that the treatment was safe, tolerated and, more importantly, resulted in significant clinical 
as well as laboratory improvements [273]. The efficacy of anti-TNF therapy in RA was 
subsequently confirmed in randomised controlled trials which further established the central 
role of TNF in the disease [274-276]. There are currently three drugs (Humira [adalibumab], 
Remicade [infliximab] and Enbrel [etanercept]) licensed as TNF-blocking agents and used 
to treat RA and other inflammatory diseases. However, one limitation of anti-TNF treatment 
of RA is that approximately only 60% of patients respond. Furthermore, the high cost, 
limited convenience of injections and risk of systemic side-effects are the reason for further 
research into the molecular mechanisms of the inflammatory response in RA leading to 
identification and validation of new therapeutic targets.  
 
Overall, SNPs in the gene coding for the transcription factor IRF5 are clearly associated 
with a number of autoimmune diseases in several case-control studies. The SNPs seem to 
predominantly affect either the transcription of the IRF5 gene itself or the stability of the 
resulting mRNA and it has been suggested that these changes lead to an increase in the 
amount of IRF5 protein. However, the effect of increased IRF5 protein on downstream 
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signalling is mostly unknown due to an absence of defined IRF5-specific target genes. 
Furthermore, as shown in murine cells, the expression of IRF5 protein is cell-type specific 
but we currently lack knowledge of IRF5 protein expression in human immune cells. It is 
therefore important to identify IRF5 target genes and determine the IRF5 protein expression 
profile in human cells in order to get a better understanding of its association with as well as 
contribution to autoimmune diseases.  
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1.6 Hypothesis of investigation 
TNF is the major cytokine associated with chronic inflammatory diseases such as 
inflammatory bowel diseases and rheumatoid arthritis and tight regulatory control must be 
maintained over its production. Many investigators have focused on NF-κB proteins, a 
dominant transcription factor family in the production of TNF and other proinflammatory 
cytokines, but recent studies suggest a role for IRF5 in regulating inflammatory processes. 
As mentioned previously, the genes that are regulated in an IRF5-dependent manner are ill-
defined but studies in IRF5-deficient mice suggest that the TNF gene is a possible target of 
IRF5. However, the molecular mechanisms of IRF5-mediated TNF gene expression are not 
known. 
 
The initial focus of this study was to dissect the role of IRF5 in regulating human TNF gene 
expression in human myeloid cells with the working hypothesis that “IRF5 is required for 
TNF transcription in human MDDCs in response to LPS”.  
 
 
1.6.1 Specific aims for TNF study (Chapter 3): 
1. Characterise the expression of IRF5 protein in primary human myeloid cells during 
cell differentiation and upon activation. The identification of a particular level of IRF5 
expression amongst the myeloid lineage will determine the cell type(s) for future 
experiments. 
2. Investigate the requirement of IRF5 for activation of human TNF gene expression. In 
particular, determine if IRF5 is directly regulating TNF transcription or perhaps is 
involved in post-transcriptional/translational processes. 
3. If aim 2 indicates a direct transcriptional regulation of TNF gene expression by IRF5, 
I intend to identify regulatory elements in the human TNF locus to which IRF5 binds 
in vivo.  
4. Search for protein-protein interactions between IRF5 and other transcription factors 
with a focus on NF-B family members. 
 
 
 
 
Chapter 1 - Introduction 
 53  
During this part of the project I observed a low expression of IRF5 in monocyte-derived 
macrophages (differentiated in M2 polarizing conditions) which prompted me to investigate 
IRF5 levels under M1 conditions. M1 macrophages are in many ways similar to monocyte-
derived DCs, thus I expected a high expression of IRF5 in these cells and hypothesised that 
“IRF5 is a determining factor of human macrophage polarization”. 
 
 
1.6.2 Specific aims for macrophage polarization study (Chapter 4 and 5) 
1. Investigate the expression of IRF5 during macrophage polarization using different 
protocols. There is limited knowledge about environmental signals that induce IRF5 
expression in human macrophages, thus every trigger of IRF5 expression would be 
novel.  
2. Determine if IRF5 expression is static during macrophage polarization. 
Macrophages can adopt their phenotype in response to environmental changes and 
a subset-defining transcription factor should also change accordingly.  
3. Investigate whether any subset-defining cytokines are under the transcriptional 
control of IRF5. Determine if IRF5 is directly regulating these cytokines, 
demonstrated for human TNF, and if yes, identify regulatory elements to which IRF5 
binds in vivo.  
4. Characterise if ectopic expression of IRF5 or siRNA-mediated inhibition has adverse 
effects on macrophage phenotype and cytokine profile. 
5. Results from Chapter 3 indicated that ectopic expression of IRF5 promotes a potent 
Th1 response. However, it is important to further characterise the effect of ectopic 
IRF5 on T lymphocyte fate and expand to other known T lymphocyte subsets with a 
focus on the Th1/Th17 lineage.  
6. Determine the phenotype of macrophages obtained from wild-type and IRF5-
deficient mice. If IRF5 functions as a subset-defining transcription factor in both man 
and mouse, I intend to investigate the in vivo role of IRF5 in macrophage 
polarization using wild-type and IRF5-deficient mice. 
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2. Methods 
 
2.1 Cell culture 
All cell cultures were maintained at 37°C in 5% CO2 and 95% humidity. 
 
2.1.1 Maintenance of cell lines 
Cell lines used in this study were purchased from Invitrogen, USA, and are listed in Table 
2.1. All cell lines were maintained in Dulbecco's Modified Eagle's Medium (DMEM; PAA, 
USA) supplemented with 10% foetal calf serum (FCS; Gibco, USA) and 1% 
penicillin/streptomycin (PAA, USA). In addition, HEK293-TLR3 cells were supplemented 
with 10 mg/ml of blasticidin (Invitrogen, USA) and HEK-293-TLR4-CD14/Md2 cells were 
supplemented with 10 mg/ml and 50 mg/ml of blasticidin and HygroGoldTM (Invivogen, USA) 
respectively. Cells were passaged upon reaching a confluency of approximately 70-80%. 
The culture media was aspirated and cells were washed once with Dulbecco‟s phosphate 
bufferd saline (PBS; PAA, USA) before addition of trypsin/EDTA (PAA, USA) for 5-10 
minutes at 37°C. Afterwards cells were resuspended in a suitable volume of media to obtain 
an approximate dilution of 1 in 6. 
All cell lines were regularly screened for mycoplasma infection while they remained in long 
term culture. This procedure was kindly performed by Mrs P Amjadi. 
 
Table 2.1: Cell lines used in this study 
 
Cell line Description 
HEK293-TLR3 Human embryonic kidney (HEK)-293 cells that stably express toll-like 
receptor 3 
HEK293-TLR4 Human embryonic kidney (HEK)-293 cells that stably express toll-like 
receptor 4 as well as the co-receptors CD14 and Md2 
HT1080 Human fibrosarcoma cell line 
 
 
Cells were stimulated where indicated with either 100 ng/ml LPS (Alexis Biochemicals, 
USA) or 25 µg/ml Polyinosinic Polycytidylic Acid (pI:C; Invitrogen, USA).  
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2.1.2 Cryopreservation of cells 
Cell lines subjected to cryopreservation were first collected and then resuspended in a 
mixture of 90% FCS and 10% dimethylsulfoxide (DMSO; Invitrogen, USA) at a 
concentration of 107 cells/ml. They were then transferred into cryovials in 1ml aliquots and 
placed at -70°C in an insulated container to ensure slow freezing. The cryovials were 
subsequently transferred into a liquid nitrogen tank for long term storage. Upon re-culture, 
cryovials were placed in a waterbath at 37°C until the contents were thawed after which 
cells were quickly washed to remove the DMSO and resuspended in the appropriate culture 
media. 
 
 
 
2.2 Work with primary human myeloid cells 
 
2.2.1 Isolation of human peripheral blood mononuclear cells  
Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation of 
platelet-pheresis residues from healthy donors that were purchased from North London 
Blood Transfusion Service (Colindale, UK). Heparinised residues were diluted 1:1 with 
Hank's Balanced Salt Solution (HBSS; PAA, USA) and layered over an equal volume of 
Ficoll-Hypaque lymphoprepTM (Axis-Shield, UK) in sterile 50 ml tubes. Centrifugation was 
performed at 2,200 revolutions per minute (rpm) for 20 min at room temperature in a Sorvall 
RT7 (Kendro Laboratory products, UK) with a minimum deceleration setting on the brake. 
The interface layer was collected and washed twice with HBSS followed by centrifugation 
for 10 min at 1,800 rpm. PBMCs were then resuspended in 45 ml of HBSS before being 
passed through a cell strainer (BD Bioscience, UK) to remove any clumps. 
 
 
2.2.2 Isolation of human monocytes 
Enriched populations of monocytes were obtained by centrifugation at 2,500 rpm in a 
Beckman JE6 elutriator (Beckman Coulter, UK). Elutriation is a process that separates a 
heterogeneous cell population based on size. Cells are loaded into a specialised chamber 
and subjected to a centrifugal field, which is counter-balanced by pumping media through 
the chamber at a constant rate. As the flow rate gradually increases cells of increasing size 
are ejected from the chamber and collected. Monocytes were ejected when the flow rate 
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was increase to 18-22 ml/minute and their purity was determined by analysis of cell size 
and granularity using flowcytometry. Only fractions containing more than 80% monocytes 
and less than 5% granulocytes were used in experiments. 
 
 
2.2.3 In vitro differentiation of human monocytes 
Upon collection of monocyte-enriched fractions cells were counted and resuspended in 
Roswell Park Memorial Institute media 1640 (RPMI; PAA, USA) supplemented with 10% 
FCS, 1% penicillin/streptomycin to a concentration of 106 cells/ml. 10 ml of this cell 
suspension was seeded per 10 cm tissue culture dish (Falcon, UK).  
 
For differentiation of monocytes into DCs, GM-CSF and IL-4 (Peprotech, UK) were added at 
a final concentration of 50 ng/ml and 10 ng/ml respectively. 5-7 days later non-adherent 
cells were harvested, resuspended in fresh culture media to a concentration of 106 cells/ml 
and seeded appropriately. Macrophages were generated from monocytes either by addition 
of 100 ng/ml M-CSF (for M2 differentiation) or 50 ng/ml GM-CSF (for M1 differentiation) 
(Peprotech, UK). 4-6 days later adherent cells were harvested by scraping, resuspended in 
fresh culture media to a density of 106 cell/ml and seeded appropriately.   
 
 
 
2.3 Work with mice and murine cells 
I would like to thank Miss Katrina Blazkova (Kennedy Institute of Rheumatology, London, 
United Kingdom) who routinely performed isolation of bone marrow cells as well as organ 
extraction. Katrina was also instrumental in establishing and optimising in vivo experiments.  
 
 
2.3.1 Isolation of bone marrow cells 
C57BL/6 wild type or Irf5-/- (on a C57BL/6 background) were sacrificed by cervical 
dislocation and the abdomen as well as the hind legs were sterilised with 70% ethanol. Skin 
was removed from hind limbs and bones (femur and tibia) were removed by cutting through 
the bones at the ankle and as near the pelvis as possible. Scissors were used to trim as 
much muscle and fat from the bones as possible. Next, bones were separated by cutting 
through the knee joint resulting in an opening into the bone marrow cavity at both ends of 
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each bone. Bone marrow progenitors were flushed out of the bones into 50 ml tubes with 
RPMI media using a 5 ml syringe and a 25 gauge needle. Bone marrow progenitors were 
pipetted up and down to bring the cells into a single cell suspension. Cells were then 
passed through a cell strainer and the strainer washed with 5 ml RPMI. Cells were pelleted 
by centrifugation at 1,800 rpm for 5 min and resuspend in 1 ml of RPMI supplemented with 
10% FCS, 1% penicillin/streptomycin and 0.01% 2-mercaptoethanol (bone marrow media, 
BM media). The bone marrow progenitors were counted and adjusted to a concentration of 
106 cells/mL in BM media and subsequently used for in vitro differentiation.  
 
 
2.3.2 In vitro differentiation of bone marrow cells 
Bone marrow cells were isolated as described in section 2.3.1, counted and 5 x 106 cells in 
10 ml BM media were seeded in 10 cm bacterial dishes (Falcon, UK). Macrophages were 
generated either by addition of 50 ng/ml murine M-CSF (for M2 differentiation) or 20 ng/ml 
murine GM-CSF (for M1 differentiation) (Peprotech, UK). On day 3, 10 ml of BM media 
supplemented with either M-CSF (50 ng/ml) or GM-CSF (20 ng/ml) was added to the 
cultures. On day 6, 10 ml of media was collected and cells were pelleted by centrifugation at 
1,800 rpm for 5 min. Pellets were resuspended in 10 ml of BM media supplemented with 
either M-CSF (50 ng/ml) or GM-CSF (20 ng/ml) and transferred back to the original culture 
dishes. Cells were harvested between days 8-9, resuspended in fresh BM media (without 
cytokines) to a density of 106 cell/ml and seeded appropriately. 
 
 
2.3.3 Isolation and culture of spleen cells 
Mice were sacrificed by cervical dislocation and the abdomen sterilised with 70% ethanol. 
The spleen was subsequently removed and put in RPMI at 4°C. Spleens were then 
homogenised and passed through a cell strainer and the strainer washed with 5 ml BM 
media. Cells were pelleted by centrifugation at 1,500 rpm for 5 min, resuspended in 2 ml of 
Red Blood Lysis Buffer (Sigma, UK) and left for 15 min at RT. The buffer was diluted with 
20 ml of BM media followed by centrifugation at 1,500 rpm for 5 min. Cells were washed 
twice with 20 ml of BM media, counted and adjusted to a density of 6 x 106 cells/ml. Of this 
suspension, 0.5 ml was plated per well in 24 well plates and the media supplemented with 
antibody to CD3 (anti-CD3; 10 ng/ml; 145-2c11; BD Bioscience) where indicated. In other 
applications, 0.5 ml of suspensions were pelleted and used directly for RNA extraction.  
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2.3.4 In vivo experiment with IRF5 knock-out mice 
For in vivo experiments, Irf5−/− mice and their wild-type littermates were injected 
intraperitoneally with 20 μg LPS in 200 μl sterile PBS. Mice were sacrificed after 3 h, blood 
collected by cardiac puncture and peritoneal cells collected by performing peritoneal lavage 
using sterile PBS. The blood was collected in 1.5 ml tubes, stored at 4°C overnight and then 
centrifuged next day at 14,000 rpm for 15 min. The serum (top layer) was carefully 
transferred to a new tube and stored at -20°C until further use. The peritoneal cells were 
counted and equal amounts (usually 5 x 105 cells) used for RNA extraction. Spleens and 
mesenteric lymph nodes were removed and either snap frozen and stored at -80°C until 
further use or cultured for 48 h in BM media supplemented with antibody to CD3 (anti-CD3; 
10 ng/ml; 145-2c11; BD Bioscience). Following culture, supernatants were collected and 
stored at -80°C and cells used for RNA extraction. The experimental protocol was approved 
by the UK Home Office. 
 
 
 
2.4 MTT cell viability assay 
The 3-(4,5,-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide cell viability assay is 
based on the principle that tetrazolium salts are reduced to water-insoluble formazan 
crystals in metabolically active cells as a function of redox potential of mitochondria. The 
overall activity of mitochondrial dehydrogenases is directly correlated with the number of 
viable cells. Thus, this assay can be used to measure factor-induced cytotoxicity or non-
specific cell death in a population of cells, since treatment with a cytotoxic factor will affect 
the rate of formazan crystal formation.  
 
Following the end of the experimental conditions, supernatants were removed and replaced 
with fresh culture medium containing 5 µg/ml MTT and cultured at 37°C for 4 h. Cells were 
then lysed by addition of one volume of 10M hydrochloric acid containing 10% SDS and 
placed at 37˚C overnight. Absorbance was read at 620nm on a Multiskan BiochromaticTM 
plate reader (Labsystems, UK) using Ascent 2.4.2 software (Labsystems, UK) to measure 
the levels of viable cells. All samples were analysed in triplicate. 
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2.5 Quantitative real-time PCR  
Real-time PCR allows the quantification of mRNA levels within distinct populations of cells. 
All gene expression analyses carried out in this study used TaqMan primer probes to 
amplify mRNA which had previously been reverse-transcribed to generate cDNA.   
 
 
2.5.1 RNA extraction and quantification 
Total RNA was extracted from cells using either a QiaAmp RNA Blood mini kit or RNeasy 
mini Kit (both from Qiagen, Germany) as per manufacturer‟s instructions. Contaminating 
genomic DNA was removed from RNA samples using RNase-Free DNase Set (Qiagen, 
Germany) which can be used in combination with the RNA extraction kits mentioned above. 
The procedure routinely removed DNA contamination to levels below the detection limits of 
a standard real-time PCR. RNA concentration was quantified using a nanodrop 1000 
(Thermo Scientific, USA). 
 
 
2.5.2 cDNA synthesis 
cDNA synthesis reactions contained 0.1-1 µg of total RNA and cDNA was synthesised 
using SuperScript® III Reverse Transcriptase (Invitrogen, USA) and 18-mer oligo dT 
primers (Eurofins MWG, UK) as per manufacturer‟s instructions. Following synthesis 
samples were diluted 1 in 4 in nuclease free water and stored at -20°C until required.  
 
 
2.5.3 Quantitative real-time PCR 2 standard curve method 
Real-time PCR 2-standard curve method requires cDNAs of both the gene of interest and a 
housekeeping gene to generate a standard curve. A human TNF cDNA clone was kindly 
provided by Mrs N. Ito (Kennedy Institute of Rheumatology, London, United Kingdom). A 
human ribosomal protein (PO) cDNA clone was created as follows. Total RNA was 
extracted from human M2 macrophages and 1 µg of total RNA was used to synthesise 
cDNA. PO cDNA was amplified by PCR using the following primers:  
F: 5‟TGCCCAGGGAAGACAGGGCG and R: 5‟- ATATGGGATTTGGTCTCTTTGACTAA; 
then cloned into TOPO TA vector (Invitrogen, USA). 
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The cDNA clones were serially diluted 1 in 25 to generate standard curves that covered a 
range of cycle thresholds (Cts) that reflected the heterogeneity of gene expression within 
the samples. The top value for each standard curve was arbitrarily chosen but the values of 
the each consecutive point on the standard curve reflected the dilution factor 1 in 25. The Ct 
values of both the gene of interest and the house-keeping gene were then converted into 
concentrations according to their respective standard curve. Finally, mRNA levels were 
normalised by dividing the calculated value of the gene of interest by the calculated value of 
the house-keeping gene within each sample.   
 
Real-time PCR reactions were performed in a Corbett Rotor-gene 6000 machine (Corbett 
Research Ltd, Cambridgeshire, UK) and analysed using Corbett Rotogene 6000 software or 
in a ABI 7900HT machine (Applied Biosystems, USA) and analysed manually. TaqMan 
PreAmp Master Mix (Applied Biosystems, USA) and TaqMan gene expression assays 
(Applied Biosystems, USA) were used as per the manufacturer‟s instructions. Table 2.2 
contains a detailed list of TaqMan probes used in this study. Reactions were either carried 
out in 10 µl volumes (Corbett Rotor-gene 6000) or 6 µl volumes (ABI 7900HT machine) in 
duplicate. Thermocycling conditions were as follows:  
 
10 min at 95ºC 
45 cycles of 10s at 95ºC + 35s at 60ºC   
 
 
Table 2.2: TaqMan primers used in this study 
 
Gene Species Catalogue no. 
Arg1 Mouse Mm00475988_m1 
Chi3l3 Mouse Mm00657889_mH 
FOXP3 Human Hs01085834_m1 
GATA3 Human Hs00231122_m1 
Hprt1 Mouse Mm00446968_m1 
IFNG Human Hs00174143_m1 
Il1b Mouse Mm99999061_mH 
IL6 Human Hs00174131_m1 
Il6 Mouse Mm00446190_m1 
IL10 Human Hs00174086_m1 
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Il10 Mouse Mm00439616_m1 
IL12A Human Hs00168405_m1 
Il12a Mouse Mm99999066_m1 
IL12B Human Hs00233688_m1 
Il12b Mouse Mm01288990_m1 
IL17A Human Hs00174383_m1 
IL17F Human Hs00369400_m1 
IL21 Human Hs00222327_m1 
IL22 Human Hs01574154_m1 
IL23A Human Hs00372324_m1 
Il23a Mouse Mm00518984_m1 
IL23R Human Hs00332759_m1 
IL26 Human Hs00218189_m1 
IRF5 Human Hs00158114_m1 
Irf5 Mouse Mm00496477_m1 
Mrc1 Mouse Mm00485148_m1 
RelA Human Hs00153294_m1 
Retnla Mouse Mm00445109_m1 
RPLPO Human 4326314E 
TBX21 Human Hs00203436_m1 
TNF Human Hs00174128_m1 
Tnf Mouse Mm00443258_m1 
 
 
 
RORt gene expression was detected by SybrGreen with a primer set specific for human 
RORC2 (RORC2_F1, TGAGAAGGACAGGGAGCCAA; and RORC2_R1: 
CCACAGATTTTGCAAGGGATCA). 
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2.6 Micro array analysis 
The quality control of the RNA samples and the hybridisation was carried out by Dr Dilair 
Baban (Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom). Micro array 
analysis was kindly performed by Mrs Helen Lockstone and Miss Natasha Sahgal (both 
Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom).  
Gene expression data were obtained by hybridising RNA from a total of 24 samples from 6 
experimental groups (n=4 per group) to Illumina HumanHT-12 Expression BeadChips. Raw 
data were exported from the Illumina GenomeStudio software (v1.0.6) for further processing 
and analysis using R statistical software [277] (v2.10) and BioConductor packages [278]. 
Raw signal intensities were background corrected using array-specific measures of 
background intensity based on negative control probes, prior to being transformed and 
normalised using the „vsn‟ package [279]. Quality control analyses did not reveal any outlier 
samples. The dataset was then filtered to remove probes not detected (detection score 
<0.95) in any of the samples, resulting in a final dataset of 25,620 probes. 
 
Statistical analysis was performed using the Linear Models for Microarray Analysis (limma) 
package [280]. Differential expression between the experimental groups was assessed by 
generating relevant contrasts corresponding to the relevant comparisons. Raw p-values 
were corrected for multiple testing using the false discovery rate controlling procedure of 
Benjamini and Hochberg [281], adjusted p-values below 0.01 were considered significant. 
Significant probe lists were then annotated using the relevant annotation file (HumanHT-
12_V3_0_R2_11283641_A) that was downloaded from the Illumina website 
(http://www.illumina.com) for further biological investigation.  
 
 
 
2.7 Enzyme linked immunosorbent assay (ELISA) 
ELISA allows the quantification of proteins that have been secreted into the supernatant by 
cultured cells. Antibodies were used to specifically capture the protein of interest from 
culture supernatants. Biotin-antibody conjugates were subsequently incubated with the 
immuno-complexes before the addition of streptavidin-HRP. Finally HRP substrate was 
added to the samples which induced a colour change that can be quantified. Running a 
standard curve of known protein concentrations in parallel to the samples enabled absolute 
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concentrations of secreted proteins to be inferred. All ELISA antibodies used in this thesis 
are listed in Table 2.3 and recombinant proteins are listed in Table 2.4. 
 
Capture antibodies were diluted in PBS and applied to 96-well plates overnight at 4ºC to 
adhere. The PBS was then removed and plates were blocked with PBS containing 2% 
Bovine Serum Albumin (BSA) for 1 h at room temperature. In between all subsequent steps, 
plates were washed 3 times with PBS containing 0.05% tween. A 7-point standard curve 
was generated by 1 in 3 serial dilutions of the protein of interest in PBS containing 0.5% 
BSA, with the top concentration ranging from 4-10 ng/ml. After removing the blocking 
solution from the plates, standards and samples of interest were placed on top of the 
capture antibody and incubated for 2 h at room temperature or at 4°C over night. The 
biotinylated detection antibody was diluted in PBS containing 0.05% BSA and then applied 
to the plates for 1 h at room temperature after washing. This procedure was repeated 
except streptavidin-HRP was incubated with the immuno-complexes instead of the 
biotinylated detection antibody. Finally, the plates were washed, TMB Microwell Peroxidase 
Substrate (KP Inc, USA) was added to the appropriate wells and the enzymatic reaction 
was terminated by addition of 1M H2SO4. Absorbance was read at 450nm by a 
spectrophotometric ELISA plate reader (Labsystems Multiscan Biochromic) and analysed 
using Ascent Labsystems software. All samples were analysed in triplicate in a volume of 
50 µl. A list of all buffers and their composition used in ELISA experiments can be found in 
section 2.19.3. 
 
 
Table 2.3: Antibodies used for ELISA 
 
Antigen type Species Clone/Lot. number Catalogue no. Supplier 
CCL2 capture Human 5D3-F7 14-7099 eBioscience 
CCL2 detect Human 2H5 13-7096 eBioscience 
CCL5 capture Human 21418 MAB678 R&D Systems 
CCL5 detect Human VC08 BAF278 R&D Systems 
CCL13 capture Human 73506 MAB327 R&D Systems 
CCL13 detect Human Lot. No. BJ103 BAF327 R&D Systems 
CCL22 capture Human 57226 MAB336 R&D Systems 
CCL22 detect Human Lot. No. C1G02 BAF336 R&D Systems 
IFN- capture Human NIB42 551221 BD Bioscience 
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IFN- detect Human 4S.B3 554550 BD Bioscience 
IFN- capture Mouse AN-18 551309 BD Bioscience 
IFN- detect Mouse R4-6A2 551506 BD Bioscience 
IL-1 capture Human 2805 MAB601 R&D Systems 
IL-1 detect Human 802700 BAF201 R&D Systems 
IL-4 capture Human 8D4-8 500701 BioLegend 
IL-4 detect Human MP4-25D2 500803 BioLegend 
IL-10 capture Human JES3-19F1 554705 BD Bioscience 
IL-10 detect Human JES3-12G8 554499 BD Bioscience 
IL-10 capture Mouse JES5-16E3 14-7101 eBioscience 
IL-10 detect Mouse JES5-2A5 33-7102 eBioscience 
IL-12/IL-23 p40 capture Human C8.3 551227 BD Bioscience 
IL-12p70 capture Human 20C2 555065 BD Bioscience 
IL-12/IL-23 p40 detect Human C8.6 554660 BD Bioscience 
IL-12/IL-23 p40 capture Mouse C15.6 14-7125 eBioscience 
IL-12p70 capture Mouse C18.2 14-7122 eBioscience 
IL-12/IL-23 p40 detect Mouse C17.8 13-7123 eBioscience 
IL-17A capture Human BL127 512602 BioLegend 
IL-17A detect Human BL23 512703 BioLegend 
IL17a capture Mouse TC11-18H10 555068 BD Bioscience 
IL17a detect Mouse TC11-8h4.1 555067 BD Bioscience 
IL-23p19 capture Human eBio473P19 14-7238 eBioscience 
IL-23p19 capture Mouse G23-8 14-7232 eBioscience 
IP-10 capture Human 4D5 555046 BD Bioscience 
IP-10 detect Human 6D4/D6/G2 555048 BD Bioscience 
TNF capture Human MAb1 551220 BD Bioscience 
TNF detection Human MAb11 554511 BD Bioscience 
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Table 2.4: Recombinant proteins used as standards for ELISA 
 
Protein Species Catalogue no. Supplier 
CCL2 Human 14-8398 eBioscience 
CCL5 Human 278-RN-010 R&D Systems 
CCL13 Human 327-P4 R&D Systems 
CCL22 Human 336-MD R&D Systems 
IFN- Human 554617 BD Bioscience 
IFN- Mouse 554587 BD Bioscience 
IL1 Human 201-LB-005 R&D Systems 
IL-4 Human 560602 BioLegend 
IL-10 Human 554611 BD Bioscience 
IL-10 Mouse 39-8181 eBioscience 
IL-12p40 Human 554633 BD Bioscience 
IL-12p70 Human 554613 BD Bioscience 
IL-12p40 Mouse 398122 eBioscience 
IL-12p70 Mouse 14-8121 eBioscience 
IL-17a Human 570509 BioLegend 
IL-17a Mouse 421-ML-025 R&D Systems 
IL-23 Human 14-8239 eBioscience 
IL-23 Mouse 14-8231 eBioscience 
IP-10  Human 551130 BD Bioscience 
TNF Human 554618 BD Bioscience 
 
 
 
2.7.1 BD™ Cytrometic bead assay (CBA) 
The CBA system (BD Bioscience, UK) uses the sensitivity of amplified fluorescence 
detection by flow cytometry to measure a soluble protein. Each bead in a CBA provides a 
capture surface for a specific protein and is analogous to an individually coated well in an 
ELISA plate. The CBA capture bead is a single bead population with distinct fluorescence 
intensity that allows the detection of a specific protein in a small sample volume. Each bead 
population is given an alpha-numeric position indicating its position relative to other beads 
in the CBA system. Beads with different positions can be combined in assays to create a 
multiplex assay. In a CBA assay the capture bead, PE-conjugated detection reagent, and 
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standard or test samples are incubated together to form sandwich complexes. The sample 
results obtained from flow cytometry are analysed using the FCAP Array™ software (BD 
Bioscience, UK). Assays were performed as per manufacturer‟s instructions and details of 
antibodies as well as standards used are shown in Table 2.5. 
 
 
Table 2.5: Antibodies and standards used for CBA 
 
Antigen type Species Bead position Catalogue no. Supplier 
IL-1 capture Mouse E5 51-9005790 BD Bioscience 
IL-1 detect Mouse  51-9005788 BD Bioscience 
IL-1 standard Mouse  51-9005500 BD Bioscience 
IL-6 capture Mouse B4 51-9005236 BD Bioscience 
IL-6 detect Mouse  51-9004153 BD Bioscience 
IL-6 standard Mouse  51-9003526 BD Bioscience 
IL-10 capture Mouse C4 51-9005234 BD Bioscience 
IL-10 detect Mouse  51-9004152 BD Bioscience 
IL-10 standard Mouse  51-9003528 BD Bioscience 
TNF capture Mouse C8 51-9005324 BD Bioscience 
TNF detect Mouse  51-9004161 BD Bioscience 
TNF standard Mouse  51-9003536 BD Bioscience 
 
 
 
2.8 Western blotting 
Western blotting allowed the identification and semi-quantitation of specific proteins and 
specific post-translational modifications of proteins e.g. phosphorylation. Following lysis of 
cellular membranes, total protein concentration was determined and equal amounts were 
resolved by Sodium Dodecyl Sulphate Poly Acrylamide Gel Electrophoresis (SDS-PAGE). 
Resolved proteins were then transferred onto a membrane prior to immunoblotting with 
antibodies specific for the protein of interest. All antibodies used for western blotting in the 
study are listed in Table 2.6. A list of all the buffers and their composition used in western 
blotting experiments can be found in section 2.19.2. 
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2.8.1 Preparation of whole cell protein extracts 
Cells were harvested, transferred to 1.5 ml tubes and washed once with ice cold PBS. Cells 
were then resuspended in 50-100 µl of the appropriate lysis buffer containing protease and 
phosphatase inhibitors and the tubes were placed on ice for approximately 20 min. Cellular 
debris was then pelleted by centrifugation and the lysate was transferred into new tubes 
and stored at -80ºC until required.  
 
 
2.8.2 Protein quantification: BCA assay 
Protein concentrations were determined using BCA Protein Assay Reagent (Thermo 
Scientific, USA) as per the manufacturer‟s instructions. Briefly, a 7-point standard curve was 
generated by 1 in 2 serial dilutions of BSA in water, with the top standard at a concentration 
of 4 µg/ml. BCA reagent A and B were mixed at a ratio of 50:1 and 200 µl was dispensed 
into an appropriate number of wells in a 96-well plate. 2 µl of sample and 10 µl of standard 
was added per well. Additionally, 2 µl of lysis buffer only served as a blank. The plate was 
incubated for 1 h at 37ºC, after which the absorbance was read at 540nm on a Multiskan 
BiochromaticTM  plate reader (Labsystems, UK). Protein concentrations were calculated 
according to the standard curve using Ascent 2.4.2 Labsystems software (Labsystems, UK). 
All samples were analysed in duplicate. 
 
 
2.8.3 SDS-PAGE 
10-15 µg of total protein and an appropriate volume of 4X loading buffer were boiled at 95°C 
for 10 min. The denatured proteins were then separated at 150-200 volts on a pre-cast 
NuPAGE® Novex 4-12% Bis-Tris gel (Invitrogen, USA) that was immersed in NuPAGE® 
MOPS SDS Running Buffer (Invitrogen, USA). A Full-Range Rainbow Molecular Weight 
Marker (RPN800; GE Healthcare, UK) was run in parallel so that the molecular weight of 
visualised proteins could be estimated. 
 
 
2.8.4 Protein transfer 
Following SDS-PAGE, resolved proteins were transferred to a polyvinylidene difluoride 
(PVDF) membrane (GE Healthcare, UK). PVDF membranes were cut to a suitable size, 
dehydrated in methanol and then equilibrated in transfer buffer. The PVDF membrane was 
Chapter 2 - Methods 
 68  
placed on top of the gel containing resolved proteins, then sandwiched between 4 pieces of 
transfer-buffer soaked filter paper. The assembly was then placed in a transfer cassette in 
between two transfer soaked sponges and inserted into a transfer tank filled with pre-cooled 
transfer buffer. A constant voltage of 30V was applied for 2 h at room temperature. 
 
 
2.8.5 Immunoblotting and protein detection 
After protein transfer membranes were incubated in blocking buffer and placed on a shaker 
at RT for at least 1 h. Primary antibodies were diluted in blocking solution and usually 
incubated with the membranes at 4°C over night with gentle agitation. In between all 
subsequent steps membranes were subjected to 4x 15 min washes with washing buffer. 
HRP-conjugated secondary antibodies were diluted in blocking buffer and sequentially 
incubated with the membranes for 1 h at room temperature with gentle agitation. Immuno-
complexes were detected using the chemiluminescent substrate solution ECL (GE 
Healthcare, UK), visualised using Hyperfilm MP (Amersham Pharmacia Biotech, UK) and 
developed using an AGFA Cruis-60 automatic film processor (AGFA-Gaevert, UK). When 
multiple protein detections were required on the same membranes, antibodies were 
stripped from the membrane using ReBlot Plus Strong Antibody Stripping Solution 
(Chemicon, UK) as per the manufacturer‟s instructions. 
 
 
Table 2.6: Antibodies used for western blotting 
 
Antibody  Source Dilution Catalogue no. Supplier  
anti-HA HRP Rat 1:1.000 12013819001 Roche 
anti-FLAG HRP mouse 1:1.000 A8592 Sigma 
-Actin Mouse 1:10.000 65541 Sigma 
IRF1 Rabbit 1:5000 sc-479 Santa Cruz 
IRF3  Rabbit  1:4.000 sc-9082 Santa Cruz 
IRF4 Rabbit 1:5000 sc-28696 Santa Cruz 
IRF5 Goat 1:1.000 ab2932 Abcam 
IRF5 Rabbit 1:5.000 ab21689 Abcam 
IRF5 mouse 1:5000 sc-56714 Santa Cruz 
IRF7 Rabbit 1:5.000 sc-9083 Abcam 
IRF8 Rabbit 1:5000 sc-13043 Santa Cruz 
IRF9 Rabbit 1:5.000 sc-10793 Santa Cruz 
p50/p105 Rabbit 1:5.000 sc-114 Santa Cruz 
Chapter 2 - Methods 
 69  
p52/p100 Rabbit 1:10.000 sc-298 Santa Cruz 
p65/RelA Rabbit 1:500 sc-372 Santa Cruz 
RelB Rabbit 1:5.000 sc-226 Santa Cruz 
c-Rel Rabbit 1:5.000 sc-17 Santa Cruz 
 
 
 
2.9 Electrophoretic mobility shift assay (EMSA) 
EMSAs were kindly performed by Dr Irina Udalova and Mrs Alessandra Lanfrancotti (both 
Kennedy Institute of Rheumatology, London, United Kingdom). A list of all the buffers and 
their composition used in western blotting experiments can be found in section 2.19.4. 
 
 
2.9.1 DNA probe labelling 
The two complementary oligonucleotides (Table 2.7) were dissolved in TE to a final 
concentration of 15 pmole/µl (15 µM). 10 µl of each oligonucleotide is mixed with 10 µl of 
10x buffer H (Boehringer, UK) and 70 µl of water in a 1.5 ml tube. The mixture was then 
layered with 50 µl of mineral oil. Primers were annealed by placing tubes in a beaker with 
approximately 1 L of boiling water for 5 min and then allowed to cool down to room 
temperature overnight. 2 µl of the annealed duplex (6 pmoles of ends) were mixed with 2 µl 
(6 pmoles) of [-32P] dCTP (Perkin Elmer, USA), 1 µ  of a dNTP mixture (containing 3 mM of 
each dATP, dGTP, dTTP), 2 µ  µl of water and 1 µl of 
Klenow enzyme. The mixture was incubated at room temperature for 30-45 min and the 
radiolabelled oligoduplexes were purified through Chroma spin TE-10 spin columns (Takara 
Bio, USA). The level of incorporation was estimated by monitoring the radioactivity left in the 
column and the radioactivity recovered in the flowthrough. The probes were diluted down to 
approximately 20000 CPM/µl.  
 
 
2.9.2 Binding reaction and gel run 
The binding reaction contained 50 ng of bacterially expressed and purified IRF5 DBD, 2μl of 
radiolabelled probe and 4 μl of 2x EMSA binding buffer and was incubated at room 
temperature for 10-15 min. The reaction was analyzed by electrophoresis in a 
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nondenaturing 5% polyacrylamide gel (0.5 x TBE) at 200 V for 2 hours at 4 °C. The gels 
were then dried and quantified using the PhosphorImager (FujiFilm, Japan). 
 
Table 2.7: Oligonucleotide sequences used for generating EMSA probes: 
 
Name Sequence (5’ – 3’) 
B4_for agctGGGCATGGGAATTTCCAACTCT 
B4_rev agctGAGTTGGAAATTCCCATGCCC 
B4a_for agctAACTCTGGGAATTCCAATCCTT 
B4a_rev agctAAGGATTGGAATTCCCAGAGTT 
B4b_for agctCTTGCTGGGAAAATCCTGCAG 
B4b_rev agctGCTGCAGGATTTTCCCAGCAAG 
ISRE1_for agctGAAGCCAAGACTGAAACCAGCATTA 
ISRE1_rev agctTAATGCTGGTTTCAGTCTTGGCTTC 
ISRE2_for agctCCGGGTCAGAATGAAAGAAGAAGG 
ISRE2_rev agctCCTTCTTCTTTCATTCTGACCCGGT 
ISRE5_for agctGGAGAAGAAACCGAGACAGAAGGTG 
ISRE5_rev agctCACCTTCTGTCTCGGTTTCTTCTCC 
ISRE16_for agctTTTGCTTAGAAAAGAAACATGGTCTC 
ISRE16_rev agctGAGACCATGTTTCTTTTCTAAGCAAA 
ISRE17_for agctACATAAACAAAGCCCAACAGAATATTCC 
ISRE17_rev agctGGAATATTCTGTTGGGCTTTGTTTATGT 
PRDI-III (IFN)_for agctGGGAAACTGAAAGGGAAAGTGAAAGTGG 
PRDI-III (IFN)_rev agctCCACTTTCACTTTCCCTTTCAGTTTCCC 
 
 
 
2.10 Cloning and genetic constructs used in this study 
 
2.10.1 Gene reporter and expression constructs used in this study 
Wild-type (wt) and dominant negative (dn, lacking the whole DNA binding domain [DBD]) 
IRF3 and IRF5 constructs as well as constructs coding for all NF-B subunits were already 
available in our laboratory. They are listed in Table 2.8 together with a brief description. All 
constructs were also cloned into pENTR4.3F and subsequently recombined into pAD/PL 
DEST for delivery into human primary myeloid cells. A list of luciferase gene reporter 
constructs used are summarised in Table 2.9.  
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Table 2.8: Expression constructs used in this study 
 
Construct  Description Vector Tag 
IRF3-C full lenght wt pENTR4.3 HA C-terminal 
IRF3-N full lenght wt pENTR4.3 HA N-terminal 
DN-IRF3-C lacks DBD pENTR4.3 HA C-terminal 
DN-IRF3-N lacks DBD pENTR4.3 HA N-terminal 
IRF5-N full lenght wt pENTR4.3 HA N-terminal 
IRF5 Strep full lenght wt pENTR4.3 One-strep N-terminal, HA C-terminal 
DN-IRF5-C lacks DBD pENTR4.3 HA C-terminal 
DN-IRF5-N lacks DBD pENTR4.3 HA N-terminal 
IRF5A68P mutation in DBD pENTR4.3 HA N-terminal 
RelA full lenght wt pENTR4.3 HA C-terminal 
RelB full lenght wt pENTR4.3 HA C-terminal 
c-Rel full lenght wt pENTR4.3 HA C-terminal 
p50 full lenght wt pENTR4.3 HA C-terminal 
p52 full lenght wt pENTR4.3 HA C-terminal 
 
 
Table 2.9: Luciferase gene reporters 
 
Construct  Lenght Descrption Vector 
IL-10 wt 195 bp 5‟  wt promoter pENTR4.3 
IL-10 ISRE mut 195 bp 5‟  Mutation of ISRE (AATTGAAA → gtTaGtAc) pENTR4.3 
TNF 5‟wt/3‟wt 
1171 bp 5‟  
1252 bp 3‟  
wt promoter and 3‟ region pGL3 
TNF 5‟mut/3‟wt 
1171 bp 5‟  
1252 bp 3‟  
Mutation of B sites in the 5‟ region 
B2 (GTGAATTCCC → tTGAATTCCC 
B (GTGATTTCAC → aTccTTTCAC 
B2a (GGGCTGTCCC → taGCTGTGCCC) 
pGL3 
TNF 5‟wt/3‟mut 
1171 bp 5‟  
1252 bp 3‟  
Mutation of B sites in the 3‟ region 
B4 (GGGAATTTCC → cGcAATgTgC) 
B4a (GGGAATTCCA → cGcAAgTgCA) 
pGL3 
TNF 5‟mut/3‟mut 
1171 bp 5‟  
1252 bp 3‟  
Mutation of all B sites (B2, B, B2a, 
B4, B4a 
pGL3 
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2.10.2 PCR 
PCR reactions were performed in a DYAD Peltier Thermal Cycler (Bio-Rad, UK), in 50 µl 
volumes.  Taq polymerase and dNTPs were obtained from Roche, UK, and primers were 
obtained from MWG, Germany. 50 ng of template DNA was used per reaction. PCR 
reactions were resolved by electrophoresis in 1% agarose 1x TAE gel. Addition of either 
ethidium bromide or SYBR green allowed visualisation under UV light. Hyperladder IV 
(Bioline, UK) was used to determine the molecular weight of DNA fragments. All PCR 
reactions used touch-up PCR under the following thermal cycling conditions: 95C for 10 
min; 4 cycles of 95C for 30s, 52C for 1 min, 68C for 3 min; 4 cycles of 95C  for 30s, 
57C for 1 min, 68C for 3 min; 4 cycles of 95C  for 30s, 57C for 1 min, 68C for 3 min; 4 
cycles of 95C  for 30s, 62C for 1 min, 68C for 3 min; 18 cycles of 95C for 30s and 68C 
for 3 min; 10 min at 68C; 15 min at 4C.  
 
 
2.10.3 Restriction digests 
Restriction digests were performed using New England Biolabs (NEB, UK) enzymes and 
buffers as per manufacturer‟s guidelines. Typically, restriction digests were performed in  
20-50 µl reactions for 1-2 h in a water bath set to 37C. 
 
 
2.10.4 DNA purification 
PCR or restriction digest reaction mixtures were resolved on a standard 1% agarose 1xTAE 
gel containing SYBR Green II.  Desired DNA fragments were excised and purified using a 
Qiagen gel extraction kit (Qiagen, Germany) according to manufacturer‟s instructions.   
 
 
2.10.5 DNA ligation   
Purified DNA was quantified by resolution on an agarose 1x TAE gel. Ligations contained 
an insert to vector ratio of 3:1, where 50 ng of vector was used per ligation. The mass of 
insert used was calculated by the formula: 
 
mass of insert = mass of vector x length of insert 
 length of vector 
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Ligation reactions were performed in 10 µl volumes using 1 µl of T4 ligase and buffer 
respectively, with an appropriate volume of distilled water. Reactions were carried out 
overnight at room temperature. Vector only ligations were performed in parallel to indicate 
the efficiency of self-ligation.  
 
 
2.10.6 Transformation of chemically competent cells 
Chemically competent DH5- or TOP10 cells (Invitrogen, USA) were transformed with 
ligation products as per manufacturer‟s guidelines. Cells were grown on LB agar plates 
containing the appropriate antibiotic.    
 
 
2.10.7 Amplification and isolation of plasmids 
5ml aliquots of LB Broth were inoculated with individual bacterial colonies and grown 
overnight at 37°C in an Innovar 44 shaker (New Brunswick Scientific, USA) set to 200 rpm. 
Plasmids were harvested using Qiagen Mini-Prep Kit (Qiagen, Germany) as per 
manufacturer‟s instructions. The Qiagen Maxi-Prep Kit (Qiagen, Germany) was used for 
large scale purifications  
 
 
2.10.8 Identification of positive clones 
Plasmids were subsequently subjected to restriction digest to identify positive clones. 
Sequencing of putative positive clones was performed by MWG, Germany. 
 
 
 
2.11 Transfection and adenoviral infection of cell cultures 
In this study siRNA oligonucleotides were delivered into cell lines and primary human 
myeloid cells in order to knock down specific proteins. Expression constructs and luciferase 
gene reporter constructs (see sections 2.10.1) were delivered into cell lines by transfection. 
Plasmids are inefficiently transfected into primary human myeloid cells therefore the 
aforementioned constructs were delivered into these cells using adenoviridae. The 
purification of adenoviral counstructs was kindly performed by Mrs Alessandra Lanfrancotti 
(Kennedy Institute of Rheumatology, London, United Kingdom). 
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2.11.1 Transfection of siRNA oligonucleotides into cell lines 
siRNA knockdown in cell lines was performed using Lipofectamine™ RNAiMAX 
Transfection Reagent (Invitrogen, UK) as per the manufacturer‟s instructions. Briefly, cells 
were seeded in 96-well plates in 100 µl penicillin/streptomycin free media. The following day 
the desired concentration of siRNA oligonucleotide was mixed with Optimem (Invitrogen, 
UK) to a final concentration of 10 µl. Then 0.2 µl of RNAiMAX was added to 10 µl of 
Optimem in a separate tube. These two mixtures were incubated for 5 min, then mixed 
together and incubated for a further 20 min at room temperature. The 20 µl mixture was 
then added to the culture media and incubated at 37ºC overnight. The following day the 
supernatants were aspirated and replaced with standard media. 72 h post-transfection the 
desired experimental conditions were applied.   
 
 
2.11.2 Transfection of siRNA oligonucleotides into primary human cells 
siRNA knockdown in MDDCs and M1 macrophages was performed in 96-well plates (in 
triplicate) using the transfection protocol stated below. Cells were differentiated for 4 days 
under appropriate conditions, harvested (supernatant was collected and stored at 4°C until 
further use), resuspended in fresh RPMI (10% serum, no P/S) and seeded into 96-well 
plates at a density of 105 cells/ml. Next day, cells were washed gently once with RPMI 
(lacking phenol red, serum, and P/S) followed by adding 30 µl of RPMI (lacking phenol red, 
serum, and P/S) to each well. The desired concentration of siRNA oligonucleotide was 
incubated with 20 µl of Optimem as well as 0.25 µl of DharmaFECT® Transfection Reagent 
I and incubated for 20 min at room temperature. The mixture was then added to the cells 
and incubated at 37°C for 2 h. The supernatant was subsequently replaced with 100 µl 
media, consisting of 50 µl fresh RPMI (10% serum, no P/S) and 50 µl of the old media 
(collected after differentiation). 48 h post transfection, 50 µl of fresh RPMI (10% serum, no 
P/S) was added to each well. 72 h post-transfection the desired experimental conditions 
were applied. 
 
 
2.11.3 Transfection of plasmids into cell lines  
Transfection of plasmids into cell lines was performed using Lipofectamine™ 2000 
Transfection Reagent (Invitrogen, UK) as per the manufacturer‟s instructions. Briefly, cells 
were seeded appropriately and the following day the desired concentration of the plasmid 
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was added to 100 µl of Optimem. Then 4 µl of pre-warmed Lipofectamine was added to 200 
µl pre-warmed Optimem. These two mixtures were incubated for 5 min, then mixed together 
and incubated for a further 30 min at room temperature. The media was then aspirated from 
the cells and replaced with the mixture containing the plasmid. The cells were incubated at 
37ºC for 2 h after which the supernatant was replaced with standard media. 48 h post 
transfection the desired experimental conditions were applied. 
 
For luciferase gene reporter experiments, HEK-293–TLR4-CD14/Md2 cells were seeded 
onto polylysine-coated 96-well plates at a density of 30,000 cells per well. The next day, 
cells were transfected with 10 ng of the indicated expression vector, 50 ng of TNF luciferase 
reporter, and 50 ng of pEAK8-Renilla using Lipofectamine2000 and the above protocol. 
Total amount of DNA was kept at 120 ng per well. At 48 h after transfection, the reporter 
activity was measured using the Dual-Glo Luciferase system (Promega, Germany) 
optimised for 96-well plate format according to the manufacturer‟s protocol (Section 2.12). 
Each experiment was performed in triplicate. 
 
 
2.11.4 Adenoviral infection of primary human myeloid cells 
Adenoviral infections of primary human myeloid cells were performed in 96-well plates in 
triplicate. Cells were seeded appropriately and the following evening standard media was 
replaced with serum free RPMI containing the desired number of viral particles (at a 
multiplicity of infection of 50:1 unless stated otherwise) in a final volume of 50 µl. The plates 
were centrifuged at 1,200rpm for 30 min then placed at 37ºC overnight. The following day 
the supernatants were aspirated and replaced with 100 µl of standard media and the cells 
were allowed to recover for 24 h before the application of experimental conditions. 
 
For luciferase gene reporter assays in primary human cells, M2 macrophages were first 
infected with expression constructs coding for IRF3, IRF5 or empty vector for 2 h followed 
by aspiration of the supernatants and replacement with 100 µl of standard media per well 
and a recovery phase of 6 h . After that, cells were infected with indicated IL-10 luciferase 
constructs for 2 h followed by aspiration of the supernatants and replacement with 100 µl of 
standard media per well. Cells were allowed to recover for a further 24 h before 
experimental assay.   
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2.12 Luciferase gene reporter assays 
Luciferase gene reporter assays allow the transcriptional activity of specific DNA sequences 
to be assessed in cell cultures. This technique utilises the firefly luciferase gene: a 
bioluminescent enzyme that catalyses the conversion of luciferin into oxyluciferin and light. 
The DNA sequence of interest was cloned directly upstream of the luciferase gene and the 
resulting genetic construct was transfected into the cell line of choice. The cells were then 
subjected to the desired experimental conditions and then the transcriptional activity of the 
respective DNA sequence was inferred by measuring photon release after the addition of 
luciferin to the cell lysate. In experiments with cell lines, cells were co-transfected with a 
plasmid encoding Renilla luciferase, which was under the control of the tyrosine kinase 
promoter. This promoter was not responsive to the experimental conditions, therefore 
measuring Renilla activity was used to normalise for transfection efficiencies, cytotoxic 
effects and differences in cell number. In experiments with primary human myeloid cells, 
luciferase activity was normalised by presenting data as fold induction. 
 
Luciferase assays were performed in triplicate in 96-well plates using Dual-Glo™ Luciferase 
Assay System reagent (Promega, Germany). After transfection of cell lines (see section 
2.11.3) or infection of primary human myeloid cells (see section 2.11.4) cells were 
stimulated as indicated in the result text. Supernatants were then harvested and 25 µl of 
PBS and the Dual-Glo™ Luciferase Reagent was added to each well respectively. Cells 
were placed on a shaker for 20 min after which lysates were transferred into luminometer 
plates and luciferase activity was measured using a 1450 MicroBeta® JET (PerkinElmer). 
25 µl of Dual-Glo™ Stop & Glo® Reagent was then added to each well and after 10 min 
Renilla activity was measured. Data were normalised by dividing luciferase activity values 
by renilla activity values.   
 
 
 
2.13 Immuno-precipitation 
HEK-293-TLR4-CD14/Md2 cells were transfected with an onestrep-IRF5-HA construct or 
corresponding empty vector. 24 h post transfection cells were fixed with 1% formaldehyde 
for 10 min at room temperature prior to high salt lysis and affinity purification on Strep-
Tactin MacroPrep sepharose (IBA, Germany). The eluates were de-crosslinked by 
incubating at 65ºC overnight prior to separation by SDS-PAGE. Exogenous IRF5 and 
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endogenous RelA were detected by immunoblotting with anti-HA-HRP (12013819001; 
Roche, UK) and anti-RelA (sc-372; Santa-Cruz, US). Alternatively, cells were transfected 
with RelA-FLAG or BAP-FLAG control protein. 24 h post transfection cells were lysed and 
affinity purified with anti-FLAG M2 sepharose beads (Sigma, UK). Exogenous RelA and 
endogenous IRF5 were detected by immunoblotting with anti-FLAG-HRP (A8592; Sigma, 
UK) and anti-IRF5 (ab2932; Abcam, UK). Interaction of endogenous RelA and IRF5 was 
detected by overnight incubation of the cell lysates with goat anti-IRF5 antibody (ab2932, 
Abcam, UK) or no antibody control prior to precipitation with protein G beads. IRF5 was 
detected by immunoblotting with mouse anti-IRF5 antibody (sc-56714; Santa-Cruz, USA) 
and RelA with rabbit anti-RelA antibody (sc-372; Santa-Cruz, US). 
 
 
 
2.14 Chromatin immuno-precipitation 
Chromatin immuno-precipitation (ChIP) is a technique that allows the interaction between 
endogenous transcription factors and endogenous promoters to be analysed in cell cultures.  
Cells were subjected to the desired experimental conditions then fixed by adding 
formaldehyde which cross-links any protein-DNA interactions. Nuclear extracts were 
subsequently sonicated to shear the DNA, after which the transcription factor of interest, 
and any interacting DNA fragmants, was immuno-precipitated with specific antibodies (see 
Table 2.10 for a list of antibodies used for ChIP). After rigorous washing, immuno-
complexes were eluted, cross-linked interactions reversed and DNA fragments were 
purified. The immuno-precipitated DNA fragments were then interrogated by real-time PCR. 
Table 2.11 shows the list of primer sequences used for TNF ChIP analysis and Table 2.12 
includes primer sequences for other gene targets. A list of all the buffers and their 
composition used in ChIP experiments can be found in section 2.19.5. 
 
 
2.14.1 Fixation and preparation of nuclear extracts 
6-7 x 106 cells were seeded in 10 cm tissue culture dishes and stimulated the following day 
as desired. When handling non-adherent cells, the cells were collected into 14 ml falcon 
tubes and treated with 1% formaldehyde (final concentration) for 5 min at room 
temperature. Formaldehyde was then quenched by adding 125mM Tris (final concentration) 
pH 7.5, rinsed with ice cold PBS and placed on ice. 3 washes were performed with ice cold 
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PBS to remove the formaldehyde. When handling adherent cells, formaldehyde was added 
directly into the tissues culture dishes for 10 min, followed by quenching and washing, 
before harvesting cells by scraping. Cells were then pelleted by centrifugation at 1,200 rpm 
at 4 ºC, resuspended in 900 µl of cytoplasmic lysis buffer and placed on ice for 5 min. Cell 
lysates were then transferred into 1.5 ml eppendorf tubes and spun in a microcentrifuge for 
5 min at 4ºC to pellet the nuclei. The supernatant was aspirated and the pellet was 
resuspended in 600 µl nuclear lysis buffer and stored at -80ºC until required. 
 
 
2.14.2 Sonication 
Nuclear extracts were sonicated using a Vibra CellT.M.VCX130 (Sonics). Each sample was 
subjected to 6 times 12 second pulses at 20% amplitude.  To ensure that the DNA was 
sheared to a suitable size i.e. 500-1,000 base pairs, a 40-50 µl aliquot was removed from 
each sample and analysed by electrophoresis. Briefly, the cross-linking was reversed by 
placing the aliquots at 65ºC overnight, followed by a standard phenol chloroform extraction 
and ethanol precipitation. The samples were resuspended in 30 µl of water, and 10 µl was 
loaded onto a 1% agarose TAE gel and run at 100V until the samples were sufficiently 
resolved to ascertain the DNA fragment size. 
 
 
2.14.3 Immuno-precipitation 
Unless otherwise stated all immuno-precipitation steps were carried out at 4ºC with rotation. 
120 µl of nuclear extract was used per immuno-precipitation. The sample was first diluted 
10 times with dilution buffer to reduce the concentration of SDS, and then pre-cleared with 
80 µl Protein G Sepharose™ bead slurry (GE Healthcare, USA) for 2 h. All sepharose 
beads used during ChIP experiments had previously been saturated with sonicated salmon 
sperm (Invitrogen, UK) to reduce any non-specific binding to the beads. The sepharose 
beads were then pelleted by centrifugation and the supernatants transferred to fresh tubes. 
2 µg of the desired antibody was added to each sample, and incubated overnight. Immuno-
complexes were then collected with 30 µl of protein G sepharose beads for 30 min, and 
subsequently washed 3 times with wash buffer, followed by 3 washes with TE. An aliquot of 
unbound sample was retained for normalisation purposes (the unbound material shall be 
referred to as the input). The beads were then resuspended in 125 µl of extraction buffer for 
20 min, after which they were pelleted and the supernatant was transferred to a fresh tube. 
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Table 2.10: Antibodies used for ChIP 
 
Antibody  Source Catalogue no. Supplier 
IgG control Rabbit PP64 Milipore 
IRF5 Goat ab2932 Abcam 
p65/RelA Rabbit sc-372 Santa Cruz 
Pol II Rabbit sc-899 Santa Cruz 
 
 
 
2.14.4 DNA purification 
Immuno-precipitated complexes and “input” fractions were heated to 65ºC overnight to 
reverse the cross-linked protein-DNA interactions. The DNA fragments were then purified 
using the QIAquick PCR Purification Kit (Qiagen, Germany) as per the manufacturer‟s 
instructions. Immuno-precipitated DNA and “input” DNA were eluted in 200 µl and 300 µl 
respectively and stored at -20ºC until required. 
 
 
2.14.5 ChIP primer design 
ChIP primers were designed using the free software Primer3 
(http://frodo.wi.mit.edu/primer3/). The guidelines listed below were applied during primer 
design and followed as closely as possible.   
 
 Amplicon of 100-200bp 
 Primer length of 20-27bp (optimal 22) 
 GC content of 40-60% (optimal 50%) 
 Tm 63-67°C (optimal 65°C) 
 Tm of forward and reverse primer must not largely differ (max. 1°C) 
 Pairs should not have a complementary sequence of more than 2 bases at the 3„ 
end 
 Complementary sequence of more than 3 bases should not exist within a primer 
 3„ end should not be T (optimal G or C) 
 No more than 2 G or C within the last 5bp of 3„ end 
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Several of the above parameters, like amplicon length or GC content, can be pre-set in the 
Primer3 software whereas others (3„ end should not be T) have to be corrected manually.  
 
Each single primer and primer pair was also analysed with the free software OligoAnalyzer 
(http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/) in addition to the above rules. 
This program predicts the possibility of homodimer or hairpin formation of a single primer as 
well as the possibility of heterodimer formation between primer pairs. All primer sets used in 
this study have passed the computational analysis and guideline points.  
 
 
2.14.6 ChIP primer testing and optimisations 
Primer pairs were ordered (Eurofins MWG, Germany) and validated on genomic DNA 
(gDNA) which had been fixed and sonicated beforehand. A good primer set should have a 
cycle threshold (Ct, the cycle at which the fluorescence from a sample crosses the 
threshold) below 25 cycles and follow the dilutions of gDNA (e.g. dilution of gDNA 1 in 8 = 1 
in 23 should equate to a decrease of the Ct value by 3 cycles). All primer sets used in this 
study were successfully tested for their Ct value and exponential function with serial 
dilutions of gDNA (data not shown).  
 
When determining the Ct values of each primer pair, melt curves were also examined for 
sequence specificity. The high specificity of a primer set is manifested by the presence of 
only one peak, usually around 85°C, occurring during melt curve analysis. Therefore, the 
more peaks detected during this type of analysis the more non-specific regions have been 
amplified. Furthermore, multiple peaks can also be a sign of primer-dimer formation 
resulting in false-positive signals. Examples of poor (Figure 2.1a) and good (Figure 2.1b) 
melt curves are shown below.  
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Figure 2.1 Melt curve analysis of ChIP primer pairs 
(a) Melt curves of three unspecific primers (blue, red, black) and one non-working primer (green) 
tested on gDNA (fixed and sonicated). Primers were considered non-specific because two peaks, 
one around 65°C and one around 80°C, occurred indicating the amplification of two different regions. 
(b) Melt curves of 4 primers (blue, red, black, green) amplifying the same regions as in (a). Only one 
very sharp peak around 85°C is visibly after melt curve testing indicating high specificity of primers.  
 
 
Another factor that can greatly influence primer behaviour and efficiency is the master mix 
used for ChIP RT-PCR. Two different types of SYBR Green master mixes were tested for 
ChIP RT-PCR, one from Applied Biosystems (SYBR®Green PCR master mix) and another 
from Takara Bio (SYBR®Premix Ex Taq™ master mix II). The Takara master mix 
consistently out-performed the Applied Biosystems master mix for 10 primer sets that were 
tested and primer E is shown as a representative in Figure 2.2. There was a difference of 3 
cycles between mastermixes equating to a 8 fold greater sensitivity with the Takara 
mastermix (shown in blue) over that from Applied Biosystems (shown in black). Therefore, 
all subsequent ChIP RT-PCR reactions were performed using the Takara SYBR®Premix Ex 
Taq™ master mix II. 
 
 
 
 
 
 
a
°C
b
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Figure 2.2 Improvement of Ct values with Takara master mix 
10 different primers were run in parallel with two different master mixes. Primer E is representative 
and the corresponding Ct values are shown in blue (Takara, SYBR
®
Premix Ex Taq™ master mix II) 
and black (Applied Biosystems, SYBR
®
Green PCR master mix).  
 
 
 
2.14.7 Real-time PCR analysis 
Analysis of DNA fragments were performed in a Corbett Rotor-gene 6000 machine (Corbett 
Research Ltd, UK) and analysed using Corbett Rotor-Gene 6000 software. All reactions 
used SYBR®Premix Ex Taq™ master mix II (Takara Bio, USA), 5 µl of DNA and a final 
primer concentration of 0.1 µM. Primers used for TNF analysis are shown in Table 2.11 and 
for other gene targets in Table 2.12. The following thermal cycling conditions were used: 
 
30 seconds at 95ºC  
40 cycles of: 10s at 95ºC + 25s at 60ºC 
 
 
Table 2.11: ChIP primers used for analysing human TNF locus: 
 
Region Binding sites  Forward primer 5’-3’ Reverse primer 5’-3’ 
control  
no ISRE 
no B 
TGTGTGTCTGGGAGTGAGAACT TCTTCTCAGCTTCTCCTTTGCT 
A NF-B 1 CCACAGCAATGGGTAGGAGAATGT GAGGTCCTGGAGGCTCTTTCACT 
B 
ISRE 1+2 /  
NF-B 2//2a 
GGAAGCCAAGACTGAAACCAGCA CCGGGAATTCACAGACCCCACT 
C ISRE 3+4 TCCCTCCAACCCCGTTTTCT TAGGACCCTGGAGGCTGAAC 
Primer E - Takara
Primer E – Applied Biosystems
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D ISRE 5 AACTTTCCAAATCCCCGCCC GGTGTGCCAACAACTGCCTT 
E 
ISRE 6+7+8 / 
NF-B 3 
CAGCAAGGACAGCAGAGGAC TCCCGGATCATGCTTTCAGT    
F ISRE 9+10 GGCAGTCAGTAAGTGTCTCCAA TACCTACAACATGGGCTACAGG    
G ISRE 11 ACAGCTTTGATCCCTGACATCT CTCCGTGTCTCAAGGAAGTCTG 
H 
no ISRE 
NF-B 4/4a/4b 
ATATTCCCCATCCCCCAGGAAACA CTGCAACAGCCGGAAATCTCACC 
I ISRE 12 GAGGACCTCACTCAGCCCTT CGGCAGTTCGGTTCCTTGTT 
J ISRE 13 ACTGGTCTTTGTGGTGAAGGAG GAACTAGTGGGCTCAAGTGGTC    
K ISRE 14 GCTATGATCATGCCACTGTACCC TACCACATGGTTTTCTCCTGCC 
L ISRE 15 GCTGAAAGTCAGCCATGAAGTA CACTTAGGGTGTCCCATTTAGG    
 
Each primer pair is specific for the designated region of the human TNF locus. The types of transcription 
factor binding sites present in each region are listed under column “binding sites”.  
 
 
 
Table 2.12: Primers used for ChIP analysis: 
 
Gene Forward primer 5’-3’ Reverse primer 5’-3’ 
IL-10 CCTGTGCCGGGAAACCTTGATTGTGGC GTCAGGAGGACCAGGCAACAGAGCAGT 
IL-12p35  TCATTTTGGGCCGAGCTGGAG TACATCAGCTTCTCGGTGACACG 
IL-12p40 TCCAGTACCAGCAACAGCAGCAGA GTAGGGGCTTGGGAAGTGCTTACCTT 
IL-23a ACTGTGAGGCCTGAAATGGGGAGC ACTGGATGGTCCTGGTTTCATGGGAGA 
 
Each primer pair is specific for the designated human gene and its promoter region.  
 
 
 
2.15 Flow cytometry (FCM) analysis 
Cells were stained for surface markers with desired antibodies in FCM buffer for 30 min at 
4°C. Cells were then washed twice with FCM buffer and fixed with Cytofix solution (BD 
Bioscience, UK) for 15 min at RT. Cells were wash again twice and either analysed 
immediately or stored for up to 5 days at 4°C.  
 
For intracellular cytokine (ICC) stainin, cells were stimulated for 3-4 h with phorbol myristate 
acetate (PMA), ionomycine and Brefeldin A (Sigma, UK). Cells were then stained for 
surface markers as described above followed by fixing in Cytofix solution (BD Bioscience, 
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UK). Cells were washed twice with FCM buffer and permeabilized for 30 min at 4°C using 
PBS containing 1% FCS, 0.01% sodium azide, and 0.05% saponin. Intracellular cytokines 
were stained with desired antibodies in FCM permeabilization buffer for 30 min at 4°C. Cells 
were then washed twice with FCM permeabilization buffer followed by resuspension in FCM 
buffer. ICC stained cells were always analysed immediately. Samples were run on a FACS 
Canto II (BD Bioscience, UK) and analysed using FlowJo software (TreeStar, USA). A list of 
antibodies used in this study is shown in Table 2.13 
 
 
Table 2.13: Antibodies used for FCM analysis 
 
Antibody  Conjugate Clone 
Catalogue 
no. 
Supplier  
CD4 PE-Cy7 RPA-T4 25-0049 eBioscience 
CD8a PerCP-Cy5 RPA-T8 45-0088 eBioscience 
CD40 APC 5C3 17-0409 eBioscience 
CD163 PE 215927 FAB1607P R&D Systems 
IFN- PB S4.B3 48-7311 eBioscience 
IL-17A PE eBio64CAP17 12-7178 eBioscience 
 
 
 
2.16 Mixed lymphocyte reactions (MLR) 
 
2.16.1 MLR with MDDCs as APCs 
Human MDDCs were plated in 96-well, flat-bottom tissue plates at 2 x 104 cells/well. T 
lymphocytes were isolated from the blood of healthy MHC mismatched donors by 
elutriation, analysed by FCM and used if purity was >90%. T lymphocytes were added to 
MDDCs at 5 x 105, such that the final MDDC to T lymphocyte ratio was 1:25. Control 
cultures contained medium, T lymphocytes or MDDCs alone. 10 μg/ml of anti-TNFR1 
antibody (MAB 625, R&D Systems) or IgG control antibody (MAB 002, R&D Systems) was 
added to the co-cultures after 6 h or 24 h were indicated. Cultures were established in 
duplicate and incubated at 37°C in 5% CO2 for a total of 72 h. Following culture, 
supernatants were collected and stored at -20°C for later detection of cytokines. 
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2.16.2 MLR with macrophages as APCs 
Human M2 macrophages were plated in 96-well plate as in section 2.12.1. M2 
macrophages were infected with adenoviral vectors encoding IRF5, IRF3 or empty vector 
(pENTR) where indicated. Following infection, cells were left to recover for 24 h before 
addition of 5 x 105 T lymphocytes per well. Control cultures contained medium, T 
lymphocytes or M2 macrophages alone. After 72-96 h of co-culture supernatants were 
collected for detection of cytokines. In certain experiments, T lymphocytes were harvested 
48 h after co-culture for mRNA analysis. For proliferation experiments, cells were pulsed 
with 37,000 Bp of [3H] thymidine (Amersham Biosciences, USA) 16 h before harvest and 
DNA synthesis was measured by [3H] thymidine incorporation using a Beckman beta 
scintillation counter (Beckman Instruments, USA). The [3H] thymidine incorporation assays 
were kindly performed by Dr Saba Alzabin (Kennedy Institute of Rheumatology, London, 
United Kingdom). 
 
 
2.17 Bioinformatic analysis 
Genomic sequences were obtained using the publicly available UCSC Genome Browser 
website (http://genome.ucsc.edu/) and the Ensembl website 
(http://www.ensembl.org/index.html). Predicted transcription factor binding sites were 
obtained using the websites Genomatrix (http://www.genomatix.de/) and JASPAR 
(http://jaspar.cgb.ki.se/). The website Primer 3 (http://frodo.wi.mit.edu/) was used for primer 
design in general whereas the program OligoAnalyzer 
(http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/) was utilised for predicting the 
possibility of hairpin, self- or heterodimer formation of primers.  
 
 
 
2.18 Statistical analyses 
Quantitative data are presented as mean ± standard deviation or standard error as 
indicated. All statistical analyses were performed using GraphPad Prism 5.0 software. 
Experiments containing only two measurments were analysed using a T-test. Experiments 
containing three or more measurments were analysed using one-way ANOVA.  
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2.19 Buffers and Solutions 
 
2.19.1 General buffers 
PBS with pH 7.2: 
 4.3mM Na2HPO4 
 1.4mM KH2CO3 
 1.4mM KCl 
 137mM NaCl 
 
FCM buffer 
 1% BSA in PBS 
 0.01% sodium azide 
 
FCM permeabilization buffer 
 PBS 
 1% FCS 
 0.01% sodium azide 
 0.05% saponin 
 
 
2.19.2 SDS-PAGE and Western blotting 
Whole cell lysis buffer for cell lines: 
 20mM Tris pH 8.0 
 300mM NaCl  
 0.1% NP-40  
 10% glycerol 
 
Whole cell lysis buffer for primary human myeloid cells: 
 20mM Tris pH 8.0 
 150mM NaCl  
 1% NP-40  
 10% glycerol 
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Cytoplasmic lysis buffer: 
 10mM HEPES, PH 7.9  
 10mM KCl  
 0.1mM EDTA  
 0.1mM EGTA 
 
Nuclear lysis buffer: 
 20mM HEPES, pH 7.9 
 400mM NaCl 
 1mM EDTA 
 1mM EGTA 
 
4X loading buffer: 
 250mM Tris, pH 6.8 
 6% SDS 
 40% Glycerol 
 0.04% Bromphenol Blue 
 20% 2-mercaptoethanol 
 
SDS-PAGE running buffer: 
 25mM Tris-base 
 192mM Glycine 
 0.1% SDS 
 
Transfer buffer: 
 25mM Tris-base 
 192mM glycine 
 10% methanol 
 
Blocking buffer: 
 PBS 
 5% dried milk powder 
 0.1% tween 
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Wash buffer: 
 0.1% tween in PBS 
 
 
2.19.3 ELISA buffers 
ELISA blocking buffer 
 2% BSA in PBS 
 
ELISA dilution buffer 
 0.5% BSA in PBS 
 
ELISA wash buffer 
 0.1% Tween 20 in PBS 
 
ELISA stop solution 
 940ml H2O 
 60ml H2SO4 
 
 
2.19.4 EMSA 
2x Binding buffer 
 20mM Hepes, pH 7.9  
 2mM EDTA  
 2mM EGTA  
 25% glycerol  
 0.125-0.250 mg/ml dI-dC  
 
 
2.19.5 Chromatin immuno-precipitation 
Cytoplasmic lysis buffer: 
 50mM Tris, pH 8.0  
 2mM EDTA, pH 8.0 
 0.1% NP40 
 10% Glycerol 
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Nuclear lysis buffer: 
 50mM Tris pH 8.0 
 5mM EDTA 
 1 % SDS 
 
Dilution buffer (DB): 
 50mM Tris, pH 8.0 
 5mM EDTA 
 200mM NaCl 
 0.5 % NP40 
 
Wash Buffer (WB):  
 20mM Tris, pH 8.0 
 2mM EDTA 
 0.1 % SDS 
 1 % NP40 
 500 mM NaCl 
 
Extraction Buffer (EB):  
 1X TE  
 2 % SDS 
 
 
2.19.6 Molecular biology solutions 
Lennox L broth base (LB) 
 20g LB (Invitrogen, UK) 
 1l H2O 
 Autoclave before use 
 
Lennox L agar (LB agar) 
 32g LB agar (Invitrogen, UK) 
 1l H2O 
 Autoclaved, added antibiotics once cooled and poured into plates 
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Ampicillin 
 100 mg/ml Ampicillin (Sigma, UK) 
 Diluted in autoclaved H2O and stored at -20°C 
 
Kanamycin 
 30 mg/ml Kanamycine (Sigma, UK) 
 Diluted in autoclaved H2O and stored at -20°C 
 
SYBR Green II 
 Add 1:10 to DNA products 
 Store stock at -20°C 
 
Ethidium bromide 
 Used at a final concentration of 0.1 µg/ml (Sigma, UK) 
 Stored at 4°C 
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3. IRF5-mediated human TNF gene expression 
 
3.1 Introduction 
As well as playing a central role in host defence against infection, TNF is a major factor in 
the pathogenesis of chronic inflammatory disease such as RA and IBD [282]. Its central role 
in the pathogenesis of RA is exemplified by the success of anti-TNF therapy developed at 
the Kennedy Institute of Rheumatology, which has proved to be therapeutically successful 
in more than 500,000 RA patients world-wide. However, the high cost, limited convenience 
of injections and risk of systemic side-effects are the major reason for further research into 
the molecular mechanisms that govern inflammatory response and identification of new 
targets for specific and ideally orally administrated therapeutic intervention.  
 
Regulation of transcription for many immune genes in response to TLR signalling involves a 
combination of NF-B and IRF factors [283]. IRFs appear to provide a mechanism for 
conferring signal specificity to a variety of target gene subsets, with IRF3 being essential for 
type I IFN response [284] and a suggestive role for IRF5 in the transcriptional regulation of 
pro-inflammatory cytokines, including TNF, IL-6 and IL-12p40 [190]. However, the molecular 
mechanisms underlying the role of IRF5 in regulating murine TNF gene expression were not 
further investigated by Takaoka and co-workers and are therefore poorly understood. 
Moreover, the contribution of IRF5 to the human TNF gene induction remains currently 
unknown. 
 
The initial goal of this study was to clarify and establish conclusively the molecular 
mechanisms employed by IRF5 to regulate human TNF gene expression. In the focus of 
this study were primary human myeloid cells, as those are the major producers of TNF, and 
thus it has an immediate relevance to the human inflammatory response.  
 
Observations made in this part of the study paved the way for the detailed investigation of 
the role of IRF5 in macrophage polarization and are presented in Chapter 4 and 5 of this 
thesis.  
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3.2 Results 
 
3.2.1 IRF5 expression is high in MDDCs and controls late phase TNF 
secretion 
Myeloid cells from Irf5-/- mice show impaired induction of pro-inflammatory cytokines 
including TNF upon stimulation by different TLR ligands [190]. I therefore first examined 
levels of IRF5 protein following human monocyte differentiation into MDMs (in the presence 
of M-CSF) and MDDCs (in the presence of GM-CSF plus IL-4). No increase in the levels of 
IRF5 protein was observed in MDMs even after 5 days of differentiation (Figure 3.1). 
However, increased expression of IRF5 protein was detected following 1 day of monocyte 
differentiation into MDDCs and remained at an elevated level until day 7 (Figure 3.1). 
Significantly, whereas at least three different IRF5 isoforms were observed in human 
monocytes, only some of them accounted for high levels of IRF5 protein in MDDCs: one is 
likely to be IRF5v3/v4 [180]. Other IRF family members were not expressed in resting cells 
as expected (IRF7) or did not show this pattern of cell-type specific expression (IRF3 and 
IRF9; Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
Figure 3.1 IRF5 is highly expressed in MDDCs 
Cells were collected at day 0 (monocytes); day 1, 3, 5 and 7 (MDDCs) post differentiation with GM-
CSF (50 ng/ml) and IL-4 (10 ng/ml); day 1, 3 and 5 post differentiation with M-CSF (50 ng/ml) 
(MDMs) and total protein extracts were subjected to western blot analysis with antibodies to IRF 
family members. p38 MAPK was used as loading control. A representative blot of 5 independent 
experiments each using monocytes derived from a different donor.   
 
 
IRF3
IRF7
IRF9
p38
IRF5
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Next, I wanted to know if MDMs and MDDCs differ in their production of TNF in response to 
TLR4 stimulation. TNF protein is below the limit of detection in the supernatants of resting 
cells (Figure 3.2a). Following 4 h of LPS stimulation, TNF is secreted at similar levels in 
MDMs and MDDCs (early phase). However, a marked difference in TNF production was 
observed in MDMs and MDDCs stimulated with LPS for 24 h (late phase). While the level of 
TNF significantly decreased in MDMs, there was an increase in TNF levels in MDDCs 
(Figure 3.2a) in each individual blood donor (Figure 3.2b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Prolonged TNF secretion in MDDCs 
(a) MDDCs and MDMs were left unstimulated or stimulated with LPS (10 ng/ml) for 4 h or 24 h and 
secreted TNF was measured by ELISA. Data show mean ± standard error of the mean (SEM) of 5 
independent experiments each using monocytes derived from a different donor: *p<0.05, ** p<0.01 
(Student‟s T-test). (b) Data show the trend in TNF secretion in 5 (MDMs) or 6 (MDDCs) donors 
stimulated as in (a). 
 
 
Human TNF acting through TNF receptor 1 (TNFR1, also known as p55) is involved in 
activation of Th1 lymphocytes, measured by the release of Interferon gamma (IFN-) [285]. 
Thus, I examined whether the late phase secretion of TNF by MDDCs is needed for IFN- 
production by T lymphocytes in a mixed lymphocyte reaction (MLR). A MLR is an in vitro 
method for assessing T lymphocyte proliferation and activation state. This assay is based 
on the observation that T lymphocytes will get activated and expand when they are cultured 
together with allogeneic (MHC mismatched haplotype) APCs. The proliferation of the 
lymphocyte population can be analysed by measuring the incorporation of [3H] thymidine 
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(which occurs during each cell division) and the activation state can be assessed by 
measuring T lymphocyte-specific cytokines in the culture supernatants by ELISA.  
 
One essential variable of the MLR that needs to be optimised is the ratio of APCs to T 
lymphocytes. I started by setting up MLRs with MDDCs (used as the APC population) 
isolated from 2 donors and T lymphocytes isolated from 2 different (MHC mismatched) 
donors. I used two independent donors per population in order to minimise the effect of 
donor variations. The MDDCs from the two donors were plated in 96-well plates at a 
concentration of 2 x 104 cells per well and stimulated for 2 h with LPS prior to co-culture with 
each T lymphocyte population at a ratio of either 1:1, 1:2, 1:5, 1:10, 1:25, 1:50 or 1:100. 
Cultures were set up in duplicate and the amount of secreted IFN- was determined after  
72 h of co-culture by ELISA. Two independent donors per cell population supplied me with 4 
supernatants per cell ratio helping me to determine the right culture conditions. The highest 
amount IFN- was detected in the 4 co-cultures containing a MDDC to T lymphocyte ratio of 
1:25 (data not shown) and this ratio was subsequently used in MLR assays.  
 
After establishing optimal cell culture conditions I started to examine the importance of late 
phase TNF secretion by MDDCs for T lymphocytes activation state. MDDCs were 
stimulated with LPS for 2 h and exposed to T lymphocytes from a MHC mismatched donor 
at a ratio of 1:25. Antibodies against TNF receptor 1 (TNFR1) or isotype IgG control were 
added to the reaction. T lymphocytes incubated with MDDCs treated with anti-IgG 
antibodies produced high levels of IFN- (Figure 3.3), while the control reactions (MDDCs or 
T lymphocytes cultured on their own) secreted no detectable IFN- (data not shown). 
Blocking TNF 6 h after co-culture start resulted in strong reduction of IFN-, but no effect 
was observed when anti-TNFR1 antibodies were added to the reaction after 24 h, 
suggesting that most of T lymphocytes are in activated state after the prolonged exposure 
to TNF (Figure 3.3). This suggests that the observed sustained expression of TNF by 
MDDCs is involved in establishing a robust Th1 phenotype. 
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Figure 3.3 Late phase TNF secretion is required for potent T lymphocyte response 
MDDCs were stimulated with LPS for 2 h and then co-cultured with T lymphocytes. Anti-TNFR1 (grey 
bars) or anti-IgG control antibodies (black bars) were added 6 h or 24 h after co-culture start. IFN- 
secretion was determined by ELISA after 72 h of co-culture. Data show mean ± SEM of 3 
independent experiments each using cells derived from a different donor. *p<0.05 (Student‟s T-test). 
–AB, a no antibody control.  
 
 
Based on the above results, I hypothesised that the difference in TNF secretion profile in 
MDDCs and MDMs might be due to the difference in IRF5 expression in these cells. To test 
this hypothesis, MDMs that have low levels of endogenous IRF5 protein (Figure 3.1) were 
infected with adenoviral expression vector encoding IRF5, IRF3 (as a control) or an empty 
vector (pBent).  
 
Adenoviruses are efficient tools for delivering transgenes to cells both in vitro and in vivo. 
The expression of transgenes was limited to transfection of cell lines and not possible in 
primary human cells prior to the discovery of adenoviruses. There are now many different 
delivery strategies, such as retroviral, lentiviral and adenoviral systems, that exploit the 
ability of viruses to transport DNA to cells. The advantage of the adenovirus system is the 
fact that they will infect both proliferating and quiescent cells making them suitable for 
targeting terminally differentiated cells such as macrophages. Disadvantages include the 
transient transfection of cells as viral DNA will not integrate into the host genome and the 
initiation of an immune response following virus administration. It is this immune response 
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that can be a potential problem when working with myeloid cells such as macrophages. 
However, I routinely analysed the secretion of endogenous IFN-1 protein as well as mRNA 
induction of type I IFNs and observed no significant effect on resting cells 48 h or 72 h post 
infection. Another crucial issue is the degree of overexpression of the transgene. If a protein 
is overexpressed at a massive level, e.g. 100-1000-fold greater expression than the 
endogenous protein, resulting phenotypes could be artifacts. 
 
IRF5 and IRF3 vectors expressed similar levels of proteins (Figure 3.4a, anti-HA blot) and 
blotting for endogenous IRF5 indicated an increased expression but not a swamping of the 
system (Figure 3.4a, anti-IRF5 blot). The overexpression of IRF5 resulted in a significant 
increase in TNF secretion in unstimulated cells (Figure 3.4b) which was not observed in 
control or IRF3 expressing cells. Consistent with previously published data, IRF3 induced 
IFN-1 secretion, demonstrating the functionality of this construct [286], whereas ectopic 
IRF5 showed no effect (Figure 3.4c). Strikingly, TNF secretion in MDMs with over-
expression of IRF5 remained at a steady sustained level up to 48 h post LPS stimulation 
(Figure 3.4d), similar to that of MDDCs with high levels of endogenous IRF5 (Figure 3.2a).  
 
Finally, I looked at the effect of ectopic IRF5 expression in MDMs on T lymphocyte 
activation. MDMs were infected with adenoviral expression vector encoding IRF5 or the 
corresponding empty vector pBent. Exposure of T lymphocytes to MDMs with endogenous 
IRF5 protein resulted in an increase of IFN- secretion to the levels comparable to T 
lymphocytes exposed to MDDCs (Figure 3.4e). Taken together, these results suggest that 
sustained TNF secretion by MDDCs leads to a robust T lymphocytes activation and is likely 
to be a consequence of a high amount of IRF5 protein in these cells. 
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Figure 3.4 Ectopic expression of IRF5 in MDMs results in prolonged TNF secretion  
(a) MDMs were infected with adenovirus encoding IRF5-HA or IRF3-HA. The expression of each 
construct was determined 48 h post-infection by subjecting equal amounts of whole cell protein 
lysates to western blot analysis and probing with anti-HA or anti-IRF5. Actin was used as a loading 
control and a representative blot is shown. (b) MDMs were left untreated (cells) or infected with 
adenovirus coding for IRF5, IRF3 or empty vector (pBENT) and the amount of secreted TNF protein 
in unstimulated cells was measured by ELISA. Data show 9 independent experiments each using 
MDMs derived from a different donor. (c) The 8 h post LPS supernatants from (b) were analysed by 
ELISA for IFN-λ1 secretion. Data show 2 independent experiments each using MDMs derived from a 
different donor. (d) MDMs were treated as in (a) and stimulated with LPS for the indicated times. The 
amount of secreted TNF protein was determined by ELISA. Data show mean ± standard deviation 
(SD) and are representative of 3 independent experiments each using MDMs derived from a different 
donor. (e) MDMs were left untreated (-) or infected with adenoviral vectors encoding IRF5 or empty 
vector pBent, stimulated with LPS for 2 h and co-cultured with T lymphocytes. IFN- secretion was 
determined by ELISA after 72 h of co-culture. Data show mean ± (SD) and are representative of 3 
independent experiments each using MDMs derived from a different donor. 
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3.2.2 si-RNA mediated depletion of IRF5 reduces late-phase TNF 
secretion 
Next, I wanted to know what the effect of the complementary experiment, targeting 
endogenous IRF5 in MDDCs by RNA-mediated interference, would have on TNF 
production. RNA interference (RNAi) is a mechanism for RNA-guided regulation of gene 
expression in which double-stranded ribonucleic acid inhibits the expression of genes with 
complementary nucleotide sequences. A set of four individual On Target Plus short 
interfering RNA (siRNA) sequences targeting the human IRF5 gene were purchased from 
Dharmacon, UK.  
 
I first attempted to optimise the transfection protocol in the cell lines HT1080 (data not 
shown) and HEK-293-TLR4-CD14/Md2 (Figure 3.5) before targeting IRF5 in MDDCs as the 
transfection of primary human cells is known to be difficult. A pool of 4 random non-
targeting siRNA sequences (siC) was used as a control for non-sequence-specific effects. 
Changes in protein levels in cells treated with siC reflect a non-specific baseline of cellular 
response to which the levels in cells treated with target-specific siRNA can be compared. 
Unfortunately, neither the individual sequences nor their pool showed IRF5 knock-down at 
the protein level. Technical difficulties with the transfection itself were discounted as a 
potential problem as the siRNA pool targeting RelA worked well and equal loading of protein 
onto the protein gel was confirmed by the equal amounts of -actin detected in the lysates.  
 
 
 
 
 
 
 
 
Figure 3.5 siRNA-mediated depletion of IRF5 is not possible in HEK-293-TLR4 cells 
HEK-293-TLR4-CD14/Md2 cells were transfected with non-targeting siRNA (siC), individual siRNAs 
targeting IRF5 (siIRF5_1 to siIRF5_4), a pool consisting of these four sequences (siIRF5_P) or 
siRNA targeting RelA. Whole cell protein lysates were subjected to western blot analysis 72 h post 
transfection and IRF5 protein levels were compared to siC treated cells. Actin was used as a loading 
control. A  
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The above experiment was repeated in HEK-293-TLR4-CD14/Md2 cells in order to exclude 
individual errors. Furthermore, quantitative RT-PCR was performed in addition to western 
blot analysis to assess the knock-down of IRF5 at mRNA level as siRNA interferes with 
protein expression by targeting the respective mRNA for degradation. Each individual 
siRNA targeting IRF5 as well as the pooled sequences showed convincing depletion of 
IRF5 mRNA expression (data not shown) yet no effect on protein level was observed.  
 
The following experiments were performed in order to further optimise IRF5 protein knock-
down in cell lines: 
1. Transfection of cells for a longer period (western blot analysis 96 h and 120 h post-
transfection; data not shown) 
2. The amount of siRNA was increased up to 100nM (data not shown) 
3. Additional sequences targeting IRF5 were tested (data not shown) 
4. Double transfection (second transfection 48 h after the first one, western blot 
analysis 96 h after first transfection) 
 
None of the conditions stated above resulted in the knock-down of IRF5 protein although a 
decrease of IRF5 mRNA was observed. This led to the conclusion that the IRF5 protein was 
likely to be a very stable protein with a long half-life. The half-life of a protein can be 
assessed by blocking protein re-synthesis with cycloheximide followed by monitoring protein 
levels over time. Interestingly, no changes of IRF5 protein levels, even at later time points  
(8 h), were observed when cycloheximide was added to HEK-293-TLR4-CD14/Md2 cells 
(data not shown). I concluded that the knock-down of IRF5 in the cell lines tested was not 
working likely due to cell type specific reasons and decided to attempt the knock-down in 
MDDCs. As a rationale, these cells have at least 3 times more endogenous IRF5 protein 
compared to the cell lines used and are non-dividing cells where the loss of siRNA 
sequences during cell division should not occur. Initial experiments in MDDCs showed only 
a minimal depletion of IRF5 protein prompting me to further optimise the transfection 
protocol and the final working conditions are listed in the methods section 2.10.2.  
 
The protein knock-down of IRF5 in MDDCs was usually between 50 and 60% (Figure 3.6a), 
which is comparable to other RNAi knock-downs achieved in these cells (e.g. RelA, data not 
shown). The expression of both protein and mRNA of other IRF family members (IRF3, 
IRF7 and IRF9) was not affected in si-IRF5 treated cells (data not shown). Although other 
potential off-target effects cannot be ruled out, this conferred some confidence as to the 
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sequence specificity of the si-IRF5 pool used. I also analysed the induction of type I IFNs, 
known to be a major obstacle for RNAi experiments, on mRNA level and found it to be 
minimal (3 fold induction compared to untreated cells, data not shown). However, the 
siRNA-mediated depletion of IRF5 in MDDCs resulted in reduction of TNF secretion at 8 
and 24 h post LPS stimulation (Figure 3.6b) supporting the notion that IRF5 may be 
required for the late phase TNF expression. 
 
 
 
 
 
 
 
 
 
Figure 3.6 siRNA-mediated depletion of IRF5 affects late phase secretion of TNF 
(a) MDDCs were transfected with siRNAs targeting IRF5 (siIRF5) or control siRNA (siC). ~50% of 
IRF5 protein was degraded as estimated by serial dilutions of the siC control sample analysed by 
western blotting. (b) MDDCs were transfected with siIRF5 and stimulated with LPS (10 ng/ml) for the 
indicated time. TNF secretion was compared to control cells transfected with siC. Data shown are the 
mean ± SD and are representative of 2 independent experiments each using MDDCs derived from a 
different donor.   
 
 
3.2.3 IRF5 is involved in transcriptional regulation of TNF  
I next sought to investigate whether IRF5 is involved in transcriptional regulation of TNF 
gene expression. In human MDDCs stimulation with LPS resulted in a rapid up-regulation of 
TNF mRNA expression, which reached the peak between 1 and 2 h but remained at a 
steady level until 8 h post stimulation (Figure 3.7a). Consistent with the observed 
differences in protein secretion, TNF mRNA expression in MDMs was characterised by 
more transient kinetics (Figure 3.7a). The siRNA-mediated depletion of IRF5 in MDDCs 
reduced TNF mRNA expression (Figure 3.7b) and the observed inhibition was statistically 
significant when analysed in multiple blood donors (Figure 3.7c). In the same cells siRNA-
mediated inhibition of NF-B RelA, a transcription factor previously shown to be important 
for an efficient TNF production by human MDDCs [287], resulted in reduction of TNF mRNA 
a b
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expression at the initial phase of gene induction (1-2 h post LPS stimulation) (Figure 3.7b). 
Within this time window, depletion of both IRF5 and RelA had the strongest effect on mRNA 
expression (Figure 3.7b), indicating that RelA and IRF5 may cooperate in controlling 
transcription of the TNF gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 LPS-induced expression of TNF mRNA is IRF5 dependent 
(a) MDDCs and MDMs from the same donor were stimulated with LPS for the indicated time and 
TNF mRNA expression was determined by 2-standard curve RT-PCR. Data shown are from a 
representative experiment. (b) MDDCs were transfected with siRNAs targeting IRF5 (siIRF5), RelA 
(siRelA) or both (si(IRF5+RelA)) and stimulated with LPS (10 ng/ml) for the indicated time. TNF 
mRNA expression was compared to control cells transfected with non-targeting siRNA (siC). Data 
shown are the mean ± SD and are representative of 4 independent experiments each using MDDCs 
derived from a different donor. (c) MDDCs were transfected with siRNAs targeting IRF5 (siIRF5) or 
control siRNA (siC). ~60% of IRF5 mRNA was degraded and affected LPS-induced TNF mRNA 
expression in MDDCs. Data shown are the mean ± SEM of 4 independent experiments presented as 
a % of reduction in TNF mRNA levels by siIRF5: *p< 0.05, ** p<0.01 (Student‟s T-test). 
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To investigate whether IRF5 can directly modulate transcription of the TNF gene, I used a 
gene-reporter plasmid in which the luciferase gene was flanked with 1171 bp 5‟ upstream 
and 1252 bp 3‟ downstream of the human TNF gene (TNF 5‟wt/3‟wt). This construct 
encompassed all evolutionary conserved sequences in the region and contained known B 
sites [288, 289]. It was generated by combining a luciferase construct containing the 1171 
bp 5‟ upstream region of the TNF gene (pGL3 TNF 5‟wt) and a construct containing the 
1252 bp 3‟ downstream region (TOPO TA TNF 3‟wt, kindly provided by Dr. Tim Smallie, 
Kennedy Institute of Rheumatology, London, United Kingdom). The 3‟ downstream region 
was excised form the TOPO TA vector with XbaI/SalI and sub-cloned into the pGL3 TNF 
5‟wt luciferase construct using the same restriction enzymes. Positive clones were identified 
by restriction digest and sequencing.  
 
The TNF 5‟wt/3‟wt was co-expressed with constructs coding for IRF5, IRF3 and NF-B 
subunits in HEK-293-TLR4-CD14/Md2 cells, and luciferase activities were compared to 
empty vector pBent. RelA and IRF5 transfected cells showed a significant increase in 
luciferase activity (Figure 3.8a). Other NF-B subunits or IRF3 had little or no effect (Figure 
3.8a and b). Of interest, a deletion of the IRF5 DNA-binding domain (IRF5 DBD) or a point 
alanine to proline mutation in it (IRF5 A68P) previously shown to act as dominant negative 
mutant of IRF5 [189, 290], resulted either in a slight inhibition (IRF5 DBD) of luciferase 
activity or had no effect (IRF5 A68P) as compared to control transfected cells  
(Figure 3.8c). Preliminary experiments using ectopic expression of IRF5 DBD in MDDCs 
showed a decrease in TNF mRNA expression (4 h and 8 h post LPS stimulation, data not 
shown) as well as a diminished secretion of TNF protein (24 h post LPS stimulation, data 
not shown) further highlighting the importance of this domain.  
 
I concluded that IRF5 along with RelA is likely to be directly involved in the transcriptional 
regulation of the human TNF gene. While the initial phase of TNF induction depends on 
both factors, only IRF5 appears to be crucial for maintaining prolonged TNF transcription in 
MDDCs. Moreover, the DNA-binding domain of IRF5 is required for the optimal level of TNF 
gene induction.  
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Figure 3.8 IRF5 is involved in transcriptional regulation of TNF 
(a) HEK-293-TLR4-CD14/Md2 cells were co-transfected with the TNF 5‟wt/3‟wt reporter plasmid and 
equal amounts of expression plasmids encoding for human IRF5, RelA, IRF3 or empty vector 
(pBent). 48 h post-transfection cells were harvested and luciferase activity was measured as 
described. Data are presented as a fold over pBent ± SEM from 4 independent experiments: 
*p<0.05, ** p<0.01 (One-way ANOVA). (b) HEK-293-TLR4-CD14/Md2 cells were co-transfected with 
the TNF 5‟wt/3‟wt reporter plasmid and equal amounts of expression plasmids encoding NF-κB 
subunits or empty vector (pBent). (c) HEK-293-TLR4-CD14/Md2 cells were co-transfected with the 
TNF 5‟wt/3‟wt reporter plasmid and equal amounts of expression plasmids encoding IRF5, IRF5 
ΔDBD, IRF5 A68P or empty vector (pBent). (b,c) Data are presented as a fold over pBent ± SD from 
a representative experiment. 
 
 
3.2.4 Computational analysis of the human TNF locus 
The fact that IRF5 is involved in the transcriptional regulation of TNF (Figure 3.7b and c) 
and that its DBD is required for this effect (Figure 3.8c) prompted me to investigate IRF5 
recruitment to the human TNF locus in vivo using chromatin immuno-precipitation (ChIP) 
analysis.  
 
The principle of this assay is that DNA-binding proteins (e.g. transcription factors) can be 
cross-linked to chromatin in living cells by formaldehyde fixation. Following fixation, the cells 
are lysed and the chromatin is broken down to 0.5 - 1 kb in length by sonication. Once the 
proteins are immobilized on the chromatin and the chromatin is fragmented, whole protein-
DNA complexes can be immunoprecipitated by using specific antibodies against the 
protein/transcription factor of interest. The DNA from the isolated protein/DNA fraction can 
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then be purified. The identity of the DNA fragments isolated in complex with the protein of 
interest can then be determined by quantitative RT-PCR using primers specific for the DNA 
regions under investigation. The DBD of IRF factors is well-conserved and recognises a 
class of DNA sequences termed IFN-stimulated response element (ISRE). I therefore 
analysed the human TNF locus for the presence of putative ISREs.  
 
The genomic sequence of human TNF gene was obtained from the publicly available 
Ensembl website (http://www.ensembl.org/index.html). The region chosen for further 
analysis is spanning from -1,420bp to 2,222bp relative to the transcription start site or in 
other words, the whole region between Lymphotoxin  and Lymphotoxin . The prediction 
of transcription factor binding sites was conducted using the websites Genomatix 
(http://www.genomatix.de/) and JASPAR (http://jaspar.cgb.ki.se/). The combination of these 
two websites allowed me to identify 15 putative ISREs within the TNF locus which are 
shown schematically in Figure 3.9. Only ISREs with a perfect match or no more than two 
alterations to the binding sequence GAAANNGAAACT were considered as putative ISREs. 
Interestingly, some of the putative ISREs were located in a close proximity to the four 
known NF-B binding regions, namely NF-B1, NF-B2//2a, NF-B3 and NF-B4/4a/4b. 
Thus, I decided to include these regions in the final list of transcription factor binding sites of 
interest.  
 
 
 
 
 
 
 
Figure 3.9 Schematic of the human TNF locus 
The region shown is spanning from -1,420 bp to 2,222 bp relative to the TSS (indicated as +1) of the 
human TNF gene Protein coding and non-coding exons are shown in black and white, respectively. 
Putative ISREs are allocated as white ovals and B sites as black circles.   
 
 
 
+1
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3.2.5 Design of ChIP primers 
The specificity of in vivo transcription factor binding detection greatly depends on the 
selection of primers used in the final step of the RT-PCR analysis. Therefore, I paid special 
attention to the design and optimisation of my primer pairs.  
 
The analysed TNF locus was first of all segmented into smaller regions, each containing 
either ISREs or NF-B binding sites, or both. This resulted in a total of 12 regions named 
region A to region L. A further region, termed control region (CO), containing no ISRE or 
NF-B site was chosen as a negative control (Figure 3.10a). Altogether 13 primer pairs, 
named primer A to primer L and primer CO, were designed and ordered from Eurofins 
MWG, Germany. More details and guidelines about primer design can be found in chapter 
2, section 2.12.5. The primer sets were analysed for their Ct values and melt curves (see 
chapter 2, section 2.12.6) on genomic DNA (gDNA) which had been fixed and sonicated 
beforehand. In summary, I tested 53 primer pairs for their Ct values and melt curves in order 
to get the 13 (12 regions plus one control region) working sets needed for ChIP 
experiments.  
 
 
3.2.6 IRF5 is recruited to a 5’ upstream and 3’ downstream region of TNF  
Once the primer design was completed I started to perform ChIP experiments in HEK-293-
TLR4-CD14/Md2 cells in order to investigate the effect of LPS stimulation on recruitment of 
IRF5 to the TNF locus. A schematic diagram of the TNF locus illustrating primer amplicons 
and binding regions of interest is shown in Figure 3.12 a.  
 
I observed an increased occupancy of IRF5 at regions A, B, C, G and H 4 h post LPS 
stimulation followed by a decrease after 24 h (Figure 3.10b). Taking into consideration the 
average ChIP fragment size of around 500 bp and the close proximity of the sequences 
amplified, some degree of overlap in regions A-C was inevitable and might have accounted 
for the observed symmetrical distribution of enrichment at regions A, B and C. While the 
enrichment of IRF5 signal at region B was expected due to the presence of putative ISRE 1 
and 2, it was surprising to observe the recruitment of IRF5 at region H since this region 
contains no putative ISREs (Figure 3.10a). Neighbouring regions showed either a weaker 
(region G) or no (region I) signal compared to region H indicating that the binding of IRF5 
was occurring in region H. It is worth noting, that formaldehyde cross-linker used in these 
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experiments can cross-link proteins which are bound directly to DNA but also proteins 
interacting with proteins already bound to DNA. Therefore, it is possible to detect protein 
recruitment to DNA even if there is no actual binding site for the protein in question.  
 
Thus, one potential interpretation of these results was that the recruitment of IRF5 to region 
H was indirect and dependent on other co-factors. The presence of B sites made NF-B 
family members strong candidates. Therefore, I also investigated the recruitment of NF-B 
RelA to the TNF locus and observed LPS-induced binding of RelA to regions B, E and H 
(Figure 3.10c), which correlated with the distribution of multiple NF-B binding sites in these 
regions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Recruitment of IRF5 to 5’ upstream and 3’ downstream region of TNF 
(a) Schematic diagram of the TNF locus. Protein coding and non-coding exons are shown in black 
and white; the TSS is indicated as +1. Putative ISREs are allocated as white ovals; B sites as black 
circles. The approximate amplicon size of primer sets spanning the TNF locus (A to L) are indicated 
by black lines. CO – a control primer set containing neither an ISRE nor a B site. (b, c) HEK-293-
TLR4-Md2/CD14 cells were left unstimulated or stimulated with LPS (1 μg/ml) for 4 and 24 h and 
analysed by ChIP with antibodies specific to IRF5 (b) or RelA (c). Data show mean % input relative 
to genomic DNA (gDNA) ± SD of a representative experiment. –AB, a no antibody control. 
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In order to further investigate the observed IRF5 binding pattern I performed EMSA 
experiments. An EMSA is a common in vitro affinity electrophoresis technique which can be 
used to study protein-DNA interactions. This procedure can determine if a protein or mixture 
of proteins is capable of binding to a given DNA sequence and can sometimes indicate if 
more than one protein is involved in the binding complex. The principle of an EMSA is 
based on the fact that the speed at which different molecules move through the gel is 
determined by their size and charge, and to a lesser extent, their shape. The binding of a 
protein to a given DNA sequence will result in a less mobile (slower moving) complex which 
is 'shifted' up on the gel compared to DNA on its own. An antibody that recognizes a 
candidate protein can be added to the mixture to create an even larger complex that 
migrates even slower. This method is referred to as supershift assay and is used to identify 
a protein present in the protein-DNA complex. The DNA sequence usually contains a 
radioactive or fluorescent label for visualization purposes.  
 
The EMSA experiments were performed with radio-labeled probes corresponding to 
selected ISREs from the TNF promoter region (ISRE1, ISRE2 and ISRE5) as well as B 
sites from the 3‟ downstream region H (B4, B4a and B4b). A sequence identical to the 
positive regulatory domain (PRD) I to III of the human IFN promoter served as a positive 
control. Recombinant full-length IRF5 protein was not available therefore, recombinant DBD 
of IRF5 (bacterially expressed and purified), kindly provided by Dr Daniel Wong (Wellcome 
Trust Centre for Human Genetics, Oxford, United Kingdom), was used. EMSA experiments 
were kindly performed by Dr Irina Udalova and Mrs Alessandra Lanfrancotti (both Kennedy 
Institute of Rheumatology, London, United Kingdom).  
 
As shown in Figure 3.11, IRF5 can bind to ologonucleotides encompassing ISRE1 and 
ISRE5 and to a lesser extent to ISRE2 in vitro. A slower migrating complex observed in the 
ISRE1, ISRE5 and PRDI-III lanes could represent the simultaneous binding of two IRF5 
DBD proteins (indicated as IRF5DBD:IRF5DBD) to the oligonucleotide probes. No IRF5-
DNA binding to oligonucleotides corresponding to the Bbinding sites in region H (B4, 4a 
and 4b) or at additional non-consensus control sites, called „ISRE‟16 and „ISRE‟17, in the 
vicinity of region H were observed (Figure 3.11). This further supports the hypothesis that 
IRF5 is recruited indirectly to region H, likely via yet unknown co-factors.  
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Figure 3.11 In vitro binding of IRF5 to 5’ upstream and 3’ downstream regions of TNF 
Recombinant purified IRF5 DBD was used in an EMSA with radioactive probes corresponding to 
selected ISREs and B sites. PRDI-III from the IFN-β rol and 
non-consensus ISRE16 and ISRE17 served as negative controls. Probes bound by single 
(IRF5DBD) or multiple IRF5 DBD proteins (IRF5DBD:IRF5DBD) are indicated.  
 
 
Next, I validated the pattern of IRF5 and RelA recruitment to the TNF locus in MDDCs 
stimulated with LPS for 0, 1 and 4 h. Enrichment of both IRF5 (Figure 3.12a) and RelA 
(Figure 3.12b) was observed at regions B and H. This was reproducible and statistically 
significant when analysed in cells derived from multiple blood donors. 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 IRF5 and RelA are recruited to 5’ upstream and 3’ downstream regions of 
the TNF gene 
(a, b) MDDCs were left unstimulated or stimulated with LPS (10 ng/ml) for 1 h or 4 h followed by 
ChIP with antibodies specific to IRF5 (a) or RelA (b). Data are shown as the mean % input relative to 
gDNA ± SEM of 5 (IRF5) or 4 (RelA) independent experiments each using MDDCs derived from a 
different donor: *p< 0.05, ** p<0.01 (One-way ANOVA). –AB, a no antibody control. 
 
a b
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In summary, IRF5 along with RelA is efficiently recruited to the 5‟ upstream region B and 3‟ 
downstream region H of the human TNF gene in response to LPS stimulation. Significantly, 
the lack of putative ISRE binding sites in the 3‟ downstream region of the TNF gene strongly 
suggested that recruitment of IRF5 to this region may be mediated via interactions with 
other transcription factors, like NF-B RelA, or accessory proteins.   
 
 
3.2.7 IRF5 forms specific physical interactions with RelA 
The experiments described in this section were performed either by or with great help from 
Dr David Saliba (Kennedy Institute of Rheumatology, London, United Kingdom). In order to 
acknowledge his input results are discussed in plural. 
 
To tease out whether IRF5 recruitment to region H was indeed mediated via its interactions 
with RelA, we conducted sequential ChIP analysis of region H. We first performed a ChIP 
with anti-RelA antibodies and analysed the pulldown efficiency which was comparable 
between experimental groups (Figure 3.13a). We then assessed the co-recruitment of IRF5 
by performing a ChIP with IRF5-specific antibodies on the same samples and found that 
IRF5 binding to region H was co-dependent on RelA following LPS stimulation  
(Figure 3.13b). 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Co-recruitment of RelA and IRF5 to region H 
HEK-293-TLR4-CD14/Md2 cells were left unstimulated or stimulated with LPS (1 μg/ml) for 4 h. (a) 
RelA binding to region H was analysed using anti-RelA antibodies. (b) The co-recruitment of RelA 
and IRF5 to region H was assessed by re-ChIP of the samples from (a) with IRF5-specific antibodies 
or a no antibody control (-AB). (a, b) Data show mean % input relative to gDNA ± SD of a 
representative experiment.  
RelA+IRF5 RelA+(-AB)
region H
RelA input
for +IRF5
RelA input
for +(-AB)
region H
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This finding prompted us to investigate whether IRF5 and RelA interact physically. IRF5 
with an N-terminal one-strep tag and a C-terminal HA tag was expressed in HEK-293-TLR4-
CD14/Md2 cells. Figure 3.14a shows that in conditions similar to ChIP analysis (i.e. in-vivo 
crosslinking with formaldehyde) ectopically expressed IRF5 efficiently pulls down 
endogenous RelA (Figure 3.14a, compare lanes 3 and 4). To determine whether this 
interaction was specific, we immunoblotted for other NF-B family members: Rel-B, c-Rel, 
p50 and p52, or a control protein tubulin. None of these resulted in a positive interaction 
(Figure 3.14a). Furthermore we conducted a complementary experiment, in which human 
RelA containing C-terminal FLAG tag was expressed in HEK-293-TLR4-CD14/Md2 cells 
and immunoprecipitated in the absence of a cross-linking agents on anti-FLAG sepharose. 
Specific interactions between ectopically expressed RelA and endogenous IRF5 were 
observed. No interaction was detected between a control FLAG-tagged protein, bacterial 
alkaline phosphatase (BAP), and IRF5 (Figure 3.14b, compare lanes 1 and 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Ectopic IRF5 specifically interacts with RelA in HEK-293 cells 
(a) HEK-293-TLR4-Md2/CD14 cells were transfected with human IRF5 tagged with onestrep tag (N-
terminus) and HA tag (C-terminus) (lanes 1 and 3) or an empty vector pBent (lanes 2 and 4) and 
fixed with formaldehyde. Cell lysates were immunoprecipitated using streptavidin columns followed 
by reversion of the crosslink and immunoblotting for bait IRF5 (anti-HA antibodies), or NF-κB 
subunits as well as tubulin. (b) HEK-293-TLR4-Md2/CD14 cells were transfected with RelA-FLAG 
(lane 1) or BAP-FLAG (lane 2). Cell lysates were immunoprecipated with M2 anti-FLAG sepharose 
and immunobloted for bait RelA (anti-FLAG antibodies) or IRF5.  
 
a b
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Next, we examined whether an interaction between endogenous RelA and IRF5 could be 
detected in MDDCs and if this interaction may be inducible upon LPS stimulation. IRF5 was 
immunoprecipitated from the cells stimulated with LPS for 0 or 1 h using anti-IRF5 
antibodies. The western blot for RelA revealed a specific interaction with IRF5  
(Figure 3.15a). A densitometry analysis of quantities of the bait and target proteins indicated 
that the quantity of RelA bound to IRF5 was somewhat higher in LPS stimulated cells 
(Figure 3.15a, lane 4) compared to unstimulated cells. Finally, we asked the question 
whether the observed RelA-IRF5 interactions are dependent on the simultaneous binding of 
both TFs to DNA, i.e. RelA and IRF5 interact only when bound to corresponding B and 
ISRE binding sites in close proximity to each other. To address this, we extracted nuclei 
from HEK-293-TLR4-CD14/Md2 cells stimulated with LPS for 0, 1, 4 and 8 h and subjected 
the chromatin to DNase I digestion. Subsequent precipitation of endogenous immune 
complexes with anti-IRF5 antibodies revealed that RelA interacted with IRF5 even in the 
absence of DNA bridging (Figure 3.15b, lanes 5-8). Once again, the number of RelA-IRF5 
complexes increased with LPS stimulation, corresponding to the rise in nuclear RelA 
(Figure 3.15b, lanes 1-4).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Endogenous IRF5 interacts with RelA in MDDCs 
(a) MDDCs were left untreated or stimulated with LPS for 1 h. The endogenous interaction between 
RelA and IRF5 was examined by IP with anti-IRF5 antibody and blotting with anti-RelA antibody. -AB 
– a mock IP. (b) Nuclear pellet from triton extracted HEK-293-TLR4-Md2/CD14 cells was solubilised 
with DNase I and endogenous interaction between RelA and IRF5 was examined after IP as in (b).  
a
b
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In summary, IRF5 can specifically interact with RelA but not with any of the other NF-B 
family members. The interaction is not dependent on IRF5 binding to DNA and the quantity 
of IRF5/RelA complexes is increased in response to LPS stimulation. Thus, we 
hypothesised that IRF5 recruitment to the 3‟ downstream region of the TNF gene lacking 
putative ISRE sites is a consequence of direct physical interactions between DNA-bound 
RelA and IRF5.  
 
 
3.2.8 RelA is required for IRF5-dependent transactivation of the TNF gene 
To test the above hypothesis, I first analysed IRF5 recruitment to the TNF locus in the cells 
in which the levels of RelA protein were significantly reduced. In HEK-293-TLR4-CD14/Md2 
cells, siRNA-mediated depletion of RelA mRNA resulted in approximately 75% reduction in 
RelA protein (Figure 3.16a) and about a 10-fold decline in its recruitment to region H 
following 4 h of LPS stimulation (Figure 3.16b). As predicted, the IRF5 recruitment to the 
same region was prevented (Figure 3.16c) further supporting a RelA-dependent recruitment 
of IRF5 to region H.  
 
Next, I examined the effect of site-specific mutations in the B sites on the ability of IRF5 to 
activate the TNF gene. A panel of four gene-reporter constructs was used in this analysis: 
 
(1) 5‟wt/3‟wt (as in Figure 3.8) 
(2) 5‟mut/3‟wt (mutated B2/2/2a sites in the TNF 5‟ upstream region) 
(3) 5‟wt/3‟mut (mutated B4/4a sites in the 3‟ TNF downstream region) 
(4) 5‟mut/3‟mut (all B sites described above mutated) 
 
The reporter constructs were co-expressed with IRF5 and RelA in HEK-293-TLR4-
Md2/CD14 cells and luciferase activities were compared to empty vector pBent. As 
expected, removal of either 5‟ upstream or 3‟ downstream B sites diminished the ability of 
RelA to drive the gene-reporter activity (Figure 3.17). However, the transactivation of the 
reporter constructs by IRF5 (supported by ectopically expressed Myd88) appeared to be 
largely unaffected by mutations in the 5‟ upstream B sites, suggesting that IRF5 does not 
utilise B2/2/2a sites for its binding to the TNF 5‟ upstream and its likely to involve the 
identified ISRE1 and ISRE 2 sites. However, the transactivation of the reporter construct 
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with mutations in B4/4a sites by IRF5 was significantly reduced, suggesting that IRF5 
activity depends on NF-B binding to this region (Figure 3.17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 RelA is required for IRF5-binding to region H of the TNF gene  
(a-c) HEK-293-TLR4-Md2/CD14 cells were transfected with siRNA against RelA (siRelA) or with non-
targeting siRNA (siC) and used in ChIP analysis of RelA and IRF5 recruitment. Data indicate mean % 
input relative to gDNA ± SD of a representative experiment. –AB, a no antibody control. (a) 75% of 
RelA protein was degraded as estimated by serial dilutions of the siC control sample analysed by 
western blotting. (b, c) Reduction in LPS-induced RelA (b) and IRF5 (c) recruitment to region H in 
siRelA treated cells. 
 
 
 
 
 
 
 
a
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Figure 3.17 RelA is required for IRF5-mediated activation of TNF 
HEK-293-TLR4-Md2/CD14 cells were transfected with RelA, IRF5 and MyD88 expression constructs 
together with the TNF 5‟ upstream/luciferase/TNF 3‟ downstream reporter plasmids: 5‟wt/3‟wt - wild 
type construct, 5‟mut/3‟wt - mutated B2/B/B2a sites in TNF 5‟ upstream; 5‟wt/3‟mut - mutated 
B4/B4a sites in TNF 3‟ downstream; 5‟mut/3‟mut - all B sites mutated. Data show means ± SD 
and are representative of 3 independent experiments, each performed in triplicate. 
 
 
 
Thus, IRF5 recruitment to the TNF 3‟ downstream region is mediated by way of a complex 
assembly with RelA and does not involve a direct contact to DNA. Importantly, another 
mode of function of IRF5 in TNF regulation is a direct recruitment to the TNF gene 5‟ 
upstream. The two functional modes also imply the possibility of a higher order enhancer 
structure at the TNF locus which might involve IRF5/RelA mediated intrachromosomal 
looping.   
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3.3 Conclusion 
Production of the key immune modulator TNF is both cell-type and stimulus-specific with 
myeloid cells among the major producers of TNF in response to TLR4 stimulation [291]. 
Consequently, a tight control of the amount and duration of TNF expression by these cells is 
critical for a self-limited immune response. In this chapter, I aimed to understand the 
molecular bases of differential TNF expression in primary human dendritic cells and 
macrophages. I demonstrate that IRF5 appears to be a defining factor in maintaining TNF 
gene transcription in monocyte-derived dendritic cells and unravel a complex molecular 
mechanism employed by IRF5 to control the human TNF gene expression: two spatially 
separated regulatory regions and two independent modes of actions are involved. 
 
IRF5 is highly expressed in MDDCs (Figure 3.1) which acquire a particular phenotype 
during differentiation, characterized amongst other markers by higher levels of late-phase 
TNF secretion compared to MDMs (Figure 3.2). Interestingly, forced expression of IRF5 in 
MDMs led to prolonged TNF secretion (Figure 3.4), while depletion of IRF5 in MDDCs 
resulted in reduction of TNF expression, particularly at later time (4 h) post LPS stimulation 
(Figures 3.6 and 3.7). One of the main problems associated with RNAi technology is the 
non-specific effect on other transcripts than the target sequence. However, if results 
obtained with overexpression show the opposite phenotype to siRNA, it is less unlikely that 
results using siRNA-mediated depletion are due to off-target effects. Furthermore, I can not 
formally rule out other factors that might feed into the TNF expression system at a later time 
but the ability of IRF5 to activate the TNF gene-reporter construct (Figure 3.8) and its 
efficient recruitment to the TNF locus (Figures 3.10 and 3.12) strongly suggest a direct role 
for IRF5 in TNF gene induction in response to TLR4 stimulation. 
 
The recruitment of IRF5 to the human TNF locus was examined by ChIP experiments 
conducted in the cell line HEK-293-TLR4-CD14/Md2 (Figure 3.10) and MDDCs (Figure 
3.12). The data indicate that IRF5 is recruited to two specific regions, region B and region 
H, within the TNF locus (Figures 3.10 and 3.12). Of particular interest was region H 
because it contains binding sites for NF-B family members (NF-B 4/4a/4b) but not 
putative ISRE (Figure 3.9). Additional ChIP experiments conducted in HEK-293-TLR4-
CD14/Md2 with depleted RelA protein demonstrated that IRF5 recruitment to region H is 
RelA dependent whereas its recruitment to region B occurred RelA-independent, probably 
via direct binding of IRF5 to identified ISRE sites (Figure 3.11). The importance of RelA-
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binding to NF-B sites in the 3‟ region and subsequent recruitment of IRF5 was confirmed in 
re-ChIP experiments (Figure 3.13) and in vitro using coexpression of IRF5 with sets of TNF 
luciferase constructs containing mutations in NF-B 4/4a/4b sites (Figure 3.17).  
 
A subsequent analysis of protein-protein interactions demonstrated an interaction between 
RelA and IRF5 (Figure 3.14). This interaction is induced following stimulation of MDDCs 
with LPS, while no other NF-B family member appears to from complexes with IRF5 
(Figures 3.15). Considering that the Rel homology domain is a highly conserved domain, 
present in all NF-B proteins, the exclusiveness of IRF5 interactions with RelA is somewhat 
surprising. The precise interface of the IRF5/RelA interaction is currently being mapped in 
the laboratory of Dr Irina Udalova. 
 
Overall, this suggests IRF5-induced TNF expression involves two spatially separated 
regulatory regions (region B and H) and two independent modes of actions (direct binding to 
DNA and co-recruitment mediated via protein-protein interactions with RelA) (Figure 3.18). 
Another member of the IRF family, IRF3 was shown to interact with RelA [292, 293] and to 
specifically activate the expression of selected NF-B target genes like Scyb9 or Clic4 
[293]. Similarly, IRF5 might interact with RelA to ensure a specific activation of another yet 
to be defined subset of genes.  
 
 
 
 
 
 
 
 
Figure 3.18 Modes of IRF5 recruitment to regions of the human TNF locus 
(a) Binding of IRF5 to TNF at region B. After cell activation IRF5 dimerises and translocates to the 
nucleus where it binds to the identified ISREs present in region B. IRF5 binding, which occurs 
independently of RelA, induces TNF gene expession. (b) Binding of IRF5 to TNF at region H. IRF5 
activation leads to its translocation into the nucleus where it interacts with RelA. The interaction is 
essential for RelA-mediated recruitment of IRF5 to region H which is necessary for the full induction 
of TNF gene expression.  
a b
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Why is there a functional advantage for maintaining TNF secretion for longer in MDDCs 
compared to MDMs (Figure 3.2)? Dendritic cells are professional antigen-presenting cells 
that are crucial for both innate and adaptive responses to infection. They sense invading 
pathogens and respond by secreting various cytokines as well as by upregulating the 
expression of MHC II and costimulatory molecules, essential for efficient antigen 
presentation to T lymphocytes [294]. The mature dendritic cells migrate to the draining 
lymph nodes, where they initiate Th1 differentiation. TNF acting through TNF receptor is 
involved in DC maturation from bone marrow progenitors [295, 296] and a recent study 
demonstrated that TNF blockade impaired DC survival and function in RA [297]. My data 
showing that TNF produced by MDDCs is a key factor in human Th1 activation support this 
study. Moreover, it is the late phase TNF secretion that is needed to achieve the full 
activation potential of T lymphocytes (Figure 3.3). Macrophages, on the other hand, do not 
migrate to the draining lymph nodes but accumulate in large numbers at a site of 
inflammation, secrete inflammatory cytokines and attract other immune cells via chemotaxis 
[298]. Thus, a mechanism which would restrain the degree and duration of TNF secretion 
by macrophages would be important for ensuring resolution of acute inflammatory response 
thereby limiting tissue damage.  
 
However, macrophages are a heterogeneous cell population that can be classified as either 
pro-inflammatory M1 macrophages or anti-inflammatory M2 macrophages [43]. Although 
both human macrophages subsets are somewhat different to MDDCs, it is the M1 
phenotype that has a higher phenotypic resemblance to MDDCs. Similar to MDDCs, M1 
macrophages upregulate the expression of HLA molecules and co-stimulatory receptors 
such as CD40, CD80 and CD86 upon TLR4 stimulation making them good antigen 
presenters. In addition to surface receptor expression, the cytokine profile of M1 
macrophages is in many ways comparable to that of MDDCs [64, 67]. Here I used 
monocyte-derived macrophages differentiated in the presence of M-CSF which leads to the 
generation of the anti-inflammatory M2 subset. When I generated macrophages with an M1 
differentiation protocol (treatment of monocytes with GM-CSF) I observed a similar TNF 
secretion profile to MDDCs after LPS stimulation, that is, prolonged and sustained (data not 
shown). It is reasonable to speculate that the different TNF production by M1 macrophages 
compared to M2 macrophages is also due to variations in IRF5 protein levels. However, the 
role of IRF5 in macrophage subsets is yet to be determined. I therefore set out to 
investigate the expression and function of IRF5 in macrophage populations in more detail 
and results are presented in chapter 4 and 5 of this thesis.  
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Regulation of IRF5 activity is an important issue since the excessive activation of this 
protein may lead to pathology. Interestingly, another member of the IRF family, IRF4, was 
shown to act as a negative regulator of TLR signalling by inhibiting the production of 
selected IRF5-dependent genes, including TNF, via direct competition with IRF5 for 
interactions with Myd88 [299]. This could indicate that a self-controlled IRF5-IRF4 
regulatory system might have developed to finely modulate TLR signalling pathways and 
production of IRF5-dependent inflammatory cytokines. The rivalry between IRF5 and IRF4 
will also be discussed later in light of their different roles in shaping different macrophage 
phenotypes.   
 
In summary, my data suggest that sustained TNF secretion in human MDDCs is mediated 
by cooperative action of IRF5 and RelA at the 5‟ upstream and 3‟ downstream regions of 
the human TNF gene. TLR4 stimulation induces protein-protein interactions between RelA 
and IRF5 and allows for DNA-independent recruitment of IRF5 to the TNF 3‟ downstream 
region. Based on the resistance of Irf5-/- mice to lethal endotoxic shock and impaired 
production of pro-inflammatory cytokines, IRF5 was proposed as a target for therapeutic 
interventions [190]. Here I define RelA-IRF5 interactions as a putative target for cell-specific 
modulation of TNF expression, and possible other selected inflammatory mediators. 
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4. IRF5 promotes inflammatory macrophage 
polarization 
 
4.1 Introduction 
Macrophages are a heterogeneous population of immune cells that are essential for the 
initiation and resolution of pathogen- or tissue damage-induced inflammation [42]. They 
demonstrate remarkable plasticity that allows them to efficiently respond to environmental 
signals and change their phenotype and physiology in response to cytokines and microbial 
stimuli [43]. These changes can give rise to populations of macrophages with distinct 
functions, which are phenotypically characterised by production of pro-inflammatory and 
anti-inflammatory cytokines [46]. Based on the Th1/Th2 polarization concept [44] these cells 
can roughly be classified as M1 (classical) macrophages, that produce pro-inflammatory 
cytokines (IL-12high, IL-23high, IL-10low) and mediate resistance to pathogens and tissue 
destruction and M2 (alternative) macrophages, that produce anti-inflammatory cytokines (IL-
12low, IL-23low, IL-10high ) and promote tissue repair and remodelling as well as tumour 
progression [45, 46]. 
 
The activation of a subset-defining transcription factor is characteristic of a particular T 
lymphocyte lineage commitment: T-bet is associated with Th1, GATA3 with Th2, FOXP3 
with Treg lymphocytes and RORT with Th17 lymphocytes [99, 101, 109, 124]. Dendritic 
cells also employ subset-selective expression of IRF4 and IRF8 for their commitment, 
discussed in Chapter 1.3.3. However, transcription factors underlying macrophage 
polarization remain largely undefined. In mouse models, activation of NF-B p50 has been 
previously associated with inhibition of M1 polarizing genes [300], whereas CREB mediated 
induction of C/EBP has been shown to upregulate M2-specific genes [301]. More recent 
evidence suggests that, again in mice, IRF4 may control M2 macrophage polarization by 
stimulating the expression of selected M2 macrophage markers [302].  
 
The observed low expression of IRF5 in monocyte-derived macrophages (Chapter 3.2.1) 
which were differentiated in M2 polarizing conditions prompted me to investigate IRF5 
levels under M1 conditions. The overall phenotype of M1 macrophages is quite similar to 
monocyte-derived DCs and therefore it was expected that M1 macrophages would express 
a high level of IRF5 protein. I speculated that IRF5 might be employed by M1 macrophages 
Chapter 4 - IRF5 promotes inflammatory macrophage polarization 
 120  
to fine-tune (like late-phase TNF secretion which was only seen in MDDCs with high IRF5 
levels) or even define different macrophage phenotypes. If IRF5 is indeed a transcription 
factor that influences macrophage polarization the following questions were of particular 
interest: 
 
 Which environmental signals can induce IRF5 expression in human macrophages? 
 Is IRF5 expression static or can changes occur dependent on different experimental 
conditions?  
 Are any subset-defining cytokines under the transcriptional control of IRF5?  
 What is the effect of overexpression or siRNA-mediated depletion of IRF5 on 
macrophage phenotype and cytokine profile? 
 
The identification of a master regulator of macrophage phenotype and function would have 
ramifications for all inflammatory diseases characterised by excessive type 1 cytokines and 
would provide a potential new target for immune intervention.  
 
 
4.2 Results 
 
4.2.1 IRF5 expression is high in human M1 macrophages 
Macrophages evolve within a specific microenvironment out of monocytes [30] and the 
differentiation of monocytes depends on lineage-determining cytokines, with M-CSF and 
GM-SCF among the most important ones [64]. The M1 macrophage phenotype is induced 
by IFN- followed by stimulation with bacterial products like LPS or by treatment of 
monocytes with GM-SCF. [63-67]. Conversely, the M2 macrophage phenotype manifests 
when monocytes are cultured in the presence of M-CSF [63-65, 67]. Before analysing IRF5 
levels in macrophage subsets I had to be sure that these culture methods are actually 
working in my hands and therefore compared the cytokine profile of M1 and M2 
differentiated human macrophages (Figure 4.1). Consistent with previously published data 
[64, 67], human monocytes cultured in the presence of GM-CSF and stimulated with LPS 
displayed an M1 phenotype with high expression of IL-12p70 and IL-23 but low expression 
of IL-10 whereas differentiation with M-CSF led to the opposite phenotype (Figure 4.1).  
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Figure 4.1 The cytokine environment determines macrophage phenotype 
Monocytes from the same donor were differentiated with M-CSF (100 ng/ml) or GM-CSF (50 ng/ml) 
for 5 days. Cells were stimulated with LPS (10 ng/ml) for 24 h and the secretion of IL-12p70, IL-23 
and IL-10 was determined by ELISA. Data shown are the mean ± SEM from 4 to 5 independent 
experiments each using macrophages derived from a different donor: *p< 0.05 and **p<0.01 (One-
way ANOVA). 
 
 
After gaining confidence in the differentiation protocols I examined the levels of IRF5 
expression in primary human monocytes or in macrophage subsets and I observed an 
increase in IRF5 protein expression in the population differentiated with GM-CSF compared 
with that differentiated in the presence of M-CSF (Figure 4.2a and b). Furthermore, 
treatment of monocytes with GM-CSF resulted in upregulation of IRF5 mRNA expression 
within 2 h of stimulation but treatment with M-CSF did not (Figure 4.2c). Surprisingly, the 
expression of IRF4 protein, which was previously shown to control polarization towards the 
M2 phenotype [302], was equally induced during monocyte differentiation into M1 or M2 
macrophages (Figure 4.2a). The expression of IRF3 protein, another member of the IRF 
family central to the innate immune response, was not affected by differentiation into 
macrophage subtypes (Fig 4.2a). In addition, I observed no significant difference between 
M1 and M2 macrophages in the basal or LPS-induced levels of NF-B p50 protein, 
previously implicated in macrophage polarization towards M2 phenotype [300] (data not 
shown). I also examined the effect of LPS on IRF3, IRF4 and IRF5 protein expression. I 
observed no changes in the protein levels of IRF3 and IRF4 upon TLR4 activation but a 
weak upregulation of IRF5 protein in all cell types tested (Figure 4.2a). To confirm that 
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stimulation of the cells was successful membranes were routinely re-probed for IRF7, a 
transcription factor that is strongly induced by LPS (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 High expression of IRF5 in M1 macrophages and upregulation by GM-CSF 
(a) Western blot analysis of total protein extracts from monocytes collected at day 0 (Mono) or 
differentiated for 5 d into M1 macrophages with GM-CSF (50 ng/ml) or into M2 macrophages with M-
CSF (100 ng/ml), then left untreated (-) or simulated for 24 h with 10 ng/ml LPS (+). Actin serves as a 
loading control. A representative blot of at least 4 independent experiments, each using cells derived 
from a different donor is shown. (b) IRF5 protein expression was analysed in total cell lysates of cells 
differentiated as in (a). Densitometric analysis was performed using Quantity One software and data 
were normalised to actin. Shown are the mean ± SEM from 3 independent experiments presented as 
% of increase in IRF5 protein levels relative to monocytes. *p<0.05 (One-way ANOVA with Dunnett's 
Multiple Comparison Post Test). (c) RT-PCR analysis of IRF5 mRNA in monocytes left untreated (0) 
or stimulated for 2, 4, 8, 24 or 48 h with GM-CSF (50 ng/ml) or M-CSF (100 ng/ml) Results are the 
mean ± SEM from 5 independent experiments each using monocytes derived from a different donor 
presented relative to those of untreated monocytes, set as 1. *p<0.001 (two-way ANOVA).  
a b
c
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To account for possible differences in macrophage in vitro differentiation protocols, I 
analysed the level of IRF5 in macrophages treated with either IFN- alone or in combination 
with LPS for 24 h and found that IRF5 protein levels were similar to the ones in GM-CSF 
treated cells (Figure 4.3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 IRF5 expression is induced by M1 macrophage maturation protocols 
M2 macrophages were left untreated or treated with GM-CSF (50 ng/ml), IFN-(50 ng/ml), or LPS 
(10 ng/ml) plus IFN-for 24 h and total protein extracts were subjected to Western blot analysis 
followed by densitometry. Data shown are the mean ± SEM from 6 independent experiments 
presented as % increase in IRF5 protein levels relative to untreated cells. **p<0.01 (One-way 
ANOVA with Dunnett's Multiple Comparison Post Test).  
 
 
 
Thus, I concluded that IRF5 is induced in pro-inflammatory M1 macrophages independently 
of the in vitro differentiation protocol, whereas the levels of IRF4 and IRF3 are comparable 
between the macrophage populations.  
 
 
4.2.2 IRF5 expression is plastic in human macrophages 
Macrophages are able to respond to environmental changes and cytokines by adopting 
their phenotype as well as their physiology. To examine whether IRF5 contributes to the 
plasticity of macrophage polarization, I attempted to convert one population into another by 
culturing M2 macrophages with GM-CSF and M1 macrophages with M-CSF. Following LPS 
stimulation GM-CSF treated M2 macrophages were now capable of producing the M1 
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phenotypic markers IL-12p70 and IL-23 whereas the levels of IL-10 decreased (M2 to M1; 
Figure 4.4a). Conversely, treatment of M1 macrophages with M-CSF led to higher LPS-
induced levels of the M2 marker IL-10 but a diminished production of IL-12p70 and IL-23 
(M1 to M2; Figure 4.4b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Plasticity of macrophages in respond to environmental changes 
(a) For M2 to M1 cytokine profiles, M-CSF-derived M2 macrophages at day 5 were either left in M-
CSF containing medium or washed with PBS and exchanged for GM-CSF (100 ng/ml) containing 
medium and after 24 h subjected to LPS stimulation (10 ng/ml). (b) For M1 to M2 cytokine profiles, 
GM-CSF derived M1 macrophages at day 5 were either left in GM-CSF containing medium or 
washed with PBS and exchanged for M-CSF (100 ng/ml) containing medium and after 24 h 
subjected to LPS stimulation (10 ng/ml). (a, b) Data shown are the changes in secretion of IL-12p70, 
IL-23 and IL-10 determined by ELISA from 3 independent experiments each using macrophages 
derived from a different donor.  
 
 
 
a
b
M2 to M1
M1 to M2
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More strikingly, western blot analysis demonstrated that M2 to M1 conversion enhanced the 
protein levels of IRF5 whereas M1 to M2 macrophages showed the opposite result (Figure 
4.5a and b). The changes seen in IRF5 protein levels were reproducible and statistically 
significant when analysed in multiple independent blood donors (Figure 4.5c and d). Once 
again, the expression of IRF4 and IRF3 proteins was unchanged (Figure 4.5a and b).  
 
These results indicate that IRF5 expression rapidly responds to environmental stimuli and 
suggest that it participates in establishing macrophage plasticity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Plastic expression of IRF5 in macrophages 
(a, b) Western blot analysis of total protein extracts from (a) M2 macrophages left untreated (−) or 
treated (+) for 24 h with GM-CSF (50 ng/ml) for M2 to M1 polarization and from (b) M1 macrophages 
left untreated (−) or treated (+) for 24 h with M-CSF (100 ng/ml) for M1 to M2 polarization. A 
representative blot of 4 independent experiments, each using macrophages derived from a different 
donor is shown. (c, d) The change in IRF5 protein expression of cells treated as in (a) and (b) was 
analysed by western blotting followed by densitometric analysis using Quantity One software. The 
IRF5 measurements were normalised to actin. Shown are the mean ± SEM from 4 independent 
experiments presented as % of increase (c) or decrease (d) in IRF5 protein levels relative to the 
initial condition: *p<0.05 (One-way ANOVA with Dunnett's Multiple Comparison Post Test). 
 
a b
c d
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4.2.3 IRF5 influences the polarization of human macrophages  
Based on the above results, I hypothesised that the phenotypic differences between M1 and 
M2 macrophages might be due to differential IRF5 protein expression in these populations 
(Figure 4.2). To test this hypothesis, M2 macrophages were infected with adenoviruses 
containing expression constructs encoding IRF5, IRF3 (as a control) or an empty vector 
(pENTR) and the production of IL-12p70, IL-23 and IL-10 protein was analysed. I detected 
IL-12p70 and IL-23 in M2 macrophages infected with IRF5 expressing construct but only 
minimal amounts after infection with a construct encoding IRF3 or empty vector (Figure 
4.6a). The secretion of both IL-12p70 and IL-23 induced by IRF5 overexpression peaked at 
24 h after stimulation with LPS and remained sustained up to at least 48 h (Figure 4.6b). 
IRF5 overexpression also induced a vast increase in secretion of the p40 subunit which is 
shared by the two cytokines (Figure 4.6a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Ectopic IRF5 influences the production of IL-12p70 and IL-23 
(a) ELISA of IL-12p70, IL-23 and IL-12p40 protein secretion in M2 macrophages infected with 
adenoviral vector encoding IRF5, IRF3 or empty vector (pENTR) and stimulated for 24 h with LPS. 
Data are mean ± SEM of 7 to 9 independent experiments, each with macrophages derived from a 
different donor. ***p<0.001 (one-way ANOVA with Dunnett‟s multiple-comparison post-test). (b) M2 
macrophages were infected as in a and left unstimulated or stimulated with LPS (10 ng/ml) for 4, 8, 
24, 32 or 48 h. The amount of secreted IL-12p70 and IL-23 protein was determined by ELISA. Data 
shown are the mean ± SD and are representative of 3 independent experiments each using 
macrophages derived from a different donor. 
a
b
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I also observed higher production of other key pro-inflammatory cytokines, such as IL-1β 
and TNF, by IRF5-expressing M2 macrophages (Figure 4.7). The effect of ectopic IRF5 on 
TNF expression is supported by my previous findings in Chapter 3 where I describe in detail 
the IRF5-mediated induction of TNF.  
 
In line with the previously reported low expression of IL-10 in M1 macrophages, the 
expression of this cytokine was reduced significantly after LPS stimulation in macrophages 
overexpressing IRF5 (Figure 4.7). I also observed a reduction of IL-10 protein secretion in 
cells overexpressing IRF3 (Figure 4.7), which might represent a negative feedback 
regulation of IL-10 expression via dual specificity protein phosphatase 1 (DUSP1) [303], 
since the main direct target of IRF3, IFN-, induces IL-10 [304].  
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Ectopic IRF5 induces IL-1 and TNF but inhibits IL-10 secretion 
M2 macrophages were infected with adenoviral vectors encoding IRF5, IRF3 or empty vector 
(pENTR) and stimulated with LPS for 24 h. The amount of secreted IL-1, TNF and IL-10 protein 
was determined by ELISA. Data show the mean ± SEM of 4 to 8 independent experiments each 
using M2 macrophages derived from a different donor: ** p<0.01, ***p<0.001, (One-way ANOVA with 
Dunnett's Multiple Comparison Post Test). 
 
 
Next, I performed the complementary experiment of targeting endogenous IRF5 in M1 
macrophages by RNA-mediated interference (Figure 4.7). I used the same protocol as 
previously optimised (Methods section 2.11.2) which usually resulted in 50 to 60% knock-
down of IRF5 protein in M1 macrophages estimated by serial dilutions of the control siRNA 
treated cells (Figure 4.8). The delivery of nucleic acids into macrophages runs the risk of 
mimicking viral infection, associated with induction of type I IFN genes, thus potentially 
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creating an artefact of the experimental system. As mentioned previously, I routinely 
analysed the mRNA induction of type I IFNs and the secretion of IP-10 (a known type I IFN-
inducible gene) which were found to be minimal.  
 
 
 
 
 
 
 
 
Figure 4.8 siRNA-mediated knock-down of IRF5 in M1 macrophages 
M1 macrophages were transfected with siRNA pool targeting IRF5 (siIRF5) or control siRNA (siC) 
and total protein extracts were analysed by Western blot. Actin is used as a loading control. Blots 
shown are from a representative experiment.  
 
 
 
The response to TLR4 stimulation and subsequently cytokine production of siRNA 
transfected M1 macrophages was generally lower compared to untreated cells from the 
same donor (data not shown). I therefore opted for a costimulation of LPS (10 ng/ml) plus 
IFN- (50 ng/ml) in order to provoke a more robust and reproducible response after siRNA 
transfection.  
 
The siRNA-mediated knock-down of IRF5 in M1 macrophages resulted in significant 
inhibition of LPS plus IFN- costimulation-induced production of both IL-12p70 and IL-23 
(Figure 4.9). Secretion of IL-12p40 was also lower in these cells (Figure 4.9), consistent 
with data obtained with Irf5-deficient mouse myeloid cells [190]. However, the production of 
IL-10 was higher in IRF5-depleted macrophages compared to siC transfected cells mirroring 
the data from the overexpression experiments (Figure 4.7).  
 
Together these results suggest that IRF5 influences M1 macrophage polarization by 
equipping the cells with an IL-12hi, IL-23hi and IL-10low cytokine profile.  
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Figure 4.9 Depletion of IRF5 influences the production of lineage-specific cytokines 
ELISA of the secretion of IL-12p70, IL-23, IL-12p40 and IL-10 by M1 macrophages transfected with 
siRNA targeting IRF5 (siIRF5) or nontargeting control siRNA (siC) and stimulated for 24 h with LPS 
(10 ng/ml) plus IFN- (50 ng/ml). Data are the mean ± SEM of 6 to 8 independent experiments, each 
with macrophages derived from a different donor. **p<0.01, ***p<0.001 (Student‟s t-test). 
 
 
 
4.2.4 IRF5 induces the mRNA expression of macrophage lineage-
specific cytokines 
IRF5 is a transcription factor that can bind to the regulatory regions of target genes and 
modulate their expression. I therefore thought to investigate whether the role of IRF5 in the 
differential regulation of the secretion of IL-12p70, IL-23 and IL-10 cytokines was a direct 
consequence of its function as a transcription factor. The expression of mRNA for IL-12p40, 
IL-12p35 and IL-23p19 was considerably induced in resting M2 macrophages infected with 
an adenoviral vector construct encoding IRF5 but not in those infected with a construct 
encoding IRF3 or with empty vector (Figure 4.10). Consistent with the protein-secretion 
data, the expression of IL-10 mRNA was inhibited by ectopic IRF5 (Figure 4.10). However, 
the expression of IL-10 mRNA was not altered by IRF3 (Figure 4.10), which suggests the 
lack of a direct role for IRF3 in transcription of the gene encoding IL-10.  
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Figure 4.10 IRF5 induces the mRNA expression of lineage–specific cytokines 
Quantitative RT-PCR analysis of mRNA for IL-12p40, IL-12p35, IL-23p19 and IL-10 in M2 
macrophages infected with adenoviral vector encoding IRF5 or IRF3; basal expression is presented 
relative to that of control cells infected with empty vector. Data are the mean ± SEM of 3 to 6 
independent experiments, each with macrophages derived from a different donor. *p<0.05, **p<0.01 
and ***p<0.001 (one-way ANOVA with Dunnett‟s multiple-comparison post-test).  
 
 
 
 
Depletion of endogenous IRF5 in M1 macrophages via RNA-mediated interference resulted 
in lower expression of mRNA for IL-12p40, p35 and IL23p19 at 8 h after stimulation with 
LPS (Figure 4.11). Conversely, the expression of IL-10 mRNA was higher in M1 
macrophages with suppressed expression of IRF5 protein (Figure 4.11). 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 IRF5 depletion influences mRNA expression of lineage-specific cytokines 
Quantitative RT-PCR analysis of mRNA expression of IL-12p40, IL-12p35, IL-23p19 and IL-10 in M1 
macrophages transfected with siRNA targeting IRF5 and left untreated or stimulated for 8 h with LPS 
(10 ng/ml). Results are presented as percent inhibition relative to those of control cells transfected 
with nontargeting control siRNA. Data are the mean ± SEM of 5 to 6 independent experiments, each 
with macrophages derived from a different donor. **p<0.01 and ***p<0.001 (Student‟s t-test).  
 
 
Chapter 4 - IRF5 promotes inflammatory macrophage polarization 
 131  
To formally define the global expression profile induced by IRF5, I performed genome-wide 
expression analysis in which I compared M2 macrophages overexpressing IRF5 with 
previously defined human M1 and M2 macrophage subset [67, 305]. Gene expression data 
were obtained by hybridising RNA from a total of 8 samples from two experimental groups 
to Illumina HumanHT-12 Expression BeadChips. The experimental groups consisted of 
RNA obtained from macrophages infected with empty vector pENTR and macrophages 
infected with vector encoding IRF5 (n=4 per group as the macrophages used were derived 
from monocytes of 4 independent blood donors). Similar to previous experiments the RNA 
extraction was performed 48 h post infection. An aliquot of each RNA sample was first 
reverse transcribed to obtain cDNA and subsequently analysed for the induction of genes 
and transcription factors associated with cell activation. The quality control of the RNA 
samples (which did not reveal any outlier samples) and the hybridisation reaction was 
carried out by Dr Dilair Baban at the Wellcome Trust Centre for Human Genetics, Oxford, 
United Kingdom.  
 
Raw signal intensities were background corrected based on background intensity of 
negative control probes on the array. Next, the dataset was filtered to remove probes not 
detected (detection score <0.95) in any of the samples, resulting in a final dataset of 25,620 
probes. The raw p-values were then corrected for multiple testing and adjusted p-values 
below 0.01 were considered significant. The resulting probe lists were annotated and used 
for further biological investigation. The Micro array analysis was kindly performed by Mrs 
Helen Lockstone and Miss Natasha Sahgal (both Wellcome Trust Centre for Human 
Genetics, Oxford, United Kingdom).  
 
The mRNA expression of NF-B family members, IRF3, IRF4 and IRF7 as well as type I 
IFNs was not affected 48 h post infection in IRF5 or empty vector treated cells. Therefore, 
changes in gene expression observed are likely due to the presence and activity of ectoptic 
IRF5 although other potential secondary effects cannot be entirely ruled out. Overall, the 
expression of about 90% of known human polarization-specific markers was affected by 
ectopic IRF5 (Figure 4.12). Overexpression of IRF5 induced 20 M1-specific genes and 
inhibited 19 M2-specific genes encoding cytokines, chemokines, costimulatory molecules 
and surface receptors (Figure 4.12) in resting cells. Moreover, by using this genome-wide 
approach I was able to identify many previously unknown IRF5-regulated genes that 
probably contribute to the main functional features of macrophage subsets, such as 
phagocytosis and antigen presentation (Table 4.1). 
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Figure 4.12 IRF5 influences the global expression profile of macrophage subsets 
Global mRNA expression (for sets of M1- and M2-specific genes [67, 305]; above plot) by 
unstimulated M2 macrophages infected with adenoviral vector encoding IRF5, presented relative to 
that of unstimulated M2 macrophages infected with empty vector. Results are presented as higher 
(red) or lower (green) expression (log2 fold change) after infection with vector encoding IRF5. Data 
are from a representative experiment with four different donors.  
 
 
M1-specific genes that were induced by exogenous IRF5 include IL12A, IL12B and IL23A 
(coding for IL-12p35, IL-12p40 and IL-23p19 respectively) further supporting the 
dependence of these genes on IRF5. Interestingly, Epstein-Barr virus induced 3 (EBI3), 
also belonging to the IL-12 gene family, was highly upregulated in IRF5 expressing cells as 
well (Table 4.1). In line with my previous results, TNF was another gene whose expression 
was induced in the presence of IRF5 (Chapter 3). Genes coding for costimulatory molecules 
that were induced by IRF5 include CD40, CD80, CD83 as well as members of the tumor 
necrosis factor (ligand) superfamily (TNFSF, Table 4.1). CCR7, CXCR3 CXCR4 CXCR5 
and CXCR7 were amongst the M1-specific surface receptors upregulated in IRF5-
expressing macrophages. On the contrary, genes coding for surface receptors associated 
with M2 macrophage polarization (CD36, CD163, FCGR1A, FCGR1B and MRC1) were 
decreased. Furthermore, ectopic expression of IRF5 in M2 macrophages reduces mRNA 
expression of IL-10 and other cytokine markers of M2 macrophages, such as CCL2 and 
CCL13.  
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Table 4.1 Newly identified IRF5 target genes 
 
Genes up-regulated by ectopic IRF5 
Gene symbol Entrez Gene ID Fold change 
CXCR3 2883 2.9 
CXCR4 7852 3.8 
CXCR5 643 9.4 
CXCR7 57007 4.1 
EBI3 10148 38.2 
TNFSF4 7292 17.9 
TNFSF7 970 25.5 
TNFSF9 8744 15.0 
LTA 4049 13.1 
LTB 4050 8.9 
IFN- 3458 2.5 
CCL1 6346 18.6 
CCL3 6348 8.1 
CXCL5 6374 7.4 
IL-19 29949 4.2 
IL-32 9235 4.2 
   
Genes down-regulated by ectopic IRF5 
Gene symbol Entrez Gene ID Fold change 
CSF1R 1436 0.28 
IL-1R2 7850 0.28 
IL-1RA 3557 0.38 
TGF1 7045 0.42 
 
Global mRNA expression was analysed as in Figure 4.12. Results are presented for selected genes 
and are presented as fold change in IRF5 expressing macrophages relative to that of unstimulated 
M2 macrophages infected with empty vector. Data are from a representative experiment with four 
different donors.  
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The data from the genome-wide mRNA expression analysis corresponded well with the 
protein data of the cytokines investigated so far in this chapter (IL-12p70, IL-23, TNF, IL-1 
and IL-10). In order to improve on the validity of the micro array data set, I decided to 
confirm additional genes by performing ELISAs as well as FCM analysis using M2 
macrophages with exogenous IRF5. As expected, these experiments resulted in an 
increased production of M1-specific proteins (Figure 4.13a) but decreased production of 
M2-associated proteins (Figure 4.13b). Thus, IRF5 influences the expression of most 
cytokines that define human macrophage lineage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 IRF5 drives the production of selected lineage specific cytokines 
M2 macrophages were infected with adenoviral vectors encoding IRF5 or empty vector (pENTR) and 
stimulated with LPS for 24 h. The amount of secreted CCL5, CCL22 (a) or CCL2, CCL13 (b) protein 
was determined by ELISA. The amount of CD40 (a) or CD163 (b) surface expression was 
determined by FCM and expressed as MFI. Data are shown as the mean ± SEM of 4 to 6 
independent experiments each using M2 macrophages derived from a different donor: *p<0.05 and 
**p<0.01, (Student's t-test). 
 
b
a
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4.2.5 IRF5 directly regulates mRNA expression of lineage-specific 
cytokines 
IRF5 overexpression in resting M2 macrophages resulted in a profound change in basal 
levels of mRNA expression of lineage-specific genes. This suggested that IRF5 might be 
directly involved in the transcriptional regulation of lineage-specific genes and I therefore 
initiated the investigation into the LPS-induced recruitment of IRF5 to the promoter loci of 
selected genes. 
 
All IRF family members share a well-conserved amino-terminal DNA-binding domain that 
recognises ISREs binding sites. Computational analysis of the regions 2,000 bp 5′ upstream 
and 2,000 bp downstream of the transcription start sites of IL12A (IL-12p35), IL12B (IL-
12p40), IL23A (IL-23p19), IL10 and other IRF5-regulated genes led to the identification of 
several ISREs (Table 4.2).  
 
 
Table 4.2 putative IRF5 binding sites in -2000/+2000 bp relative to the TSSs of 
selected genes 
 
Genes up-regulated by ectopic IRF5 
Gene symbol 
Entrez  
Gene ID 
Number of  
ISREs 
Sequence Strand 
IL12A 3592 9 gctctcaTTTCtttttctttc - 
   atgtaaattaGAAActgtgtc + 
   gcgaacaTTTCgctttcattt - 
   atttcgcTTTCattttgggcc - 
   atccGAAAgcgccgcaagccc + 
   gaaggagacaGAAAgcaagag + 
   tcgtagaggaGAAActgaggc + 
   cacctggtctgggTTTCcctg - 
   tgtctccagaGAAAgcaagag + 
     
IL12B 3593 8 gttacagTTTTttttttttaa - 
   cccgggtTTCCcatttccccc - 
   gagggtaTTTCactttctgct - 
   aagtcagTTTCtagtttaagt - 
   tttctagtttaagTTTCcatc - 
   tgtacagTGTCcattttaaaa - 
   gttaaaaaatGAAAagctatt + 
   actgGAATctgaaattgtatg + 
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Gene symbol 
Entrez  
Gene ID 
Number of  
ISREs 
Sequence Strand 
IL23A 51561 6 accaggaagtGAAAcaaagag + 
   gggtagaTTTCcatttttttt - 
   gtgatgaaatcggTGTCagtg - 
   ccatGAAAccaggaccatcca + 
   ctgaGAAAaagaagcccgttt + 
   ttgggaaagaGAAAtcgatgg + 
     
TNFSF4 7292 9 aatgtactttacaTTTCccac - 
   cacaaacTTTCtcttttaagt - 
   tgcctcaTTTCcattttttct - 
   agatcttTTTCtttttctttg - 
   agaccagTTCCactttcccat - 
   taaaataTTTCcatttttctt - 
   atttttcTTTCactttattct - 
   attattttttcttATTCagta - 
   cacctccaatGAAAccagaat + 
     
EBi3 10148 9 ctctgtgTTTCtctttctgtt - 
   gtttctcTTTCtgtttccatc - 
   gtatctcTGTCactttctctg - 
   ctgtcacTTTCtctgtcatct - 
   cctttggTTTCtttttggttt - 
   tttttggttttgtTTTTtgag - 
   ccagGAATtcgagaccagcct + 
   gcaacatagtGAAAccggacc + 
   tagtGAAAccggaccccacca + 
     
TNFSF7 970 14 ctgcctcattcagTTTCtgtt - 
   cattcagTTTCtgtttctgtt - 
   gtttctgTTTCtgttttcaca - 
   agggGAATaggaagattgaat + 
   catgGAAAtggaagatgactc + 
   ccagGAAAacgattcgggaaa + 
   aaaataaaatGAAAtaaaatc + 
   gagggaaacgGAGAgggggag + 
   agaaGAAGgggaaagaaagaa + 
   cggagaaagaGAAAaaagaca + 
   aagaagaaagGAAAagaaaaa + 
   aaaagaaaaaGAAAgaaagga + 
   aaaggaaaaaGAAAgaagaaa + 
   agaagaaagaGAAAaaaagaa + 
     
TNFSF9 8744 7 tcaacacTGTCcctttcttgc - 
   gagacaaagaGAGActaaaga + 
   cagaGATAacggagccagaga + 
   cagaGATAacggagccagaga + 
   agggagaaagGAACctggagc + 
   gccggaaacgGAAAggagagc + 
   gtaccccTCTCcctttcaaga - 
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Gene symbol 
Entrez  
Gene ID 
Number of  
ISREs 
Sequence Strand 
CCL1 6346 6 ttcatgaTTTCaatgcctaga - 
   aacaaaaaggGAAAattcccc + 
   aatagaaatgGCAAatatcta + 
   gtgtGAATatgaatttgggta + 
   actctacTTTCtctatcagtg - 
   actggaaagaGCAAgggaacc + 
     
CCL3 6348 12 gctttcaTTTCtttttctact - 
   caaagaaatgGGAAatcaaga + 
   ccattgaacaGAAActtcagc + 
   ttcagaaaaaGAAAaaaataa + 
   ctcatgcTTTCtattcctcca - 
   cccccagattccaTTTCccca - 
   gcccccaagaGAAAagagaac + 
   cttggtcTTTCtctttaagac - 
   cagagaaacaGAGAacccact + 
   agaggaaaggGACAggaagaa + 
   aatttattttcgaTTTCacag - 
   agtttggttttgtTTTCctgg - 
     
IL-2Ra 3559 5 ggagggtTTTCtttttgttaa - 
   aattGAACttgaaaaaaaaaa + 
   caatgaatttcctTTTAttct - 
   tgcaaattttaaaTTTCattc + 
   ccaaGAACaggaaaatcttga + 
     
CCR7 1236 9 tcaagaaagtGAAAagatgat + 
   aaaaaaaaaaGAAAaaagaaa + 
   tcaacaaTTTCacttctaggt - 
   agctaaaaggGAAAacagccc + 
   ttcaGAATaggaaaatctata + 
   aaagGAAAaggaagggagggg + 
   accccagactaggTTTAgggg - 
   gggagggTTTCtgttacacaa - 
   tacacaaaatGAAAactccca + 
     
CXCR5 643 8 ttggtgaTTTCactttttttt - 
   tttttttTTTCttttagagac - 
   aagttgaTTTCatttttgtct - 
   tgagGAAAatgaaggtttgga + 
   gtggtggTTTCattacaagtt - 
   gaaaGAAGctgaaatgcttga + 
   caaaaaaacaGAAAagaccca + 
   aatgcaaaatGAAAacatggg + 
     
     
     
Chapter 4 - IRF5 promotes inflammatory macrophage polarization 
 138  
Genes down-regulated by ectopic IRF5 
Gene symbol 
Entrez  
Gene ID 
Number of  
ISREs 
Sequence Strand 
IL-10 3586 7 cttgttatttcaaCTTCttcc - 
   acaactaaaaGAAActctaag + 
   acgcGAATgagaacccacagc + 
   tgcaaaaattGAAAactaagt + 
   caggGAAAtttaaattgcctc + 
   cttctgcTTTCccttcaaaat - 
   ttgctcaTTTCtctttgagca - 
     
CD163 9332 10 ggatgaaactGGAAaccatca + 
   ttgctaatttttgTTTCacca - 
   gtatGAAAtggaacctcagct + 
   gtagcctTTTCattttcatga - 
   tcatGAAAgtgaagtgatttt + 
   gatgttgTTTCcattttccag - 
   gccctctTTTCtttttcacag - 
   caaaggaggaGAAActtcaga + 
   agataagTTTCagtctagcgt - 
   ctagtcttttcatCTTCataa - 
     
MS4A6A 64231 12 aaagacaagaGAAAggagaat + 
   agccaaaatgGAAAaaaaaag + 
   cgctGAGAactaatccagcct + 
   tgactggctctggTTTCcttg - 
   tgggGAATtagaaaagcaaga + 
   ttagaaaactGAAGcttcaag + 
   aatttaacttGAAActccttg + 
   gaaggagTATCtgtttttaac - 
   ccgtGAAAagggatccaagct + 
   tccatacTATCagtttctttc - 
   ctatcagTTTCtttctctaat - 
   gactgagTTACtgtttttgga - 
     
CXCL10 3627 11 caactaaaatAAAActgtcac + 
   tttgcctTTCCggtttcccac - 
   ccaacacttttttTTTCtttt - 
   cttttttTTTCtttttctttg - 
   caacctgTTTCccttctgtct - 
   atgatgtTTTCattcagggac - 
   tataagacgtGAAActtgttt + 
   tttggaaagtGAAAcctaatt + 
   aagtGAAAcctaattcactat + 
   catgcagagtGAAActtaaat + 
   ttaggaaacgGCAAtcttggg + 
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Gene symbol 
Entrez  
Gene ID 
Number of  
ISREs 
Sequence Strand 
CLEC4A 50856 5 gacttggtgtgggTTTCagaa - 
   gaaagacaatGAAAgcaggtt + 
   gagaGAAAtccactccagttc + 
   tagagtacaaGAAActatggg + 
   actatagTTACgctttctaaa - 
     
IL-1R2 isoform1 7850 13 ggcatggttttgcTTCCtctc - 
   ccaaatatttcacCTTCtaat - 
   gtaaGAAAatgaagatctgca + 
   ctctGAAAacaaaacaaaaca + 
   gaaaaataggGAAActtatgc + 
   cagagaaacaGAGAcagaaag + 
   cagagaaacaGACAgagatag + 
   gacaGAGAcagagaccaagac + 
   gctctcgggtggtTTTCtggg - 
   ctcagggTCTCcatttccacc - 
   ctctctgTCTCtgtttctctc - 
   ctctatgTCTCtgtttctccc - 
   taattgcattcccTTTTgggg - 
     
IL-1R2 isoform2 7850 11 ttcactcTTCCagtttctcac - 
   tttgctcTCTCcctttcctgg - 
   gaacaaaattTAAActgttct + 
   acgatggcttcacTTACatgg - 
   ttataagacaGAAAgcaaaat + 
   gacaGAAAgcaaaatttgttt + 
   tttaGAAActgaagctgtatc + 
   tgaacactttcttTTTGcagc - 
   gggaGAATttgaagcctgtgg + 
   ttgaatgagcGAAAacatgag + 
   ccatctgTATCagtttctgcc - 
     
IL-1RA isoform1 3557  ggaaGAAAtccaatctatttc + 
   aatctagtttctgATTCttta - 
   agagGAAAttgaaggccctta + 
   attctgaTTTCattatatata - 
   ctctaattttaagTTTCtaat - 
   ttttaagTTTCtaatttaaaa - 
   taaataaaatGAAAtaaaata + 
   agaggaaatgGATAtagagag + 
   actcggactgGAAActggaag + 
   actggaaactGGAAgggtgag + 
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Gene symbol 
Entrez  
Gene ID 
Number of  
ISREs 
Sequence Strand 
IL-1RA isoform4 3557 11 tacaaaaaatGAAAatgaact + 
   aaatGAAAatgaactaaactt + 
   cacacagTTTGaattcctggg - 
   tgggaaaactGAATctcaaaa + 
   ctcaGAAAaggaagctggttt + 
   ggaggaaaatGCAAattgaaa + 
   aatgcaaattGAAAagttgct + 
   ccttgctTTTCcctttgaatg - 
   aagaggaataGGAActgcacc + 
   cctcttccttcagTTTCagct - 
   ccttcagTTTCagcttgaata - 
 
Putative ISREs of selected genes were identified using the bioinformatic programs Genomatix and 
JASPAR. Capital letters in the binding sequence indicate the core binding sequence of ISREs 
(perfect match equals GAAA on + strand and TTTC on – strand)  
 
 
 
I designed primers encompassing the ISREs of IL12A (IL-12p35), IL12B (IL-12p40), IL23A 
(IL-23p19) and IL10 and used them in quantitative ChIP experiments with M1 macrophages 
stimulated with LPS for 0, 1, 2, 4, 8 or 24 h. RNA polymerase II ChIP was used in 
combination with IRF5 ChIP to provide an estimate of active transcription of the genes of 
interest upon LPS-stimulation. I observed LPS-induced enrichment of IRF5 at the promoter 
regions of IL12A, IL12B and IL23A up to 8 h after stimulation which matched the kinetics of 
the recruitment of RNA polymerase II to the genes (Figure 4.14 a-c).  
 
In contrast to the positively regulated genes, at the IL10 promoter region, LPS-induced 
recruitment of IRF5 took place between 1 h and 4 h after stimulation, whereas RNA 
polymerase II bound to the region only 8 h after stimulation (Figure 4.14d). This suggests a 
previously unknown inhibitory role for IRF5 in the transcriptional regulation of selected 
genes.  
 
Together these results suggest that in M1 Macrophages, IRF5 directly regulates the 
transcription of genes encoding IL-12p40, IL-12p35, IL-23p19 and IL-10 through its 
recruitment to their promoter regions. Furthermore, it shifts the global expression profile of 
M2 macrophages to a more pro-inflammatory “M1-like” phenotype.   
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Figure 4.14 LPS-induced recruitment of IRF5 to promoter regions of lineage-specific 
cytokines 
Recruitment of proteins to the promoters of genes encoding IL-12p35 (IL12A; a),IL-12p40 (IL12B; b), 
IL-23p19 (IL23A; c) or IL-10 (d) in M1 macrophages left unstimulated (0) or stimulated for 1, 2, 4, 8 or 
24 h with LPS (10 ng/ml), assessed by ChIP with anti-IRF5, anti-RNA polymerase II (Pol II) or 
immunoglobulin G (IgG; control); results are presented relative to those obtained with genomic DNA 
(input). Data show the mean ± SD from one experiment representative of three. 
 
 
4.2.6 IRF5 inhibits the transcription of the human IL-10 gene 
The observed effect of IRF5 on IL-10 gene expression led me to investigate whether it can 
directly repress the transcription of the gene encoding IL-10. To test this, I used an 
adenovirus construct with a gene reporter in which the luciferase reporter construct was 
flanked with 195 bp 5′ upstream of the human IL-10 gene [306]. I coinfected M2 
macrophages with that construct plus a vector encoding IRF5 or empty vector and 
quantified luciferase activity. IRF5-expressing cells showed significantly less luciferase 
activity, both in resting cells and at 4 h after stimulation with LPS (Figure 4.15a). To confirm 
the importance of the binding of IRF5 to the IL10 promoter, I used a mutant of IRF5 lacking 
the DNA-binding domain IRF5 (IRF5ΔDBD). This IRF5 mutant was not able to inhibit the 
wild-type IL-10 luciferase reporter construct (Figure 4.15a). To further explore the molecular 
a b
c d
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mechanism of IRF5-mediated suppression of IL10 transcription, I introduced point mutations 
into the ISRE identified (positions −182 to −172 relative to the transcription start site) and 
coinfected M2 macrophages with this mutated luciferase reporter construct and vector 
encoding IRF5 or empty vector. The luciferase reporter construct with a mutated ISRE 
produced a different response than did the wild-type construct in that ectopic IRF5 was no 
longer able to suppress luciferase activity (Figure 4.15b), which suggested that IRF5 inhibits 
IL-10 by direct binding to the ISRE of the IL10 promoter. This was opposite to the positive 
regulatory activity of IRF5 at the TNF promoter (Chapter 3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 IRF5 inhibits the transcriptional activation of the human IL-10 gene 
(a) Luciferase activity of M2 macrophages infected for 24 h with a wild-type IL10 luciferase reporter 
plasmid (WT), plus a construct encoding IRF5 or an IRF5 mutant lacking the DNA-binding domain 
(IRF5ΔDBD) or empty vector, then left unstimulated (US) or stimulated for 4 h with LPS (10 ng/ml). 
(b) Luciferase activity of M2 macrophages infected for 24 h with the wild-type reporter in (a) or an 
IL10 luciferase reporter plasmid with site-specific mutations in the ISRE site at positions −180 to 
−173 (ISREmut), plus the constructs in (a) and stimulated for 4 h with LPS (10 ng/ml). Data are the 
mean ± SEM from three independent experiments, each with macrophages derived from a different 
donor. *p<0.01 (one-way ANOVA with Dunnett‟s multiple-comparison post-test).  
 
 
Therefore, IRF5 can act not only as a transcriptional activator but also as a suppressor of 
certain target genes, in this case the gene encoding the anti-inflammatory mediator IL-10. 
The mode of inhibition is mediated by direct binding of IRF5 to the promoter region of IL10 
and may involve engagement of as-yet-unidentified cofactors. 
a b
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4.3 Conclusion 
Macrophages are key mediators of the immune response during inflammation. Plasticity 
and functional polarization are hallmarks of the macrophage system resulting in phenotypic 
diversity of macrophage lineage populations [61]. Here I investigated whether IRF5 is 
involved in macrophage polarization. I demonstrate that IRF5 is indeed a major factor 
defining macrophage lineage commitment: it is highly expressed in M1 macrophages and 
induces a characteristic gene expression and cytokine secretion profile. I also unravel a 
new regulatory role for IRF5 as an inhibitor of M2 macrophage marker expression. Finally, 
IRF5 contributes to the macrophage system plasticity, i.e. modulation of its levels leads to 
the conversion of one macrophage subset‟s phenotype into the other.  
 
IRF5 protein levels are induced in M1 macrophages differentiated with GM-CSF (Figure 4.2) 
or M2 macrophages stimulated with IFN- plus LPS (Figure 4.3). In priming experiments, a 
24 h treatment of M2 macrophages with GM-CSF significantly upregulates IRF5 protein 
levels suggesting that it is likely to be a direct consequence of GM-CSF treatment (Figure 
4.5). This was further supported by the kinetics of IRF5 mRNA expression in monocytes 
stimulated with GM-CSF, which showed rapid upregulation of mRNA 2 h post stimulation 
(Figure 4.2c). IFN- stimulation of monocytes also induced IRF5 expression, with the 
magnitude and kinetic comparable to that of GM-CSF treatment (data not shown). 
Altogether, this strongly supports the conclusion that IRF5 is induced by either in vitro M1 
macrophage differentiation protocol.  
 
The rapid and potent transcriptional response developed by macrophages encountering 
microbial stimuli, such as LPS, or subsequently cytokines, is orchestrated by many TFs. 
Among them are class III TFs, such as PU.1, C/EBPb, RUNX1 and IRF8, which are lineage-
specific transcriptional regulators turned on during macrophage differentiation [307]. The 
combinatorial expression of these proteins specifies the macrophage phenotype via 
constitutive activation or repression of genes and chromatin remodelling at inducible loci. 
For instance, PU.1 is required for maintaining H3K4me1 enhancer marks at macrophage-
specific enhancers [308]. But only a small proportion of the macrophage transcriptome is 
altered by cell polarization [305] and among the genes differentially expression between the 
M1 and M2 subsets are those regulated by IRF5, such as IL-12p40, IL-12p35, IL-23p19, IL-
1, TNF, macrophage inflammatory protein 1a, Rantes, CD1a, CD40, CD86, CCR7 (Figure 
4.12). Another member of the IRF family, IRF4, known to inhibit IRF5 activation by 
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competing for interaction with Myd88 [299], has been recently reported to control the 
expression of prototypical mouse M2 macrophage markers [302]. Of interest, the 
expression of IRF4 is equally induced by M-CSF or GM-CSF differentiation (Figure 4.2) and 
is further enhanced by exposure to IL-4 [309]. IRF5 expression, on the other hand, is 
specifically induced by GM-CSF or IFN- (Figures 4.2 and 4.3), but is unresponsive to IL-4 
(data not shown). Thus, IRF5 and IRF4 may be classified as class III TFs but with the 
difference that they define specific macrophage subsets rather than the global macrophage 
lineage.  
 
Consistent with published studies [213, 215], I found no expression of the most widely used 
prototypical mouse M2 markers (Arg1, Ym1 and Fizz 1) in human macrophages (data not 
shown) – after all, man is not a mouse. On that note, a number of molecules not involved in 
macrophage polarization in the murine system have been shown to be markers for human 
macrophage alternative activation, including fibrinoligase (F13A1), fibrinogen-like 2 (FGL2) 
and insulin-like growth factor 1 (IGF1) [305], all of which were decreased in the presence of 
endogenous IRF5 (Figure 4.12). Furthermore, expression of some chemokines defined as 
M1 markers (CXCL10) or M2 markers (CCL17, CCL18 and CCL22) in mouse macrophages 
did not follow the expected pattern of IRF5 dependence (that is, induction for M1 and 
inhibition for M2), which possibly reflects again species-specific gene repertoires [214, 310]. 
Although human M1 macrophages but not M2 macrophages have been shown to secrete 
large amounts of CCL22 upon LPS stimulation [67], there is some controversy in the 
literature about whether CXCL10 is a marker of the M1 or M2 macrophage phenotype [67, 
304, 305]; my data would classify CXCL10 as an M2 macrophage marker. Therefore, 
investigators have to be cautious against direct mouse-to-human translation of polarization 
markers and a direct comparison based on expression profiling results will be required to 
fully describe interspecies variability. 
 
I used adenoviral delivery of an IRF5 expression construct to further explore the effect of 
IRF5 on macrophage polarization. It is known that the initiation of an immune response 
following virus administration can be a potential problem when working with myeloid cells 
such as macrophages. However, I routinely analysed the secretion of endogenous IFN-1 
protein as well as mRNA induction of type I IFNs and observed no significant effect on 
resting macrophages 48 h or 72 h post infection. Similarly, the mRNA expression of 
transcription factors associated with an immune response (NF-B family members, IRF3 
and IRF7) was not affected in adenoviral treated cells (data not shown). Although other 
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potential effects cannot be entirely ruled out, this conferred some confidence as to the 
suitability of this technique.  
 
Ectopic expression of IRF5 in M2 macrophages resulted in the upregulation of both mRNA 
and protein levels of IL-12p70 and IL-23 (Figures 4.6 and 4.10). Conversely, siRNA-
mediated inhibition of IRF5 in M1 macrophages showed a reduction of these cytokines upon 
LPS stimulation (Figures 4.8 and 4.9). In order to clarify the type of involvement of IRF5 in 
regulation of IL-12p40, IL-12p35 and IL-23p19, I employed a ChIP approach and detected 
LPS-induced recruitment of IRF5 to all promoter regions in M1 macrophages (Figure 4.14). 
The binding of IRF5 to the aforementioned gene promoters was accompanied by the 
recruitment of Pol II which suggests active transcription of the genes. Although more work is 
required to thoroughly dissect the contribution of other bioinformatically predicted ISRE sites 
in IRF5 binding, since no significant IRF5 recruitment was observed before LPS induction, I 
concluded that IRF5 was needed to induce the subset-specific gene expression rather than 
to alter the chromatin state.  
 
The role of IRF5 in the inhibition of IL-10 gene transcription is novel and important in view of 
its well documented immunosuppressive activity. Il-10-/- mice develop spontaneous 
autoimmune diseases and show increased resistance to infection [311-313]. IL-10 
represses immune responses by down-regulating inflammatory cytokines like TNF [314, 
315] and major producers of IL-10 include M2 macrophages, B cells and T lymphocytes 
[316], whereas M1 macrophages and monocyte-derived DCs are only weak producers [67]. 
Ectopic expression of IRF5 in M2 macrophages reduces IL-10 secretion upon LPS 
stimulation (Figure 4.7) and also affects mRNA expression of IL-10 (Figure 4.10) as well as 
a number of other markers of human M2 macrophage phenotype, such as mannose 
receptor C type I, insulin-like growth factor 1, CCL2, CCL13, CD163, MCSF receptor and 
macrophage scavenger receptor 1 (Figure 4.12).  
 
I used IL-10 luciferase constructs to further characterise IRF5-mediated inhibition of IL-10 
and found that direct DNA binding of IRF5 was necessary, as a DNA-binding mutant of 
IRF5 (IRF5 DBD) was not able to inhibit the reporter gene (Figure 4.15a). Moreover, I 
showed that the previously identified ISRE site, involved in IFN- but not LPS-induced IL-10 
secretion [306], was absolutely required for the inhibitory effects of IRF5 as the mutation of 
this site abolished the IRF5-mediated inhibition (Figure 4.15b). The recruitment of IRF5 to 
the promoter ISRE of IL-10 occurred between 1 and 4 h post stimulation in counter-phase 
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with Pol II recruitment which was only detectable 8 h after activation (Figure 4.14d), 
suggesting that binding of IRF5 inhibited the recruitment of Pol II presumably via 
interactions with yet unknown co-factors.  
 
In summary, a distinct systemic role of IRF5 in macrophages is the orchestration of 
transcriptional activation of pro-inflammatory cytokines, chemokines and co-stimulatory 
molecules asscociated with the M1 phenotype. I suggest that IRF5 should be considered as 
the transcription factor that defines the M1 macrophage phenotype and IRF5 participates, 
together with other established factors of the M2 macrophage phenotype (C/EBP, IRF4 
and NF-B p50), in regulating macrophage polarization (Figure 4.16). Taken into account 
that IRF5 and IRF4 seem to have opposing function, it is possible that relative 
concentrations of IRF5 and IRF4 are important for defining a particular macrophage 
phenotype. This would suggest a new paradigm for macrophage polarization and 
designates the IRF5-IRF4 regulatory axis as a new target for therapeutic intervention: 
inhibition of IRF5 activity would specifically affect the pro-inflammatory M1 macrophage 
phenotype and dampen innate immune responses.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 Transcription factors underlying macrophage polarization 
C/EBP and IRF4 both regulate M2-specific genes with apparently no effect on M1-specific genes 
[301, 302]. NF-B p50 too, regulates the M2 phenotype but is also able to inhibit certain M1-specific 
genes [300]. This thesis defines IRF5 as the transcriptional activator of M1-specific genes with 
additional inhibitory properties regarding M2-specific genes. Mono - Monocyte, M1 Mac - M1 
macrophage, M2 Mac - M2 Macrophage 
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5. IRF5 promotes Th1/Th17 responses and its 
importance for in vivo inflammation 
 
5.1 Introduction 
The differences in cytokine production between M1 and M2 macrophages (Chapter 4) have 
implications for other immune cells, especially T lymphocytes. One of the hallmarks of M1 
macrophage polarization is the acquisition of antigen-presenting features, which leads to 
efficient T lymphocyte responses [63, 64]. IL-12p70 drives polarization of naïve T 
lymphocytes towards Th1 cell development and induces the predominant release of IFN- 
[106]. IFN- mainly serves to activate macrophages at the site of inflammation resulting in 
increased production of IL-12p70 and other M1-associated cytokines and therefore 
promotes a positive feedback loop. IL-23 has recently been identified as an IL-12-like 
cytokine [106] which affects T lymphocyte proliferation and Th17 lineage commitment [317]. 
IL-10, on the other hand, can repress immune responses by down-regulating inflammatory 
cytokines like TNF [314, 315] and is important for generation of regulatory T lymphocytes 
that act to suppress activation of the immune system and thereby maintain immune system 
homeostasis and tolerance to self-antigens [318, 319]. In this Chapter, I specifically wanted 
to know what effect forced expression of IRF5 in M2 macrophages would have on the 
development and activation state of T lymphocytes. 
 
Furthermore, as our group obtained Irf5-/- animals during the final year of my PhD, I also 
thought it would be important to gather more information on the in vivo role of IRF5 during 
inflammatory responses. The use of experimental animals was essential to address this 
question because these responses cannot be dissected in vivo in humans and in vitro 
culture techniques cannot entirely replicate the dynamics or complexity of what occurs in 
vivo. In addition, the use of animals would allow me to gauge the contribution of IRF5-
expressing macrophages during inflammation and to have the opportunity to influence and 
manipulate the immunological system. In order to investigate the function of IRF5 in 
pathological conditions, I used a mouse model of M1 inflammation and compared the 
outcome in wild-type and Irf5-/- animals.  
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5.2 Results 
 
5.2.1 IRF5 promotes human T lymphocyte proliferation and Th1 
responses 
To determine whether IRF5 aided the polarization of T lymphocyte proliferation, fate or 
activation state I intended to perform MLR experiments. I previously optimised the ratio of 
APC to T lymphocyte in the MLRs performed in chapter 3 and expected that a similar ratio 
should work in MLRs using macrophages as APCs. However, I first needed to make sure 
that adenoviral delivery of constructs in the reduced number of macrophages (2 x 104 
cells/well for MLR compared to the usual 1 x 105 cells/well) would still be efficient and not 
toxic to the cells. I titrated the number of human M2 macrophages (1 x 105, 5 x 104 and 2 x 
105 cells/well), infected them with expression constructs for IRF5, IRF3 or empty vector and 
measured the expression of GFP which was proportional to the cell number and equal 
between groups (data not shown). I also determined cell viability in these optimisation 
experiments using the colorimetric MTT assay and found that the metabolic activity of the 
cells expressing IRF5, IRF3 or empty vector was again proportional to the cell number and 
not different between groups (data not shown). I concluded that I could reduce the number 
of macrophages per well to 2 x 104 in MLR experiments without compromising construct 
expression or cell viability. Next, I determined the ratio of M2 macrophages to T 
lymphocytes extracted and purified from the peripheral blood of MHC mismatched donors 
and performed initial experiments using the ratios 1:10, 1:25 and 1:50. Similar to the MLRs 
performed in chapter 3, the best ratio of macrophages to T lymphocytes was 1:25, 
assessed by secretion of IFN- (as a measure of T lymphocyte activation) and T lymphocyte 
proliferation. Therefore, I used 2 x 104 macrophages per well and cultured them with T 
lymphocytes in a ratio of 1:25 in all following MLR experiment. 
 
Next, I infected human M2 macrophages with viral expression constructs coding for IRF5 or 
IRF3 or empty vector and exposed the cells to human T lymphocytes in a MLR using the 
parameters described above. The proliferation of T lymphocytes was assessed 3 days after 
co-culture by [3H] thymidine incorporation and was considerably greater when they were 
cultured together with IRF5-expressing macrophages (Figure 5.1) compared to control or 
IRF3 expressing cells. The [3H] thymidine incorporation assays were kindly performed by Dr 
Saba Alzabin (Kennedy Institute of Rheumatology, London, United Kingdom). 
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Figure 5.1 IRF5 induced T lymphocyte proliferation 
M2 macrophages were infected with adenoviral vectors encoding IRF5, IRF3 or empty vector 
(pENTR) and cultured in triplicate for 72 h with T lymphocytes from MHC mismatched donors. 
Cultures were pulsed with [
3
H] thymidine for the last 16 h to measure DNA synthesis. Control cultures 
contained macrophages or T lymphocytes alone. Results are expressed as counts per minute (CPM) 
minus proliferation of macrophage-only cultures. Data are shown as the mean ± SEM of 6 
independent experiments each using macrophages derived from a different donor: ***p<0.001 (One-
way ANOVA with Dunnett's Multiple Comparison Post Test). 
 
 
Next I analysed the activation of specific T lymphocyte subsets by flow cytometry analysis. 
Flow cytometry (FCM) allows the simultaneous multiparametric analysis of the physical 
and/or chemical characteristics of up to thousands of cells per second. The detectable 
parameters of FCM are constantly expanding and include amongst other things cell surface 
antigens, intracellular antigens such as cytokines and transcription factors as well as cell 
cycle analysis. There are a wide range of fluorophores available for FCM with each having a 
characteristic peak excitation and emission wavelength. However, the combination of labels 
which can be used depends on the wavelength of the laser(s) used to excite the 
fluorophores and on the detectors available as the mission spectra of the labels often 
overlap.  
 
Here, I wanted to know what the effect of ectopic expression of IRF5 in M2 macrophages 
would have on T lymphocyte activation state and fate. I focused on the T helper lymphocyte 
population which is characterised by the surface expression of CD4 and can be further 
divided into Th1 (identified by intracellular IFN-), Th17 (identified by intracellular IL-17) and 
Th2 (identified by intracellular IL-4) populations. The MLR optimization experiments 
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revealed only very low or no intracellular expression of IL-4 in all experimental groups (data 
not shown) and thus was not analysed in further experiments. Upon analysis of the T 
lymphocytes I found that only IRF5-expressing macrophages provided the cytokine 
environment necessary for the population expansion and activation of Th1 lymphocytes, 
indicated by an increase in CD4+/IFN-+ T lymphocytes (Figure 5.2a) which was 
reproducible in multiple donors (Figure 5.2b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 IRF5-expressing macrophages induce Th1 activation 
(a) M2 macrophages were infected with adenoviral vectors encoding IRF5 or empty vector (pENTR) 
and cultured with T lymphocytes from mismatched donors. After 4 days, cells were stimulated for 3 h 
with PMA/ionomycin/Brefeldin A and stained for CD4 and IFN-. Representative FCM plots are 
shown. (b) The percentage of CD4
+
/IFN
+
 cells was determined by ICC staining in cells treated as in 
a. Data are shown as the percentage of CD4
+
/IFN-
+
 cells and are the mean ± SEM of 8 independent 
experiments each using cells derived from a different donor. p<0.001 (One-way ANOVA with 
Dunnett's Multiple Comparison Post Test). 
 
bpENTR
IRF5
a
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The increase in CD4+/IFN-+ lymphocytes was accompanied by higher expression of IFN- 
mRNA in the total T lymphocyte population (Figure 5.3a) as well as increased production 
and secretion of IFN- protein (Figure 5.3b and c). Furthermore, there was significant 
induction of expression of mRNA for the Th1-specifying transcription factor T-bet (TBX21) in 
T lymphocytes cultured together with IRF5-expressing macrophages but not control or IRF3 
expressing cells (Figure 5.3d).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 IRF5-expressing macrophages induce Th1 development 
(a-d) M2 macrophages were infected with adenoviral vectors encoding IRF5, IRF3 or empty vector 
(pENTR) and cultured with T lymphocytes from MHC mismatched donors. (a) Expression of IFN- 
mRNA in T lymphocytes after 2 days of co-culture presented in arbitrary units (AU) relative to those 
obtained with empty vector control. (b) Immunocytochemical staining of IFN- in T lymphocytes after 
2 days of co-culture and then stimulated for 3 h with PMA/ionomycin/Brefeldin A. Results are 
presented as mean fluorescence intensity (MFI). (c) IFN- in supernatants of the cells in (b) 
determined by ELISA. (d) Expression of TBX21 (T-bet) mRNA in T lymphocytes from (a) presented 
as in (a). Data are shown as the mean ± SEM of 6 to 9 independent experiments each using cells 
derived from a different donor. *p<0.05, **p<0.01 and ***p<0.001 (One-way ANOVA with Dunnett's 
Multiple Comparison Post Test). 
 
 
5.2.2 IRF5 promotes human Th17 responses  
Next I analysed the activation of Th17 lymphocytes by FCM analysis and found that again 
only IRF5-expressing macrophages provided the cytokine environment necessary for the 
population expansion and activation of Th17 lymphocytes. I observed an increase in 
CD4+/IL-17+ T lymphocytes (Figure 5.4a) which was reproducible and significant when 
a c
c
b d
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analysed in multiple donors (Figure 5.4b). In line with studies demonstrating that IL-23 
enhances the emergence of an IL-17+/IFN-+ population of T lymphocytes [228], about 25% 
of IL-17+ lymphocytes were also IFN-+ (data not shown), which supported the idea of a 
close developmental relationship between human Th17 and Th1 lymphocytes [320]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 IRF5-expressing macrophages induce Th17 activation 
(a) M2 macrophages were infected with adenoviral vectors encoding IRF5 or empty vector (pENTR) 
and cultured with T lymphocytes from MHC mismatched donors. After 4 days, cells were stimulated 
for 3 h with PMA/ionomycin/Brefeldin A and stained for CD4 and IL-17A. Representative FCM plots 
are shown. (b) The percentage of CD4
+
/IL-17A
+
 cells was determined by ICC staining in cells treated 
as in (a). Data are shown as the percentage of CD4
+
/IL-17A
+
 cells and are the mean ± SEM of 8 
independent experiments each using cells derived from a different donor. ***p<0.001 (One-way 
ANOVA with Dunnett's Multiple Comparison Post Test). 
 
 
b
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Similar to before, the increase in IL-17-producing CD4+ lymphocytes was accompanied by 
higher expression of IL-17A mRNA in the total T lymphocyte population (Figure 5.5a) as 
well as increased production and secretion of IL-17A protein (Figure 5.5b and c). As 
expected, there was significant induction of expression of mRNA for the Th17-specifying 
transcription factor RORγt (RORC2) in T lymphocytes cultured together with IRF5-
expressing macrophages but not control or IRF3 expressing cells (Figure 5.5d).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 IRF5-expressing macrophages induce Th17 development 
(a-d) M2 macrophages were infected with adenoviral vectors encoding IRF5, IRF3 or empty vector 
(pENTR) and cultured with T lymphocytes from MHC mismatched donors. (a) Expression of IL-17A 
mRNA in T lymphocytes after 2 days of co-culture presented in arbitrary units (AU) relative to those 
obtained with empty vector control. (b) Immunocytochemical staining of IL-17A in T lymphocytes after 
2 days of co-culture and then stimulated for 3 h with PMA/ionomycin/Brefeldin A. Results are 
presented as MFI. (c) IL-17A in supernatants of the cells in (b) determined by ELISA. (d) Expression 
of RORC2 (RORT) mRNA in T lymphocytes from (a) presented as in (a). Data are shown as the 
mean ± SEM of 4 to 8 independent experiments each using cells derived from a different donor. 
*p<0.05 and ***p<0.001 (One-way ANOVA with Dunnett's Multiple Comparison Post Test). 
 
 
Deciphering the precise cytokine profile of Th-17 lymphocytes has been the focus of many 
recent studies [111, 321]. It is now clear that there are many other phenotypic markers of 
these cells in addition to the expression of RORT and the subsequent IL-17A production. I 
therefore analysed the expression of mRNA coding for IL-17F, IL-21, IL-22, IL-26 and IL-23 
receptor (IL-23R) in MLR experiments. I found that all of the above genes were upregulated 
in T lymphocytes co-cultured with IRF5-expressing macrophages whereas control or IRF3-
expressing cells showed no effect (Figure 5.6).  
c
a cb d
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Figure 5.6 IRF5-expressing macrophages induce Th17 cytokine profile 
M2 macrophages were infected with adenoviral vectors encoding IRF5, IRF3 or empty vector 
(pENTR) and cultured with T lymphocytes from MHC mismatched donors. The Expression of IL-17F, 
IL-21, IL-22, IL-26 and IL-23R mRNA in T lymphocytes after 2 days of co-culture was determined by 
RT-PCR and is presented as arbitrary units (AU) relative to those obtained with empty vector control. 
Data are shown as the mean ± SEM of 5 to 6 independent experiments each using cells derived from 
a different donor: *p<0.05, **p<0.01 and  ***p<0.001 (One-way ANOVA with Dunnett's Multiple 
Comparison Post Test). 
 
 
Of interest, expression of GATA-3 (essential for Th2 lineage commitment) and Foxp3 
mRNA (essential for Treg lineage commitment) was lower in the presence of IRF5-
expressing macrophages (Figure 5.7). Signature cytokines of the Th2 lymphocyte lineage 
include IL-4 as well as IL-13 and the lack of Th2 development is further supportet by the fact 
that IL-4 protein levels were below the limit of detection in all MLR experiments (data not 
shown)  
 
Hence, IRF5-expressing macrophages promote the proliferation of T lymphocytes and 
provide the cytokine environment for the activation of the Th1 and Th17 lineage but do not 
induce the Th2 or Treg lineage. This further highlights the importance of IRF5 in 
establishing the M1 cytokine profile (IL-12hiIL-23hiIL-10low) which is required for a robust 
Th1/Th17 response.   
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Figure 5.7 IRF5-expressing macrophages do not induce the Treg or Th2 lineage 
M2 macrophages were infected with adenoviral vectors encoding IRF5, IRF3 or empty vector 
(pENTR) and cultured with T lymphocytes from MHC mismatched donors. The expression of FOXP3 
and GATA-3 mRNA in T lymphocytes after 4 days of co-culture was determined by RT-PCR and is 
presented as arbitrary units (AU) relative to those obtained with empty vector control. Data are shown 
as the mean ± SEM of 8 independent experiments each using cells derived from a different donor: 
*p<0.05 and ***p<0.001 (One-way ANOVA with Dunnett's Multiple Comparison Post Test). 
 
 
 
5.2.3 IRF5 regulates the phenotype of mouse macrophages 
In the last part of my detailed study into the diverse roles of IRF5 in regulating immune 
responses I wanted to investigate its role during a mouse model of M1 inflammation. As all 
my previous experiments were exclusively performed in primary human cells or where 
appropriate in human cell lines I first had to establish that the role of IRF5 is similar in 
human and mouse. Therefore, I analysed IRF5 protein levels in mouse bone marrow–
derived macrophages (BMDMs) differentiated either with GM-CSF or M-CSF. Similar to 
their human counterparts, GM-CSF differentiated BMDMs had higher expression of IRF5 
protein than M-CSF-derived BMDMs (Figure 5.8). Simultaneously, I analysed IRF5 protein 
expression in BMDMs obtained form IRF5-deficient animals and found it to be undetectable 
as expected.  
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Figure 5.8 IRF5 expression is high in GM-CSF differentiated BMDMs 
Bone marrow cells were obtained form a wild-type (wt) and IRF5
-/-
 (ko) mouse and differentiated for 8 
days into M1 macrophages with GM-CSF (20 ng/ml) or M2 macrophages with M-CSF (100 ng/ml). 
Total protein extracts were subjected to western blot analysis with antibodies to IRF5 and actin as a 
loading control. A representative blot of three independent experiments is shown. 
 
 
Next, I analysed the cytokine profile of GM-CSF or M-CSF differentiated BMDMs. GM-CSF-
derived BMDMs but not M-CSF-derived BMDMs were capable of secreting IL-12p70 and  
IL-23 upon LPS stimulation (data not shown) which is in line with previously published data 
[63-67]. However, BMDMs obtained from Irf5−/− mice and differentiated with GM-CSF 
secreted significantly less IL-12p70 and IL-23 but produced higher amounts of IL-10 in 
response to stimulation with LPS than did wild-type cells (Figure 5.9). This is an 
independent validation of the results obtained using siRNA targeting IRF5 in human cells 
and adds to the mounting evidence that IRF5 regulates M1-specific cytokines.  
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Impaired induction of M1 cytokines in BMDMs of IRF5−/− mice 
ELISA of IL-12p70, IL-23 and IL-10 secreted by M1 macrophages obtained from Irf5
−/−
 or littermate 
C57BL/6 wt mice and stimulated for 24 h with LPS (100 ng/ml). Data shown are the mean ± SEM of 6 
to 8 BMDM cultures from three independent experiments.  *p<0.05 and **p<0.01 (Student‟s t-test).  
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5.2.4 Importance of IRF5 in a mouse model of M1 inflammation 
To investigate the function of IRF5 in pathologic conditions associated with M1 polarized 
inflammation, I conducted an intra peritoneal challenge of Irf5−/− mice with bacterial derived 
LPS. I would like to thank Miss Katrina Blazkova (Kennedy Institute of Rheumatology, 
London, United Kingdom) who was instrumental in establishing and optimising these in vivo 
experiments.  
 
I needed to optimise this model first as it has not been performed before at the Kennedy 
Institute and started with injecting PBS on its own into wild-type C57BL/6 mice followed by 
collecting serum after 3 h. I could not detect cytokines, such as TNF, IL-23 and IL-10, by 
ELISA in any of the PBS treated animals (data not shown) indicating that the injection does 
not induce measurable cellular responses. Next, I injected wild-type C57BL/6 mice with 1 μg 
of LPS or PBS (as a control) and collected serum 3 h later. Analysis of cytokines in the 
serum by ELISA and CBA revealed very low levels of TNF and IL-6 but IL-23 and IL-10 
were not detectable (data not shown) suggesting that a higher dose of LPS is needed for a 
better induction of these cytokines. I performed additional experiments using 10 μg and 20 
μg of LPS for 3 h as well as 6 h and found that 20 μg was sufficient to induce detectable 
amounts of cytokines (TNF, IL-23, IL-6 and IL-10, data not shown) while not harming the 
mice. This was important as our animal licence only allows me to conduct an intra 
peritoneal challenge with a sub-lethal dose of LPS and for a short time. Levels of the 
cytokines mentioned above were higher at 3 h compared to 6 h therefore all following intra 
peritoneal challenges were terminated after 3 h.  
 
I injected IRF5-deficient and wild-type littermate control mice with 20 μg of LPS or PBS (as 
a control) for 3 h followed by collecting serum, peritoneal cells, lymph nodes and spleens. I 
used a total of 10 mice (5 males and 5 females), ranging from 8 to 14 weeks old, per 
experimental condition. Within 3 h there was a significant difference between wild-type and 
Irf5−/− mice in the serum concentrations of selected macrophage-subset specific cytokines. 
The responses were consistent with both the human and mouse data; that is, Irf5−/− mice 
had lower serum concentrations of IL-12p40 and IL-23 but expressed increased amounts of 
IL-10 (Figure 5.10). In addition, the expression of IL-1, TNF as well as IL-6 was 
considerably lower in Irf5−/− mice compared to their wild-type littermate controls (Figure 
5.10). Thus, confirming the in vitro results obtained with human si-IRF5 depleted 
macrophages or mouse BMDMs derived from IRF5-deficient mice.  
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The expression of IL-12p70 was below the limit of detection in the experimental conditions 
described above (data not shown). Control animals injected with PBS secreted 
undetectable levels of the cytokines measured (data not shown).  
 
 
 
 
 
 
 
 
 
 
Figure 5.10 Impaired induction of M1 cytokines in LPS challenged Irf5−/− mice 
ELISA (IL-12p40 and IL-23,) or cytrometric bead assay (IL-10, IL-1, TNF and IL-6) of the serum 
concentrations of cytokines in Irf5
−/−
 mice (n = 10) and their wild-type littermates (n = 10) injected 
intraperitoneally with LPS (20 μg), assessed 3 h later. Data shown are the mean ± SEM of 8 to 10 
serum samples from three independent experiments. *p<0.05 and **p<0.01 (Student‟s t-test).  
 
 
Overall, this data supported the idea that IRF5 is important for inflammatory responses in an 
animal model of inflammation. The in vivo model provided an additional line of evidence for 
the central role of IRF5 in the induction of M1-specific cytokines and validated both human 
and mouse in vitro data. However, measuring the concentration of cytokines in the serum 
did not give me further information on which cells or organs were in particular dependent on 
IRF5 protein expression. I therefore analysed the responses in specific organs, like 
peritoneum, lymph node and spleen, which were collected during the inflammation model.  
 
I focused first on the peritoneum, as macrophages should be readily recruited into the 
peritoneal cavity during the intra peritoneal LPS challenge. I performed a peritoneal lavage 
and found that the number of macrophages recruited into the peritoneal cavity of LPS-
challenged mice was similar for wild-type and Irf5−/− mice (data not shown). However, RT-
PCR analysis of these cells showed an impaired induction of genes coding for M1 
macrophage markers IL-12p35, IL-12p40, IL-23p19, IL-1, TNF and IL-6 in IRF5-deficient 
animals (Figure 5.11). The expression of genes coding for M2-specific markers in Irf5−/− 
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mice was either significantly higher (IL-10, Retnla (Fizz1), Arg1, Figure 5.11) or showed a 
positive trend (MRC1 and Chi3l3 (Ym1), data not shown). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Impaired mRNA induction of M1-specific cytokines in peritoneal cells from 
Irf5−/− mice 
mRNA expression of M1 and M2 markers (horizontal axis) in peritoneal cells obtained from the LPS-
injected mice in Figure 5.2.10. mRNA expression of the genes analysed is presented relative to that 
of the wild-type sample with the lowest relative expression, set as 1. Data shown are the mean ± 
SEM of 10 wild-type and Irf5
−/−
 samples from three independent experiments. *p<0.05, **p<0.01 and 
***p<0.001 (Student‟s t-test). 
 
 
 
Next, I analysed the mesenteric lymph nodes (lymph nodes of the large intestine and lower 
abdomen) from the LPS challenged animals. Again, there was no difference in size or cell 
number between wild-type and Irf5−/− mice (data not shown). Furthermore, mRNA 
expression of T lymphocyte- specific cytokines (IFN- and IL-17A) was also similar between 
experimental groups, probably due to the short time of exposure of the animals to the 
inflammatory agent.  
 
The last organ I collected and focused on in more detail was the spleen. I extracted 
splenocytes from LPS challenged Irf5−/− and wild-type littermate controls and cultured them 
ex vivo for an additional 48 h in the presence of anti-CD3 antibodies. Here I observed 
significantly less secretion of IFN- and IL-17 in the cultures obtained from Irf5−/− mice 
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(Figure 5.12) further supporting the importance of IRF5 for Th1/Th17 responses which is in 
accordance with the data obtained with human cells (Figures 5.2 to 5.6).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 Reduction in IFN- and IL-17 production in ex vivo splenocyte cultures 
ELISA of IFN- and IL-17A in spleen cells obtained from the LPS-injected mice in Figure 5.2.10 and 
cultured for 48 h in the presence of antibody to CD3. Data shown are the mean ± SEM of 4 to 5 
spleen cultures from two independent experiments *p<0.05 and **p<0.01 (Student‟s t-test). 
 
 
In summary the data presented here supports the idea that IRF5 is important in establishing 
a pro-inflammatory macrophage phenotype in animal models of M1-polarizing inflammation. 
In addition, IRF5 is essential for a robust Th1/Th17 response under these experimental 
conditions which is in accordance with the data obtained in human MLR experiments 
(Figures 5.2 to 5.6).  
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5.3 Conclusion 
One of the hallmarks of macrophage polarization is the acquired ability to promote adaptive 
immune responses. The type of adaptive immune response is shaped by the cytokine 
environment provided by macrophage subsets, with M1 macrophages setting up the 
environment for Th1/Th17 responses and M2 macrophages favouring Th2 responses [63, 
64]. Here I investigated whether forced expression of IRF5 in M2 macrophages would alter 
their ability to control adaptive immunity and examined the in vivo role of IRF5 during 
polarizing inflammation. I demonstrate that IRF5-expressing macrophages induce T 
lymphocyte proliferation and are essential for a robust Th1/Th17 response. I also show that 
IRF5 expression is similar in man and mouse, that is, high in M1 and low in M2 
macrophages. Consequently, IRF5-deficient mice produced significantly less M1-specific 
cytokines compared to wild-type littermate controls during an in vivo model of polarizing 
inflammation.  
 
IRF5-expressing macrophages were better in promoting T lymphocyte proliferation 
compared to control or IRF3-expressing macrophages (Figure 5.1). Macrophages with 
exogenous IRF5 initiated a potent Th1 response (Figure 5.2) measured by induction and 
secretion of significant IFN- protein levels (Figure 5.3). The effect of IRF5 on Th1 
development was further highlighted by an increase in T-bet (Tbx21) mRNA expression 
(5.3d), which is the established master regulator of Th1 development, in co-cultures 
containing IRF5-expressing macrophages. This priming effect is most likely due to the 
secretion of IL-12 [106] and the upregulation of co-stimulatory molecules such as CD40, 
CD80 and CD83 (Figure 4.12) by IRF5-expressing macrophages.  
 
Of particular interest was the increased production of IL-17 from T lymphocytes co-cultured 
with IRF5-expressing macrophages (Figure 5.5). Th17 lymphocytes are characterized by 
the expression of the subset-defining transcription factor RORC2 (RORT) as well as  
IL-23R, IL-17A/F, IL-21, IL-22 and IL-26 all of which are up-regulated in the presence of 
IRF5-expressing macrophages (Figure 5.6). Human Th17 lymphocytes seem to exhibit 
different features from murine Th17 lymphocytes: while murine Th17 originate from a 
progenitor common to Treg lymphocytes when IL-6 is produced in combination with TGF-, 
human Th17 lymphocytes originate from CD161+CD4+ progenitors in the presence of IL-23 
and IL-1, with little involvement of IL-6 and indirect role for TGF- [114]. In line with that, 
human IRF5-expressing macrophages produce significant amounts of IL-23 and IL-1 
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(Figure 4.6 and 4.7) but perhaps not unexpectedly, the dependence of IL-6 expression on 
IRF5 is much greater in mouse macrophages (Figures 5.10 and 5.11 for mouse IL-6, data 
not shown for human IL-6). Both Th1 and Th17 lymphocytes promote cellular immune 
function and have the capacity to cause inflammation and autoimmune diseases, such as 
inflammatory bowel disease and rheumatoid arthritis [112, 113].  
 
Recently, two independent laboratories reported that GM-CSF is crucial for the 
proinflammatory properties of Th17 lymphocytes [322, 323]. Using the EAE mouse model of 
multiple sclerosis, both groups found that IL-23 promotes the production of GM-CSF in 
Th17 lymphocytes and that GM-CSF is essential for the ability of Th17 lymphocytes to drive 
inflammation in the central nervous system. One group suggested that GM-CSF stimulates 
the production of IL-23 as well as other proinflammatory cytokines and this would promote 
both, continued activation of Th17 lymphocytes and the de novo generation of Th17 effector 
lymphocytes [323]. In light of my data, I propose a potential positive feedback loop whereby 
IRF5-expressing M1 macrophages initially provide the cytokine environment for Th17 
lineage commitment. The secretion of IL-23 would induce the production of GM-CSF by 
Th17 lymphocytes which in turn would increase or maintain IRF5 protein expression in M1 
macrophages. This would enhance their ability to produce proinflammatory cytokines and 
further sustaining a Th17 response (Figure 5.13). If not tightly controlled, this  
IRF5/IL-23/GM-CSF axis could lead to the prolongation of an inflammatory response and 
ultimately result in chronic inflammation.  
 
Similar to the situation in human (Chapter 4), mouse macrophage subsets display 
differences in IRF5 protein levels when differentiated in vitro using M-CSF and GM-CSF 
respectively [65]. High expression of IRF5 was again characteristic of M1 macrophages 
(Figure 5.8) and consequently the production of M1-signature cytokines was reduced in 
IRF5 deficient animals upon LPS stimulation whereas an increase in IL-10 production was 
observed (Figure 5.9). In order to investigate the function of IRF5 in pathologic conditions 
associated with M1 polarized inflammation, I conducted an intra-peritoneal challenge of 
Irf5−/− mice with a sublethal dose of LPS. Compared to wild-type littermate controls, the 
serum levels of IL-12p40, IL-23, TNF, IL-1 and IL-6 were all reduced in Irf5−/− mice (Figure 
5.10). In general, I would expect a bigger effect under more extreme conditions but as 
mentioned previously, we are somewhat limited by our animal licence which only allows us 
to conduct an intra peritoneal challenge with a sub-lethal dose of LPS and for a short time. 
Nevertheless, all effects observed here in vivo are statistically significant and confirmed 
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results obtained in vitro using either human macrophages treated with siRNA targeting IRF5 
(Figure 4.9 and 4.11) or bone-marrow derived macrophages from IRF5-deficient animals 
(Figure 5.9).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 Potential feedback loop involving IRF5, IL-23 and GM-CSF 
(a) M1 macrophages (shown in red) secrete IL-23 which is needed for the maintenance of Th17 
lymphocytes (Th17, shown in blue) but also for GM-CSF production by them (b). GM-CSF will signal 
via GM-CSFR expressed on macrophages and induce the transcription of downstream target genes, 
including IRF5 (c). Increased IRF5 protein in turn promotes further Th17 activation leading to an 
increase in GM-CSF production and sustained inflammation.  
 
 
 
I also analysed the response of organ-specific cells after LPS-challenge and found an 
impaired induction of M1-specific cytokines in peritoneal macrophages derived from IRF5 
deficient animals (Figure 5.11). Interestingly, I observed a slight increase in the expression 
of mouse-specific M2-signature genes such as Fizz1 and Arg1 in Irf5−/− mice compared to 
wild-type controls (Figure 5.11) further supporting a shift from M1 to M2 macrophage 
polarization in the absence of IRF5. Lastly, IRF5-deficient mice showed an impaired 
production of Th1/Th17 cytokines in ex vivo splenocyte cultures (Figure 5.12) confirming the 
role of IRF5-expressing macrophages in the orchestration of immune responses.  
 
In summary, IRF5-expressing M1 macrophages are essential for a robust Th1 response 
and furthermore provide the cytokine environment for Th17 lineage activation. Using an 
IL-23 Th17
GM-CSF
GM-CSFR
IRF5
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independent approach, such as IRF5-deficient animals, I was able to demonstrate that IRF5 
induces M1-specific but represses M2-specific genes validating my previous data obtained 
with human cells. Overall, these results strongly suggest that IRF5 is a defining transcription 
factor of both human and mouse macrophage polarization. The data presented here make 
IRF5 a new target for therapeutic intervention as its inhibition would potentially affect pro-
inflammatory cytokine expression and decrease the number of effector T lymphocytes. 
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6. Discussion 
 
IRF5 was mostly known for its ability to regulate the expression of type I IFNs in response to 
virus infection such as NDV, HSV-1 and VSV [186, 192]. However, the generation of Irf5-/- 
mice revealed an unexpected anti-inflammatory phenotype. Myeloid cells of these animals 
showed a significant decrease in the expression of pro-inflammatory cytokines, especially 
TNF, IL-6 and IL-12p40 upon TLR stimulation [190]. Consequently, Irf5-/- mice survived 
lethal shock induced by CpG-B and were resistant to LPS-induced endotoxic shock. 
However, the molecular mechanism of IRF5-mediated induction of pro-inflammatory 
cytokines had not been investigated and the role of IRF5 in human myeloid cells was to 
date unclear. My study provides an insight into the regulation of IRF5 expression in primary 
human myeloid cells as well as its involvement in the gene induction of human TNF 
downstream of TLR4 signalling. Furthermore, I establish IRF5 as a subset-defining 
transcription factor of macrophage polarization and describe a mechanism of IRF5-
mediated inhibition of IL-10 expression.  
 
 
In Chapter three, I demonstrated that MDDCs acquire a particular phenotype during 
differentiation, characterised by higher levels of IRF5 protein and higher levels of late-phase 
TNF secretion compared to M2 macrophages. I have found that ectopic expression of IRF5 
in M2 macrophages restored their potential to secrete TNF for a longer period whereas 
depletion of IRF5 in MDDCs resulted in reduction of TNF expression, especially at later time 
points post stimulation. The molecular mechanism of IRF5-induced TNF expression was 
examined using luciferase reporter assays and ChIP experiments. Results obtained with 
ChIP indicated that IRF5 is recruited to two specific regions, region B and region H, within 
the TNF locus. I could demonstrate that IRF5 recruitment to region H is dependent on the 
interaction with RelA whereas recruitment to region B seems to be RelA-independent. The 
importance of RelA-binding to NF-B sites in the 3‟ region H and subsequent recruitment of 
IRF5 were confirmed in re-ChIP experiments and also by performing IRF5-specific ChIP in 
RelA depleted cells. A subsequent analysis of protein-protein interactions demonstrated an 
interaction between RelA and IRF5 but not other NF-B family members. I concluded that 
IRF5-induced TNF expression involves two spatially separated regulatory regions (region B 
and H) and two independent modes of actions (direct binding to DNA and co-recruitment 
mediated via protein-protein interactions with RelA).  
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Regions B and H are characterized by high levels of sequence conservation [288, 324] and 
both contain cell type-specific DNase I hypersensitivity sites [324, 325]. Moreover, these 
regions have been shown to physically interact in T lymphocytes in vitro leading to the 
formation of an intrachromosomal loop [324]. Tsytsykova and co-workers proposed that this 
loop formation would promote the re-initiation of transcription. This model could be of 
relevance to TNF expression by MDDCs, in which a co-operative action of RelA and IRF5 at 
both the 5‟ upstream and 3‟ downstream region appears to be essential for maintaining TNF 
gene transcription over a prolonged period of time. Therefore, a third mode of action could 
involve a locus circularization in MDDCs directed via the newly unraveled protein-protein 
interactions between RelA and IRF5.  
 
The precise mechanism of transmitting the activation signal from the 3‟ end of the TNF gene 
to Pol II and the possibility of intrachromosomal looping requires further investigation. 
However, the two independent modes of IRF5 recruitment to the gene promoter/enhancer 
described in this thesis raises 2 important questions: 
 
1. Are there other genes with a similar recruitment profile (5‟ upstream and 3‟ 
downstream)? 
2. Are there other genes that show RelA-mediated recruitment of IRF5? 
 
In order to answer these questions I suggest making use of novel genomic technologies, 
such as ChIP followed by deep-sequencing (ChIP-Seq). Using ChIP-Seq, it is possible to 
systematically identify the recruitment of a specific transcription factor throughout the entire 
genome. A good yield of chromatin material is necessary for ChIP-Seq and consequently a 
large number of cells per time point is required. The number of cells obtained from one 
single human blood donor is not sufficient to performing a ChIP-Seq that includes a binding 
kinetic profile of the protein of interest following stimulation. Therefore, most ChIP-Seq 
experiments are currently performed using mouse bone marrow-derived cells.  
 
It would be interesting to perform a ChIP-Seq experiment in LPS-stimulated bone marrow-
derived M1 macrophages using anti-IRF5, anti-RelA and anti-Pol II antibodies. Bioinformatic 
analysis of several positively regulated IRF5 target genes (e.g. IL-12 family member genes, 
TNFSF4, TNFSF7 and CCR7) revealed putative ISREs within the respective promoters as 
well as 3‟ downstream regions (data not shown). I therefore hypothesise that the 
recruitment of IRF5 to 5‟ upstream and 3‟ downstream regions of target genes would be a 
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common feature. As RelA ChIP-Seq would be performed in parallel, it would also be 
possible to bioinformatically identify genes with overlapping recruitment of IRF5 and RelA. 
At genes that show recruitment of both IRF5 and RelA to the same region, the 
corresponding binding sequence of IRF5 peaks could be further analysed to single out 
peaks that contain no ISRE sites. By using this approach, it should be possible to identify 
genes that are potentially dependent on RelA-mediated recruitment of IRF5 and therefore 
determine the gene subset that is regulated in an IRF5/RelA-dependent manner. The 
addition of Pol II ChIP-Seq into the experimental setup would give further information on 
which genes of the IRF5/RelA-dependent subset are actively transcribed upon cell 
activation. Furthermore, it would be desirable to map the IRF5/RelA interface and once 
identified, try to disrupt the interaction, e.g. using a peptide-based approach. As a functional 
readout, I would suggest to first use TNF gene expression and later other genes identified 
by ChIP-Seq as being IRF5/RelA-dependent.  
 
The expression of IRF5 protein analysed in primary human myeloid cells demonstrated that 
IRF5 is highly expressed in MDDCs as well as M1 macrophages and to a far lesser extent 
in monocytes and M2 macrophages. A number of different IRF5 isoforms were observed: 
one isoform (of higher molecular mass) was present in all unstimulated myeloid cell types 
tested and another (of lower molecular mass) was present in unstimulated MDDCs and M1 
macrophages. The different IRF5 isoforms are likely a product of alternative splicing of exon 
6 [180]. Splicing can give rise to an IRF5 protein with 498 amino acids (sometimes referred 
to as variant 3/4), whereas alternative splicing can result in an isoform with a length of 514 
amino acids (sometimes referred to as variant 5). The IRF5 expression constructs used in 
this study to ectopically express IRF5 in primary human cells and cell lines is the 498 amino 
acids (aa) isoform. It has been shown that the 498aa isoform formed homodimers as well as 
heterodimers with IRF3 in NDV infected cells [191] but the 514aa isoform failed to do so 
[193]. One explanation could be that the 514aa isoform is not activated by NDV or that it 
might be a self inhibiting protein.  
 
In this respect, it would be very interesting to further investigate and dissect the role of the 
nine IRF5 isoforms (also known as variants 1 to 9) in a cell-type specific manner and to 
determine whether the trans-activation potential is similar between isoforms. Considering 
that the IRF5 variant 7 lacks the DBD, variant 8 has deficiencies in the IAD and variant 9 
lacks the whole C-terminus, one would expect differences in their ability to induce gene 
transcription. Interestingly, IRF5 variants 7, 8 and 9 were found to be expressed in 
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haematological malignancies [180] which could suggest that these isoforms may play an 
important role in establishing the tumor environment by acting as dominant-negative 
mutants to endogenous IRF5. Furthermore, it would also be important to investigate 
whether all isoforms are able to interact with RelA. Similar to above, TNF gene expression 
could be used as a functional readout. Expression constructs coding for human IRF5 
isoforms are available and the Udalova laboratory is currently trying to obtain them for 
further characterisation.  
 
 
In Chapter four I described a new role for IRF5 in inhibiting gene transcription of human  
IL-10. Overexpression of IRF5 in M2 macrophages affected their ability to secrete IL-10 
upon LPS stimulation by actively inhibiting IL-10 mRNA expression and direct DNA binding 
of IRF5 was necessary for this, as a DNA-binding mutant of IRF5 (IRF5 DBD) was not 
able to inhibit IL-10 expression. Using ChIP, I showed that IRF5 binds to the promoter 
region of IL-10 but in contrast to IRF5 positively-regulated genes, Pol II recruitment was 
only detectable upon dissociation of IRF5 from the IL-10 promoter. Furthermore, a 
previously identified ISRE site within the IL-10 promoter [306] was required for the inhibitory 
effects of IRF5 as mutation of this site abolished the IRF5-mediated inhibition of IL-10. This 
suggests that IRF5 binding to the promoter ISRE inhibits the recruitment of Pol II and 
subsequent IL-10 mRNA expression presumably via interactions with yet unknown  
co-factors.  
 
It is known that different IRF heterodimers can either repress or activate gene transcription. 
For instance, the IRF8/IRF1 complex generally acts as a transcriptional repressor on ISREs 
whereas the IRF8/PU.1 complex is associated with gene induction [326]. However, the co-
factors that enable IRF5 to distinguish between induction and inhibition of gene expression 
remain mostly unknown. A recent study suggested a model whereby IRF5 switches from a 
silencing to an activating complex depending on the interaction with either histone 
acetyltransferases (HATs) or histone deacetylases (HDACs) [327]. Feng et al demonstrated 
that IRF5 binds to the IFN- promoter in unstimulated cells but the transcription is silenced 
through the binding of co-repressor proteins such as Sin3a and silencing mediator for 
retinoid or thyroid-hormone receptor (SMRT) to the N-terminus of IRF5. Virus infection 
leads to the nuclear export of Sin3a and SMRT resulting in IRF5-mediated recruitment of 
the co-activator proteins p300/CBP and induction of gene transcription. However, I did not 
detect IRF5 recruitment to the IL-10 promoter in unstimulated cells suggesting that the 
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mode of IL-10 inhibition is different to IRF5-mediated inhibition of IFN- transcription. 
Furthermore, IRF5 participates in both the repression as well as induction of IFN- in the 
mechanism described by Feng et al whereas I only observed a role for IRF5 in the 
transcriptional silencing of IL-10. It would therefore be interesting to identify IRF5 interaction 
partners, for example by using IRF5 overexpression followed by immuno-precipitation and 
mass spectrometry analysis. The characterisation of novel IRF5 binding partners would 
possibly help to further dissect the IRF5-mediated inhibition of IL-10 expression and allow 
the postulation of an IRF5-mediated transcriptional repression model. 
 
In Chapter four, I also investigated the role of IRF5 in regulating macrophage lineage 
commitment. I showed that IRF5 protein expression is a hallmark of M1 macrophages in 
which it is involved in the induction of the characteristic M1 gene expression and cytokine 
secretion profile (IL-12high, IL-23high, IL-10low). IRF5 mRNA expression was rapidly induced in 
monocytes treated with GM-CSF or IFN- and similar to MDDCs but a distinct IRF5 isoform 
expression pattern was observed. Stimulation of monocytes with GM-CSF (M1 
differentiation) induced the protein expression of an isoform of lower molecular mass which 
was not detected in monocytes differentiated in the presence of M-CSF (M2 differentiation). 
Preliminary experiments using IRF5 variant-specific TaqMan RT-PCR probes indicate that 
treatment of monocytes with GM-CSF or IFN- induces variants 1, 2, 3/4 and 5 in a similar 
way. However, the specificity of these probes is under question and the design of our own 
variant-specific primer sets might result in a better discrimination between variants. 
Furthermore, a practical and valuable tool for studying IRF5 isoforms in a cellular context 
would be the generation of isoform-specific antibodies. 
 
Signalling via the GM-CSF and IFN- receptor leads to the downstream activation of the 
STAT pathway [328, 329]. Using oligonucleotide binding assays, it has been shown 
previously that STATs can bind to IRF5 promoter sequences upon IFN- stimulation [180] 
which suggests a contribution of STATs to the activation of IRF5 gene expression. It would 
be interesting to further investigate which STAT proteins are involved in regulating IRF5 
expression and if IRF5 isoform expression is dependent on the binding of different STAT 
homo- or heterodimer complexes. A recent publication also suggests that IRF4 participates 
in the regulation of IRF5 expression [330]. Xu et al show that IRF5 expression is inhibited 
both in vitro and in vivo by IRF4 in Epstein-Barr virus transformed B lymphocytes. In 
addition to this direct effect on IRF5 expression, it is known that IRF4 inhibits IRF5 function 
by competing for interaction with Myd88 [299] and IRF4 has been recently reported to 
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control the expression of prototypical mouse M2 macrophage markers [302]. The regulation 
of these M2 macrophage markers is in stark contrast to the role of IRF5 in defining the M1 
macrophage phenotype described in this thesis. Consistent with its role as a negative 
regulator of TLR signalling, LPS-induced proinflammatory cytokine expression is enhanced 
in Irf4-/- macrophages and Irf4-/- mice are highly sensitive to endotoxic shock induced by 
CpG [299, 331]. This further supports the idea that IRF5 and IRF4 have opposing roles in 
regulating immune responses and their function is controlled by negative feedback 
regulation and by antagonizing each other.  
 
Another question that remains is how IRF5 is activated by TLR4 signalling. Takaoka et al 
demonstrated that ectopically expressed IRF5 translocates to the cell nuclei in response to 
LPS, and that this translocation is dependent on the presence of Myd88 [190]. I observed 
endogenous nuclear IRF5 even in resting MDDCs and M1 macrophages and its level was 
not increased after LPS stimulation (data not shown). It is possible that an active nuclear 
export-import mechanism, induced by phosphorylation at previously described serine 
residues [193], enables IRF5 to shuttle in these cells. However, I was not able to test this 
hypothesis due to the lack of phospho-specific antibodies to IRF5 but the recent acquisition 
of IRF5-deficient animals will provide new approaches for studying IRF5 activation. I 
suggest experiments where the phenotype of IRF5-deficient cells is rescued with either 
IRF5 wild-type protein or IRF5 protein with mutations in previously described serine/leucine 
residues supposedly important for activation or translocation [187, 188, 193].  
 
 
In Chapter five I examined the relationship of IRF5-expressing macrophages and T 
lymphocytes as the type of adaptive immune response is shaped by the cytokine 
environment provided by macrophage subsets. I demonstrated that IRF5-expressing 
macrophages set up the environment for Th1/Th17 responses both in vitro and in vivo. 
Genetic polymorphisms in the IRF5 gene, leading to expression of several unique isoforms 
of IRF5 or increased expression of IRF5 mRNA, are associated with a number of 
autoimmune diseases. The remarkable consistency of IRF5 detection in genome-wide 
association studies of autoimmune diseases is likely to relate to their common inflammatory 
origin. Many autoimmune diseases are characterised by the predominant presence of Th1 
and Th17 lymphocytes as well as macrophages with an M1 phenotype (IL-12high, IL-23high, 
IL-10low) which can be characterized by high expression of IRF5 protein. As described in this 
thesis, the expression of IRF5 is induced upon stimulation of cells with GM-CSF.  
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M-CSF is constitutively produced by several cell types, including fibroblasts, endothelial 
cells, stromal cells and osteoblasts. It is likely that this steady state production of M-CSF 
polarizes macrophages towards the M2 phenotype. By contrast, GM-CSF production by the 
same cell types requires stimulation and occurs usually at a site of inflammation or infection. 
In this respect, it has been shown that in vitro cultured RA synovial macrophages 
spontaneously produce GM-CSF [261]. Furthermore, in the collagen-induced arthritis (CIA) 
mouse model of RA, GM-CSF depletion has therapeutic benefits [332, 333]. In these 
studies, GM-CSF deficient mice failed to develop arthritis despite making a normal humoral 
immune response to the arthritogenic stimulus [332]. Furthermore, the blockade of GM-CSF 
in wild-type mice controlled disease activity and decreased the levels of pro-inflammatory 
mediators, including TNF, in the joints during CIA [333]. One possible explanation for the 
positive effects of GM-CSF blockade on inflammation and autoimmunity is the link between 
its expression and its potential to control differentiation of macrophage subpopulations by 
inducing the gene expression of IRF5. Therefore, if therapeutic targeting of IRF5 is not 
possible, for example due to its cellular distribution, the next best approach would be to 
target IRF5 inducing stimuli such as GM-CSF.  
 
New emerging data on the role of GM-CSF in autoimmunity suggest a positive feedback 
loop involving IL-23 and Th17 lymphocytes [322, 323]. Th17 lymphocytes produce many 
pro-inflammatory cytokines, including IL17A/F and IL-22, and are characterized by the 
expression of the IL-23R [110]. The blockade of Th17-mediated disease, such as IBD and 
CIA, has proven to be only partially effective when neutralizing antibodies to IL-17A/F or  
IL-22 were used, which suggests that additional factors may be more important for Th17 
function. One consistent finding is that neutralizing IL-23 effectively abrogates the effector 
response of Th17 lymphocytes in most models tested [110]. A link between IL-23 and Th17 
lymphocytes was established when investigators showed that IL-23 promotes the 
production of IL-17 by activated T lymphocytes [334] and that IL-23-expanded T 
lymphocytes are able to transfer CIA [112]. Support for the importance of IL-23 signalling 
comes from genome-wide association studies demonstrating that SNPs in the human IL-
23R confer an increased risk to Crohn‟s disease [230], ulcerative colitis [231] and psoriasis 
[335].  
 
A common feature of IL-23-producing cells, including MDDCs and M1 macrophages, is the 
high expression of IRF5 protein. I demonstrated that IRF5 is involved in the transcriptional 
regulation of IL-23 expression in M1 macrophages and that IRF5-expressing cells provide 
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the cytokine environment for Th17 activation. The fact that Th17 lymphocytes are able to 
produce GM-CSF in response to IL-23 indicates an even tighter relationship between IL-23-
producing cells and Th17 responses than previously expected. In fact, GM-CSF secreted by 
Th17 lymphocytes will not only stimulate cells already present at the site of inflammation but 
also affect newly recruited monocytes/macrophages (Figure 6.1). As demonstrated, IRF5 
expression is GM-CSF dependent and infiltrating monocytes/macrophages would rapidly 
induce IRF5 expression and subsequently adopt the M1 macrophage phenotype. This 
suggests that the IRF5/IL-23/GM-CSF feedback loop could potentially be a new target for 
therapeutic intervention. Considering the data described in this thesis, IRF5 could be 
regarded as the initiation factor of this feedback loop and therefore targeting IRF5 function 
might be beneficial when interfering with this vicious cycle.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Interplay between M1 macrophages, T lymphocytes and infiltrating cells 
(a) IRF5-expressing M1 macrophages (M1 Mac) secrete inflammatory mediators, including IL-12 and 
IL-23, which promote Th1 and Th17 lineage commitment (b). Once activated, Th1 and Th17 
lymphocytes will produce IFN- and GM-CSF respectively, which will act on M1 macrophages 
present at the site of inflammation as well as infiltrating monocytes/macrophages (shown in pink). 
Stimulation of newly recruited monocytes/macrophages with IFN- or GM-CSF induces the 
expression of IRF5 (c) which will in turn promote polarization towards the M1 phenotype (d) resulting 
in prolonged inflammation.  
 
 
 
M1 Mac
Inflammatroy 
mediators
Th17
Th1
IFN-
GM-CSF
IL-12
IL-23
IRF5
(a)
(c)
(d)
(b)
 
Chapter 6 - Discussion 
 173  
We are only at the beginning of understanding how IRF5 regulates immune responses and 
further investigations using mouse models of inflammatory diseases associated with the M1 
macrophage phenotype, such as CIA and colitis models, will be crucial to further dissect the 
full functional properties of this transcription factor.  
 
Recent discoveries into the role of IRF5 in SLE demonstrated its importance in B 
lymphocyte development and consequently autoantibody production [213-215]. 
Macrophages and DCs were minimally analysed in these studies, although Tada et al noted 
that splenic DCs from IRF5-deficient animals produced lower levels of inflammatory 
cytokines in vitro following TLR7 or TLR9 stimulation [215]. 
 
In order to determine the role of IRF5 in IBD, colonic inflammation could be induced in wild-
type and IRF5-deficient mice, by using either the dextran sodium sulphate (DSS) or the 
Helicobacter hepaticus-induced IBD model. DSS causes acute T lymphocyte-independent 
colitis which provides a useful model of acute intestinal pathology [336]. Conversely, 
Helicobacter hepaticus induces chronic IBD-like inflammation in C57BL/6 mice when 
administered in combination with a blocking antibody to the IL-10 receptor [337, 338]. Both 
models could be performed in parallel allowing the characterisation of chronic inflammation 
in Helicobacter hepaticus-infected mice and comparison of the results with those obtained 
from acute inflammation evoked by DSS. The phenotype of colonic macrophages isolated 
during various phases of disease pathology could be assessed using a combination of flow 
cytometry, ELISA and RT-PCR. It has been shown previously that switching of 
macrophages from an M1 toward an alternatively activated M2 phenotype is an essential 
step for resolution of other inflammatory diseases, such as peritonitis [339]. I would 
therefore expect that IRF5-deficient mice display a protective phenotype in both IBD models 
as the quantity of M2 macrophages should be significantly increased in these animals. 
Furthermore, it is generally accepted that IL-23 and its effect on Th17 lymphocytes is crucial 
in mouse models of IBD [228, 234]. Considering the data presented in this thesis, the 
amount of IL-23 should be reduced in IRF5-deficient mice resulting in a diminished Th17 
response and consequently protection in mouse models of IBD.  
 
The involvement of IRF5 in RA pathogenesis could be determined using the collagen-
induced arthritis (CIA) model. CIA is an animal model of RA that is widely used to 
characterise the pathogenesis of immune cells and to validate therapeutic targets. Arthritis 
is normally induced in mice by immunisation with autologous or heterologous type II 
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collagen in adjuvant. CIA is considered to be a good model for human RA because of the 
observed similarities with respect to synovial inflammation, cartilage/bone destruction as 
well as a robust T and B lymphocyte response to the inducing agent [340, 341]. Similar to 
above, CIA could be induced in wild-type and IRF5-deficient mice and macrophage 
phenotype analysed by flow cytometry, ELISA and RT-PCR. T lymphocyte responses could 
be characterised using the same techniques and additionally, in vitro proliferation and type 
II collagen re-call experiments could be performed. Again, I expect that IRF5-deficient 
animals would be protected form CIA due to a shift from M1 toward M2 macrophage 
phenotype.  
 
A completely different approach of investigating IRF5 function would be to focus on chronic 
inflammatory diseases associated with a shift toward M2 macrophage polarization, with 
asthma being a prime example. Murine models of asthma demonstrated the presence of M2 
macrophages and enhanced expression of Th2 cytokines in the airway tissue [68, 86, 87]. 
Rather than being protected, IRF5-deficient animals should be more susceptible to asthma 
models. The strategy here would be to boost IRF5 expression in affected animals and 
therefore provoke a shift from Th2 to Th1 lymphocyte responses. A possible experiment 
would be the transfer of either in vitro differentiated M1 macrophages, M2 macrophages or 
M2 macrophages with exogenous IRF5 expression into Irf5-/- mice. I would expect that the 
transfer of both M1 macrophages and M2 macrophages with exogenous IRF5 protein are 
beneficial for the recipient animals whereas M2 macrophages with endogenous levels of 
IRF5 protein will be detrimental to the animal.  
 
 
In summary, I intended to provide new insights into the regulation and function of the 
transcription factor IRF5 in human myeloid cells. I demonstrated that GM-CSF and IFN- 
are potent inducers of IRF5 expression which is a hallmark of M1 macrophages. In these 
cells, IRF5 transcriptionally regulates M1-specific cytokines, chemokines and co-stimulatory 
molecules but represses genes associated with the M2 phenotype. As shown for IL-10, 
IRF5-mediated inhibition involves direct binding to the promoter and subsequent prevention 
of Pol II recruitment and is likely dependent on yet to be identified co-factors. Conversely, 
IRF5-induced gene activation of TNF involves two spatially separated regulatory regions (5‟ 
upstream and 3‟ downstream of the gene) and two independent modes of actions (direct 
DNA binding and formation of IRF5/RelA complex). As a consequence of IRF5 function, 
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IRF5-expressing M1 macrophages are essential for a robust Th1 response and furthermore 
provide the cytokine environment for Th17 lineage commitment.  
 
Although the full mechanism underlying IRF5-mediated responses remains to be elucidated 
in more detail in vivo, the data presented here make IRF5 a new target for therapeutic 
intervention as its inhibition would affect pro-inflammatory cytokine expression and 
decrease the number of effector T lymphocytes. 
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7. Abbreviations 
Amino acids aa 
Antigen presenting cell APC 
Anti-nuclear antibodies ANA 
Arbitrary units AU 
B cell–activating factor  BAFF 
Bacterial alkaline phosphatase BAP 
Base pair bp 
Bone marrow media BM media 
Bone marrow–derived macrophages BMDM 
Bovine Serum Albumin BSA 
Chemokine receptor CCR 
Chromatin immuno-precipitation ChIP 
Cluster of differentiation CD 
Collagen induced arthritis CIA 
Common myeloid progenitor  CMP 
Conventional DC cDC 
Counts per minute CPM 
CREB binding protein CBP 
Cycle thresholds CT 
Cytometric bead assay CBA 
Cytotoxic T-lymphocyte CTL 
Danger-associated molecular patterns  DAMPs 
Dendritic cell DC 
Dextran sodium sulphate  DSS 
Dimethylsulfoxide DMSO 
DNA binding domain DBD 
Dominant negative DN 
Double negative DN 
Dual specificity protein phosphatase 1  DUSP1 
Dulbecco's Modified Eagle's Medium DMEM 
Encephalomyocarditis virus EMCV 
Enzyme linked immunosorbent assay ELISA  
Epstein-Barr virus induced 3  EBI3 
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Experimental autoimmune encephalomyelitis EAE 
Flow cytometry  FCM 
Foetal calf serum FCS 
Genome-wide association studies GWAS 
Genomic DNA gDNA 
Granulocyte-macrophage colony-stimulating factor GM-CSF 
Hank's Balanced Salt Solution HBSS 
Herpes simplex virus-1 HSV-1 
Histone acetyltransferases HATs 
Histone deacetylases  HDACs 
Human embryonic kidney HEK 
Human leukocyte antigen HLA 
IFN-stimulated regulatory element ISRE 
IL-23 receptor IL-23R 
Inflammatory bowel disease IBD 
Inhibitor of NF-B kinase- IKK 
Interferon gamma  IFN- 
Interferon regulatory factor 3 IRF3 
Interferon regulatory factor 4 IRF4 
Interferon regulatory factor 5 IRF5 
Interferon regulatory factor 8 IRF8 
Interferon regulatory factor IRF 
Interleukin 1 receptor-associated kinase 1 IRAK1 
Interleukin IL 
Intestinal epithelial cells IEC 
Intracellular cytokine staining ICC 
IRF association domain IAD 
Lennox L agar LB agar 
Lennox L broth base LB 
Leucin-rich repeat-containing receptors NLRs 
Lipopolysaccharide LPS 
Macrophage-colony stimulating factor receptor I M-CSF-R 
Macrophage-colony stimulating factor M-CSF 
Major histocompatability complex  MHC 
Major histocompatability complex class I MHC I 
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Major histocompatability complex class II MHC II 
Mean fluorescence intensity MFI 
Mixed lymphocyte reaction  MLR 
Monocyte-derived dendritic cell MDDC 
Monocyte-derived macrophage MDM 
Mononuclear phagocyte system  MPS 
Mouse embryonic fibroblasts MEF 
MyD88-adaptor-like Mal 
Myeloid differentiation primary-response protein 88 MyD88 
Natural killer NK 
Newcastle disease virus NDV 
Non-targeting siRNA siC 
Nuclear export signal NES 
Nuclear factor B NF-B 
Nuclear localisation signals NLS 
Pathogen-associated molecular pattern PAMP 
Pattern recognition receptor PRR 
Peripheral blood mononuclear cells PBMC 
Phorbol myristate acetate PMA 
Phosphate bufferd saline PBS 
plasmacytoid DC pDC 
Polyinosinic Polycytidylic Acid pI:C 
Polyvinylidene difluoride PVDF 
Protein tyrosine phosphatase nonreceptor type 22 PTPN22 
Quantitative real-time polymerase chain reaction RT-PCR 
Regulatory T lymphocyte Treg 
Rel homology domain RHD 
Retinoic acid-inducible gene I  RIG-I 
Revolutions per minute RPM 
Rheumatoid arthritis RA 
RIG-I-like receptors  RLRs 
RNA Polymerase II Pol II 
Roswell Park Memorial Institute media RPMI 
Short interfering RNA  siRNA 
Signal and transducer and activator of transcription  STAT 
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Silencing mediator for retinoid or thyroid-hormone receptor  SMRT 
Single-nucleotide polymorphism  SNP 
Single-stranded RNA ssRNA 
siRNAs targeting IRF5  siIRF5 
Sodium Dodecyl Sulphate Poly Acrylamide Gel Electrophoresis SDS-PAGE 
Standard deviation SD 
Standard error of the mean SEM 
Systemic lupus erythematosus SLE 
TANK binding kinase 1 TBK1 
T-cell receptor TCR 
T-helper Th 
TIR domain-containing adapter inducing IFN TRIF 
TNF receptor 1 TNFR1 
Toll/IL-1R TIR 
Toll-like receptor TLR 
Transcription start site  TSS 
Transforming growth factor beta  TGF-β  
TRIF-related adaptor molecule TRAM 
Tumor necrosis factor  TNF 
Tumor necrosis factor (ligand) superfamily  TNFSF 
Tumor necrosis factor receptor-associated factor 6 TRAF6 
Tumor-associate macrophages  TAMs 
Type I Interferon IFN 
Untranslated region UTR 
Vesicular stomatitis virus VSV 
Virus responsive elements VRE 
Wild-type WT 
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Macrophages are a heterogeneous population of immune cells that 
are essential for the initiation and resolution of pathogen- or tissue 
 damage–induced inflammation1. They demonstrate considerable 
plasticity that allows them to respond efficiently to environmental 
signals and change their phenotype and physiology in response to 
cytokines and microbial signals2. These changes can give rise to popu-
lations of cells with distinct functions that are phenotypically charac-
terized by the production of proinflammatory and anti-inflammatory 
cytokines3. On the basis of the T helper type 1 (TH1) and TH2 polariza-
tion idea4, these cells are now referred to as M1 (classic) macrophages, 
which produce proinflammatory cytokines and mediate resistance to 
pathogens and contribute to tissue destruction, and M2 (alternative) 
macrophages, which produce anti-inflammatory cytokines and pro-
mote tissue repair and remodeling as well as tumor progression3,5.
The activation of a subset-defining transcription factor is character-
istic of commitment to a particular T cell lineage: T-bet is associated 
with the TH1 subset; GATA-3 is associated with the TH2 subset; Foxp3 
is associated with regulatory T cells; and RORγt is associated with the 
TH17 subset6. Dendritic cells (DCs) also use subset-selective expres-
sion of the transcription factors IRF4 and IRF8 for their commitment. 
CD4+ DCs have high expression of IRF4, but plasmacytoid DCs have 
low expression of IRF4. As a consequence, the CD4+ DC population 
is absent from Irf4−/− mice. Conversely, plasmacytoid DCs and CD8+ 
DCs have high expression of IRF8; thus, Irf8−/− mice are largely devoid 
of these DC subsets7. However, the transcription factors that under-
lie macrophage polarization remain largely undefined. Activation of 
the transcription factor NF-κB subunit p50 has been associated with 
the inhibition of M1-polarizing genes8, whereas transcription factor 
CREB–mediated induction of the transcription factor C/EBPβ has 
been shown to upregulate M2-specific genes9. Subsequent evidence 
has suggested that in mice, IRF4 controls M2 macrophage polarization 
by stimulating the expression of specific M2 macrophage markers10.
IRF5, another member of the interferon-regulatory factor (IRF) 
family, has diverse activities, such as the activation of genes encod-
ing type I interferon, inflammatory cytokines (including tumor 
 necrosis factor (TNF), IL-6, IL-12 and IL-23) and tumor suppres-
sors11. Consequently, Irf5-deficient mice are resistant to lethal endo-
toxic shock12. Human IRF5 is expressed in many splice variants 
with distinct cell type–specific expression, cellular localization, 
differences in regulation and functions13. Moreover, genetic poly-
morphisms in human IRF5 that lead to the expression of various 
unique isoforms or higher expression of IRF5 mRNA have been 
linked to autoimmune diseases, including systemic lupus erythema-
tosus, rheumatoid arthritis, Sjogren’s syndrome, multiple sclerosis 
and inflammatory bowel disease14–18. Here we demonstrate a role 
for IRF5 in determining commitment to the M1 macrophage line-
age. M1 macrophages were characterized by large amounts of IRF5, 
whose expression was induced during their differentiation. Forced 
expression of IRF5 in M2 macrophages drove global expression of 
M1-specific cytokines, chemokines and costimulatory molecules 
and led to a potent TH1-TH17 response. Conversely, the induction of 
M1-specific cytokines was impaired in human M1 macrophages with 
knockdown of IRF5 expression mediated by small interfering RNA 
(siRNA) and in the peritoneal macrophages of Irf5−/− mice. Our 
data suggest that activation of IRF5 expression defines commitment 
to the macrophage lineage by driving M1 macrophage polarization 
and, together with published results demonstrating a role for IRF4 in 
controlling M2 macrophage markers10, establish a new paradigm for 
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IRF5 promotes inflammatory macrophage 
polarization and TH1-TH17 responses
Thomas Krausgruber1, Katrina Blazek1, Tim Smallie1, Saba Alzabin1, Helen Lockstone2, Natasha Sahgal2,  
Tracy Hussell3, Marc Feldmann1 & Irina A Udalova1
Polymorphisms in the gene encoding the transcription factor IRF5 that lead to higher mRNA expression are associated with many 
autoimmune diseases. Here we show that IRF5 expression in macrophages was reversibly induced by inflammatory stimuli and 
contributed to the plasticity of macrophage polarization. High expression of IRF5 was characteristic of M1 macrophages, in which 
it directly activated transcription of the genes encoding interleukin 12 subunit p40 (IL-12p40), IL-12p35 and IL-23p19 and 
repressed the gene encoding IL-10. Consequently, those macrophages set up the environment for a potent T helper type 1 (TH1)-
TH17 response. Global gene expression analysis demonstrated that exogenous IRF5 upregulated or downregulated expression 
of established phenotypic markers of M1 or M2 macrophages, respectively. Our data suggest a critical role for IRF5 in M1 
macrophage polarization and define a previously unknown function for IRF5 as a transcriptional repressor.
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macrophage polarization and highlight the potential for therapeutic 
interventions via modulation of the IRF5-IRF4 balance.
RESULTS
High expression of IRF5 in human M1 macrophages
The M1 macrophage phenotype is induced by interferon-γ 
(IFN-γ), followed by stimulation with bacterial products such 
as lipopolysaccharide (LPS) or by treatment of monocytes with 
granulocyte-macrophage colony-stimulating factor (GM-CSF)19–21 
(Supplementary Fig. 1a). IRF5 mRNA expression was higher in 
primary human monocytes and in monocyte-derived macrophages 
differentiated with GM-CSF than in those differentiated with M-CSF 
(Fig. 1a and Supplementary Fig. 1b). Treatment of monocytes with 
GM-CSF resulted in upregulation of IRF5 mRNA expression within 
2 h of stimulation, but treatment with macrophage colony stimulating 
factor (M-CSF), an M2-differentiating factor, did not (Fig. 1b). To 
account for possible differences in protocols for the in vitro differen-
tiation of macrophages, we analyzed the amount of IRF5 in macro-
phages treated for 24 h with IFN-γ alone or in combination with LPS 
and found that these were similar to those in GM-CSF-treated cells 
(Supplementary Fig. 1c). The expression of IRF4, which controls M2 
polarization in mice10, was induced equally during the differentiation 
of monocytes into M1 or M2 macrophages (Fig. 1a). The expres-
sion of IRF3, another member of the IRF family central to the innate 
immune response, was not affected by differentiation into macro-
phage subtypes (Fig. 1a). Thus, IRF5 is induced in proinflammatory 
M1 macrophages independently of the in vitro differentiation proto-
col, whereas the abundance of IRF4 and IRF3 protein is similar in the 
macrophage populations. There was no substantial difference between 
M1 and M2 macrophages in their basal or LPS-induced NF-κB p50 
protein (Supplementary Fig. 1d,e), which has been linked before to 
the polarization of macrophages toward the M2 phenotype8.
Plastic expression of IRF5 in human macrophages
To examine whether IRF5 contributes to the plasticity of macrophage 
polarization, we attempted to convert one population into another 
by culturing M2 macrophages with GM-CSF and M1 macrophages 
with M-CSF. As expected, treatment of M2 macrophages with GM-
CSF or IFN-γ led to the production of M1 phenotypic markers 
after stimulation with LPS (M2-to-M1; Supplementary Fig. 2a). 
Conversely, treatment of M1 macrophages with M-CSF led to the 
production of M2 phenotypic markers after stimulation with LPS 
(M1-to-M2; Supplementary Fig. 2b). M2-to-M1 conversion of macro-
phages resulted in more IRF5 protein (Fig. 1c and Supplementary 
Fig. 2c), whereas M1-to-M2 macrophages had less IRF5 (Fig. 1d 
and Supplementary Fig. 2d). Once again, the quantities of IRF4 and 
IRF3 were unchanged (Fig. 1c,d). These results demonstrate that IRF5 
expression is quickly adapted to environmental stimuli and suggest 
that it participates in establishing macrophage plasticity.
IRF5 influences polarization of human M1 macrophages
We next investigated whether IRF5 would directly induce the expres-
sion of M1 macrophage phenotypic markers. We detected bioactive 
IL-12p70 and IL-23 in M2 macrophages infected with an adenoviral 
expression construct encoding human IRF5 (variant 3/4)13 but detected 
minimal amounts after infection with a construct encoding IRF3 or 
an empty vector22 (Fig. 2a). The upregulation of IL-12p70 and IL-23 
was reflected by much more secretion of the p40 subunit shared by 
the two cytokines (Fig. 2a). The secretion of both IL-12p70 and IL-23 
peaked at 24 h after stimulation with LPS and remained sustained up 
to at least 48 h (Supplementary Fig. 3a). We also observed much more 
production of other key proinflammatory cytokines, such as IL-1β  
and TNF, by IRF5-expressing macrophages (Supplementary Fig. 3b). 
Notably, IL-10 production was much lower in the IRF5-expressing 
cells (Fig. 2a). We also observed inhibition of IL-10 protein in cells 
overexpressing IRF3 (Fig. 2a), which might represent a negative feed-
back regulation of IL-10 expression23, as the main direct target of 
IRF3, IFN-β, induces IL-10 (ref. 24). The complementary experiment 
targeting endogenous IRF5 in M1 macrophages by RNA-mediated 
interference (Supplementary Fig. 3c) resulted in significant inhibi-
tion of IL-12p70 and IL-23 and more IL-10 (Fig. 2b). Secretion of 
IL-12p40 was also lower in these cells (Fig. 2b), consistent with data 
obtained with Irf5-deficient mouse myeloid cells12. Together these 
results indicate that IRF5 influences M1 macrophage polarization by 
equipping the cells with an IL-12hiIL-23hiIL-10lo cytokine profile.
IRF5 promotes human TH1-TH17 responses
One of the hallmarks of M1 macrophage polarization is the acqui-
sition of antigen-presenting features, which leads to efficient TH1 
responses20,21. To determine whether IRF5 aided the polariza-
tion of the T lymphocyte proliferation, fate or activation state, we 
infected human M2 macrophages with viral expression constructs 
for IRF5 or IRF3 or empty vector and exposed the cells to human 
T lymphocytes extracted and purified from the peripheral blood of 
major histocompatibility complex–mismatched donors in a mixed-
lymphocyte reaction. We assessed total T lymphocyte proliferation 
3 d after infection and analyzed activation of specific T cell subsets 
by flow cytometry (Supplementary Fig. 4a). The proliferation of 
Figure 1 High expression of IRF5 in M1 
macrophages and upregulation by GM-CSF.  
(a) Immunoblot analysis of total protein extracts 
from monocytes collected at day 0 (Mono) or 
differentiated for 5 d into M1 macrophages with 
GM-CSF (50 ng/ml) or into M2 macrophages 
with M-CSF (100 ng/ml), then left untreated 
(−) or simulated for 24 h with LPS (+). Actin 
serves as a loading control throughout. (b) RT-
PCR analysis of IRF5 mRNA in monocytes left 
untreated (0) or stimulated for 2, 4, 8, 24 or 
48 h with GM-CSF (50 ng/ml) or M-CSF (100 
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ng/ml); results are presented relative to those of untreated monocytes, set as 1.  
*P < 0.001 (two-way analysis of variance (ANOVA)). (c) Immunoblot analysis of total protein  
extracts from M2 macrophages left untreated (−) or treated (+) for 24 h with GM-CSF (50 ng/ml) for M2-to-M1 polarization. (d) Immunoblot  
analysis of total protein extracts from M1 macrophages left untreated or treated for 24 h with M-CSF (100 ng/ml) for M1-to-M2 polarization.  
Results are from at least four independent experiments, each with cells derived from a different donor (a,c,d), or are from five independent experiments, 
each with cells derived from a different donor (b; mean and s.e.m.).
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T lymphocytes (Supplementary Fig. 4b) was considerably greater 
when they were cultured together with IRF5-expressing macro-
phages. Furthermore, only IRF5-expressing macrophages provided 
the cytokine environment necessary for the population expansion and 
activation of TH1 cells, indicated by more IFN-γ-producing CD4+ cells 
(Fig. 3a and Supplementary Fig. 4c) and higher expression of IFN-γ 
mRNA (Supplementary 4d) and IFN-γ protein (Fig. 3b). There was 
significant induction of expression of mRNA for the TH1-specifying 
transcription factor T-bet in T cells cultured together with IRF5-
expressing macrophages (Fig. 3c). In these cultures we also observed 
population expansion and activation of TH17 cells, indicated by more 
IL-17-producing CD4+ cells (Fig. 3d and Supplementary Fig. 4e), 
secretion of IL-17A (Fig. 3e) and expression of mRNA for IL-17A, 
IL-17F, IL-21, IL-22, IL-26 and IL-23R (Supplementary 4f). In line 
with studies demonstrating that IL-23 enhances the emergence of 
an IL-17+IFN-γ+ population of T cells25, about 25% of IL-17+ cells 
were also IFN-γ+ (data not shown), which supported the idea of a 
close developmental relationship between human TH17 cells and TH1 
cells26. There was significant induction of expression of mRNA for 
the TH17-specifying transcription factor RORγt in T cells cultured 
together with IRF5-expressing macrophages (Fig. 3f). Of interest, 
expression of GATA-3 mRNA and Foxp3 mRNA was lower in the 
presence of IRF5-expressing macrophages (data not shown). Hence, 
IRF5 promotes the proliferation of T lymphocytes and activation of 
the TH1 and TH17 lineages but does not induce the TH2 lineage or 
regulatory T cell lineage.
IRF5 directly induces transcription of human M1 genes
IRF5 is a transcription factor that can bind to the regulatory regions 
of target genes and modulate their expression. We next determined 
whether the role of IRF5 in the differential regulation of the secretion 
of IL-12p70, IL-23 and IL-10 cytokines was a direct consequence of 
its function as a transcription factor. The expression of mRNA for 
IL-12p40, IL-12p35 and IL-23p19 was considerably induced in M2 
macrophages infected with an adenoviral vector construct encoding 
IRF5 but not in those infected with a construct encoding IRF3 or 
with empty vector (Fig. 4a). Moreover, the IRF5-driven expression of 
IL-12p40 mRNA was sustained until at least 16 h after stimulation 
with LPS (Supplementary Fig. 5a). Consistent with the protein-
 secretion data, the expression of IL-10 mRNA was inhibited by IRF5 
(Fig. 4a). However, the expression of IL-10 mRNA was not altered by 
IRF3, which suggests the lack of a direct role for IRF3 in transcription 
of the gene encoding IL-10. Inhibition of endogenous IRF5 in M1 
macrophages via RNA-mediated interference resulted in lower expres-
sion of mRNA for IL-12p40, p35 and IL23p19 at 8 h after stimulation 
with LPS (Fig. 4b). IL-12p40 was considerably inhibited through-
out the time course analyzed, even 16 h after stimulation with LPS 
(Supplementary Fig. 5b). The expression of IL-10 mRNA was higher 
in the cells with knocked-down expression of IRF5 (Fig. 4b).
To formally define the global expression profile induced by IRF5, 
we did genome-wide expression analysis in which we compared M2 
macrophages transduced with ectopic IRF5 with previously defined 
human M1 and M2 macrophage subsets21,27. We found that the 
expression of about 90% of known human polarization-specific 
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Figure 2 IRF5 influences the production of macrophage lineage–specific 
cytokines. (a) Enzyme-linked immunosorbent assay (ELISA) of the 
secretion of IL-12p70, IL-23, IL-12p40 and IL-10 by M2 macrophages 
infected with adenoviral vector encoding IRF5 or IRF3 or empty vector 
(pENTR) and stimulated for 24 h with LPS. *P < 0.01 and **P < 0.001 
(one-way ANOVA with Dunnett’s multiple-comparison post-test).  
(b) ELISA of the secretion of IL-12p70, IL-23, IL-12p40 and IL-10 
by M1 macrophages transfected with siRNA targeting IRF5 (siIRF5) or 
nontargeting (control) siRNA (siC) and stimulated for 24 h with LPS  
(10 ng/ml) plus IFN-γ (50 ng/ml). *P < 0.01 and **P < 0.001 (Student’s 
t-test). Data are representative of seven to nine (a) or six to eight (b) 
independent experiments, each with cells derived from a different donor 
(mean and s.e.m.).
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Figure 3 IRF5 promotes lymphocyte proliferation and TH1-TH17 
responses. (a) Immunocytochemical staining of IFN-γ in T lymphocytes 
cultured for 4 d together with M2 macrophages obtained from 
mismatched donors and infected with adenoviral vector encoding IRF5 or 
IRF3 or empty vector, then stimulated for 3 h with PMA, ionomycin and 
brefeldin A; results are presented as mean fluorescence intensity (MFI). 
(b) IFN-γ in supernatants of the cells in a after 4 d of coculture.  
(c) Expression of T-bet mRNA in T lymphocytes cultured for 2 d together 
with M2 macrophages obtained from mismatched donors and infected 
with adenoviral vectors as in a; results are presented in arbitrary  
units (AU) relative to those obtained with empty vector control.  
(d) Immunocytochemical staining of IL-17A in the T lymphocytes in a.  
(e) IL-17A in supernatants of the cells in a after 4 d of coculture.  
(f) Expression of RORγt mRNA, assessed and presented as in c.  
*P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA with Dunnett’s 
multiple-comparison post-test). Data are representative of seven (a,d), six 
(b,c,f) or four (e) independent experiments, each with cells derived from a 
different donor (mean and s.e.m.).
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markers was driven by IRF5 (Fig. 4c). IRF5 induced 20 M1-specific 
genes and inhibited 19 M2-specific genes encoding cytokines, 
chemokines, costimulatory molecules and surface receptors 
(Fig. 4c), which resulted in more or less production of the corres-
ponding proteins, respectively (Supplementary Fig. 5c–e). 
Moreover, we identified many previously unknown IRF5-regulated 
genes that probably contribute to the main functional features of 
macrophage subsets, such as phagocytosis and antigen presentation 
(Supplementary Table 1).
Next we investigated the LPS-induced recruitment of IRF5 to the 
promoter loci of the genes noted above. All IRF family members 
share a well-conserved amino-terminal DNA-binding domain 
that recognizes interferon-stimulated response elements (ISREs). 
Computational analysis of the regions 2,000 nucleotides 5′ upstream 
and 1,000 nucleotides downstream of the transcription start sites of 
IL12A (IL-12p35), IL12B (IL-12p40), IL23A (IL-23p19), IL10 and 
other IRF5-regulated genes (Fig. 5 and Supplementary Table 1) 
led to the identification of several ISREs (Supplementary Table 2). 
We designed primers encompassing these ISREs and used them in 
quantitative chromatin-immunoprecipitation experiments with 
M1 macrophages stimulated for 0, 1, 2, 4, 8 or 24 h with LPS. We 
observed LPS-induced enrichment of IRF5 at the promoter regions of 
IL12A, IL12B and IL23A up to 8 h after stimulation, which matched 
the kinetics of the recruitment of RNA polymerase II to the genes 
(Fig. 5a–c). In contrast, at the IL10 promoter region, LPS-induced 
recruitment of IRF5 took place between 1 h and 4 h after stimulation, 
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Figure 4 IRF5 regulates the expression of mRNA for macrophage lineage–specific cytokines. (a) Quantitative PCR  
analysis of mRNA for IL-12p40, IL-12p35, IL-23p19 and IL-10 in M2 macrophages infected with adenoviral vector  
encoding IRF5 or IRF3; basal expression is presented relative to that of control cells infected with empty vector.  
*P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA with Dunnett’s multiple-comparison post-test). (b) Expression  
of mRNA for IL-12p40, IL-12p35, IL-23p19 and IL-10 in M1 macrophages transfected with siRNA targeting IRF5 and left untreated or stimulated for 
8 h with with LPS (10 ng/ml); results are presented (as percent inhibition) relative to those of control cells transfected with nontargeting control siRNA. 
*P < 0.01 and **P < 0.001 (Student’s t-test). (c) Global mRNA expression (for sets of M1- and M2-specific genes21,27; above plot) by unstimulated M2 
macrophages infected with adenoviral vector encoding IRF5, presented relative to that of unstimulated M2 macrophages infected with empty vector. 
Results are presented as higher (red) or lower (green) expression after infection with vector encoding IRF5 (key (below), log2 fold change). Data are from 
three to six independent experiments, each with cells derived from a different donor (a; mean and s.e.m.), are from five to six independent experiments 
(b; mean and s.e.m.) or are representative of one experiment with four different donors (c).
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Figure 5 IRF5 is directly involved in the transcriptional regulation of lineage-specific cytokines. Recruitment of proteins to the promoters of genes 
encoding IL-12p40 (IL12B; a), IL-12p35 (IL12A; b), IL-23p19 (IL23A; c) or IL-10 (d) in M1 macrophages left unstimulated (0) or stimulated for 
1, 2, 4, 8 or 24 h with LPS (10 ng/ml), assessed by chromatin immunoprecipitation with antibody to IRF5, antibody to RNA polymerase II (PolII) 
or immunoglobulin G (IgG; control); results are presented relative to those obtained with genomic DNA (input). Data are from one experiment 
representative of three (error bars, s.d.).
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whereas RNA polymerase II bound to the region only 8 h after stimu-
lation (Fig. 5d), which suggests a previously unknown inhibitory role 
for IRF5 in the transcriptional regulation of selected genes. Together 
these results indicate that IRF5 regulates the transcription of genes 
encoding IL-12p40, IL-12p35, IL-23p19 and IL-10 through its recruit-
ment to their promoter regions. It also influences the expression of 
most cytokines that define human lineage.
IRF5 inhibits the transcription of human IL10
To investigate whether IRF5 can directly repress transcription of the 
gene encoding IL-10, we used an adenovirus construct with a gene 
reporter in which a luciferase reporter construct was flanked with 195 
nucleotides 5′ upstream of the human gene encoding IL-10 (ref. 28). 
We coinfected M2 macrophages with that construct plus a vector 
encoding IRF5 or empty vector and quantified luciferase activity. 
IRF5-expressing cells had significantly less luciferase activity, both 
in the unstimulated condition and 4 h after stimulation with LPS 
(Fig. 6a). To confirm the importance of the binding of IRF5 to the IL10 
promoter, we generated a mutant of IRF5 lacking the DNA-binding 
domain. This IRF5 mutant was not able to inhibit the wild-type IL-10 
luciferase reporter construct (Fig. 6a). To further explore the 
molecular mechanism of IRF5-mediated suppression of IL10 tran-
scription, we introduced point mutations into the ISRE identified 
(positions −182 to −172 relative to the transcription start site) and 
coinfected M2 macrophages with this mutated luciferase reporter 
construct and vector encoding IRF5 or empty vector. The luciferase 
reporter construct with a mutated ISRE produced a different response 
than did the wild-type construct in that ectopic IRF5 was no longer 
able to suppress luciferase activity (Fig. 6b), which suggested that 
IRF5 inhibits IL-10 by direct binding to the ISRE of the IL10 pro-
moter. This was opposite to the positive regulatory activity of IRF5 
at the TNF promoter22 and IL12A promoter (Supplementary Fig. 6). 
Therefore, IRF5 can act not only as a transcriptional activator but also 
as a suppressor of certain target genes, in this case the gene encod-
ing the anti-inflammatory mediator IL-10. The mode of inhibition is 
mediated by direct binding of IRF5 to the promoter region of IL10 and 
probably by engagement of as-yet-unidentified cofactors.
Importance of IRF5 in a mouse model of M1 inflammation
Similar to their human counterparts, mouse bone marrow–derived 
macrophages (BMDMs) differentiated with GM-CSF had higher 
expression of IRF5 protein than did M-CSF-derived BMDMs 
(Fig. 7a) and were the only cells secreting IL-12p70 and IL-23 (data 
not shown). Consequently, BMDMs obtained from Irf5−/− mice and 
differentiated with GM-CSF secreted significantly less IL-12p70 and 
IL-23 or more IL-10 in response to stimulation with LPS than did 
wild-type cells (Fig. 7b). We observed no difference between wild-
type and Irf5−/− M-CSF-derived BMDMs in their IL-10 secretion 
(data not shown). To investigate the function of IRF5 in an in vivo 
model of M1-polarized inflammation, we challenged Irf5−/− mice 
with a sublethal dose of LPS injected intraperitoneally. Within 3h 
there was a significant difference between wild-type and Irf5−/− 
mice in the serum concentrations of certain cytokines. Responses 
were consistent with the human data; that is, Irf5−/− mice had lower 
pENTR
IRF5
IRF5∆DBD
US
WT
LPS
*
*
a
0
25
50
75
100
125
150
175
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (
A
U
)
W
T
IS
RE
m
ut W
T
IS
RE
m
ut W
T
IS
RE
m
ut
0
50
100
150
200
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (
A
U
)
bFigure 6 IRF5 inhibits the transcriptional activation of human IL10.  
(a) Luciferase activity of M2 macrophages infected for 24 h with a wild-
type IL10 luciferase reporter plasmid (WT), plus a construct encoding 
IRF5 or an IRF5 mutant lacking the DNA-binding domain (IRF5∆DBD)  
or empty vector, then left unstimulated (US) or stimulated for 4 h with  
LPS (10 ng/ml). (b) Luciferase activity of M2 macrophages infected 
for 24 h with the wild-type reporter in a or an IL10 luciferase reporter 
plasmid with site-specific mutations in the ISRE site at positions  
−180 to −173 (ISREmut), plus the IRF5 constructs in a or empty 
vector, then stimulated with LPS as in a. *P < 0.01 (one-way ANOVA 
with Dunnett’s multiple-comparison post-test). Data are from three 
independent experiments, each with cells derived from a different  
donor (mean and s.e.m.). 
a
Irf5
WT1 WT2
M
-C
SF
GM
-C
SF
M
-C
SF
GM
-C
SF
e
Irf
5
–/
–
W
T
0
2
4
6
8
*
IF
N
-γ
 (
ng
/m
l)
Irf
5
–/
–
W
T
0
200
400
600
*
IL
-1
7 
(p
g/
m
l)
c
IL
-1
2p
40
 (
ng
/m
l)
W
T
0
5
10
15
20
**
Irf
5
–/
–
IL
-2
3 
(p
g/
m
l)
W
T
0
100
200
300
400
*
Irf
5
–/
–
IL
-1
0 
(p
g/
m
l)
W
T
0
500
1,000
1,500
2,000
2,500
*
Irf
5
–/
–
d
0
2
4
6
** ***
***
** ** *
**
m
R
N
A
 (
A
U
)
IL
-1
2p
40
IL
-1
2p
35
IL
-2
3p
19
IL
-1
β
TN
F
IL
-6
IL
-1
0
Fi
zz
1
Ar
g1
WT
Irf5–/–
IL
-2
3 
(p
g/
m
l)
W
T
0
100
200
300
400
*
Irf
5
–/
–
IL
-1
0 
(p
g/
m
l)
W
T
0
500
1,000
1,500
**
Irf
5
–/
–
b
IL
-1
2p
70
 (
pg
/m
l)
W
T
Irf
5
–/
–
0
100
200
300
400
**
Figure 7 Impaired production of M1 and TH1-TH17 cytokines in Irf5−/− mice. (a) Immunoblot analysis of total protein  
extracts from wild-type C57BL/6 bone marrow cells differentiated for 8 d into M1 macrophages with GM-CSF (20 ng/ml)  
or into M2 macrophages with M-CSF (100 ng/ml); extracts of adherent cells were probed with antibody to IRF5. Data are  
representative of three experiments. (b) ELISA of IL-12p70, IL-23 and IL-10 secreted by M1 macrophages obtained from  
C57BL/6 mice (n = 8) and stimulated for 24 h with LPS (100 ng/ml). *P < 0.05 and **P < 0.01 (Student’s t-test). Data are  
representative of three experiments (mean and s.e.m. of one sample per mouse analyzed in triplicate). (c) ELISA (IL-12p40  
and IL-23) or cytrometric bead assay (IL-10) of the serum concentrations of cytokines in Irf5−/− mice (n = 10) and their  
wild-type littermates (n = 10) injected intraperitoneally with LPS (20 µg), assessed 3 h later. *P < 0.05 and **P < 0.01  
(Student’s t-test). Data are from three independent experiments (mean and s.e.m. of eight to ten serum samples). (d) Expression of mRNA for M1 and 
M2 markers (horizontal axis) in peritoneal cells from the LPS-injected mice in c. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test). Data are 
from three independent experiments (mean and s.e.m. of ten samples). (e) ELISA of IFN-γ and IL-17A in spleen cells obtained from the LPS-injected 
mice in c and cultured for 48 h in the presence of antibody to CD3. *P < 0.05 and **P < 0.01 (Student’s t-test). Data are from two independent 
experiments (mean and s.e.m. of four to five spleen cultures).
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serum concentrations of IL-12p40, IL-23 (Fig. 7c) and TNF, as well 
as IL-6 (Supplementary Fig. 7) but had more IL-10 (Fig. 7c). Mice 
injected with PBS secreted no cytokines. The number of macrophages 
recruited into the peritoneal cavity of LPS-challenged mice was similar 
for wild-type and Irf5−/− mice (data not shown), but the expression 
of genes encoding M1 macrophage markers (Il12a, Il12b, Il23a, Il1b, 
Tnf and Il6) was significantly impaired in these cells (Fig. 7d). The 
expression of genes encoding M2 markers in Irf5−/− mice (Il10, Arg1, 
Retnla (Fizz1) and Chi3l3 (Ym1)) was either significantly higher or 
showed a positive trend (Fig. 7d and data not shown). In addition, 
in splenocytes from LPS-challenged Irf5−/− mice cultured ex vivo 
for an additional 48 h, we observed significantly less production 
of IFN-γ and IL-17 (Fig. 7e). In summary, our data here, together 
with the reported role of IRF5 in LPS-induced lethal endotoxic 
shock12, support of the idea that IRF5 is important in establishing a 
 proinflammatory macrophage phenotype in animal models of M1-
polarizing inflammation.
DISCUSSION
Macrophages are key mediators of the immune response during 
inflammation. Plasticity and functional polarization are hallmarks 
of macrophages that result in the phenotypic diversity of macrophage 
populations29. Given that deficiency in IRF5 in mice leads to less 
production of IL-12p40 and IL-23p19 (refs. 11,12), which are uni-
versal markers of M1 macrophage subsets, we investigated whether 
IRF5 is involved in macrophage polarization. We found that IRF5 
was indeed a major factor in defining macrophage polarization: it 
had high expression in M1 macrophages and induced a character-
istic gene-expression and cytokine-secretion profile and promoted 
robust TH1-TH17 responses. We also identified a previously unknown 
regulatory role for IRF5 as an inhibitor of M2 macrophage marker 
expression. Finally, IRF5 contributed to macrophage plasticity; that is, 
modulation of its expression led to the conversion of one macrophage 
subset phenotype into the other.
The rapid and potent transcriptional response developed by 
macrophages encountering microbial stimuli (such as LPS) or, 
subsequently, cytokines is orchestrated by many transcription 
factors. Among these are class III transcription factors, such as PU.1, 
C/EBPβ, Runx1 and IRF8, which are lineage-specific transcriptional 
regulators turned on during macrophage differentiation30. The 
combinatorial expression of these proteins specifies macrophage 
phenotype through the constitutive activation or repression of genes 
and chromatin remodeling at inducible loci. For example, PU.1 is 
required for maintaining monomethylated histone 3 Lys4 enhancer 
marks at macrophage-specific enhancers31. However, only a small 
proportion of the macrophage transcriptome is altered by cell polari-
zation27, and among the genes with differences in expression in the 
M1 and M2 subsets are those regulated by IRF5, including IL12A, 
IL12B, IL23A, IL1B, TNF, CCL3 (encoding MIP-1α), RANTES, 
CD1A, CD40, CD86 and CCR7. Another member of the IRF family, 
IRF4, known to inhibit IRF5 activation by competing for interaction 
with the adaptor Myd88 (ref. 32), is reported to control the expres-
sion of prototypical mouse M2 macrophage markers10. We found 
that in human cells, IRF4 expression was induced equally well by 
 differentiation with M-CSF or GM-CSF and was further enhanced by 
exposure to IL-4 (ref. 33). IRF5 expression, in contrast, was induced 
specifically by GM-CSF or IFN-γ but was unresponsive to IL-4. Thus, 
IRF5 and IRF4 may be classified as class III transcription factors 
with the caveat that they define specific macrophage subsets rather 
than the global macrophage lineage. NF-κB proteins, in particular 
c-Rel and RelA, are important for the expression of M1-specific 
cytokines34,35. IRF5 and RelA act together in inducing the gene 
encoding TNF22. We speculate that the genes encoding IL-12, 
IL-23 subunits and other M1-specific markers might be under similar 
joint transcriptional control. Thus, IRF5 may participate in combi-
natorial assembly with macrophage-specific transcription factors 
such as PU.1 and environmentally induced NF-κB31 to define the 
activity of specific M1 enhancers.
The role of IRF5 in inhibiting the transcription of the gene encod-
ing IL-10 that we have identified here is important given its well-
documented immunosuppressive activity. Il10−/− mice develop 
spontaneous autoimmune diseases and show greater resistance to 
infection36. IL-10 represses immune responses by downregulating 
inflammatory cytokines such as TNF37 and is important for the 
generation of regulatory T cells that act to suppress activation of the 
immune system and thereby maintain immune system homeostasis 
and tolerance to self antigens38. The main producers of IL-10 include 
M2 macrophages, B cells and T cells39, whereas M1 macrophages and 
DCs are only weak producers21. Ectopic expression of IRF5 in M2 
macrophages results in less IL-10 secretion after stimulation with LPS 
and also affects the expression of mRNA for IL-10 and many other 
markers of the human M2 macrophage phenotype, such as MRC1, 
IGF-1, CCL2, CCL13, CD163, M-CSFR and MSR1. Consistent with 
published studies40, we found no expression of the most widely used 
prototypical mouse M2 markers (Arg1, Ym1 and Fizz 1) in human 
macrophages (data not shown), whereas their expression in LPS-
elicited mouse peritoneal macrophages showed a positive trend in 
the absence of IRF5. Expression of some chemokines defined as M1 
markers (CXCL10) or M2 markers (CCL17, CCL18 and CCL22) in 
mouse macrophages did not follow the expected pattern of IRF5 
dependence (that is, induction for M1 and inhibition for M2), which 
possibly reflects species-specific gene repertoires41. Although human 
M1 macrophages but not M2 macrophages have been shown to secrete 
large amounts of CCL22 (ref. 21), there is some controversy in the 
literature about whether CXCL10 is a marker of the M1 or M2 macro-
phage phenotype21,24,27; our data would classify CXCL10 as an M2 
macrophage marker.
The swift modulation of IRF5 expression and cytokine production 
by colony-stimulating factors can help to explain the considerable 
plasticity of macrophages in adjusting their phenotype in response to 
environmental signals2. M-CSF is constitutively produced by several 
cell types, including fibroblasts, endothelial cells, stromal cells and 
osteoblasts. This steady-state production of M-CSF probably polarizes 
macrophages toward the M2 phenotype by keeping IRF5 expression 
low. In contrast, GM-CSF production by the same cell types requires 
stimulation and usually occurs at a site of inflammation or infection, 
which is also characterized by large amounts of IFN-γ. The resolution 
of inflammation may once again coincide with the predominance of 
M-CSF and a switch in IRF5-driven cytokine production, as treat-
ment of M2-to-M1 macrophages with M-CSF restored the original 
M2 phenotype (M2-to-M1-to-M2). The activation of receptors for 
both GM-CSF and IFN-γ stimulates the Jak kinase–STAT transcrip-
tion factor pathway29, and an ISRE in the Irf5 promoter can bind 
STAT1 and STAT2 (ref. 13), which suggests a possible mechanism for 
IRF5 expression induced by GM-CSF and IFN-γ. Consequently, high 
expression of IRF5 results in polarization of the macrophage pheno-
type toward M1. IRF5 induces expression of IFN-γ mRNA, which 
indicates an autocrine loop in macrophage polarization.
We found that IRF5-expressing macrophages promoted the pro-
liferation and activation of T lymphocytes and drove them toward 
TH1 or TH17 phenotype through IL-12 secretion42 or secretion of 
IL-23 and/or IL-1β43, respectively. TH1 cells constitutively express 
©
20
11
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
nature immunology  aDVaNCE ONLINE PUBLICaTION 
A rt i c l e s
IFN-γ and T-bet, whereas TH17 cells express RORγt, IL-23R, 
IL-17A–IL-17F, IL-21, IL-22 and IL-26. All these TH1 and TH17 
markers are upregulated in the presence of IRF5-expressing macro-
phages. Human TH17 cells and mouse TH17 cells seem to have dif-
ferent characteristics: whereas mouse TH17 cells originate from a 
precursor common to regulatory T cells when IL-6 is produced 
in combination with TGF-β, human TH17 cells originate from 
CD161+CD4+ precursors in the presence of IL-23 and IL-1β, with 
little involvement of IL-6 and an indirect role for TGF-β43. Perhaps 
not unexpectedly, the dependence of IL-6 expression on IRF5 is 
much greater in mouse macrophages.
Both the TH1 subset and the TH17 subset promote cellular immune 
function and can cause inflammation and autoimmune diseases, such 
as inflammatory bowel disease and collagen-induce arthritis44,45. 
Notably, more IRF5 mRNA has been found in splenic cells from certain 
autoimmune-prone mouse strains than in non-autoimmune mice46, 
whereas IRF5-deficient mice show impaired production of TH1 or 
TH17 cytokines. This indicates a possible broad effect of therapies 
targeting the induction of IRF5 expression by macrophages, such as 
by targeting IRF5-inducing stimuli. Related to this, GM-CSF-deficient 
mice fail to develop arthritis despite having a normal humoral immune 
response to the arthritogenic stimulus47, and blockade of GM-CSF 
in wild-type mice controls disease activity and the concentration of 
proinflammatory mediators in the joints48. In summary, a distinct 
systemic role for IRF5 in macrophages is the orchestration of tran-
scriptional activation of proinflammatory cytokines, chemokines and 
costimulatory molecules that leads to efficient effector T cell responses, 
rather than induction of a type I interferon–induced transcriptional 
network49. Our data have established a new paradigm for macrophage 
polarization and have designated the IRF5-IRF4 regulatory axis as a 
new target for therapeutic intervention in which inhibition of IRF5 
activity would specifically affect the expression of proinflammatory 
cytokines and would result in fewer effector T cells.
METHODS
Methods and any associated references are available in the online version 
of the paper at http://www.nature.com/natureimmunology/.
Note: Supplementary information is available on the Nature Immunology website.
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ONLINE METHODS
Plasmids. Expression constructs encoding full-length human IRF3, IRF5 
variant 3/4 and the IRF5 mutant lacking the DNA-binding domain have been 
described22. Vectors encoding IRF5 and IRF3 expressed similar amounts of 
protein but only IRF5 resulted in much more TNF secretion, whereas only 
IRF3 induced type III interferons22. The IL10 promoter–driven luciferase 
reporter constructs have been described28. The constructs with wild-type and 
mutated ISREs in the IL12A promoter50 were a gift from X. Ma. Sequences and 
restriction maps are available on request.
Mice. The generation of Irf5−/− mice has been described12. For the generation 
of BMDMs differentiated with GM-CSF, bone marrow of wild type or Irf5−/− 
was cultured in RPMI-1640 medium (PAA Laboratories) supplemented with 
recombinant mouse GM-CSF (20 ng/ml; Preprotech) or recombinant mouse 
M-CSF (100 ng/ml; Peprotech). After 8 d, adherent cells were washed with 
PBS and replated, then stimulated with LPS (100 ng/ml; Alexis Biochemicals). 
For in vivo experiments, Irf5−/− mice and their wild-type littermates were 
injected intraperitoneally with 20 µg LPS in 200 µl sterile PBS. Mice were 
killed after 3 h and serum was collected. Spleens were removed and cultured 
for 48 h in DMEM supplemented with antibody to CD3 (anti-CD3; 10 ng/ml; 
145-2c11; BD Bioscience). The experimental protocol was approved by the 
UK Home Office.
Cell culture. Enriched populations of human monocytes were obtained from 
the blood of healthy donors by elutriation as described22. M1 and M2 macro-
phages were obtained after 5 d of culture of human monocytes in RPMI-
1640 medium (PAA Laboratories) supplemented with GM-CSF (50 ng/ml) or 
M-CSF (100 ng/ml; Peprotech). Cells were stimulated with LPS alone 
(10 ng/ml; Alexis Biochemicals) or with LPS (10 ng/ml) plus IFN-γ (50 µg/ml; 
Peprotech). For ‘priming’ experiments, M1 macrophages at day 5 were 
simulated for 24 h with M-CSF (100 ng/ml). Similarly, M2 macrophages at 
day 5 were stimulated for 24 h with GM-CSF (50 ng/ml), with IFN-γ alone 
(50 ng/ml) \or with LPS (10 ng/ml) plus IFN-γ (50 ng/ml).
Measurement of cytokine production. Cytokine secretion was quantified by 
ELISA specific for human IL-12p40, IL-12p70, IL-10, IFN-γ, TNF, CXCL10 or 
IL-1β (BD Bioscience); IL-23 or CCL2 (eBioscience); CCL5, CCL13 or CCL22 
(R&D Systems); or IL-17A or IL-4 (Insight Biotechnology). Mouse cytokine 
secretion was quantified with ELISA specific for IL-12p70, IL-23 or IL-10 
(eBioscience) or for IFN-γ or IL-17a (BD Bioscience), and serum concentra-
tions of mouse IL-1β, TNF, IL-6 and IL-10 were determined by cytrometric 
bead assay on a FACSCanto II (BD Bioscience).
Mixed-lymphocyte reaction. Human macrophages were plated in 96-well 
plates at a density of 2 × 104 cells per well. T lymphocytes were isolated from 
the blood of healthy donors by elutriation, analyzed by flow cytometry and 
used when their purity was >90%. T lymphocytes were added to macrophages 
at a density of 5 × 105 cells per well. Control cultures contained medium only 
or T lymphocytes or M2 macrophages alone. After 72–96 h of coculture, super-
natants were collected for analysis of cytokines. For proliferation experiments, 
cells were pulsed with 37,000 Bq of [3H]thymidine (Amersham Biosciences) 16 h 
before being collected, and DNA synthesis was measured by [3H]thymidine 
incorporation with a β-scintillation counter (Beckman Instruments).
RNA-mediated interference. The ON-TARGETplus SMARTpool reagent 
(Dharmacon) designed to target human IRF5 was used for siRNA-mediated 
knockdown. DharmaFECT 1 was used as the siRNA transfection reagent 
according to the manufacturer’s instructions (Dharmacon).
Adenoviral infection. M2 macrophages were infected as described22.
RNA extraction and quantitative real-time RT-PCR. Total RNA was 
extracted from cells with an RNeasy Mini kit according to the manufactur-
er’s instructions (Qiagen), then cDNA was synthesized from total RNA with 
SuperScript III reverse transcriptase (Invitrogen) and 18-residue oligo(dT) 
(Eurofins MWG Operon). Gene expression was measured by the change-
in-threshold (∆∆CT) method based on quantitative real-time PCR in an 
ABI 7900HT (Applied Biosystems) with TaqMan primer sets for human 
IL-12p35, IL-12p40, IL-23p19, IL-10, IFN-γ, IL-17A–IL-17F, IL-21, IL-22, 
IL-26, IL-23R, TBX21 (for T-bet), Mrc1, Arg1, Rentla (for Fizz1) and PO 
(Applied Biosystems). RORγt was detected by SybrGreen with a primer set 
for human RORC2 (RORC2_F1, TGAGAAGGACAGGGAGCCAA; and 
RORC2_R1: CCACAGATTTTGCAAGGGATCA).
Luciferase reporter assay. M2 macrophages were infected in 96-well plates 
in triplicate at a multiplicity of infection of 50:1. Cells were seeded in serum-
free, antibiotic-free RPMI medium containing the desired number of viral 
particles in a final volume of 50 µl. Cells were infected for 6 h with expression 
construct encoding IRF5 or the IRF5 mutant lacking the DNA-binding domain 
or empty vector, followed by infection with the IL10 luciferase constructs. Cells 
were allowed to recover for 24 h before experimental assay. Human embry-
onic kidney (HEK293) cells expressing Toll-like receptor 4 and its coreceptor 
MD2, plus the LPS receptor CD14, were cotransfected with the constructs 
with wild-type and mutated ISREs of the promoter of the gene encoding 
IL-12p35 as described22.
Total protein extracts and immunoblot analysis. Total protein extracts were 
prepared as described22. Equal amounts of protein were resolved by SDS-
PAGE and analyzed with anti-IRF5 (ab2932 or ab21689; Abcam); anti-IRF3 
(sc-9082x), anti-IRF4 (sc-28696), anti-p50 (sc-114x) or anti-RelA (sc-372x; 
all from Santa Cruz); or anti-actin (A5541; Sigma).
Flow cytometry. For staining of T cell surfaces, cells were stained for 30 min 
at 4 °C with fluorescein isothiocyanate–conjugated anti-CD4 (RPA-T4; 
BD Bioscience) and peridinin chlorophyll protein–indodicarbocyanine–
 conjugated anti-CD8 (RPA-T8; BD Bioscience). For intracellular cytokine 
staining, cells were stimulated for 3–4 h with phorbol myristate acetate, iono-
mycin and brefeldin A (Sigma-Aldrich). Cells were stained for cell surface 
markers, were fixed in Cytofix (BD Bioscience) and then were made permeable 
with PBS containing 1% (vol/vol) FCS, 0.01% (vol/vol) sodium azide, and 
0.05% (vol/vol) saponin and were stained with Pacific blue–conjugated anti-
IFN-γ (4S.B3; eBioscience) and phycoerythrin-conjugated anti-IL-17 (eBIO-
64CAP17; eBioscience). For surface staining, macrophages were incubated for 
30 min at 4 °C with allophycocyanin-conjugated anti-CD40 (5C3; eBioscience) 
and phycoerythrin-conjugated anti-CD163 (215927; R&D Systems). Samples 
were analyzed on a FACSCanto II (BD Bioscience) and date were analyzed 
with FlowJo software (TreeStar).
Chromatin immunoprecipitation. Chromatin-immunoprecipitation assays 
were done essentially as described22 with anti-IRF5 (ab2932; Abcam), antibody 
to RNA polymerase II (sc-899; Santa Cruz) or immunoglobulin G control (PP64; 
Milipore). The immunoprecipitated DNA fragments were then analyzed by real-
time PCR with SYBR Premix Ex Taq II master mix (Takara Bio) and the follow-
ing primers: locus encoding IL-12p35, 5′-TCATTTTGGGCCGAGCTGGAG-3′ 
and 5′-TACATCAGCTTCTCGGTGACACG-3′; locus encoding IL-12p40, 
5′-TCCAGTACCAGCAACAGCAGCAGA-3′ and 5′-GTAGGGGCTTGGG 
AAGTGCTTACCTT-3′; locus encoding IL-23p19, 5′-ACTGTGAGGCCTG 
AAATGGGGAGC-3′ and 5′-ACTGGATGGTCCTGGTTTCATGGGAGA-3′; 
and locus encoding IL-10, 5′-CCTGTGCCGGGAAACCTTGATTGTGGC-3′ 
and 5′-GTCAGGAGGACCAGGCAACAGAGCAGT-3′. Data were analyzed 
with ABI 7900HT software (Applied Biosystems).
Microarray analysis, statistics and bioinformatics. Microarrays, statistics 
and bioinformatic analyses are described in the Supplementary Methods.
50. Liu, J., Cao, S., Herman, L.M. & Ma, X. Differential regulation of interleukin (IL)-
12 p35 and p40 gene expression and interferon (IFN)-γ-primed IL-12 production 
by IFN regulatory factor 1. J. Exp. Med. 198, 1265–1276 (2003).
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IRF5 is required for late-phase TNF secretion by human dendritic cells
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Spatially and temporally controlled ex-
pression of inflammatory mediators is
critical for an appropriate immune re-
sponse. In this study, we define the role
for interferon regulatory factor 5 (IRF5) in
secretion of tumor necrosis factor (TNF)
by human dendritic cells (DCs). We dem-
onstrate that DCs but not macrophages
have high levels of IRF5 protein, and that
IRF5 is responsible for the late-phase
expression of TNF, which is absent in
macrophages. Sustained TNF secretion
is essential for robust T-cell activation by
DCs. Systematic bioinformatic and bio-
chemical analyses of the TNF gene locus
map 2 sites of IRF5 recruitment: 5 up-
stream and 3 downstream of the TNF
gene. Remarkably, while IRF5 can directly
bind to DNA in the upstream region, its
recruitment to the downstream region
depends on the protein-protein interac-
tions with NF-B RelA. This study pro-
vides new insights into diverse molecular
mechanisms employed by IRF5 to regulate
gene expression and implicates RelA-IRF5
interactions as a putative target for cell-
specific modulation of TNF expression.
(Blood. 2010;115(22):4421-4430)
Introduction
Tumor necrosis factor (TNF) is one of the major cytokines
responsible for effector immune functions. As well as playing a
central role in host defense against infection, TNF is a major factor
in the pathogenesis of chronic inflammatory disease such as
rheumatoid arthritis (RA). Consequently, tightly controlled regula-
tion of its expression is critical for an appropriate immune
response. This occurs at the transcriptional and posttranscriptional
levels, with transcriptional regulation showing specificity for both
stimulus and cell type.1 The NF-B family of transcription factors
(TFs) plays a major role in transcriptional up-regulation of the TNF
gene by lipopolysaccharide (LPS) in both mouse and human
myeloid cells.2-5
Regulation of transcription for many immune genes in response
to Toll-like receptor (TLR) signaling involves a combination of
NF-B and interferon regulatory factor (IRF) factors.6 IRFs appear
to provide a mechanism for conferring signal specificity to a variety
of target gene subsets, with IRF3 being essential for type I
interferon (IFN) response,7 and IRF5 playing a key role in
induction of proinflammatory cytokines, including TNF, IL-6, and
IL-12.8 Consequently, IRF5/ mice show resistance to lethal
shock induced by CpG-B or LPS.8
Unlike other IRF family members, IRF5 contains 2 nuclear
localization signals (NLSs), 1 in the N-terminus and the other in the
C-terminus of the protein. This results in low levels of nuclear
translocation and therefore weak trans-activation activity of IRF5,
even in unstimulated cells.9 The molecular pathways leading to
IRF5 activation are not well understood, but it was shown that TLR
signaling induces the formation of MyD88-IRF5-TRAF6 com-
plexes,8 and is probably followed by phosphorylation of specific
sites within the IRF5 C-terminal autoinhibitory domain.10
Human IRF5 is expressed as multiple spliced variants with
distinct cell type–specific expression, cellular localization, differen-
tial regulation, and dissimilar functions.11 Moreover, genetic poly-
morphisms in the IRF5 gene leading to expression of several
unique isoforms have been implicated in autoimmune diseases,
including systemic lupus erythematosis (SLE), RA and Sjogren
syndrome.12-15 IRF5 mRNA expression has been detected in
B cells, dendritic cells (DCs), monocytes, and natural killer (NK)
cells but not in T cells,11 yet little is known about the IRF5 protein
expression in these cells.
Here, we demonstrate that human monocytes acquire high
levels of IRF5 protein during differentiation into monocyte-derived
DCs (MDDCs) but not monocyte-derived macrophages (MDMs).
This leads to a sustained secretion of TNF by MDDCs compared
with MDMs and efficient activation of T cells. IRF5 is recruited to
both upstream and downstream regions of the gene after LPS
induction, and its cooperative action with NF-B RelA is important
for maintaining the TNF gene transcription. Remarkably, IRF5
displays 2 independent modes of transcriptional activity: direct
binding to DNA and indirect recruitment via the formation of a
protein complex with RelA. Our results provide novel insights into
the molecular basis for cell specificity in TNF production by human
immune cells and highlight RelA-IRF5 interactions as a novel
target for cell-specific modulation of TNF expression.
Methods
Plasmids
Expression constructs encoding full-length human IRF3, IRF5v3/v4, and
NF-B subunits tagged with HA-tag in modified pENTR vector (pBent)
were described in Thomson et al.16 IRF5DBD, IRF5A68P mutants were
generated. The constructs were recombined into pAD/PL DEST vector
(Invitrogen) for adenovirus production and subsequent delivery into human
myeloid cells. The IRF5-HA fragment was subsequently transferred into the
modified pBent vector containing 1-strep-tag. The 5wt/3wt and 5wt/
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3mut TNF luciferase-reporter constructs provided by Mr T. Smallie
(Kennedy Institute) were used to generate 5mut/3wt and 5mut/3mut
constructs with mutated sites B2/2/2a.5 IRF5 DBD (amino acid 1-131)
were polymerase chain reaction (PCR) amplified and cloned into bacterial
expression vector pET21d (Novagen). All constructs were verified by
sequencing. The sequences and restriction maps are available upon request.
Cell culture
All reagents used for cell culture were tested for endotoxin and only used if
the endotoxin levels were less than 20 pg/mL (Lonza). All cell cultures were
maintained at 37°C in 5% CO2 and 95% humidity in the appropriate media
supplemented with 10% fetal calf serum (Gibco) and 1% penicillin/
streptomycin (PAA). HEK-293–TLR4-CD14/Md2 cells (Invivogen) were
cultured in Dulbecco modified Eagle medium (DMEM; PAA) supple-
mented with 10 mg/mL blasticidin and 50 mg/mL HygroGold (Invivogen)
per the manufacturer’s instruction. Enriched populations of human mono-
cytes were obtained from the blood of healthy donors by elutriation as
described previously.4 MDMs and MDDCs were obtained after 5 to 7 days
of culturing human monocytes in RPMI 1640 (PAA) supplemented with
100 ng/mL macrophage colony-stimulating factor (M-CSF) or 50 ng/mL
granulocyte-macrophage colony-stimulating factor (GM-CSF) and 10 ng/
mL IL-4 (Peprotech). MDMs, MDDCs, and cell lines were stimulated with
100 ng/mL LPS (Alexis Biochemicals) unless indicated otherwise.
ELISA
Cytokine secretion was quantified with specific enzyme-linked immunosor-
bent assays (ELISAs) for human TNF (BD Bioscience), human IFN- (BD
Bioscience), and human IFN-1/IL-29 (R&D Systems) according to
manufacturer instructions. Absorbance was read at 450 nm by a spectropho-
tometric ELISA plate reader (Labsystems Multiscan Biochromic) and
analyzed using Ascent Labsystems software. All samples were analyzed in
triplicate in a volume of 50 L.
Mixed lymphocyte reaction
Human MDDCs were plated in 96-well, flat-bottom tissue plates at 2 	 104
cells per well. T lymphocytes were isolated from the blood of healthy
donors by elutriation, analyzed by FACS, and used if purity was more than
90%. T lymphocytes were added to MDDCs at 5 	 105 so that the final
MDDC/T cell ratio was 1:25. Control cultures contained medium or
T lymphocytes, or MDDCs alone. A total of 10 g/mL anti-TNFR1
antibody (MAB 625; R&D Systems) or IgG control antibody (MAB 002;
R&D Systems) was added to the cocultures after 6 hours or 24 hours.
Cultures were established in duplicate and incubated at 37°C in 5% CO2 for
a total of 72 hours. After culture, supernatants were collected and stored at
20°C for detection of cytokines.
RNA interference
siRNA-mediated knockdown was performed using On-target plus SMART
pool reagents (Dharmacon) designed to target human IRF5 and NF-B
RelA. Lipofectamine RNAiMAX (Invitrogen) and DharmaFECT I (Dhar-
macon) were used as the siRNA transfection reagents for HEK-293–TLR4-
Md2/CD14 cells and MDDCs, respectively, according to the manufactur-
ers’ instructions. Multiple siRNAs were used to validate the knockdown
specificity and exclude off-target effects.
Adenoviral infection
Infections of MDMs were performed in 96-well plates in triplicate at a
multiplicity of infection (MOI) of 50:1. Cells were seeded in serum-free,
antibiotics-free RPMI containing the desired number of viral particles in a
final volume of 50 L. The plates were incubated overnight at 37°C
followed by aspiration of the supernatants and replacement with 100 L of
standard media per well. Cells were allowed to recover for a further
24 hours before experimental assay.
RNA extraction and quantitative real-time RT-PCR
Total RNA was extracted from cells using a QiaAmp RNA Blood mini kit
(QIAGEN) according to the manufacturer’s instructions. cDNA was
synthesized from total RNA using SuperScript III Reverse Transcriptase
(Invitrogen) and 18-mer oligo dTs (Eurofins MWG Operon). The gene
expression was analyzed by 2-standard curve or Ct methods where
appropriate based on the quantitative real-time PCR with TaqMan primer
sets for human TNF and PO (Applied Biosystems) in a Corbett Rotor-gene
6000 machine (Corbett Research Ltd).
Luciferase gene reporter assay
HEK-293–TLR4-CD14/Md2 cells were seeded into polylysine-coated
96-well plates at a density of 30 000 cells per well. Next day, cells were
transfected with 10 ng of the indicated expression vector, 50 ng of TNF
luciferase reporter, and 50 ng of pEAK8-Renilla using the Lipofectamine
2000 protocol (Invitrogen). Total amount of DNA was kept at 120 ng per
well. At 48 hours after transfection, the activity of the reporters were
measured using the Dual-Glo Luciferase system (Promega) optimized for
96-well plate format according to the manufacturer’s protocol. Each
experiment was performed in triplicate.
Nuclear and total protein extracts and Western
Cells were grown on 10-cm2 dishes and exposed to vehicle and agents;
reactions were terminated by washing cells twice with ice-cold phosphate-
buffered saline (PBS). Cells were then removed by scraping and transferred
to Eppendorf tubes. Nuclear or total protein extracts were prepared as
previously described.5 Equal amounts of proteins were resolved by Novex
Tris-glycine gel (Invitrogen), transferred onto Hybond-N membranes
(Amersham Biosciences), and subjected to incubation with antibodies
against IRF5 (ab2932; Abcam), followed by detection with horseradish
peroxidase (HRP)–conjugated secondary antibodies and the chemilumines-
cent substrate solution ECL (GE Healthcare).
EMSA
Oligonucleotide probes were radiolabeled with [
-32P]dCTP (Perkin Elmer):
B4 (Forward [F]: agctGGGCATGGGAATTTCCAACTCT; Reverse [R]: agct-
GAGTTGGAAATTCCCATGCCC); B4a (F: agctAACTCTGGGAATTC-
CAATCCTT; R: agctAAGGATTGGAATTCCCAGAGT T); B4b (F: agctCT-
TGCTGGGAAAATCCTGCAG; R: agctGCTGCAGGATTTTCCCAGCAAG);
ISRE1 (F: agctGAAGCCAAGACTGAAACCAGCATTA; R: agctTAATGCT-
GGTTT CAGTCTTGGCTTC); ISRE2 (F: agctCCGGGTCAGAATGAAA-
GAAGAAGG; R: agctC CTTCTTCTTTCATTCTGACC CGGT); ISRE5 (F:
agctGGAGAAGAAACCGAGACAGAAGG TG; R: agctCACCTTCTGTC
TCGGTTTCTTCTCC). ‘ISRE’16 (F: agctTTTGCTTAGAAAAGAAACATG-
GTCTC; R: agctGAG ACCATGTTTCTTTTCTAAGCAAA); ‘ISRE’17 (F:
agctACATAAACAAAGCCCAACAGAATATTCC; R: agctGGAATATTCTGT-
TGGGCTTTGTTTATGT); and PRDI-III(IFN-) (F: agctGGGAAACTG
AAAGGGAAAGTGAAAGTGG; R: agctCCACTTTCACTTTCCCTT-
TCAGTTTCCC). Binding reactions with 50 ng of bacterially expressed and
purified IRF5 DBD and electrophoretic mobility shift assay (EMSA) gel
separation were performed as previously described.5
Chromatin immunoprecipitation
A total of 7 	 106 MDDCs or HEK-293-TLR4-CD14/Md2 cells were fixed
by adding 1% formaldehyde (final concentration) for 5 minutes at room
temperature. Nuclear extracts were subjected to 6 	 12-second pulses of
sonication using Vibra-Cell VCX130 (Sonics) at 20% amplitude. For
immunoprecipitation reaction, nuclear extracts were precleared with pro-
tein G–Sepharose bead slurry (GE Healthcare) for 2 hours, and then
incubated with 2 g of antibodies against IRF5 (ab2932; Abcam), RelA, or
Pol II (sc-372 and sc-899; Santa Cruz Biotechnology) overnight at 4°C with
rotation. Immunocomplexes were then collected with protein G–Sepharose
beads for 30 minutes, rigorously washed, and eluted. For Re–chromatin
immunoprecipitation (ChIP), RelA ChIP eluates were subsequently incu-
bated with either IRF5 antibody or no antibody control and processed as
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described. Cross-linked protein-DNA complexes were reversed by incubat-
ing them at 65°C overnight, and DNA fragments were purified using the
QIAquick PCR Purification Kit (QIAGEN). The immunoprecipitated DNA
fragments were then interrogated by real-time PCR using SYBR Premix Ex
Taq II master mix (Takara Bio) and the following primers for TNF locus:
control region, (TGTGTGTCTGGGAGTGAGAACT and TCTTCTCAGCT-
TCTCCTTTGCT); region A, (CCACAGCAATGGGTAGGAGAATGT and
GAGGTCCTGGAGGCTCTTTCACT); region B, (GGAAGCCAAGACT-
GAAACCAGCA and CCGGGAATTCACAGACCCCACT); region C,
(TCCCTCCAACCCCGTTTTCT and TAGGACCCTGGAGGCTGAAC);
region D, (AACTTTCCAAATCCCCGCCC and GGTGTGCCAACAACT-
GCCTT); region E, (CAGCAAGGACAGCAGAGGAC and TCCCGGAT-
CATGCTTTCAGT); region F, (GGCAGTCAGTAAGTGTCTCCAA and
TACCTACAACATGGGCTACAGG); region G, (ACAGCTTTGATCCCT-
GACATCT and CTCCGTGTCTCAAGGAAGTCTG); region H, (ATATTC-
CCCATCCCCCAGGAAACA and CTGCAACAGCCGGAAATCTCACC);
region I, (GAGGACCTCACTCAGCCCTT and CGGCAGTTCGGTTCCT-
TGTT); region J, (ACTGGTCTTTGTGGTGAAGGAG and GAACTAGT-
GGGCTCAAGTGGTC); region K, (GCTATGATCATGCCACTGTACCC
and TACCACATGGTTTTCTCCTGCC); and region L, (GCTGAAAGT-
CAGCCATGAAGTA and CACTTAGGGTGTCCCATTTAGG). Data were
analyzed using Rotogene 6000 software (Corbett Research Ltd). All primer
sets were tested for specificity and equal efficiency before use.
Immunoprecipiation
HEK-293–TLR4-CD14/Md2 cells were transfected with ONE-strep–
IRF5-HA construct or corresponding empty vector. At 24 hours after
transfection cells were fixed with 1% formaldehyde for 10 minutes at room
temperature before high salt lysis and affinity purification on Strep-Tactin
MacroPrep sepharose (IBA). The eluates were de–cross-linked by incubat-
ing at 65°C overnight before separation by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE). Exogenous IRF5 and
endogenous RelA were detected by immunoblotting with anti-HA–HRP
(12013819001; Roche) and anti-RelA (sc-372; Santa Cruz Biotechnology).
Alternatively, cells were transfected with RelA-FLAG or BAP-FLAG
control protein. At 24 hours after transfection, cells were lysed and
affinity-purified with anti-FLAG M2 Sepharose beads (Sigma). Exogenous
RelA and endogenous IRF5 were detected by immunoblotting with
anti-FLAG–HRP (A8592; Sigma) and anti-IRF5 (ab2932; Abcam). Interac-
tion of endogenous RelA and IRF5 was detected by overnight incubation of
the cell lysates with goat anti-IRF5 antibody (ab2932; Abcam) or no
antibody control before precipitation with protein G beads. IRF5 was
detected by immunoblotting with mouse anti-IRF5 antibody (sc-56714;
Santa Cruz Biotechnology), while RelA was detected by immunoblotting
with anti-RelA. Triton X-100–extracted nuclei and DNase I digestion of
chromatin was performed as described previously.17
Bioinformatics and statistical analyses
The nucleotide sequence were inspected with transcription factor binding
site searching software JASPAR18 and Genomatrix19 for the presence of
putative IFN-sensitive response element (ISRE) sites (supplemental Table
1, available on the Blood Web site; see the Supplemental Materials link at
the top of the online article). Statistical analysis was performed using 1-way
analysis of variance (ANOVA) with Dunnett multiple comparison posttest
or Student t test where appropriate (*P  .05; **P  .01; ***P  .001).
Results
Sustained TNF secretion by MDDCs is important for efficient
T-cell activation
Myeloid cells (eg, macrophages and DCs) are the major producers
of the key immune modulator TNF in response to TLR4 stimula-
tion.20 TNF protein is below the limit of detection in the superna-
tants of resting cells (Figure 1A). After 4 hours of LPS stimulation,
TNF is secreted at similar levels in MDMs and MDDCs (early
phase). However, a marked difference in TNF production was
observed in MDMs and MDDCs stimulated with LPS for 24 hours
(late phase). Although the level of TNF significantly decreased in
MDMs, there was an increase in TNF levels in MDDCs (Figure
1A) in each individual blood donor (supplemental Figure 1A).
Human TNF acting through TNF receptor is involved in DC
maturation from bone marrow precursors21,22 and activation of type
I helper (Th1), measured by the release of IFN-.23 Thus, we
examined whether the late-phase secretion of TNF by MDDCs is
needed for IFN- production by T cells. MDDCs were stimulated
with LPS for 2 hours and exposed to human T cells extracted and
purified from the peripheral blood of major histocompatibility
complex (MHC)–unmatched donors in a mixed lymphocyte reac-
tion (MLR). Antibodies against TNF receptor 1 (TNFR1) or
isotype IgG control were added to the reaction. T cells incubated
with MDDCs treated with anti-IgG antibodies produced high levels
of IFN- (Figure 1B), whereas the control reactions (MDDCs or
T cells cultured on their own) secreted no detectable IFN-.
Blocking TNF at 6 hours after setting the MLR reaction resulted in
strong reduction of IFN-, but no effect was observed when
anti-TNFR1 antibodies were added to the reaction after 24 hours,
suggesting that most T cells are in an activated state after the
prolonged exposure to TNF (Figure 1B).
Thus, the observed sustained expression of TNF by MDDCs
might be of benefit to both their maturation and antigen-presenting
function and is essential for establishing a robust Th1 phenotype.
IRF5 protein is highly expressed in MDDC and controls
late-phase TNF secretion
The observed differential LPS-induced secretion of TNF by human
DCs and macrophages (Figure 1A) prompted us to examine the
molecular mechanisms of this phenomenon. Myeloid cells from
IRF5/ mice show impaired induction of proinflammatory cyto-
kines, including TNF, upon stimulation by different TLR ligands.8
We hypothesized that the difference in TNF secretion profile in
MDDCs and MDMs might be due to the difference in IRF5
expression in these cells. We examined levels of IRF5 protein after
human monocyte differentiation into MDMs and MDDCs. No
increase in the levels of IRF5 protein was observed in MDMs, even
after 5 days of differentiation (Figure 1C). However, expression of
IRF5 protein was detected after 1 day of monocyte differentiation
into MDDCs and remained at an elevated level until day 7 (Figure
1C). Significantly, whereas at least 3 different IRF5 isoforms were
observed in human monocytes, only some of them accounted for
high levels of IRF5 in MDDCs: one is likely to be IRF5v3/v4.11
Next, we looked at the effect of ectopic IRF5 expression in
MDMs that have low levels of endogenous IRF5 protein (Figure
1C) on T-cell activation. MDMs were infected with adenoviral
expression vector encoding HA-tagged IRF5 or the corresponding
empty vector pBent. At 48 hours after infection, no significant
effect on the resting cells (measured by endogenous IFN-1
response) was observed. Exposure of T cells to MDMs with
elevated levels of IRF5 protein resulted in increase of IFN-
secretion to the levels comparable with that of T cells exposed to
MDDCs (Figure 1D). Thus, we argued that IRF5 might be
responsible for sustained secretion of TNF. To test this hypothesis,
MDMs were infected with adenoviral expression vector encoding
HA-tagged IRF5 or IRF3 (as a control) or pBent. IRF5-HA and
IRF3-HA vectors expressed similar levels of proteins (supplemen-
tal Figure 1B), but only IRF5 resulted in a significant increase in
TNF secretion (Figure 1D; supplemental Figure 1C), whereas only
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IRF3 induced IFN-1 (supplemental Figure 1D), consistent with
the previously published data.16 Strikingly, TNF secretion in
MDMs with overexpression of IRF5 remained at a steady sustained
level up to 48 hours after LPS stimulation (Figure 1E), similar to
that of MDDCs with high levels of endogenous IRF5 (Figure 1C).
siRNA-mediated inhibition of IRF5 in MDDCs (supplemental
Figure 1E) resulted in reduction of TNF secretion at 8 and 24 hours
after LPS stimulation (Figure 1F), supporting the notion that IRF5
may be required for the late-phase TNF expression.
Taken together, these results suggest that sustained TNF secre-
tion by MDDCs leading to robust T-cell activation is likely to be a
consequence of a high level of IRF5 protein in these cells.
IRF5 is involved in transcriptional regulation of TNF
We next sought to investigate whether IRF5 is involved in
transcriptional regulation of the TNF gene. In human MDDCs,
stimulation with LPS resulted in a rapid up-regulation of TNF
mRNA expression, which reached the peak between 1 and 2 hours
but remained at a steady level until 8 hours after stimulation
(Figure 2A). Consistent with the observed differences in protein
secretion, TNF mRNA expression in MDMs was characterized by
more transient kinetics (supplemental Figure 2A), whereas siRNA-
mediated inhibition of IRF5 reduced TNF mRNA expression
(Figure 2A). The observed inhibition was statistically significant
when analyzed in multiple blood donors (supplemental Figure 2B).
In the same cells, siRNA-mediated inhibition of NF-B RelA, a
transcription factor previously shown to be important for an
Figure 1. IRF5 protein is highly expressed in MDDCs and control
late-phase TNF secretion. (A) Monocyte-derived dendritic cells (MDDCs)
and monocyte-derived macrophages (MDMs) were stimulated with lipopoly-
saccharide (LPS; 10 ng/mL) for 4 hours and 24 hours, and secreted tumor
necrosis factor (TNF) was measured by ELISA. Data show means 
standard error of the mean (SEM) of 5 independent experiments each
using monocytes derived from a different donor. **P  .01 (Student t test).
(B) MDDCs were stimulated with LPS for 2 hours and then were cultured
with T lymphocytes. Anti-TNFR1 or anti-IgG control antibodies were
added 6 hours or 24 hours after coculture start. IFN- secretion was
determined by ELISA after 72 hours of coculture. Data show means 
SEM of 3 independent experiments. *P  .05. (C) Cells were collected at
day 0 (monocytes); days 1, 3, 5, and 7 (MDDCs) after differentiation with
granulocyte-macrophage colony-stimulating factor (GM-CSF; 50 ng/mL)
and IL-4 (10 ng/mL); and days 1, 3, and 5 after differentiation with M-CSF
(50 ng/mL; MDMs); total protein extracts were then subjected to Western
blot analysis. p38 MAPK was used as loading control. Representative
blots of 5 independent experiments each using monocytes derived from a
different donor. (D) MDMs were left untreated (cells) or infected with
adenoviral vectors encoding IRF5 or empty vector (pBent), stimulated with
LPS for 2 hours, and cultured with T lymphocytes. IFN- secretion was
determined by ELISA after 72 hours of coculture. Data show means  SD
and are representative of 3 independent experiments each using MDMs
derived from a different donor. (E) MDMs were left untreated (cells) or
infected with adenoviral vectors encoding IRF5, IRF3, or empty vector
(pBent) and stimulated with LPS for the indicated time. The amount of
secreted TNF protein was determined by ELISA. Data show means  SD
and are representative of 3 independent experiments each using MDMs
derived from a different donor. (F) MDDCs were transfected with siRNAs
targeting IRF5 (siIRF5) and stimulated with LPS (10 ng/mL) for the
indicated time. TNF secretion was compared with control cells transfected
with nontargeting siRNA (siC). Data shown are the means  SD and are
representative of 2 independent experiments each using MDDCs derived
from a different donor.
Figure 2. IRF5 is involved in transcriptional regulation of TNF. (A) MDDCs were
transfected with siRNAs targeting IRF5 (siIRF5), RelA (siRelA), or both
[si(IRF5RelA)] and stimulated with LPS (10 ng/mL) for the indicated time. TNF
mRNA expression was compared with control cells transfected with nontargeting
siRNA (siC). Data shown are the means  SD and are representative of 4 indepen-
dent experiments each using MDDCs derived from a different donor. (B) HEK-293
cells were cotransfected with the TNF 5wt/3wt reporter plasmid and equal amounts
of expression plasmids encoding for human IRF5, RelA, IRF3, or empty vector
(pBent). At 48 hours after transfection, cells were harvested and luciferase activity
was measured as described. Data are presented as a fold over pBent  SEM from
4 independent experiments. *P  .05; ** P  .01 (1-way ANOVA).
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efficient TNF production by human MDDCs,24 resulted in reduc-
tion of TNF mRNA expression at the initial phase of gene induction
(1-2 hours after LPS stimulation; Figure 2A). Within this time
window, depletion of both IRF5 and RelA had the strongest effect
on mRNA expression (Figure 2A), indicating that RelA and IRF5
may cooperate in controlling transcription of the TNF gene.
To investigate whether IRF5 can directly modulate transcription
of the TNF gene, we used a gene-reporter plasmid in which the
luciferase gene was flanked with 1171 nt 5 upstream and 1252 nt
3 downstream of the TNF gene. This construct encompassed all
evolutionary conserved sequences in the region and contained
known B sites.25,26 It was coexpressed with HA-tagged IRF5,
IRF3, and NF-B subunits in HEK-293 cells, and luciferase
activities were compared with empty vector pBent. RelA- and
IRF5-transfected cells showed a significant increase in luciferase
activity (Figure 2B). Other NF-B subunits or IRF3 had little or no
effect (Figure 2B; supplemental Figure 2C). Of interest, a deletion
of the IRF5 DNA-binding domain (IRF5 DBD) or a point alanine
to proline mutation in it (IRF5 A68P) previously shown to act as
dominant-negative mutants of IRF5,27,28 resulted in a major drop in
luciferase activity (supplemental Figure 2D).
We concluded that IRF5 along with RelA is likely to be directly
involved in the transcriptional regulation of the human TNF gene.
Although the initial phase of TNF induction depends on both
factors, only IRF5 appears to be crucial for maintaining prolonged
TNF transcription in MDDCs. Moreover, the DBD of IRF5 is
required for the optimal level of TNF gene up-regulation.
IRF5 is recruited to the 5 upstream and 3 downstream regions
of the TNF gene in response to LPS stimulation
To further address the involvement of IRF5 in the TNF gene
regulation, we systematically analyzed the recruitment of IRF5 to
the TNF locus. A well-conserved N-terminal DBD of IRF factors
recognizes a class of DNA sequences known as ISRE, 15 of which
were computationally mapped to this locus together with known
B sites: B1, B2//2a, B3, and B4/4a/4b (Figure 3A; supple-
mental Table 1). A series of primers spanning the locus and
encompassing ISRE sites was designed and used in the quantitative
ChIP assay (Figure 3A).
HEK-293–TLR4-CD14/Md2 cells responsive to LPS were used
to investigate the effect of LPS stimulation on recruitment of IRF5
to the TNF locus. Increased occupancy of IRF5 was observed at
regions A, B, C, G, and H 4 hours after LPS stimulation, followed
by a decrease after 24 hours (Figure 3B). Taking into consideration
the average ChIP fragment size of around 500 bp and the proximity
of the sequences amplified, some degree of overlap in regions A
through C was inevitable and might have accounted for the
observed symmetrical distribution of enrichment at regions A, B,
and C. Whereas the enrichment of IRF5 signal at region B was
expected due to the presence of putative ISRE 1/2 that can interact
with IRF5 in vitro (supplemental Figure 3A), it was surprising to
observe the recruitment of IRF5 at region H because this region
contains no putative ISREs (Figure 3A). Moreover, we observed no
IRF5-DNA binding at B4/4a/4b binding sites in region H or at
additional nonconsensus ‘ISRE’16 and ‘ISRE’17 sites in the
vicinity of region H (supplemental Table 1; supplemental Figure
3A). We also investigated the recruitment of NF-B RelA to the
TNF locus and observed LPS-induced binding of RelA to regions
B, E, and H (Figure 3C), which correlated with the distribution of
multiple NF-B–binding regions.
Next, we validated the pattern of IRF5 and RelA binding to the
TNF locus in MDDCs stimulated with LPS for 0, 1, and 4 hours.
Strong enrichment in both IRF5 and RelA recruitment was
observed at regions B and H (Figure 3D-E), reproducible in
Figure 3. IRF5 is recruited to the 5 upstream and
3 downstream region of TNF. (A) Schematic of the
TNF locus. Protein coding and noncoding exons are
shown in black and white. Putative ISREs are allocated
as white ovals; B sites are shown as black circles. The
approximate amplicon size of primer sets spanning the
TNF locus (A to L) are indicated by black lines. CO
indicates a control primer set containing neither an ISRE
nor a B site. (B-C) HEK-293–TLR4-Md2/CD14 cells
were left unstimulated or stimulated with LPS (1 g/mL)
for 4 hours and 24 hours and analyzed by ChIP with
antibodies specific to IRF5 (B) or RelA (C). (D-E) MDDCs
were left unstimulated or stimulated with LPS for 1 hour
and 4 hours, followed by ChIP with antibodies specific to
IRF5 (D) or RelA (E). (F) Corecruitment of RelA and IRF5
to region H was assessed by re-ChIP analysis with
antibodies against RelA followed by IRF5-specific antibod-
ies. (B-F) Data show mean percentage input relative to
genomic DNA (gDNA) plus or minus SD of a representa-
tive experiment. AB indicates a no-antibody control.
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5 independent blood donors (supplemental Figure 3B). Impor-
tantly, LPS stimulation resulted in rapid transcription of the
full-length nascent TNF transcript (estimated by recruitment of Pol
II to the TNF 3 downstream region H), which was robustly
maintained at least up to 4 hours after stimulation (supplemental
Figure 3D).
In summary, in response to LPS stimulation IRF5 along with
RelA is efficiently recruited to the 5 upstream and 3 downstream
regions of the human TNF gene. Significantly, the lack of putative
ISRE binding sites in the 3 downstream region of the gene
strongly suggested that recruitment of IRF5 to this region might be
mediated via its interactions with other TFs or accessory proteins.
IRF5 forms specific physical interactions with RelA
To tease out whether IRF5 recruitment to region H may be
mediated via its interactions with RelA, we performed sequential
ChIP analysis of the region and found that IRF5 recruitment was
codependent on RelA after LPS stimulation (Figure 3F). This
finding prompted us to investigate whether IRF5 and RelA interact
physically.
IRF5 with an N-terminal ONE-strep–tag and a C-terminal
HA-tag was expressed in HEK-293 cells. Figure 4 shows that in
conditions similar to ChIP analysis (ie, in vivo cross-linking with
formaldehyde), ectopically expressed IRF5, purified over a Strep-
Tactin column, efficiently pulls down endogenous RelA (Figure
4A, compare lanes 3 and 4). To determine whether this interaction
was specific, we immunoblotted for other NF-B family members:
Rel-B, c-Rel, p50 and p52, or a control protein tubulin. None of
these resulted in a positive interaction (Figure 4A). Furthermore,
we conducted a complementary experiment in which human RelA
containing C-terminal FLAG tag was expressed in HEK-293 cells
and immunoprecipitated in the absence of cross-linking agents on
anti-FLAG Sepharose. Specific interactions between ectopically
expressed RelA and endogenous IRF5 were observed. No interac-
tion was detected between a control FLAG-tagged bacterial
alkaline phosphatase (BAP) and IRF5 (Figure 4B, compare lanes
1 and 2).
Next, we examined whether an interaction between the endoge-
nous RelA and IRF5 could be detected in MDDCs, and if this
interaction may be induced by LPS stimulation. IRF5 was immuno-
precipitated from the cells stimulated with LPS for 0 or 1 hour
using anti-IRF5 antibodies. The Western blot for RelA revealed a
specific interaction with IRF5 (Figure 4C). A densitometry analysis
of quantities of the bait and target proteins indicated that the
quantity of RelA bound to IRF5 was somewhat higher in LPS-
stimulated cells (Figure 4C lane 4).
Finally, we asked the question whether the observed RelA-IRF5
interactions are dependent on the simultaneous binding of both TFs
to DNA (ie, RelA and IRF5 interact only when bound to correspond-
ing B and ISRE binding sites in proximity to each other). To
address this, we extracted nuclei from HEK-293–TLR4-CD14/
Md2 cells stimulated with LPS for 0, 1, 4, and 8 hours and
subjected the chromatin to DNaseI digestion. Subsequent precipita-
tion of endogenous immune complexes with anti-IRF5 antibodies
revealed that RelA interacted with IRF5 even in the absence of
DNA bridging (Figure 4D lanes 5-8). Once again, the number of
RelA-IRF5 complexes increased with LPS stimulation, correspond-
ing to the rise in nuclear RelA (Figure 4D lanes 1-4).
In summary, IRF5 can specifically interact with RelA but not
other 4 NF-B subunits. This interaction is not dependent on IRF5
binding to DNA, and the quantity of RelA-IRF5 complexes is
increased in response to LPS stimulation. Thus, we hypothesized
that IRF5 recruitment to the 3 downstream region of the TNF gene
lacking putative ISRE sites is a consequence of direct physical
interactions between DNA-bound RelA and IRF5.
RelA is required for IRF5-dependent trans-activation of the TNF
gene
To test this hypothesis, we first analyzed IRF5 recruitment to the
TNF locus in the cells in which the levels of RelA were
significantly reduced. In HEK-293–TLR4-CD14/Md2 cells, siRNA-
mediated knockdown of RelA resulted in approximately 75%
reduction in RelA protein (Figure 5A) and about a 10-fold decline
in its recruitment to region H after 4 hours of LPS stimulation
(Figure 5B). As predicted, the IRF5 recruitment to the same region
was prevented (Figure 5C). Of interest, when we analyzed RelA
and IRF5 recruitment to region B in RelA-depleted cells, we
observed only partial reduction in IRF5 recruitment (supplemental
Figure 4), consistent with the view that IRF5 can bind directly to
DNA at this region (supplemental Figure 3A).
Next, we examined the effect of site-specific mutations in the
B sites on the ability of IRF5 to activate the TNF gene. A panel of
4 gene-reporter constructs was used in this analysis: (1) 5wt/3wt
(as in Figure 2B); (2) 5mut/3wt (mutated B2/2/2a sites in the
TNF 5 upstream); (3) 5wt/3mut (mutated B4/4a sites in the
3 TNF downstream); and (4) 5mut/3mut (mutated all B sites
just described). The reporter constructs were coexpressed with
HA-tagged IRF5 and RelA in HEK-293 cells, and luciferase
activities were compared with empty vector pBent. As expected,
removal of either 5 upstream or 3 downstream B sites dimin-
ished the ability of RelA to drive the gene-reporter activity (Figure
5D). However, the trans-activation of the reporter constructs by
IRF5 (supported by ectopically expressed Myd88) appeared to be
largely unaffected by mutations in the 5 upstream B sites,
suggesting that IRF5 does not use B2/2/2a sites for its binding to
the TNF 5 upstream and is likely to involve the identified ISRE 1
Figure 4. IRF5 specifically interacts with RelA. (A) HEK-293–TLR4-Md2/CD14
cells were transfected with human IRF5 tagged with ONE-strep–tag (N-terminus) and
HA-tag (C-terminus; lanes 1 and 3) or an empty vector pBent (lanes 2 and 4) and
fixed with formaldehyde. Cross-links were reversed by heating and immunoblotted
for bait IRF5 (anti-HA antibodies), or NF-B subunits and tubulin. (B) HEK-293–TLR4-
Md2/CD14 cells were transfected with RelA-FLAG (lane 1) or BAP-FLAG (lane 2).
Cell lysates were immunoprecipated with M2 anti-FLAG Sepharose and immuno-
bloted for bait RelA (anti-FLAG antibodies) or IRF5. (C) MDDCs were stimulated with
LPS for 1 hour or left untreated. The endogenous interaction between RelA and IRF5
was examined by immunoprecipitation (IP) with anti-IRF5 antibody and immunoblot-
ting with anti-RelA antibody. AB indicates a mock IP. (D) Nuclear pellet from
Triton-extracted HEK-293–TLR4-Md2/CD14 cells was solubilized with DNaseI, and
endogenous interaction between RelA and IRF5 was examined after IP as in panel C.
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and 2 sites. However, the trans-activation of the reporter construct
with mutations in B4/4a sites by IRF5 was significantly reduced,
indicating that IRF5 activity depends on NF-B binding to this
region (Figure 5B). Low amounts of endogenous RelA detected in
the nuclei of resting HEK-293–TLR4-CD14/Md2 cells (data not
shown) appeared to provide a necessary DNA anchor for IRF5.
Thus, IRF5 recruitment to the TNF 3 downstream region is
mediated by way of a complex assembly with RelA and does not
involve a direct contact to DNA. Importantly, another mode of
function of IRF5 in TNF regulation is a direct recruitment to the
TNF gene 5 upstream. The 2 functional modes also imply the
possibility of a higher order enhancer structure at the TNF locus,
possibly involving IRF5-RelA–mediated intrachromosomal looping.
Discussion
Production of the key immune modulator TNF is both cell and
stimulus specific. Myeloid cells are the major producers of TNF in
response to TLR4 stimulation.20 Consequently, a tight control of
the amount and duration of TNF expression by these cells is critical
for a self-limited immune response. Here, we aimed to understand
the molecular bases of differential TNF expression in human DCs
and macrophages. We demonstrate that IRF5 appears to be a
defining factor in maintaining the TNF gene transcription in
MDDCs. Remarkably, we unravel a complex molecular mecha-
nism used by IRF5 to control the human TNF gene expression:
2 spatially separated regulatory regions and 2 independent modes
of actions are involved.
IRF5 is highly expressed in MDDCs but not other myeloid cells
(Figure 1). During differentiation MDDCs acquire a particular
phenotype, characterized among other markers by higher levels of
RelB and c-Rel.29 Important for understanding the mechanisms of
sustained TNF expression, RelB was previously shown to replace
RelA at the promoters of macrophage-derived chemokine and
Epstein-Barr virus (EBV)–induced molecule 1 ligand chemokine
genes and to prolong their transcription in MDDCs.30 We also
observed an increase in the RelB and c-Rel levels during monocyte
differentiation into MDDCs, but not into MDMs (supplemental
Figure 5A). However, neither RelB nor c-Rel was able to drive
transcription of TNF (supplemental Figure 2), whereas RelA,
whose level was similar in all human myeloid cell types (supplemen-
tal Figure 5A), had a strong trans-activating effect (Figure 2). This
led us to conclude that RelA was likely to participate in the initial
phase of TNF activation, which is indistinguishable between
MDDCs and MDMs, but other MDDC-specific factors, such as
IRF5, may contribute to the observed extended expression of TNF
in MDDCs. Indeed, forced expression of IRF5 in MDMs led to
prolonged TNF secretion (Figure 1), whereas depletion of IRF5 in
MDDCs resulted in reduction of TNF expression, particularly at a
later time (4 hours) after LPS stimulation (Figure 2; supplemental
Figure 2). Although we cannot formally rule out other factors that
might feed into the TNF expression system at a later time, the
ability of IRF5 to activate the TNF gene-reporter construct (Figure
2) and its efficient recruitment to the TNF locus (Figure 3) strongly
suggest a direct role for IRF5 in TNF gene induction in response
to LPS.
TNF is an early primary response gene whose mRNA expres-
sion in MDDCs is induced approximately 100-fold within 30 min-
utes after LPS treatment (supplemental Figure 2). The genomic
locus encompassing the TNF gene is open to regulatory proteins
and in murine bone marrow–derived macrophages (BMDMs) does
not require nucleosome remodeling complexes for its activation.31
Consistent with this notion, we find a significant accumulation of
Pol II molecules at the transcription start site (TSS) of the gene
even in resting MDDCs (supplemental Figure 6), akin to the results
Figure 5. RelA is required for IRF5-mediated activa-
tion of TNF. (A-C) HEK-293–TLR4-Md2/CD14 cells were
transfected with siRNA against RelA (siRelA) or with
nontargeting siRNA (siC) and used in ChIP analysis of
RelA and IRF5 recruitment. Data indicate mean percent-
age input relative to gDNA  SD of a representative
experiment. AB indicates a no-antibody control. (A) A
total of 75% of RelA protein was degraded estimated by
serial dilutions of the siC control sample analyzed by
Western blotting. (B) Reduction in LPS-induced RelA
recruitment to region H in siRelA-treated cells. (C) Reduc-
tion in LPS-induced IRF5 recruitment to region H in
siRelA-treated cells. (D) HEK-293–TLR4-Md2/CD14 cells
were transfected with the RelA, IRF5, and MyD88 expres-
sion constructs together with the TNF 5 upstream/
luciferase/TNF 3 downstream reporter plasmids: 5wt/
3wt indicates wild-type construct; 5mut/3wt indicates
mutated B2 (GTGAATTCCC3 tTGAATTCCC), B
(GTGATTTCAC 3 aTccTTTCAC), and B2a (GGG-
CTGTCCC3 taGCTGTGCCC) sites in the TNF 5 up-
stream; 5wt/3mut indicates mutated B4 (GGG-
AATTTCC 3 cGcAATgTgC) and B4a (GGGAATT-
CCA3 cGcAAgTgCA) sites in the TNF 3 downstream;
and 5mut/3mut indicates all B sites mutated. Data
show means  SD and are a representative of 3 indepen-
dent experiments, each performed in triplicate.
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obtained in mouse BMDMs.32,33 LPS stimulation, however, results
in a robust recruitment of RelA and IRF5 to both 5 upstream
region B and 3 downstream region H (Figure 3) and in a significant
induction of Pol II recruitment to the 3 downstream region of the
gene (supplemental Figure 6). This suggests an increase
in production of full-length nascent TNF transcripts upon
LPS stimulation of MDDCs, in addition to induction of
splicing of already generated nascent transcripts reported by
Hargreavas et al.32
The recruitment of IRF5 to the 5 upstream region is likely to
involve direct binding to DNA via the identified ISRE sites
(supplemental Figure 3), whereas the recruitment of IRF5 to the 3
downstream region is mediated via protein-protein interactions
with RelA (Figure 4). These interactions are induced after stimula-
tion of MDDCs with LPS, while no other NF-B subunits appear to
complex with IRF5 (Figure 4). Previous studies demonstrated that
IRF3, another member of the IRF family, forms in vitro interactions
with RelA via its Rel homology domain (RHD).34 Considering that
the RHD is a highly conserved domain present in all NF-B
proteins, the exclusiveness of IRF5 interactions with RelA is
somewhat surprising. Further work is needed to map the interface
of RelA-IRF5 interactions.
Regions B and H are characterized by high level of sequence
conservation,25,35 and contain cell type–specific DNaseI hypersen-
sitivity sites.35,36 Moreover, the TNF 5 upstream and 3 down-
stream regions have been shown to physically interact by forming
an intrachromosomal loop, the topology that could promote the
reinitiation of transcription.35 This model may be of a particular
relevance to TNF expression by MDDCs, in which a cooperative
action of RelA and IRF5 at both the 5 upstream and downstream
regions appears to be essential for maintaining TNF gene transcrip-
tion over a prolonged period of time. Here, the locus circularization
may be directed via newly unraveled protein-protein interactions
between RelA and IRF5 (Figure 4). The observed DNA-binding–
independent corecruitment of IRF5 to the 3 downstream region
(Figure 5) further supports the possibility of high-order enhancer
structure at the locus (Figure 6).
Why is TNF secretion maintained for longer in MDDCs than in
MDMs (Figure 1)? DCs are professional antigen-presenting cells
(APCs) that are crucial for both innate and adaptive responses to
infection. They sense invading pathogens and respond by secreting
various cytokines as well as by up-regulating the expression of
MHC II and costimulatory molecules, essential for efficient antigen
presentation to T cells.37 The mature DCs migrate to the draining
lymph nodes, where they initiate Th1 differentiation. TNF acting
through the TNF receptor is involved in DC maturation from bone
marrow precursors.21,22 A recent study demonstrated that TNF
blockade impaired DC survival and function in RA.38 Our data
showing that TNF produced by DCs is a key factor in human Th1
activation support this study. Moreover, it is the late-phase TNF
secretion that is needed to achieve the full activation potential
(Figure 1). Macrophages, on the other hand, do not migrate to the
draining lymph nodes but accumulate in large numbers at a site of
inflammation, secrete inflammatory cytokines, and attract other
immune cells via chemotaxis.39 Thus, a mechanism which would
restrain the degree and duration of TNF secretion by macrophages
would be important for ensuring the resolution of acute inflamma-
tory response, thereby limiting tissue damage.
Another question is how IRF5 is activated in MDDCs by
TLR4 signaling. Takaoka et al demonstrated that ectopically
expressed IRF5 translocates to the cell nuclei in response to
LPS, and that this translocation is dependent on the presence of
Myd88.8 We observed endogenous nuclear IRF5 even in resting
MDDCs or HEK-293–TLR4-CD14/Md2 cells, and its level was
not increased after LPS stimulation (supplemental Figure 5B),
although we could not exclude the possibility of active nuclear
export-import of IRF5 induced by phosphorylation at the
previously described serine residues40 due to the lack of
phosphospecific antibodies. In the same cells, endogenous IRF3
showed a clear pattern of induced nuclear translocation (supple-
mental Figure 5B), which corresponded to its phosphorylated
form (data not shown). It is worth noting, however, that an
ectopically expressed mutant of IRF5 in which the described
critical serines at positions 427 and 4309,40 were substituted with
alanines was still transcriptionally active in the TNF reporter
assay (G.R., unpublished data, 2009), suggesting that IRF5 may
not need to be phosphorylated at these residues to activate
transcription. We also did not observe any loss in IRF5
trans-activating potential when lysines 401 and 402, implicated
in another Myd88-induced posttranslational modification of
IRF5, K63-linked polyubiquitination,41 were substituted with
arginines (G.R., unpublished data, 2009). Because the overex-
pression data generated in the HEK-293 cell line may be
misleading, we plan to test these and other mutants of IRF5 in
complementation experiments in the cells from IRF5-deficient
Figure 6. A model for IRF5-RelA–mediated induction
of TNF in myeloid cells. LPS-induced recruitment of
NF-B RelA-containing complexes (gray ovals) to the
5 upstream and 3 downstream regions leads to tran-
sient TNF expression in MDMs. The mechanisms of
transmitting the activating signal from 3 downstream to
Pol II requires further investigation. IRF5 binding to DNA
at the 5 upstream and to RelA at the 3 downstream
establishes the possibility for region circularization and
recycling of Pol II molecules, leading to sustained TNF
expression in MDDCs.
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mice to elucidate the impact of these mutations on IRF5
activation and function in vivo.
Regulation of IRF5 activity is an important issue because the
excessive activation of this protein may lead to pathology. Interest-
ingly, another member of the IRF family, IRF4, was shown to act as
a negative regulator of TLR signaling by inhibiting the production
of selected IRF5-dependent genes, including TNF, via direct
competition with IRF5 for interactions with Myd88.42 In mice,
IRF4 was observed to be differentially expressed in DCs and
regulate the development of a specific DC subset, conventional
DCs.43 In humans, IRF4 was also found to be expressed in MDDCs
but not MDMs,44 suggesting that a self-controlled IRF5-IRF4
regulatory system might have developed to finely modulate TLR
signaling pathways and production of IRF5-dependent inflamma-
tory cytokines.
In summary, sustained TNF secretion in human MDDCs is
mediated by cooperative action of IRF5 and RelA at the 5 up-
stream and 3 downstream regions of the TNF gene. TLR4
stimulation induces protein-protein interactions between RelA and
IRF5 and allows for DNA-independent recruitment of IRF5 to the
TNF 3 downstream region. IRF5 may assist in formation of a
high-order enhancer structure linking together the regulatory
regions in the TNF 5 upstream and 3 downstream and allowing
for maintaining of transcription over a longer time (Figure 6).
Based on the resistance of IRF5/ mice to lethal endotoxic shock,
impaired production of proinflammatory cytokines, and deficiency
in Th1 immune response, IRF5 was proposed as a target for
therapeutic interventions.8 Here, we define RelA-IRF5 interactions
as a putative target for cell-specific modulation of TNF expression
and possible other selected inflammatory mediators.
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